atenolol has been researched along with Blood Pressure, High in 1778 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with mild or moderate hypertension were randomised to receive either Atenolol 100 mg (N = 10) or Pindolol 15 mg (N = 11) in a once daily dosage over a two month period." | 10.16 | [Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Guillard, O; Herpin, D; Piriou, A, 1988) |
| " The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension." | 9.41 | Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. ( Akhtar, L; Elahi, A; Faisal, Z; Hussain, M; Javed, A; Majid, A, 2021) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 9.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 9.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 9.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "We evaluated the effect of atenolol vs metoprolol succinate on vascular function in patients with essential hypertension." | 9.15 | Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. ( Heffernan, KS; Karas, RH; Kuvin, JT; Mooney, P; Patvardhan, EA; Suryadevara, R, 2011) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 9.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 9.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 9.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 9.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "Although treatment with nebivolol or atenolol results in improved LV transmitral diastolic function filling parameters (E/A ratio, IVRT and DT), nebivolol has a greater effect compared with atenolol in patients with mild-to-moderate hypertension." | 9.13 | Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. ( Eryonucu, B; Gumrukcuoglu, HA; Gunes, Y; Guntekin, U; Tuncer, M, 2008) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 9.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "In this double-blind, multicentre trial, 694 patients with hypertension (mean sitting diastolic blood pressure [BP] > or = 95 and < 110 mmHg) were randomised to once-daily aliskiren 150 mg (n=231), atenolol 50 mg (n=231) or the combination (150/50 mg; n=232) for six weeks, followed by a further six weeks on double the initial doses of aliskiren and atenolol." | 9.13 | Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. ( Bheda, M; Dechend, R; Dietz, R; Ford, J; Keefe, DL; Prescott, MF; Yu, CM, 2008) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 9.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| " Our objective was to compare the effects of cilazapril and atenolol on P-wave duration and dispersion in patients with hypertension." | 9.13 | Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension. ( Eryonucu, B; Gumrukcuoglu, HA; Gunes, Y; Guntekin, U; Tuncer, M, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "To compare the effects of nebivolol, a new b-blocker that have additional vasodilating activity via acting on endothelium and nitric oxide release, and atenolol on P-wave duration and dispersion in patients with mild-to-moderate hypertension." | 9.13 | [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension]. ( Batyraliev, TA; Eryonucu, B; Fettser, DV; Guler, N; Gumrukchuoglu, KhA; Gunes, Y; Guntekin, U; Sidorenko, BA; Tuncer, M, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 9.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| " The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension." | 9.12 | Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. ( Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "The aim of the present study was to evaluate effects of long-term treatment with rilmenidine compared with atenolol on lipid and glucose metabolism and cardiovascular remodelling in hypertension." | 9.12 | How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ( Kasherininov, YR; Konrady, AO; Krutikov, AN; Shavarov, AA; Shavarova, EK; Shlyakhto, EV; Smirnova, EV; Vachrameeva, NV, 2006) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 9.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 9.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| "6 years) randomized to treatment with lacidipine or atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)." | 9.12 | Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. ( Baurecht, H; Bilo, G; Hennig, M; Mancia, G; Maronati, A; Omboni, S; Parati, G; Zanchetti, A, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 9.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "Two first-line antihypertensive therapies for initiating treatment in hypertension were compared, the angiotensin-converting enzyme inhibitor (ACEI) zofenopril and the beta-blocker atenolol." | 9.12 | Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. ( Nilsson, P, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 9.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 9.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 9.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 9.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "The objective of this open-label, parallel-group comparative study was to assess the clinical efficacy and safety of once-daily treatment for 8 weeks with telmisartan 80 mg in comparison with atenolol 50 mg on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with mild-to-moderate hypertension (morning supine SBP 141-199 mmHg, DBP 95-114 mmHg)." | 9.11 | Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. ( Alcocer, L; Bahena, J; Campos, E; de la Fuente, JJ; Dominguez-Henkel, R; Fernández-Bonetti, P; Olvera Ruiz, R; Segovia-Ayala, C, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 9.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 9.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 9.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 9.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "Propranolol inhibits platelet aggregation more than atenolol and may have a favorable effect on the management of hypertension especially in patients with increased cardiovascular risk." | 9.11 | Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. ( Bagatin, J; Lukin, A; Marković, V; Polić, S; Punda, A; Rumboldt, Z, 2005) |
| "In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens." | 9.11 | Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. ( Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 9.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Vascular Regression Study (LAARS) was a double-blind, parallel-group, randomized, controlled, multicenter study designed to compare the effects of the AII antagonist losartan and the beta-blocker atenolol on ultrasonographically determined intimamedia thickness (IMT) of the common carotid artery (CCA) in patients with mild to moderate essential hypertension." | 9.10 | Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. ( Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U, 2002) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 9.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 9.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 9.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 9.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 9.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "This was a double-blind, randomized, prospective study comparing the effects of nebivolol and atenolol on systolic diastolic left ventricular function in patients with essential hypertension." | 9.10 | Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. ( Kamp, O; Sieswerda, GT; Visser, CA, 2003) |
| "We compared the effects of 6 months administration of atenolol or nebivolol on resting and exercise hemodynamic parameters and maximal exercise capacity, in 26 patients with hypertension and left ventricular (LV) diastolic dysfunction (ejection fraction >50%, end-diastolic diameter <60 mm and increased pulmonary wedge pressure at rest and/or at peak exercise)." | 9.10 | Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. ( Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 9.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 9.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 9.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 9.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "Atenolol use may be associated with growth retardation when given in pregnancy, although the relationship to trimester of initiation, duration of treatment, and its use as monotherapy is still uncertain." | 9.09 | Atenolol and fetal growth in pregnancies complicated by hypertension. ( Beevers, DG; Beevers, M; Lip, GY; Lydakis, C, 1999) |
| "The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension." | 9.09 | Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. ( Alvarez, E; Andersson, PE; Byberg, L; Haenni, A; Lithell, H; Reneland, R, 2000) |
| "The primary objective of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of tasosartan and atenolol administered alone and concomitantly under steady-state conditions in 17 patients ages 18 to 65 years diagnosed with stage 1 to 2 essential hypertension." | 9.09 | A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ( Abernethy, DR; Andrawis, NS; Battle, MM; Burghart, PH; Klamerus, KJ; Mayer, P; Neefe, L; Weinryb, I, 2000) |
| "Nineteen untreated patients with mild essential hypertension (47+/-2 years, range 30 to 65 years; 57% male) were randomly assigned in double-blind fashion to losartan or atenolol treatment for 1 year." | 9.09 | Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. ( Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM, 2000) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 9.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 9.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 9.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 9.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "This study was undertaken to compare the efficacy and tolerability of telmisartan, a novel antihypertensive agent, and atenolol, a well-established beta-blocker, in the treatment of mild to moderate hypertension." | 9.09 | Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. ( Deichsel, G; Freytag, F; Meinicke, T; Schelling, A, 2001) |
| "These results indicate that insulin sensitivity was not modified significantly by nebivolol, whereas it was reduced by atenolol, although blood pressure was decreased to the same extent by both drugs." | 9.09 | Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. ( Cléroux, J; Lacourcière, Y; Nadeau, A; Poirier, L, 2001) |
| "Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period." | 9.09 | Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. ( Hägg, A; Kahan, T; Lind, L; Millgård, J; von zur Mühlen, B, 2001) |
| "To compare the efficacy of native carvedilol(Cv) with native atenolol(At), we treated 80 cases of essential hypertension(stage I-II) for 4 weeks, using both open-test and double blind randomized imitative methods." | 9.09 | [Efficacy of native carvedilol in patients with essential hypertension]. ( Jia, Z; Lin, S; Peng, Y; Yang, T; Zhang, Z, 1999) |
| "The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension." | 9.08 | Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. ( Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS, 1995) |
| "The primary objective in this multicentre, double-blind randomised, parallel study was to compare the metabolic effects of 12 months of treatment with an ACE inhibitor (enalapril) with those of a selective beta-blocker (atenolol) in patients with mild hypertension." | 9.08 | Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group. ( Aberg, H; Lithell, H; Mörlin, C, 1995) |
| "The efficacy and tolerability of controlled-release metoprolol (metoprolol CR/ZOK), 100-200 mg, and atenolol, 50-100 mg, once daily was compared in Chinese patients with mild to moderate essential hypertension." | 9.08 | A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. ( Chen, MF; Chen, WJ; Lee, CM; Lee, YT; Liau, CS; Wu, CC; Yang, CY, 1995) |
| "The hemodynamic effects of celiprolol (CAS 56980-93-9), a betablocker with beta 1 antagonist and beta 2 agonist properties, were compared with those of atenolol (CAS 29122-68-7) in 12 patients with mild to moderately severe hypertension (diastolic BP 95-110 mmHg)." | 9.08 | Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. ( Mahler, F; Saner, H; Seiler, A, 1995) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 9.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 9.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 9.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks." | 9.08 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension. ( Chern, MS; Lin, FC; Wu, D, 1997) |
| "The blood pressure lowering effect and tolerability of the angiotensin-converting enzyme inhibitor enalapril combined with a very low dose of hydrochlorothiazide (HCTZ) were compared with the selective betareceptor blocker atenolol in patients with mild-to-moderate hypertension." | 9.08 | Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group. ( Dollerup, J; Hotnes, T; Mogensen, CE; Os, I, 1997) |
| "The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM)." | 9.08 | Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. ( Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Van Nueten, L; Vertommen, C; Zoppi, A, 1997) |
| "A double-blind, randomised, parallel-group trial was conducted in patients with essential hypertension in British general practices, of nebivolol 5 mg, atenolol 50 mg, and placebo each given once daily." | 9.08 | Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. ( Robertson, JI; Taylor, FR; Van Nueten, L, 1998) |
| "In this multicenter, double-blind study, the antihypertensive efficacy and safety of irbesartan were compared with those of atenolol in patients with mild-to-moderate hypertension." | 9.08 | Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. ( Haworth, D; Hoglund, C; Kassler-Taub, K; Kerwin, L; Martin, A; Masson, C; Osbakken, M; Simon, T; Stumpe, KO, 1998) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 9.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "In this multicenter, double-blind, active-controlled, randomized, parallel-group comparison, 66 patients with mild-to-moderate hypertension (sitting diastolic blood pressure, SDBP, 95-114 mm Hg) and LV mass index > 102 g/m2 for males and > 88 g/m2 for females were randomized to an initial treatment with 50 mg of either mibefradil or atenolol for 4 weeks." | 9.08 | A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. ( Cifkova, R; Höglund, C; Lindberg, E; Mimran, A; Tenczer, J; Watt, A; Wilkins, MR, 1998) |
| "The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary hypertension." | 9.08 | Valsartan and atenolol in patients with severe essential hypertension. ( Botteri, F; Cifkova, R; Hradec, J; Oddou-Stock, P; Peleska, J; Pintérová, E; Rosolová, H; Thirlwell, J; Zeman, K, 1998) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 9.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension." | 9.08 | Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. ( Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA, 1998) |
| "The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)." | 9.08 | Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. ( Koch, B; Stimpel, M; Weber, MA, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 9.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "1 We have utilised a non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensation volume flow (ACVF), to assess the cardiovascular effects of amlodipine and atenolol over 3 months in 24 patients with essential hypertension." | 9.07 | Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. ( Guy, S; Herity, N; Silke, B; Tham, TC, 1993) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 9.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "The acute and short-term responses to bisoprolol and to atenolol on systemic and renal hemodynamics and on ambulatory blood pressure (BP) were compared in a randomized double-blind cross-over study including 14 patients with mild to moderate essential hypertension." | 9.07 | Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. ( Collart, F; Degaute, JP; Leeman, M; Mélot, C; Peeters, L; van de Borne, P; Vandenhoven, G, 1993) |
| " Sixteen sedentary patients with essential hypertension underwent a randomized, double-blind, cross-over study comparing atenolol and diltiazem sustained-release 300 mg, each administered during 6 weeks, after a 15-day run-in placebo period." | 9.07 | Cardiopulmonary response during exercise of a beta 1-selective beta-blocker (atenolol) and a calcium-channel blocker (diltiazem) in untrained subjects with hypertension. ( Baleynaud, S; Cohen-Solal, A; Gourgon, R; Laperche, T; Sebag, C, 1993) |
| " The aim of this study was to compare the safety and antihypertensive efficacy of 25 to 50 mg carvedilol once daily with 50 to 100 mg atenolol once daily in patients with mild to moderate essential hypertension." | 9.07 | Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. ( Ruilope, LM, 1994) |
| "This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)." | 9.07 | Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994) |
| "Fifty patients with mild to moderate essential hypertension were randomized to receive either 20 mg fosinopril daily for 16 weeks or placebo for 4 weeks followed by 12 weeks of 50 mg atenolol daily." | 9.07 | Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. ( Andersson, PE; Haenni, A; Lithell, H; Reneland, R, 1994) |
| " In the present study, the antihypertensive and negative chronotropic effects of 5 and 10 mg once-daily nebivolol were compared to those of 50 and 100 mg once-daily atenolol in 25 white, male subjects with essential hypertension, using a double-blind, crossover design, and a parallel placebo-treated group of subjects (N = 7)." | 9.07 | Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. ( Johnson, ML; Simon, G, 1993) |
| " The aim of this randomised, double-blind four way crossover study was to assess the interaction between the new calcium antagonist, lacidipine and atenolol, in patients with mild to moderate hypertension." | 9.07 | An assessment of lacidipine and atenolol in mild to moderate hypertension. ( Fowler, G; Hall, ST; Lyons, D; Petrie, JC; Webster, J, 1994) |
| "Atenolol and bisoprolol, two beta-1-selective blockers, were compared in patients with mild and medium severe hypertension." | 9.07 | [Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension]. ( Prásek, J; Soucek, M; Spinarová, L, 1993) |
| "5 mg and atenolol 50 mg (C-A) in adult black patients with mild to moderate hypertension (a resting supine diastolic blood pressure (DBP) between 95 and 115 mmHg after a two week placebo washout period)." | 9.07 | Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. ( Maharaj, B; van der Byl, K, 1993) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension." | 9.07 | Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. ( Doi, Y; Kagimoto, M; Kato, K; Kawasaki, K; Koga, S; Sakai, K; Sakaue, A; Sasaki, J; Takada, K; Takii, M, 1993) |
| "The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy." | 9.07 | Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993) |
| "The effects of six weeks of treatment with the selective peripheral alpha 1-adrenoceptor blocker terazosin, or the selective beta 1-adrenoceptor blocker atenolol on blood pressure, exercise performance and blood lipid profile were compared in a single-blind, randomized, crossover study of 17 patients with mild-to-moderate essential hypertension." | 9.07 | A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. ( Cleland, J; Coles, SJ; Humphreys, J; Ligueros, M; Unwin, R; Wilkins, MR, 1992) |
| "Terazosin is a selective alpha 1-adrenoceptor antagonist; its actions on the serum lipoprotein profile were compared with those of the cardioselective beta-adrenoceptor antagonist atenolol in 40 patients with mild to moderate hypertension." | 9.07 | Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension. ( Guy, S; Humphreys, JE; Silke, B, 1992) |
| " Perindopril's effectiveness in mild to moderate hypertension was evaluated in three studies." | 9.07 | Clinical efficacy of perindopril in hypertension. ( Anderson, A; Morgan, T, 1992) |
| "5 mg, 5 mg, or 10 mg) once daily was compared with atenolol (50 mg to 100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992) |
| "A 3-month double-blind multicenter trial compared the efficacy and safety of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor, with atenolol in mild-to-moderate essential hypertension." | 9.07 | Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. ( Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992) |
| "29 women with pregnancy induced hypertension in the third trimester, 13 randomised to atenolol and 16 to pindolol." | 9.07 | Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. ( Ingemarsson, I; Marsál, K; Montan, S; Sjöberg, NO, 1992) |
| "A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block." | 9.07 | Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992) |
| "The immediate and short-term (2 week) hemodynamic and humoral effects of the beta-1 antagonist, beta-2 agonist, celiprolol, were compared with those of more prolonged atenolol therapy in 12 patients with essential hypertension." | 9.07 | Hemodynamic effects of celiprolol in essential hypertension. ( Frohlich, ED; Kaesser, UR; Ketelhut, R; Losem, CJ; Messerli, FH, 1991) |
| "This was a double-blind multicenter study to compare the efficacy, tolerability and effects on the quality of life with isradipine and atenolol in the treatment of essential hypertension." | 9.07 | Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group. ( Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Kullman, S; Scherstén, B; Sivertsson, R; Sörensen, S, 1991) |
| "Carvedilol is a novel treatment for hypertension, having a balanced pharmacology of vasodilation and beta-receptor blockade." | 9.07 | A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. ( Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI, 1991) |
| "This study was designed to compare the antihypertensive efficacy of nitrendipine and atenolol in young and middle-aged patients with mild or moderate essential hypertension and to assess treatment effects on plasma lipids and potential changes in left ventricular mass (LVM)." | 9.07 | Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass. ( Arocha, I; Arreaza, MR; Barrios, YE; Corral, JL; Galué, GA; Giralt, J; López, NC; Rincón, LA, 1991) |
| "Six double-blind studies were designed to assess the efficacy, tolerance, and safety of the angiotensin-converting enzyme inhibitor ramipril in patients with mild-to-moderate essential hypertension." | 9.07 | Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis. ( Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C, 1991) |
| "This study assessed the effectiveness of atenolol in the treatment of moderate and severe hypertension during pregnancy." | 9.07 | Effectiveness of atenolol in the treatment of hypertension during pregnancy. ( Alvarez, L; Baglivo, HP; Cerrato, C; Drisaldi, S; Esper, RJ; Fabregues, G; Moschettoni, C; Pituelo, D; Varas Juri, P, 1992) |
| "The short-term effects of atenolol and nifedipine on plasma levels of atrial natriuretic peptide (ANP), plasma renin activity (PRA), and plasma aldosterone (PA) were studied in two groups of patients with uncomplicated essential hypertension." | 9.07 | Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. ( Bucci, V; Casale, R; Colantonio, D; Desiati, P; Giandomenico, G; Pasqualetti, P, 1991) |
| "The antihypertensive effects and safety profiles of lisinopril (10 to 40 mg) and atenolol (50 to 100 mg) were compared in a randomized, double-blind, parallel group trial in 144 patients with essential hypertension." | 9.07 | Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. ( Admani, K; Angell-James, JE; Beevers, DG; Blackwood, RA; Feely, M; Garnham, S; Husaini, MH; Kumar, S; Mehrzad, AA; Watson, M, 1991) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 9.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 125 patients (116 of whom had not previously used antihypertensive drugs) with a five times elevated diastolic pressure (DP) of between 95 and 130 mmHg were randomized and treated daily either with atenolol 50 mg o." | 9.07 | Captopril compared to atenolol in mild to moderate hypertension in a randomized double-blind controlled trial. ( Havinga, TK; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1991) |
| "Various aspects of carbohydrate and lipid metabolism have been studied in two groups of patients with mild hypertension before and after four months of treatment with either nifedipine (n = 12) or atenolol (n = 12)." | 9.07 | Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. ( Chen, YD; Hoffman, B; Reaven, GM; Sheu, WH; Swislocki, AL, 1991) |
| "In 15 patients with mild to moderate essential hypertension, the effects of diltiazem (120 mg twice daily) were compared with those of atenolol (50 mg once daily), the two drugs in combination, and placebo in a randomized double-blind cross-over study with treatment phases of 4 weeks duration." | 9.06 | Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. ( Bune, AJ; Cain, MD; Chalmers, J; Morris, MJ; Russell, AE; Tonkin, AL; West, MJ; Wing, LM, 1990) |
| "Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension." | 9.06 | Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. ( Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990) |
| "The efficacy and tolerability of doxazosin and atenolol in the management of mild and moderate hypertension were compared in a multicentre, parallel study, the first year of which was randomized and double-blind." | 9.06 | A long-term study of atenolol and doxazosin in mild and moderate hypertension. ( Daae, L; Talseth, T; Westlie, L, 1990) |
| " The influence of long-acting propranolol and of atenolol on the circadian rhythm of heart rate was assessed using 24 h electrocardiographic recordings in elderly patients with essential hypertension." | 9.06 | Influences of propranolol and atenolol on the circadian rhythm of heart rate in elderly patients with essential hypertension. ( Sakata, S; Shimamoto, H; Shimamoto, Y, 1990) |
| "In a double-blind study with parallel groups, the clinical bioequivalence of the antihypertensive effect of metoprolol CR/ZOK (controlled release formulation) 50 mg and atenolol 50 mg in ordinary tablets given once daily for uncomplicated hypertension was investigated." | 9.06 | A double-blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension. ( Berger, J; Klein, G; Menzel, T; Olsson, G, 1990) |
| " The aim of the study was to compare the efficacy and the tolerability of treatment with atenolol (50-100 mg once daily), nitrendipine (20-40 mg once daily) and their combination (atenolol 50 mg + nitrendipine 20 mg) once daily in patients with mild to moderate essential hypertension." | 9.06 | Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. ( Coulson, RR; Fitzsimons, TJ; Irvine, N; Lewis, R; Maclean, D; McDevitt, DG; McEwen, J; McLay, JS; Mitchell, ET; Slater, ND, 1990) |
| "The study objective was to determine the effects of monotherapy with clonidine and atenolol versus placebo on serum lipids, apolipoproteins, and blood pressure in patients with mild primary hypertension." | 9.06 | The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. ( Bradley, CA; Burger, C; Hays, JT; Houston, MC; Nadeau, J; Olafsson, L; Swift, L, 1990) |
| "The effect of enalapril was evaluated in 67 patients with essential hypertension, and its therapeutic efficacy was compared with atenolol in a placebo run-in, single-blind, cross-over trial." | 9.06 | Efficacy of enalapril in essential hypertension and its comparison with atenolol. ( Basha, A; Bolya, YK; el Mangoush, M; Gamati, A; Gupta, BS; Kumar, S; Singh, NK, 1990) |
| "To determine the effect of atenolol on the outcome of pregnancy in women with essential hypertension." | 9.06 | Atenolol in essential hypertension during pregnancy. ( Butters, L; Kennedy, S; Rubin, PC, 1990) |
| "A multicentre randomised double-blind trial was performed in order to compare the therapeutic efficacy and acceptability of the angiotensin converting enzyme (ACE) inhibitor perindopril with those of atenolol in mild to moderate hypertension." | 9.06 | A double blind comparison of perindopril and atenolol in essential hypertension. ( Brown, CL; Creytens, G; Mimran, A; Rorive, G; Santoni, JP; Thurston, H; Zanchetti, A, 1990) |
| "Forty-one elderly patients with mild to moderate hypertension (resting diastolic blood pressure 100-130 mmHg after an eight week placebo run-in phase) were randomised to a double-blind parallel group comparison of nifedipine retard 10 mg twice daily or atenolol 50 mg once daily." | 9.06 | Comparative trial of nifedipine retard and atenolol in the treatment of elderly patients with mild to moderate hypertension. ( Clamp, M; Holmes, B; Wilcox, R, 1990) |
| "We studied the effect of phenylpropanolamine on blood pressures in seven patients whose hypertension was controlled with beta blockers." | 9.06 | The effect of single-dose phenylpropanolamine on blood pressure in patients with hypertension controlled by beta blockers. ( Gross, CR; O'Connell, MB, 1990) |
| "A new non-imaging echo-Doppler cardiac output device that works on the principle of attenuated compensation volume flow (ACVF), has been used to assess the cardiovascular effects of atenolol and dilevalol in 24 patients with essential hypertension." | 9.06 | Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension. ( Silke, B; Taylor, SH; Tham, TC, 1990) |
| " In two, randomized, placebo-controlled, 5-way crossover trials, the pulmonary effects of celiprolol 200 and 400 mg, propranolol 40 mg and atenolol 100 mg were compared in 34 asthmatic patients." | 9.06 | Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. ( Applin, WJ; Brown, R; Caruso, FS; Doshan, HD; Rosenthal, RR; Slutsky, A, 1986) |
| "The antihypertensive effects of equivalent beta-blocking doses of atenolol and celiprolol were compared in 55 patients with mild to moderate hypertension." | 9.06 | A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension. ( Rosenthal, F; Silke, B; Taylor, S, 1986) |
| "In a multicenter, parallel, double-blind study, lisinopril was compared with atenolol in the treatment of mild to moderate essential hypertension." | 9.06 | The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. ( Arriaga, J; Bernal, R; Bernardes, H; Bolzano, K; Calderon, JL; Debruyn, J; Dienstl, F; Drayer, J; Goodfriend, TL; Gross, W, 1987) |
| "The antihypertensive effect and safety of doxazosin once-daily was compared with that of atenolol once-daily in 40 patients with mild to moderate hypertension." | 9.06 | Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1988) |
| "Once-daily administration of amlodipine, a long-acting dihydropyridine calcium-channel blocker, and atenolol, a cardioselective beta-adrenoceptor blocking agent, were compared in patients with mild to moderate hypertension in a multicenter placebo-controlled trial." | 9.06 | Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. ( Cocco, G; de Bruijn, B; Tyler, HM, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with placebo and atenolol in 125 patients with mild to moderate systemic hypertension [supine diastolic blood pressure (DBP) 90-114 mm Hg]." | 9.06 | A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1988) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 9.06 | Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Lissens, W; Staessen, J, 1989) |
| "The effects of once-daily therapy with doxazosin (1 to 8 mg/day) on exercise capacity, left ventricular performance and hemodynamics (radionuclide ventriculography) were compared with those of atenolol (50 to 100 mg/day) and placebo in a randomized, double-blind crossover trial in 16 patients (9 men) with mild hypertension." | 9.06 | Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function. ( Bautovich, GJ; Fletcher, PJ; Gillin, AG; Horvath, JS; Hutton, BF; Tiller, DJ, 1989) |
| "A total of 152 patients with essential hypertension (World Health Organization classification I/II) entered a multicenter randomized study to assess the safety and efficacy of isradipine compared with, and in combination with, the beta-blocker atenolol." | 9.06 | A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group. ( , 1989) |
| "We compared the effects of transdermal clonidine and oral atenolol on acute exercise performance and on conditioning response to an 8-week program of regular aerobic exercise in young, otherwise healthy subjects with mild hypertension." | 9.06 | Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension. ( Davidman, M; Davies, SF; Graif, JL; Husebye, DG; Iber, C; Maddy, MM; McArthur, CD; O'Connell, MB; Path, MJ, 1989) |
| "The effects of two cardioselective beta-adrenergic blocking agents--celiprolol (claimed to have bronchodilator properties) and atenolol (without such claims)--on respiratory function and control of asthma were studied in ten asthmatic patients with mild to moderate essential hypertension." | 9.06 | Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. ( Bateman, ED; Jennings, AA; Opie, LH; van Zyl, AI, 1989) |
| "Fifty milligrams of carvedilol and 100 mg atenolol were administered in a random order once a day for 2 months to 43 patients with mild to moderate hypertension, in a double-blind crossover study." | 9.06 | Carvedilol and atenolol once daily in the treatment of hypertension. ( Härkönen, R; Hilden, M; Icen, R; Kohvakka, A; Linna, M; Lukkala, K; Luurila, OJ; Sillanpää, J; Vänskä, O, 1989) |
| "In a double-blind, randomized, cross-over study in 23 diabetic patients, insulin treated (N = 11) or noninsulin treated (N = 12), with mild to moderate hypertension, the hypotensive effects of captopril and atenolol were compared." | 9.06 | A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. ( de Nobel, E; Elving, LD; Thien, T; van Lier, HJ, 1989) |
| "The antihypertensive effects of nisoldipine, a calcium channel blocker, and atenolol, a beta-adrenergic blocker, were compared in patients with mild or moderate essential hypertension." | 9.06 | Comparison of nisoldipine and atenolol in the treatment of essential hypertension. ( Fukuyama, M; Okabayashi, H; Takahashi, H; Yoneda, S; Yoshimura, M, 1989) |
| "Sixty patients, with mild to moderate essential hypertension, were considered for a double-blind trial comparing the effects of ketanserin and atenolol." | 9.06 | A double-blind comparative study of ketanserin with atenolol in essential hypertension. ( Andreoni, A; Antonicelli, R; Gambini, C; Paciaroni, E; Saccomanno, G, 1989) |
| "In an international, randomized, double-blind trial involving 229 patients, 400 mg of bevantolol was compared with 100 mg of atenolol (both in single daily doses) in the management of mild to moderate hypertension (diastolic blood pressure [BP] 95 to 115 mm Hg after a 4-week placebo washout period)." | 9.06 | Comparison of bevantolol and atenolol for systemic hypertension. ( Fairhurst, GJ, 1986) |
| "In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month." | 9.06 | Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. ( Breckenridge, A; McLoughlin, GA; Roberts, DH; Tsao, Y, 1987) |
| "Sixteen patients with mild to moderate hypertension were randomized to receive either atenolol 100 mg a day (group A: 2 females, 6 males, mean age 42." | 9.06 | [Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Herpin, D, 1987) |
| "A randomised double blind parallel group study was performed to compare the efficacy and acceptability of slow release nifedipine (maximum dose 40 mg twice a day) with those of atenolol (maximum dose 100 mg once a day) as single agents for the treatment of essential hypertension." | 9.06 | Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. ( , 1988) |
| "0, range 37-61 years; eight females) with mild essential hypertension (DBP greater than 90 mm Hg on placebo) completed a randomised, double-blind placebo controlled crossover study comparing the hypotensive effects of bisoprolol (10-20 mg) and atenolol (50-100 mg) each taken once daily." | 9.06 | A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ( Ioannides, C; Johnston, A; Lewis, R; Maclean, D; McDevitt, DG, 1988) |
| "Patients with moderate to severe essential hypertension (mean untreated supine blood pressure 190/112 mm Hg) received once daily enalapril 20-40 mg or atenolol 50-100 mg, supplemented if required by hydrochlorothiazide 25-100 mg, in a randomized observer-blind trial." | 9.06 | Enalapril in moderate to severe hypertension: a comparison with atenolol. ( Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986) |
| "The effects of lisinopril (MK-521; MSD) and atenolol in the treatment of mild-to-moderate essential hypertension were compared in a double-blind, parallel, controlled study, with 24 patients randomly assigned to lisinopril and 12 to atenolol." | 9.06 | A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension. ( Parag, KB; Seedat, YK, 1987) |
| "The aim of the present double-blind crossover study was to compare the antihypertensive efficacy and tolerability of enalapril and atenolol in 48 patients with mild to moderate essential hypertension." | 9.06 | Enalapril as a first-step agent in essential hypertension: a comparative study with atenolol. ( Edmonds, D; Greminger, P; Knorr, M; Locher, R; Vetter, H; Vetter, W, 1986) |
| "In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic)." | 9.06 | Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. ( Curry, RC; Schwartz, KM; Urban, PL, 1988) |
| "The anti-hypertensive and tolerance of penbutolol, a non-selective beta-blocker of long duration and endowed with an ISA effect were compared with those of atenolol, a cardioselective beta-blocker without ISA effect, in two groups of 20 patients each suffering from slight-to-moderate essential primary hypertension selected on the basis of a clinico-experimental design of open randomised type." | 9.06 | [Treatment of essential mild-to-moderate arterial hypertension with once-daily penbutolol. Controlled clinical study vs atenolol]. ( Bianchini, C; Gennari, C; Martinelli, M; Nami, R, 1988) |
| "The efficacy, tolerance and effect on serum lipids of acebutolol were compared with those of atenolol over a 6-month period in a large group of patients with mild arterial hypertension." | 9.06 | Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension. ( De Backer, G, 1988) |
| "The safety and efficacy of once-daily terazosin hydrochloride administered concomitantly with once-daily atenolol for the treatment of essential hypertension were evaluated in this double-blind, multiclinic, placebo-controlled study." | 9.06 | Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. ( Holtzman, JL; Kaihlanen, PM; Lewin, AJ; Oberlin, JA; Rider, JA; Spindler, JS, 1988) |
| "In this randomised, double-blind, crossover trial, the efficacy in hypertension of atenolol and nifedipine as single agents or in combination was compared." | 9.06 | Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study. ( Anderton, JL; Crowe, PF; Mittra, B; Perks, WH; Stanley, NN; Vallance, BD, 1988) |
| "This randomised, double-blind, crossover study investigated the haemodynamic effects of a beta-blocker (atenolol 50mg) and a calcium antagonist (sustained release nifedipine 20mg) given either separately or in combination in 3 groups of patients with mild to moderate essential hypertension." | 9.06 | Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension. ( Heath, ID; Larkin, H; Stanley, NN; Thirkettle, JL; Varma, MP, 1988) |
| "A randomized, double-blind study was undertaken to compare atenolol and captopril as second-step agents in the treatment of essential hypertension resistant to 5 mg bendrofluazide daily." | 9.06 | Comparative efficacy of captopril and atenolol in moderately severe essential hypertension. ( Blake, S; Carey, M, 1986) |
| "The effects of prazosin and atenolol monotherapy on plasma lipid concentrations were compared in 51 patients with mild to moderate essential hypertension." | 9.06 | Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension. ( Lowenstein, J; Neusy, AJ, 1986) |
| "Three therapies were used to treat 35 patients with mild to moderate systemic hypertension: (1) the cardioselective beta-adrenoceptor blocker atenolol, (2) the calcium antagonist nifedipine and (3) combination therapy for those who failed to reach the target diastolic blood pressure (BP) of less than 90 mm Hg with monotherapy." | 9.06 | Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone. ( Daniels, AR; Opie, LH, 1986) |
| "After a run-in period on placebo, 26 patients with essential hypertension were prescribed single-blind tibalosine, 150 mg daily." | 9.06 | Chronic treatment with tibalosine in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; M'Buyamba-Kabangu, JR; Staessen, J, 1986) |
| "The effects of graded doses of verapamil were compared with those of a combination of atenolol and hydralazine in a double-blind, randomised, crossover trial in 16 patients with essential hypertension." | 9.06 | Verapamil in essential hypertension: a comparison with atenolol plus hydralazine. ( Bailey, BP; Duggin, GG; Fletcher, PJ; Hall, B; Horvath, JS; Tiller, D, 1987) |
| "The efficacy and tolerability of the new ACE-inhibitor enalapril (MK 421) and the beta 1-selective adrenoceptor blocker atenolol for the treatment of primary hypertension were compared in a double blind parallel study." | 9.05 | Enalapril and atenolol in primary hypertension--a comparative study of blood pressure lowering and hormonal effects. ( Karlberg, BE; Ohman, KP, 1984) |
| "Twenty-five patients with moderate essential hypertension (standing diastolic blood pressure 100-125 mmHg, phase 5) completed a single-blind placebo-controlled cross-over study comparing four week periods of treatment with atenolol 100 mg, metoprolol 100 mg, metoprolol durules 200 mg, slow-release oxprenolol 160 mg, and slow-release oxprenolol 320 mg respectively." | 9.05 | Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. ( Hampton, JR; Wilcox, RG, 1981) |
| "1 The effects of 4 week treatment periods of once-daily atenolol 100 mg, nadolol 80 mg, nadolol 160 mg and placebo on resting and exercise heart rate and blood pressure were compared in a single-blind crossover trial in fifteen patients with essential hypertension." | 9.05 | Comparison between atenolol and nadolol in essential hypertension at rest and on exercise. ( Hampton, JR; Wilcox, RG, 1982) |
| "Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest." | 9.05 | Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. ( Butters, L; Clark, DM; Low, RA; Reid, JL; Reynolds, B; Rubin, PC; Steedman, D; Sumner, DJ, 1983) |
| "The efficacy of once-daily bopindolol, a nonselective beta-adrenoceptor blocking agent with partial agonist activity, and of pindolol and atenolol in the treatment of essential hypertension has been compared." | 9.05 | Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. ( Gugler, R; Schiess, W; Welzel, D, 1984) |
| "Atenolol 100 mg once daily and metoprolol SA 200 mg once daily were compared in 20 patients with mild to moderate hypertension, in a randomised, double-blind cross-over trial." | 9.05 | A comparison of once daily atenolol and metoprolol SA in mild to moderate hypertension. ( Cavalcanti, C; Morley, CA; Perrins, EJ; Sutton, R, 1983) |
| "The relationship between the oral dosage and plasma concentration of the long-acting cardioselective beta-adrenoceptor blocker atenolol and the antihypertensive response to the the degree of beta-adrenoceptor blockade and change in plasma renin activity (PRA) was evaluated in patients with mild-to-moderate essential hypertension in a double-blind, randomized, between-patient, dose-ranging (25, 50 or 100 mg once daily for 4 weeks) study." | 9.05 | A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. ( Ishizaki, T; Nakaya, H; Oyama, Y; Sasaki, T; Sato, T; Shibuya, T; Suganuma, T, 1983) |
| "Fifteen out-patients with moderate hypertension were randomly and sequentially treated with atenolol, indapamide and a combination of the two drugs after a wash-out period of at least 1 week and a 2-week placebo run-in period." | 9.05 | Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study. ( De Divitiis, O; Di Somma, S; Fazio, S; Ligouri, V; Petitto, M, 1983) |
| "Twenty-five patients with essential hypertension were randomly assigned to treatment with either captopril or atenolol." | 9.05 | Captopril or atenolol in essential hypertension. ( Andrén, L; Hansson, L; Svensson, A, 1983) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 119 patients with a diastolic pressure (DP) between 95 and 120 mmHg were randomised and treated either with 50 mg hydrochlorothiazide (n = 59) or 100 mg atenolol (n = 60)." | 9.05 | Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1984) |
| "The obstetric implications of the use of the beta-adrenoceptor antagonist atenolol have been evaluated in a prospective, randomized, double-blind, and placebo-controlled study involving 120 women with pregnancy-associated hypertension." | 9.05 | Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. ( Belfield, A; Butters, L; Clark, D; Low, RA; Pledger, D; Reid, JL; Rubin, PC; Sumner, D, 1984) |
| "A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension." | 9.05 | A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients. ( Born, A; Emanueli, A; Lavezzari, M, 1984) |
| "We describe the results of a prospective study in which 120 women who developed hypertension in the last trimester of pregnancy were randomly allocated in double blind manner to atenolol or placebo." | 9.05 | First year of life after the use of atenolol in pregnancy associated hypertension. ( Adams, T; Butters, L; Evans, J; Reynolds, B; Rubin, PC, 1984) |
| "A double-blind, crossover comparison of once-daily acebutolol (400 mg) and once-daily atenolol (100 mg) was carried out in 33 patients with mild to moderate essential hypertension." | 9.05 | Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension. ( Brocklehurst, JC; Turner, AS, 1983) |
| "In 19 men aged 50 with essential hypertension, 18 weeks' treatment with atenolol (n = 9) or oxprenolol (n = 10) increased supine plasma free dopamine concentrations by 78% (p less than 0." | 9.05 | Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension. ( Aakesson, I; Amundsen, R; Eide, I; Eriksen, IL; Kjeldsen, SE; Leren, P, 1983) |
| "1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol." | 9.05 | Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. ( Andrén, L; Asplund, J; Hansson, L; Karlberg, B; Ohman, P; Svensson, A, 1982) |
| "Thirty-two patients with primary hypertension were studied in a double-blind cross-over comparison between the cardioselective beta 1-blocking agent atenolol and the combined alpha- and beta-blocking agent labetalol." | 9.05 | Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension. ( Henningsen, NC; Karlberg, BE; Nilsson, OR; Thulin, T, 1982) |
| "The effect of once-daily dosage of the two most widely prescribed cardioselective beta-adrenoceptor antagonists used to treat hypertension--namely, atenolol and metoprolol--was studied in nine carefully selected hypertensive outpatients." | 9.05 | Atenolol and metoprolol once daily in hypertension. ( Hawksworth, GM; Lovell, HG; Petrie, JC; Rigby, JW; Scott, AK; Webster, J, 1982) |
| "1 The effects of atenolol (100 mg), a cardioselective beta-adrenoceptor blocking agent, and labetalol (300 mg), a combined alpha- and non-selective beta-adrenoceptor blocking agent given in single doses were examined in a double-blind placebo controlled study in 11 asthmatic patients with hypertension." | 9.05 | Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. ( Beevers, DG; Jackson, SH, 1983) |
| "1 The effects of propranolol and atenolol given in random order in a cross-over study to fifteen patients with essential hypertension have been studied." | 9.05 | A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. ( Harry, JD; Hawkins, T; Kerr, DN; Pickering, M; Robson, V; Stevens, IM; Wilkinson, R, 1980) |
| "Twenty-four black patients (Zulus) with hypertension participated in a double-blind, placebo-controlled cross-over trial of the efficacy of a beta-blocking agent (atenolol) 100 mg once daily as compared with chlorthalidone 25 mg once daily." | 9.05 | Trial of atenolol and chlorthalidone for hypertension in black South Africans. ( Seedat, YK, 1980) |
| "Atenolol, Pindolol and Propranolol in single daily doses administered to 18 selected patients with mild essential hypertension achieved adequate control of blood pressure." | 9.05 | Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol. ( England, JD, 1981) |
| "Atenolol 100 mg and penbutolol 40 mg given once a day were both effective in controlling moderate hypertension, as judged by a randomised controlled, double-blind trial in 45 patients treated for six weeks." | 9.05 | Use of fixed doses of beta blocking drugs in the treatment of hypertension. Randomised study of atenolol and penbutolol. ( Chadha, DR; Houtzagers, JJ; Lameijer, LD; Voermans, LA, 1981) |
| "1 In an open, randomized cross-over investigation of thirteen patients (nine and four women, aged 37-67 years) with mild or moderate essential hypertension a comparison between atenolol and metoprolol was carried out in order to study the effects of 50, 100 and 200 mg given once daily on blood pressure and heart rate at rest and during exercise." | 9.05 | A comparative study of atenolol and metoprolol in the treatment of hypertension. ( Arnung, K; Eskildsen, PC; Nielsen, PE; Rasmussen, S, 1981) |
| "This open randomised parallel trial compared the antihypertensive efficacy of enalapril and atenolol given alone once a day or with hydrochlorothiazide in 20 patients with moderate to severe hypertension." | 9.05 | Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension. ( Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 9.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "Fifty patients with mild or moderate essential hypertension were randomized (double-blindly) to treatment with either captopril (n = 26) or atenolol (n = 24)." | 9.05 | Long-term effects of captopril and atenolol in essential hypertension. ( Andrén, L; Hansson, L; Karlberg, BE; Nilsson, OR; Ohman, P; Svensson, A, 1985) |
| "In a 12-week double-blind randomised study the efficacy of atenolol and a new longer-acting formulation of trimazosin were compared when given once daily in patients with mild to moderate hypertension." | 9.05 | A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension. ( Hutcheson, MJ; Lorimer, AR; Murray, GD; Robertson, JI; Robertson, MP; Webb, DJ, 1985) |
| "The treatments of mild hypertension with atenolol and prazosin in occupationally active men and women were compared in a double blind cross-over with placebo." | 9.05 | Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication. ( Green, KA; Lange Andersen, K; Ottmann, W; Piatkowski, W, 1985) |
| "After screening two local populations in the northern part of The Netherlands for hypertension, patients with a diastolic pressure (DP) between 95 and 120 mmHg were treated daily either with 50 mg hydrochlorothiazide or 100 mg atenolol." | 9.05 | A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "Acebutolol was compared to atenolol in 33 patients with mild to moderate essential hypertension (diastolic blood pressure greater than 95 mm Hg) with the use of a double-blind crossover study design." | 9.05 | Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison. ( Brocklehurst, JC; Napier, RN; Turner, AS, 1985) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 59 patients with a diastolic pressure (DP) between 95 and 130 mmHg were randomized and treated either with 50 mg atenolol (n = 29) or 100 mg atenolol (n = 30) for 1 month." | 9.05 | Comparison of atenolol 50 mg and 100 mg as initial treatment in uncomplicated mild to moderate hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "The object of this study was to establish whether cardioselectivity of atenolol confers any advantage over noncardioselective beta-blockade in the treatment of hypertension." | 9.04 | Atenolol and three nonselective beta-blockers in hypertension. ( Waal-Manning, HJ, 1979) |
| "The antihypertensive effect of atenolol, a new beta-1-receptor blocking agent, was studied in a double-blind trial in which 45 patients with essential hypertension were randomly assigned to placebo or atenolol treatment." | 9.04 | Controlled study of atenolol in treatment of hypertension. ( Aberg, H; Hansson, L; Karlberg, BE; Westerlund, A, 1975) |
| "1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction." | 9.04 | Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. ( Chatterjee, SS; Croxson, RS; Cruickshank, JM; Perks, WH, 1978) |
| "A double-blind, crossover, multicentre study of 98 previously untreated patients with mild to moderate essential hypertension was carried out in general practice to assess the effect of 50 mg, 100 mg, and 200 mg atenolol, given once daily, compared with that of placebo over a period of 4 weeks each." | 9.04 | A dose-response study of atenolol in mild to moderate hypertension in general practice. ( Barmer, NP; Gostick, NK; Ingram, DF; Mayhew, SR; Million, R; Sagar, D; Suxena, SR, 1977) |
| "A double-blind crossover trial was completed in 15 patients with moderate hypertension and the effects of propranolol (Inderal) 80 mg twice a day and atenolol (Tenormin) 100 mg twice a day were assessed on blood pressure, pulse rate and plasma renin activity (PRA), while patients were maintained on 1 cyclopenthiazide tablet (Navidrex K) per day." | 9.04 | Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension. ( Epstein, SE; LUbbe, WF, 1977) |
| "The antihypertensive effect of atenolol, a new beta 1 receptor blocking agent, was studied in a double blind non cross-over trial in 40 patients (pts) affected by mild to moderately severe essential hypertension with normal plasma renin activity." | 9.04 | [Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)]. ( Bonaduce, D; Chiariello, M; Condorelli, M; Ferrara, N; Petretta, M; Rengo, F; Trimarco, B, 1978) |
| "The antihypertensive effect of atenolol, with and without chlorthalidone, on hypertension was assessed in an outpatient as well as in an inpatient study." | 9.04 | Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Teeuw, AH, 1979) |
| "Twenty-seven patients with mild to moderate arterial hypertension were treated "double-blind" with either atenolol of oxprenolol." | 9.04 | Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison. ( Brocklehurst, JE; Turner, AS; Watson, OF, 1979) |
| "The antihypertensive effect on the selective beta-1-adrenoceptor blocking agent, atenolol, given in doses of 100 and 200 mg once daily, was evaluated in 37 patients with primary hypertension." | 9.04 | Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. ( Karlberg, BE; Nilsson, OR; Ohlsson, O; Thulin, T; Tolagen, K, 1979) |
| "Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily." | 9.04 | Once-daily dosing with Atenolol in patients with mild or moderate hypertension. ( Cruickshank, JM; Douglas-Jones, AP, 1976) |
| "The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been investigated." | 9.04 | Atenolol in essential hypertension. ( Dollery, CT; Lewis, GR; Myers, MG; Steiner, J, 1976) |
| " The beta1-adrenoreceptor-blocking agent atenolol was studied in the treatment of twelve out-patients with essential hypertension." | 9.04 | Clinical and haemodynamic study of atenolol (Tenormin) in essential hypertension. ( Jensen, HA; Mosbaek, N; Rasmussen, K, 1976) |
| " Twenty-one hypertension trials with data on 145,811 participants were identified: 15 used atenolol, 7 were placebo-controlled trials, and 14 were active comparator trials." | 8.90 | Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. ( Khan, NA; Kuyper, LM, 2014) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 8.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "Nifedipine, as most calcium-antagonist drugs, is widely used for the treatment of angina pectoris and primary hypertension." | 8.80 | [Edema and skin ulcers of the lower limbs as a collateral effect of nifedipine. A clinical case report]. ( Luca, S; Romeo, S, 1999) |
| "Nifedipine and atenolol are first choice drugs in the treatment of arterial hypertension and angina pectoris." | 8.78 | [Pharmacology and clinical use of a fixed combination of nifedipine and slow release atenolol (Niften) in the treatment of arterial hypertension and angina pectoris]. ( Verdecchia, P, 1993) |
| "Genome-wide association analysis of BP response to atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension in the pharmacogenomic evaluation of antihypertensive responses study." | 7.81 | PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Curry, RW; Donner, KM; El Rouby, N; Gong, Y; Gums, JG; Hall, K; Hiltunen, TP; Johnson, JA; Kontula, KK; Kubo, M; Langaee, TY; McDonough, CW; O'Connell, JR; Padmanabhan, S; Pepine, CJ; Schmidt, SO; Takahashi, A; Tanaka, T; Turner, ST, 2015) |
| " We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension." | 7.79 | Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. ( Birnbaum, Y; Castillo, AC; Chen, X; Ling, S; Long, B; Perez-Polo, JR; Qian, J; Thomas, B; Ye, H; Ye, Y, 2013) |
| "Metabolic syndrome patients with hypertension (n=28) and a control group (n=20) were given atenolol (50 mg/day) for 4 weeks." | 7.77 | The enhanced effect of atenolol on hypertension in metabolic syndrome. ( Satou, Y; Ueno, N, 2011) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 7.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "beta-Adrenergic blockers, particularly atenolol, are often recommended for the tachycardia and hypertension that accompany hyperthyroidism; however, the effects of monotherapy with atenolol on both systolic blood pressure (SBP) and heart rate (HR) have not been reported." | 7.74 | Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats. ( Dolson, MK; Henik, RA; Stepien, RL; Wenholz, LJ, 2008) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 7.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "The salivary activity in pups of spontaneously hypertensive rats (SHR) and Wistar (W) rats treated with atenolol during pregnancy, and lactation was evaluated." | 7.74 | Atenolol reduces salivary activity in pups of spontaneously hypertensive and normotensive rats treated during pregnancy and lactation. ( Antoniali, C; Delbem, AC; Elias, GP; Sassaki, KT, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 7.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 7.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "To describe a case of atenolol-induced breast pain and swelling in a patient receiving atenolol." | 7.73 | Atenolol-induced breast pain in a woman with hypertension. ( Kelleher, JA, 2006) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system." | 7.72 | Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective. ( Burnier, M; Erne, P; Szucs, TD, 2004) |
| "To investigate the possible harmful effects of early antihypertensive drug therapy with atenolol versus other therapies on pregnancy outcome, we reviewed the records of 398 women referred to our antenatal hypertension clinic between 1980 and 1995." | 7.69 | Effect of atenolol on birth weight. ( Beevers, DG; Beevers, M; Churchill, D; Lip, GY; Shaffer, LM, 1997) |
| "The antihypertensive and hemodynamic effects of lisinopril and atenolol were evaluated in 21 patients with mild-to-moderate essential hypertension." | 7.68 | Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications. ( Boucher, CA; Christensen, DM; Higgins, J; Zusman, RM, 1992) |
| "A study was made of the influence of atenolol on the sinocarotid and cardiopulmonary baroreceptor reflexes (BR) in patients with essential hypertension." | 7.68 | [The relationship between the effect of atenolol on the baroreceptor reflex and its hypotensive action in hypertension patients]. ( Tsyrlin, VA; Zverev, OG, 1991) |
| " Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension." | 7.68 | Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990) |
| "In this study the clinical, biological, radiologic, electrocardiographic, and hormonal characteristics of 80 patients with slight or moderate essential arterial hypertension in whom the treatment with atenolol alone or associated with chlorthalidone or with a third agent normalized the arterial pressure during a period of one year, are revised." | 7.68 | [The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension]. ( Aguilera, MT; Coca, A; de la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 7.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "The hemodynamic effects of nitrendipine have been studied at rest and during exercise in eight patients with mild to moderate essential hypertension." | 7.67 | Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension. ( Detry, JM; Lavenne, F; Melin, JA; Nannan, ME; Vanbutsele, RJ, 1984) |
| "Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months." | 7.67 | Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984) |
| " Therefore, M-mode and Doppler techniques were used to assess changes in LV hypertrophy after 10, 30 and 50 weeks of atenolol therapy (50 or 100 mg once daily) in 19 patients with essential hypertension." | 7.67 | Effects of atenolol on left ventricular hypertrophy and early left ventricular function in essential hypertension. ( Allen, JW; Kaiser, PJ; Montenegro, A, 1989) |
| "In 13 patients, affected by hypertrophic obstructive cardiomyopathy (HOCM) and essential hypertension, antihypertensive-efficacy and effects of a new calcium-channel blocker (gallopamil) associated with a diuretic agent (chlorthalidone) on left ventricular systolic and diastolic performance assessed by phonocardiographic methods." | 7.67 | [Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle ( Brandini, V; Chieppa, S; De Simone, R; Giuliani, F; Iarussi, D; Langella, S; Lobascio, C, 1989) |
| "In 16 patients with essential hypertension the effects of enalapril 20 mg once daily were compared with those of atenolol 50 mg once daily, with the two drugs in combination and with placebo using a double-blind cross-over design with allocation of treatment order by randomised Latin squares." | 7.67 | Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. ( Bune, AJ; Cain, MD; Chalmers, JP; Morris, MJ; Russell, AE; Southgate, DO; West, MJ; Wing, LM, 1988) |
| "Slow-release nifedipine has been used in the treatment of severe hypertension in 23 pregnant women." | 7.67 | Nifedipine as a second line antihypertensive drug in pregnancy. ( Beevers, DG; Constantine, G; Luesley, DM; Reynolds, AL, 1987) |
| "Nifedipine has been used in the management of hypertension in 36 consecutive patients who could not tolerate, or were not controlled by, atenolol and thiazide diuretics." | 7.67 | Use of nifedipine as the drug of third choice in management of hypertension. ( Muir, AL; Roulston, JE; Wathen, CG, 1986) |
| "Fetal circulation was studied by means of combined real-time and pulsed Doppler ultrasound in 14 women with pregnancy-associated hypertension before and during the first and third days of treatment with the beta 1-selective blocker, atenolol; in seven of the women the maternal uterine arcuate blood velocity waveform was also studied." | 7.67 | Fetal and uteroplacental haemodynamics during short-term atenolol treatment of hypertension in pregnancy. ( Liedholm, H; Lingman, G; Marsál, K; Montan, S; Sjöberg, NO; Solum, T, 1987) |
| "Short-term treatment with 1-(p-carbamoyl-methylphenoxy)-3-isopropylamino)-2-propanol (atenolol, Tenormin) (100 mg/d for 5 days) was conducted in 12 patients with labile essential hypertension." | 7.67 | Mechanism of antihypertensive effect of atenolol in patients with borderline hypertension during short-term treatment. A comprehensive study. ( Abe, K; Imai, Y; Kasai, Y; Nihei, M; Omata, K; Sasaki, S; Sato, K; Sato, M; Sekino, H; Yoshinaga, K, 1986) |
| "Minoxidil was given to 16 men with hypertension of various degrees of severity, in conjunction with a diuretic and atenolol." | 7.67 | Once-a-day triple therapy with low-dose minoxidil for moderate hypertension. ( Boner, G; Johnsen, AM; McDonald, RH; Rosenfeld, JB; Shapiro, AP; Traub, YM, 1986) |
| "Hemodynamic (systemic and regional), metabolic and cardiovascular reflexive variables were measured before and after 4 weeks of beta blockade with atenolol in 10 patients with mild essential hypertension." | 7.66 | Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. ( Dreslinski, GR; Dunn, FG; Frohlich, ED; Messerli, FH; Reisin, E; Suarez, DH, 1982) |
| "The urinary excretion of prostaglandins (PG) E2 and F2 alpha was measured by radioimmunoassay in 15 patients with essential hypertension, before and after 2 and 4 weeks of treatment with the selective beta 1-adrenergic blocker, atenolol." | 7.66 | Effect of atenolol treatment on urinary prostaglandins E2 and F2 alpha in essential hypertension. ( Bernheim, J; Magen, A; Rath-Wolfson, L; Rathaus, M; Shapira, J, 1983) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 7.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 7.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "Plasma renin activity (PRA) and systolic time intervals (STI), including total electromechanical systole (QS2), left ventricular ejection time (LVET), pre-ejection period (PEP) and isovolumetric contraction time (ICT), were measured in patients with borderline hypertension (n = 23) before and after oral treatment with atenolol and propranolol." | 7.66 | Effects of propranolol and atenolol on plasma renin activity and systolic time intervals in borderline hypertension. ( Fong Chi, S; Gamio Capestany, F; García-Barreto, D; González-Gómez, A; Hernández-Cañero, A, 1982) |
| "Captopril (100mg/kg) administered daily by gavage to young spontaneously hypertensive rats (SHRs) from their 6th to 20th weeks of age almost completely inhibited genetic hypertension development (GHD)." | 7.66 | Captopril and hypertension development in the SHR. ( Freslon, JL; Giudicelli, JF; Glasson, S; Richer, C, 1980) |
| "Atenolol has been studied prospectively in the management of ten patients with essential hypertension during pregnancy." | 7.66 | Atenolol in the treatment of essential hypertension during pregnancy. ( Butters, L; Low, RA; Reid, JL; Rubin, PC, 1982) |
| "16 patients suffering from hypertension and angina pectoris (class II according to the NYHA) are treated with 100 mg atenolol once daily for three weeks." | 7.66 | [Effects of therapy with a association of nifedipine and atenolol in patients with systemic arterial hypertension and angina pectoris]. ( Attisano, N; Grenci, G; Martelli, G; Sarica, G; Schirripa, V, 1982) |
| "A 30 year-old male patient with accelerated arterial hypertension relatively resistent to diazoxide received a single oral dose of 100 mg of atenolol, following which hypotension of more than 24 hours duration and acute renal failure ensued." | 7.66 | [Prolonged hypotension after the first dose of atenolol (author's transl)]. ( Botey, A; Darnell, A; Montoliu, J; Revert, L, 1981) |
| "1 The pharmacological properties of atenolol suggest its possible usefulness in pregnancy-induced hypertension." | 7.66 | Atenolol in the treatment of pregnancy-induced hypertension. ( Cruickshank, JM; McAinsh, J; Thorley, KJ, 1981) |
| "The antihypertensive effect of atenolol, a cardioselective beta-blocker, was examined in 8 patients with essential hypertension." | 7.66 | [Haemodynamic response to antihypertensive treatment with atenolol in patients with hypertension (author's transl]. ( Glogar, D; Leisch, F; Niederberger, M; Steinbach, K; Uhlir, H; Zilcher, H, 1978) |
| "1 Thirteen men with untreated essential hypertension in WHO stage I were studied on an outpatient basis to evaluate the haemodynamic long-tern effect of a new beta-adrenoceptor blocker, atenolol." | 7.65 | Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. ( Lund-Johansen, P, 1976) |
| "Only enalapril was able to significantly reduce LVMI (47±12 vs 39." | 6.82 | Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation. ( Baldini, L; Berrino, L; Calabrò, R; Castaldi, B; D'Aiello, FA; Del Gaizo, F; Di Salvo, G; Fadel, BM; Gala, S; Keating, S; Mormile, A; Pacileo, G; Perna, A; Rea, A; Russo, MG; Scognamiglio, G, 2016) |
| "A significant white coat hypertension was noticed in both the arms." | 6.78 | A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension. ( Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J, 2013) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 6.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| "We randomized 40 subjects with untreated hypertension (mean +/- s." | 6.73 | Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. ( Feely, J; Mahmud, A, 2008) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 6.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 6.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation." | 6.71 | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA ( Brändström, H; Kahan, T; Kindmark, A; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; öHman, KP; Stiger, F, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 6.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 6.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 6.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 6.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "Treatment with atenolol reduced the incidence of preeclampsia from 5 of 28 (18%) to 1 of 28 (3." | 6.69 | Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. ( Brateng, D; Brown, Z; Easterling, TR; Millard, SP; Schmucker, B, 1999) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system, predisposing to a procoagulant state." | 6.69 | Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. ( Hatzizacharias, AN; Krespi, PG; Kyriakidis, MK; Makris, TK; Stavroulakis, GA; Triposkiadis, FK; Tsoukala, CG; Votteas, VV, 2000) |
| "Treatment with prazosin GITS resulted in a favourable effect on the serum lipid profile at the end of 24 weeks (p = 0." | 6.69 | Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group. ( Jaguste, V; Joglekar, SJ; Nanivadekar, AS, 1998) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Atenolol treatment had neutral properties in some metabolic aspects, but deleterious effects on lipid status." | 6.68 | Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. ( Haenni, A; Lithell, H, 1996) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 6.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 6.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Nisoldipine, which has a higher coronary vascular selectivity and less negative inotropism than nifedipine, is as effective and as well tolerated as nifedipine in patients whose hypertension is inadequately controlled on atenolol." | 6.67 | Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol. ( Earle, KA; Hoffbrand, BI; Nievel, JG; Restrick, LJ; Simmonds, NJ, 1993) |
| "Bisoprolol and atenolol were similar in the black (10 +/- 5/9 +/- 3 mm Hg [n = 22] and 10 +/- 6/6 +/- 3 mm Hg [n = 13], respectively) and young (15 +/- 1/11 +/- 1 mm Hg [n = 84] and 16 +/- 2/10 +/- 1 mm Hg [n = 66], respectively) groups." | 6.67 | Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. ( Kazempour, MK; Lefkowitz, MP; Neutel, JM; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "The efficacy and safety of carvedilol, a beta-blocker with vasodilating properties, were compared at a dosage of 25 to 50 mg once daily with those of atenolol at a dosage of 50-100 mg once daily in a double-blind, randomized, parallel-group, multicenter study." | 6.67 | A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group. ( Young, PH, 1992) |
| " The incidence of adverse events was also similar for both drugs, and serious adverse events were rare and thought to be unrelated to the study drug therapy." | 6.67 | A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group. ( , 1991) |
| " The mean dosage in the isradipine group was 7." | 6.67 | Effect of isradipine and atenolol on lung function in patients with mild essential hypertension. ( Meisner, W; Reiterer, W, 1991) |
| " The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs." | 6.67 | A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ( Dixon, MS; Sheridan, DJ; Thomas, P, 1990) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| " Sitting (and standing) blood pressure and heart rate one to four hours after dosing were recorded at entry (191/95 mmHg) and at the end of the run-in period (186/93 mmHg)." | 6.67 | Hypertension in the elderly: a study of a combination of atenolol and nifedipine. ( Cheadle, B; Duckett, GK, 1990) |
| "Nitrendipine is a dihydropyridine calcium antagonist suggested to be a new drug for first-line antihypertensive therapy, possibly active in once-daily administration." | 6.66 | Long-term hypotensive treatment with nitrendipine in mild to moderate essential hypertension: preliminary results of a placebo-controlled study versus atenolol. ( Fommei, E; Genovesi-Ebert, A; Ghione, S; Giaconi, S; Giuliano, G; Marabotti, C; Mezzasalma, L; Palombo, C, 1987) |
| " The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)." | 6.66 | [Perindopril: first-line treatment of arterial hypertension]. ( Desche, P; Zanchetti, A, 1989) |
| "Enalapril and atenolol were also equally effective, but in combination their hypotensive effects were less than fully additive, with attenuation of the potential additive response by 30-50%." | 6.66 | Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions. ( Bune, AJ; Chalmers, JP; Elliott, JM; Morris, MJ; Russell, AE; West, MJ; Wing, LM, 1987) |
| "Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels." | 6.66 | A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. ( Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ, 1987) |
| " After a placebo run-in period the patients received increasing dosages of medication every 2 weeks until the target diastolic blood pressure of 90 mm Hg or less was achieved on two consecutive visits, the maximum dosage was reached, or the patient withdrew because of adverse effects." | 6.66 | Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group. ( , 1987) |
| " Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension." | 6.66 | Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. ( Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987) |
| "The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol." | 6.66 | Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. ( Giard, MJ; Josselson, J; Lam, YW; Posner, JN; Saunders, E; Warren, JB; Weir, MR; Zaske, DE, 1987) |
| "Labetalol and atenolol were equivalent in control of blood pressure at rest, exercise tolerance and use of nitroglycerin; however, heart rates at rest and during exercise were higher with labetalol (p less than 0." | 6.66 | Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris. ( Jee, LD; Opie, LH, 1985) |
| " Patients who responded (diastolic BP less than 95 mmHg) continued on the initial dosage regimen." | 6.65 | Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents. ( Lyngstam, O; Rydén, L, 1981) |
| "1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients." | 6.65 | Atenolol and chlorthalidone in combination for hypertension. ( Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979) |
| "Prazosin appears to be a potent and appropriate third agent." | 6.64 | Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. ( Barritt, DW; Heaton, ST; Marshall, AJ; Pocock, J, 1977) |
| "5." | 6.64 | Clinical evaluation of atenolol in hypertension. ( Aberg, H; Hansson, L; Henningsen, NC; Jameson, S; Karlberg, BE; Westerlund, A, 1976) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity." | 6.36 | Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1979) |
| "Quinapril, when given as initial monotherapy or in addition to diuretics, was extensively evaluated in patients with moderate to severe hypertension, defined as sitting diastolic blood pressure (DBP) greater than or equal to 105 mm Hg with concomitant diuretic therapy or greater than or equal to 110 mm Hg during placebo baseline." | 6.16 | The treatment of moderate to severe hypertension with ACE inhibitors. ( Goldstein, RJ, 1990) |
| "Twenty-one patients with mild or moderate hypertension were randomised to receive either Atenolol 100 mg (N = 10) or Pindolol 15 mg (N = 11) in a once daily dosage over a two month period." | 6.16 | [Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Guillard, O; Herpin, D; Piriou, A, 1988) |
| " The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension." | 5.41 | Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension. ( Akhtar, L; Elahi, A; Faisal, Z; Hussain, M; Javed, A; Majid, A, 2021) |
| "Atenolol use was related to increased mortality in community-dwelling hypertensive Older adults." | 5.40 | Atenolol use is associated with long-term mortality in community-dwelling older adults with hypertension. ( Abete, P; Bonaduce, D; Cacciatore, F; Della-Morte, D; Galizia, G; Gargiulo, G; Mastrobuoni, C; Mazzella, F; Rengo, F; Testa, G, 2014) |
| "Atenolol was started on an alternate day, 37." | 5.31 | Long-term control of hypertension in dialysis patients by low dose atenolol. ( Hadjiconstantinou, VE; Hadjiyannakos, DK; Karras, SM; Mentzikof, DG; Noussias, CV; Vlassopoulos, DA, 2002) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 5.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| " Chronic administration of propranolol (5 or 50 mg." | 5.29 | Effects of propranolol and atenolol on immobilization stress-induced hypertension and down-regulation of central beta-adrenoceptors in rats. ( Kigoshi, S; Muramatsu, I; Oda, Y; Takita, M, 1995) |
| "Neuropeptide Y (NPY) has been recently characterised as a circulating vasoconstrictor peptide which is co-stored with noradrenaline (NA) in sympathetic neurons." | 5.29 | Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. ( Hänze, J; Lang, RE; Lettgen, B; Rascher, W; Wagner, S, 1994) |
| "The recently published MRC-trial on treatment of hypertension in older adults showed generally beneficial effects." | 5.28 | [Treatment of hypertension in the elderly--diuretics/atenolol?]. ( Osnes, JB, 1992) |
| " Prereduction dosage of atenolol was 100 mg in 26 and 50 mg in 15 patients." | 5.28 | [Effect of halving the dosage of atenolol in essential hypertension]. ( Brack, T; Edmonds, D; Greminger, P; Grüne, S; Vetter, W, 1992) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 5.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| "The pseudolymphoma syndrome is a reversible reactive condition consisting of fever, lymphadenopathy and generalized rash." | 5.28 | Atenolol-induced pseudolymphoma. ( Henderson, CA; Shamy, HK, 1990) |
| " The average daily dosage was 144." | 5.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| " Patients were treated with propranolol 40 to 160 mg bid for 8 weeks, followed by atenolol 50 to 100 mg given once daily for 8 weeks, and then rechallenged with the required dosage of propranolol for 8 weeks." | 5.27 | A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension. ( Chockalingam, A; Drover, A; Fifield, F; Fodor, JG; Pauls, CJ, 1987) |
| "Treatment with atenolol markedly inhibited the onset of genetic hypertension, reduced HR and PRC from the outset and diminished the heart weight/body weight ratio." | 5.26 | Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. ( Boissier, JR; Giudicelli, JF; Richer, C, 1978) |
| "9 years follow-up in 9193 patients with hypertension randomized to losartan- or atenolol-based regimens." | 5.24 | Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. ( Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM, 2017) |
| "Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials." | 5.22 | Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. ( Esler, M; Grassi, G; Kjeldsen, SE; Kreutz, R; Mancia, G; Pathak, A, 2022) |
| "Baseline estimated GFR (eGFR) and change in eGFR during follow-up were examined in relation to average on-treatment SBP in 8778 hypertensive patients with ECG left ventricular hypertrophy (LVH) randomly assigned to losartan- or atenolol-based treatment." | 5.22 | Impact of achieved systolic blood pressure on renal function in hypertensive patients. ( Devereux, RB; Kjeldsen, SE; Okin, PM, 2016) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "Post hoc analysis of the Hypertension in Hemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial." | 5.20 | Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis. ( Agarwal, R; Georgianos, PI, 2015) |
| " The risk of new-onset AF was examined in relation to last in-treatment SBP before AF diagnosis or last in-study measurement in the absence of new AF in 8831 hypertensive patients with ECG left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline ECG, randomly assigned to losartan- or atenolol-based treatment." | 5.20 | Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "The short-term effects of two sympatholytic antihypertensive drug treatments, β-blocking agent atenolol and imidazoline receptor-1 agonist moxonidine, on postmenopausal symptoms and their relationship to antihypertensive and insulin sensitivity effect were studied." | 5.19 | Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. ( Kaaja, RJ; Kujala, SM; Pöyhönen-Alho, M, 2014) |
| "We examined the effect of chlorthalidone-based stepped care on the competing risks of cardiovascular (CV) versus non-CV death in the Systolic Hypertension in the Elderly Program (SHEP)." | 5.19 | Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Kostis, WJ; Messerli, FH; Sedjro, JE; Swerdel, JN, 2014) |
| "Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations." | 5.19 | Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. ( Abraham, TN; Agarwal, R; Pappas, MK; Sinha, AD; Tegegne, GG, 2014) |
| "FMD and NMD were measured using the UNEXEF18G before and after 4-week treatment of rosuvastatin (5 mg/day) with or without atenolol (25 mg/day) in 44 hypercholesterolemic patients (70±8 years old, LDL-C >140 mg/dL) with hypertension." | 5.19 | Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "8 years randomized losartan- or atenolol-based antihypertensive treatment in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study and classified as having ISH (n = 128) if systolic BP ≥ 160 mmHg and diastolic BP < 90 mmHg, or non-ISH divided into two groups by systolic BP ≥ 160 mmHg (non-ISH ≥ 160 mmHg) (n = 645) and systolic BP < 160 mm Hg (n = 100) (non-ISH < 160 mmHg), respectively." | 5.19 | Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). ( Abdelhai, YM; Boman, K; Dahlöf, B; De Simone, G; Devereux, RB; Gerdts, E; Lønnebakken, MT; Mancusi, C; Wachtell, K, 2014) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "The results demonstrate that pretreatment with β-receptor blocker (atenolol) or angiotensin-converting enzyme inhibitor (lisinopril) reduces postoperative hypertension in patients undergoing neurosurgery, and inhibition of oxidative stress may be a potential mechanism for this effect." | 5.17 | Oxidative stress-associated hypertension in surgically induced brain injury patients: effects of β-blocker and angiotensin-converting enzyme inhibitor. ( Adhikary, SD; Babu, SK; Korula, G; Ramachandran, A; Vedantam, R; Velayutham, PK, 2013) |
| "In the Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study, a double-blinded, randomized, parallel-group study, 9193 hypertensive patients with electrocardiogram (ECG)-documented left ventricular hypertrophy (LVH), randomized to once-daily losartan- or atenolol-based antihypertensive therapy were followed for a mean of 4." | 5.16 | Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K, 2012) |
| "Data from all patients with at least two echocardiographic examinations in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) echocardiographic substudy (n = 801); high-risk patients on losartan- vs." | 5.16 | Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Greve, AM; Lønnebakken, MT; Nieminen, MS; Okin, PM; Olsen, MH; Omvik, P; Palmieri, V; Wachtell, K, 2012) |
| "A total of 9,027 patients with hypertension and ECG-LVH and without a history of HF were randomized to losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.16 | Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 5.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring." | 5.16 | Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hou, W; Johnson, JA; Langaee, TY; McDonough, CW; Turner, ST; Wang, Z, 2012) |
| " After a 4-week placebo period, 94 and 107 patients with uncomplicated hypertension were randomly assigned to treatment with atenolol (AT) at dosage of 50 mg per day or perindopril/indapamide (PER/IND) at dosage of 2/0." | 5.15 | Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. ( Dolan, E; Jin, Y; Li, Y; O'Brien, E; Protogerou, A; Richart, T; Safar, ME; Staessen, JA; Thijs, L; Wang, JG, 2011) |
| "We evaluated the effect of atenolol vs metoprolol succinate on vascular function in patients with essential hypertension." | 5.15 | Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. ( Heffernan, KS; Karas, RH; Kuvin, JT; Mooney, P; Patvardhan, EA; Suryadevara, R, 2011) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA) showed that an amlodipine-based regimen prevented more cardiovascular events than an atenolol-based regimen in patients at high risk of hypertension." | 5.15 | Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. ( Peuhkurinen, K; Peuhkurinen, S; Risteli, J; Uusimaa, P; Vuolteenaho, O; Ylitalo, A, 2011) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| " Patients with essential hypertension and without significant concomitant cardiovascular disease were randomly assigned to controlled-release carvedilol, force-titrated to 80 mg (n=22), or atenolol, force-titrated to 100 mg (n=19); each was given once daily for 4 weeks." | 5.15 | Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). ( Ashfaq, U; Epstein, BJ; Johnson, JA; Lo, MC; Nichols, WW; Satish, P; Shah, NK; Smith, SM, 2011) |
| "Eight thousand one hundred ninety-four LIFE patients with hypertension and left ventricular hypertrophy with available baseline hemoglobin measurements were randomized to losartan- or atenolol-based treatment and followed for 4." | 5.14 | Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Narayan, P; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wedel, H, 2009) |
| "The REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study is a randomized, double-blind trial comparing atenolol versus perindopril/indapamide; 375 patients with hypertension, with BP and PWV measurements at baseline and after 12 months of treatment, were divided into 3 tertiles according to baseline PWV and included in a post-hoc analysis." | 5.14 | Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. ( Achimastos, A; Blacher, J; Protogerou, A; Safar, ME; Stergiou, GS, 2009) |
| "We have reported the benefits of atorvastatin and of an amlodipine-based regimen on coronary heart disease (CHD) events in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)." | 5.14 | Coronary heart disease benefits from blood pressure and lipid-lowering. ( Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 5.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 5.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| "8 years of randomized losartan- or atenolol-based treatment within the echocardiographic substudy of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.14 | Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). ( Dahlöf, B; Devereux, RB; Franklin, S; Gerdts, E; Nieminen, M; Papademetriou, V; Rieck, A; Wachtell, K, 2009) |
| " Patients with uncomplicated hypertension were randomized to receive either hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by addition of the alternative drug." | 5.14 | Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Campbell, K; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Johnson, JA; Schmidt, S; Schwartz, GL; Turner, ST, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm)." | 5.14 | Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). ( Campbell, NR; Dahlöf, B; Dobson, JE; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "To assess clinical, hemodynamic efficacy and tolerability of a Fixed Atenolol Amlodipine Combination (FAAC) in patients with arterial 1-3 degree arterial hypertension as mono- or combination therapy." | 5.14 | [An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study]. ( Andrushchishina, TB; Morozova, TE, 2009) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH." | 5.14 | Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2009) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hypertension and other vascular risk factors and the Medical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years." | 5.14 | Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. ( Dahlöf, B; Dobson, JE; Dolan, E; Howard, SC; O'Brien, E; Poulter, NR; Rothwell, PM; Sever, PS, 2010) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "Although treatment with nebivolol or atenolol results in improved LV transmitral diastolic function filling parameters (E/A ratio, IVRT and DT), nebivolol has a greater effect compared with atenolol in patients with mild-to-moderate hypertension." | 5.13 | Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. ( Eryonucu, B; Gumrukcuoglu, HA; Gunes, Y; Guntekin, U; Tuncer, M, 2008) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 5.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "In this double-blind, multicentre trial, 694 patients with hypertension (mean sitting diastolic blood pressure [BP] > or = 95 and < 110 mmHg) were randomised to once-daily aliskiren 150 mg (n=231), atenolol 50 mg (n=231) or the combination (150/50 mg; n=232) for six weeks, followed by a further six weeks on double the initial doses of aliskiren and atenolol." | 5.13 | Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. ( Bheda, M; Dechend, R; Dietz, R; Ford, J; Keefe, DL; Prescott, MF; Yu, CM, 2008) |
| " After initial structural MRI and functional positron emission tomography imaging, subjects were randomly assigned in a double-blind fashion for treatment for 1 year with either lisinopril or atenolol." | 5.13 | Brain imaging findings predict blood pressure response to pharmacological treatment. ( Jennings, JR; Meltzer, CC; Muldoon, MF; Price, J; Scanlon, J; Whyte, EM, 2008) |
| " To determine whether thiazide-induced diabetes is mediated by changes in potassium, we analyzed data from 3790 nondiabetic participants in the Systolic Hypertension in Elderly Program, a randomized clinical trial of isolated systolic hypertension in individuals aged >or=60 years treated with chlorthalidone or placebo." | 5.13 | Changes in serum potassium mediate thiazide-induced diabetes. ( Appel, LJ; Klag, MJ; Miller, ER; Parekh, RS; Shafi, T, 2008) |
| " We compared the effect of two sympatholytic antihypertensive drug treatments, the centrally acting imidazoline receptor-1 agonist moxonidine and peripherally acting beta-blocking agent atenolol on sensitive inflammatory markers in overweight postmenopausal women with diastolic hypertension." | 5.13 | Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. ( Antikainen, RL; Ebeling, PE; Erkkola, RU; Kaaja, RJ; Katzman, P; Kibarskis, A; Manhem, K; Pöyhönen-Alho, MK; Tuomilehto, JO, 2008) |
| " Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria." | 5.13 | Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| "8 years of randomized losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint Reduction in Hypertension Echocardiography substudy." | 5.13 | Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Boman, K; Cramariuc, D; de Simone, G; Devereux, RB; Gerdts, E; Okin, PM; Wachtell, K, 2008) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| " Our objective was to compare the effects of cilazapril and atenolol on P-wave duration and dispersion in patients with hypertension." | 5.13 | Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension. ( Eryonucu, B; Gumrukcuoglu, HA; Gunes, Y; Guntekin, U; Tuncer, M, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "One-hundred and fifty-six subjects with essential hypertension were randomised to treatment with either irbesartan or atenolol." | 5.13 | Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. ( Delles, C; Klingbeil, AU; Kolloch, RE; Krekler, M; Ludwig, M; Schmieder, RE; Schneider, MP; Stumpe, KO, 2008) |
| "To compare the effects of nebivolol, a new b-blocker that have additional vasodilating activity via acting on endothelium and nitric oxide release, and atenolol on P-wave duration and dispersion in patients with mild-to-moderate hypertension." | 5.13 | [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension]. ( Batyraliev, TA; Eryonucu, B; Fettser, DV; Guler, N; Gumrukchuoglu, KhA; Gunes, Y; Guntekin, U; Sidorenko, BA; Tuncer, M, 2008) |
| "Hypertensive patients with electrocardiographic-left ventricular hypertrophy were randomized to losartan-based or atenolol-based treatment and followed for 4." | 5.13 | Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Jern, S; Kjeldsen, SE; Li, Z; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensionaL (D) ultrasound (US), to compare the effects of a 2-year treatment based on either olmesartan medoxomil or atenolol on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV)." | 5.12 | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. ( Agabiti-Rosei, E; Laeis, P; Ludwig, M; Scholze, J; Schremmer, D; Schwandt, P; Stumpe, KO; Zielinski, T, 2007) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| "Recent data suggest that atenolol may be inferior to other antihypertensive drugs in reducing cardiovascular risk in older individuals with hypertension, despite lowering peripheral blood pressure (BP)." | 5.12 | Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. ( Brown, MJ; Cockcroft, JR; Dhakam, Z; McEniery, CM; Wilkinson, IB, 2006) |
| " The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension." | 5.12 | Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. ( Chao, AC; Chen, YY; Chern, CM; Hsu, HY; Hsu, LC; Hu, HH, 2006) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "The aim of the present study was to evaluate effects of long-term treatment with rilmenidine compared with atenolol on lipid and glucose metabolism and cardiovascular remodelling in hypertension." | 5.12 | How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ( Kasherininov, YR; Konrady, AO; Krutikov, AN; Shavarov, AA; Shavarova, EK; Shlyakhto, EV; Smirnova, EV; Vachrameeva, NV, 2006) |
| " In hypertension of the 2-3 degree, beta-blockers are more effective than blockers of Ca channels, ACE, diuretics and nitroglycerin." | 5.12 | [Arterial hypertension: problems of maintenance therapy]. ( Kozlovskiĭ, IV, 2006) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2006) |
| "In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study." | 5.12 | Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006) |
| "LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy." | 5.12 | Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Hille, DA; Ibsen, H; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2007) |
| " We investigated the influence of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension." | 5.12 | Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. ( Chenevard, R; Flammer, AJ; Gay, S; Hermann, F; Hürlimann, D; Lehmann, R; Lüscher, TF; Neidhart, M; Noll, G; Riesen, W; Ruschitzka, F; Schwegler, B; Sudano, I; Wiesli, P, 2007) |
| "6 years) randomized to treatment with lacidipine or atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)." | 5.12 | Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. ( Baurecht, H; Bilo, G; Hennig, M; Mancia, G; Maronati, A; Omboni, S; Parati, G; Zanchetti, A, 2007) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2007) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 5.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "Two first-line antihypertensive therapies for initiating treatment in hypertension were compared, the angiotensin-converting enzyme inhibitor (ACEI) zofenopril and the beta-blocker atenolol." | 5.12 | Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. ( Nilsson, P, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that losartan-based treatment reduced risk of the composite endpoint of cardiovascular death, stroke and myocardial infarction compared with atenolol-based treatment in patients with hypertension and left ventricular hypertrophy with similar office blood pressure (BP) reduction." | 5.12 | Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. ( Bang, LE; Hildebrandt, PR; Ibsen, H; Larsen, J; Olsen, MH; Tuxen, C; Wachtell, K; Wiinberg, N, 2007) |
| "Sixty patients with arterial hypertension randomized in three groups were studied before and after treatment with atenolol (AT), acebutolol (AC) or talinolol (TL) until doses of 100, 600 and 300 mg/d correspondingly were reached or resting HR was decreased by 10 bpm." | 5.12 | [Interrelationship between changes of rate and variability of cardiac rhythm under influence of beta-adrenoblockers]. ( Alekseeva, IuM; Malkina, TA; Sokolov, SF, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 5.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension." | 5.11 | Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. ( Asmar, R; Battegay, E; Chamontin, B; De Leeuw, PW; Duprez, D; Hitzenberger, G; Mallion, JM; O'Brien, E; O'Rourke, MF; Rahn, KH; Romero, R; Safar, ME, 2004) |
| "The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. ( Alderman, MH; Beevers, G; Dahlöf, B; Devereux, RB; Douglas, JG; Edelman, JM; Harris, KE; Julius, S; Kjeldsen, SE; Nesbitt, S; Randall, OS; Wright, JT, 2004) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "Losartan prevented more cardiovascular complications than atenolol for the same reduction in blood pressure and have positive additional effects beyond blood pressure control in patients with hypertension and left ventricular hypertrophy." | 5.11 | [Treatment of hypertension in patients with left ventricular hypertrophy]. ( Bratland, B; Gerhardsen, G; Gisholt, K; Kjeldsen, SE; Omvik, P; Risanger, T; Smedsrud, T, 2004) |
| " We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol." | 5.11 | Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. ( Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Koren, MJ; Liu, JE; Nieminen, MS; Palmieri, V; Wachtell, K; Wright, JT; Zabalgoitia, M, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 5.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| " Baseline and year-1 ECGs and echocardiograms were assessed in 584 hypertensive patients with ECG LVH by Sokolow-Lyon or Cornell voltage-duration product criteria at entry into the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic substudy." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Liu, JE; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2004) |
| "To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment." | 5.11 | Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Roman, MJ; Smith, G; Wachtell, K, 2004) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| " The aim of this trial was to compare the effects of irbesartan versus atenolol on LVH in subjects with essential hypertension." | 5.11 | Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. ( Delles, C; Klingbeil, AU; Kolloch, RE; Krekler, M; Ludwig, M; Schmieder, RE; Schneider, MP; Stumpe, KO, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "The aim of this study was to test whether these polymorphisms were associated with the change in heart rate or blood pressure in patients with essential hypertension and left ventricular (LV) hypertrophy treated with the beta1-adrenergic receptor blocker atenolol." | 5.11 | Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol." | 5.11 | Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. ( Boman, K; Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. ( Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H, 2004) |
| "Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001." | 5.11 | Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "Patients with mild to moderate primary hypertension and LV hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta1 adrenoreceptor blocker atenolol (n = 49)." | 5.11 | Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. ( Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "The objective of this open-label, parallel-group comparative study was to assess the clinical efficacy and safety of once-daily treatment for 8 weeks with telmisartan 80 mg in comparison with atenolol 50 mg on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with mild-to-moderate hypertension (morning supine SBP 141-199 mmHg, DBP 95-114 mmHg)." | 5.11 | Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. ( Alcocer, L; Bahena, J; Campos, E; de la Fuente, JJ; Dominguez-Henkel, R; Fernández-Bonetti, P; Olvera Ruiz, R; Segovia-Ayala, C, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "This study was done to evaluate the effect of treatment with manidipine as compared with atenolol on thrombin-mediated platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus." | 5.11 | Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2005) |
| " We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction." | 5.11 | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. ( Andersen, UB; Fossum, E; Gaboury, CL; Hjerkinn, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Nesbitt, SD; Olsen, MH; Phillips, RA; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 5.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "In 183 patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy, enrolled in the LIFE Study, we measured BP and serum Nt-proANP and Nt-proBNP by immunoassay after 2 weeks of placebo treatment and after 1, 2, 4, 6, 12, 24, 36 and 48 months of randomized treatment with losartan- or atenolol-based antihypertensive regimens." | 5.11 | Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. ( Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "Propranolol inhibits platelet aggregation more than atenolol and may have a favorable effect on the management of hypertension especially in patients with increased cardiovascular risk." | 5.11 | Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. ( Bagatin, J; Lukin, A; Marković, V; Polić, S; Punda, A; Rumboldt, Z, 2005) |
| "In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens." | 5.11 | Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. ( Bella, JN; Dige-Petersen, H; Ibsen, H; Neland, K; Olsen, MH; Rokkedal, J; Wachtell, K, 2005) |
| "We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study to determine whether aspirin interacted with the properties of losartan, an angiotensin-II receptor antagonist." | 5.11 | The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. ( Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension." | 5.11 | Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. ( Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S, 2005) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "We studied 17 patients who were similar to those in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? ( Band, M; Carr, E; Davies, J; Morris, A; Struthers, A, 2005) |
| "The Losartan Vascular Regression Study (LAARS) was a double-blind, parallel-group, randomized, controlled, multicenter study designed to compare the effects of the AII antagonist losartan and the beta-blocker atenolol on ultrasonographically determined intimamedia thickness (IMT) of the common carotid artery (CCA) in patients with mild to moderate essential hypertension." | 5.10 | Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study. ( Fritschka, E; Ludwig, M; Ribeiro, A; Smith, RD; Stapff, M; Stumpe, KO; Tholl, U, 2002) |
| "To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH." | 5.10 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. ( Aurup, P; Barrios, V; Dahlof, B; Diez, J; Johansson, M; Nicholls, MG; Smith, RD; Yu, CM; Zanchetti, A, 2002) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 5.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 5.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in far walls of common carotids and bifurcations (CBM(max))." | 5.10 | Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Reid, JL; Rizzini, P; Rodicio, J; Safar, M; Zanchetti, A, 2002) |
| "The primary objective of this double-blind, randomized, parallel-group study was to compare the influence ofthe selective beta1-receptor antagonists talinolol (100 mg) and atenolol (50 mg) on the lipid metabolism in hyperlipemic patients with mild to moderate hypertension after 12 weeks of treatment." | 5.10 | Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. ( Derendorf, H; Schmidt, J; Sourgens, H, 2003) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 5.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 5.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "The aim of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study was to compare the long-term effect of the commonly used inexpensive medication with a low-dose diuretic (hydrochlorothiazide), alone or in combination with a beta-adrenoceptor (atenolol), with that of more modern but also more expensive antihypertensive treatment with an angiotensin-II-receptor blocker (candesartan), alone or in combination with a calcium antagonist (felodipine), and to do so in newly diagnosed patients with primary hypertension." | 5.10 | Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). ( Alaupovic, P; Carlberg, B; Lindholm, LH; Persson, M; Samuelsson, O; Svensson, A, 2003) |
| "Seventy-three patients with mild to moderate hypertension (DBP 90 - 109 mmHg) were allocated randomly to be administered with atenolol 25 mg/d (group A, n=37) and diltiazem-SR 90 mg/d (group B, n=36) for eight weeks." | 5.10 | [Effects of atenolol and diltiazem-SR on quality of life in the hypertensive patients]. ( Chen, BX; Chen, JZ; Fan, WH; Liu, XJ; Yao, XY; Zhu, JH, 2003) |
| "This was a double-blind, randomized, prospective study comparing the effects of nebivolol and atenolol on systolic diastolic left ventricular function in patients with essential hypertension." | 5.10 | Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. ( Kamp, O; Sieswerda, GT; Visser, CA, 2003) |
| "Cardiovascular morbidity and mortality are reduced by treatment with the angiotensin II AT(1)-receptor antagonist losartan compared with conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardiogram-defined left ventricular hypertrophy, many of whom had known vascular disease." | 5.10 | Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2003) |
| "We evaluated the influence of this polymorphism on the change in left ventricular mass index in 90 patients with essential hypertension and echocardiographically diagnosed left ventricular hypertrophy, randomised in a double-blind study to receive treatment with either the angiotensin II type I receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol for 48 weeks." | 5.10 | Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. ( Hallberg, P; Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2003) |
| "To compare efficacy and safety of atenolol, methoprolol and bisoprolol, as the most usable beta-blockers, in patients with isolated systolic arterial hypertension (ISAH) and concomitant diabetes mellitus (DM) and/or chronic obstructive pulmonary disease (COPD)." | 5.10 | [Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases]. ( Abakumov, IuE; Batutina, AM; Kukes, VG; Mamaev, VI; Ostroumova, OD; Zykova, AA, 2003) |
| " We designed a study investigating the effect of enalapril on the protection of renal function in autosomal dominant polycystic kidney disease (ADPKD)." | 5.10 | No effect of enalapril on progression in autosomal dominant polycystic kidney disease. ( Breuning, MH; Duiser, R; van Dijk, MA; van Es, LA; Westendorp, RG, 2003) |
| "We compared the effects of 6 months administration of atenolol or nebivolol on resting and exercise hemodynamic parameters and maximal exercise capacity, in 26 patients with hypertension and left ventricular (LV) diastolic dysfunction (ejection fraction >50%, end-diastolic diameter <60 mm and increased pulmonary wedge pressure at rest and/or at peak exercise)." | 5.10 | Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. ( Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 5.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 5.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 5.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "In a Swedish-Finnish long-term multicenter study 256 patients with mild to moderate hypertension were randomized to treatment with diltiazem retard (D) (n = 127) or atenolol (A) (n = 129)." | 5.09 | Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group. ( Berglund, E; Dahlöf, C; Engqvist, L; Lagerstedt, C; Lehtonen, A; Nilsson-Ehle, P; Thulin, T, 1999) |
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 5.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "Atenolol use may be associated with growth retardation when given in pregnancy, although the relationship to trimester of initiation, duration of treatment, and its use as monotherapy is still uncertain." | 5.09 | Atenolol and fetal growth in pregnancies complicated by hypertension. ( Beevers, DG; Beevers, M; Lip, GY; Lydakis, C, 1999) |
| "The short-term treatment with atenolol in patients with arterial hypertension and sleep apnea syndrome is associated with normalization of autonomic nervous control judged by heart rate and blood pressure variability." | 5.09 | The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. ( Kantola, I; Pelttari, L; Salo, TM; Viikari, JS; Voipio-Pulkki, LM, 1999) |
| "Baseline tachycardia or symptoms suggesting anxiety, emotional tension or sympathetic overactivity are associated with a more pronounced blood pressure fall to antihypertensive treatment with atenolol." | 5.09 | [Relationship between sympathetic activity and response to treatment with atenolol in hypertensive patients. Investigation group of the study of efficiency and tolerance of atenolol in hypertensive patients with increase in the sympathetic activity]. ( de la Sierra, A, 1999) |
| "Elevated levels of endothelin-1 (ET-1) and von Willebrand factor (vWF), both markers indicative of endothelial function, are associated with hypertension." | 5.09 | Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. ( Andersen, P; Arnesen, H; Aspelin, T; Kierulf, P; Seljeflot, I, 1999) |
| "The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension." | 5.09 | Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. ( Alvarez, E; Andersson, PE; Byberg, L; Haenni, A; Lithell, H; Reneland, R, 2000) |
| "The primary objective of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of tasosartan and atenolol administered alone and concomitantly under steady-state conditions in 17 patients ages 18 to 65 years diagnosed with stage 1 to 2 essential hypertension." | 5.09 | A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ( Abernethy, DR; Andrawis, NS; Battle, MM; Burghart, PH; Klamerus, KJ; Mayer, P; Neefe, L; Weinryb, I, 2000) |
| "Nineteen untreated patients with mild essential hypertension (47+/-2 years, range 30 to 65 years; 57% male) were randomly assigned in double-blind fashion to losartan or atenolol treatment for 1 year." | 5.09 | Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. ( Intengan, HD; Park, JB; Schiffrin, EL; Touyz, RM, 2000) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| "Four hundred seventy-five patients with angina pectoris were randomized to double-blind treatment with PPR (physiological pattern release) verapamil hydrochloride, amlodipine besylate, amlodipineatenolol combination, or placebo." | 5.09 | Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. ( Anderson, R; Hollenberg, NK; Williams, GH, 2000) |
| "To compare the efficacy and tolerability of angiotensin II (Ang II) antagonist losartan and the beta-blocker atenolol in the treatment of patients with isolated systolic hypertension (ISH) after 16 weeks of treatment." | 5.09 | The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. ( Baiz, AQ; Bortman, G; Farsang, C; Garcia-Puig, J; Niegowska, J; Vrijens, F, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (n = 9,194) with essential hypertension and with electrocardiographically (ECG) documented left ventricular hypertrophy (LVH)." | 5.09 | Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. ( Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 2000) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| " This study provides evidence that, in contrast to atenolol, quinapril, independent of blood pressure reduction, reduces left ventricular hypertrophy and improves left ventricular diastolic function in this population." | 5.09 | Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. ( Gerhardt, U; Hausberg, M; Hohage, H; Rahn, KH; Suwelack, B, 2000) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 5.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality." | 5.09 | Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. ( Dahlöf, B; Devereux, RB; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2000) |
| "This study was undertaken to compare the efficacy and tolerability of telmisartan, a novel antihypertensive agent, and atenolol, a well-established beta-blocker, in the treatment of mild to moderate hypertension." | 5.09 | Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. ( Deichsel, G; Freytag, F; Meinicke, T; Schelling, A, 2001) |
| "To study clinical efficiency of atenolol in pregnancy hypertension with consideration of its cardiodynamic effects." | 5.09 | [Atenolol use in gestosis: clinical and hemodynamic aspects]. ( Elokhina, TB; Petrova, SB; Shekhtman, MM; Sokolova, MIu, 2000) |
| " There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil." | 5.09 | Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. ( Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F, 2001) |
| "The Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)." | 5.09 | Regression of left ventricular hypertrophy in human hypertension with irbesartan. ( Edner, M; Hägg, A; Held, C; Kahan, T; Lind, L; Malmqvist, K; Müller-Brunotte, R; Nyström, F; Ohman, KP; Osbakken, MD; Ostergern, J, 2001) |
| "This study, ancillary to the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), involved nifedipine 30 mg or co-amilozide (hydrochlorothiazide 25 mg and amiloride 2." | 5.09 | Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. ( Gariépy, J; Levenson, J; Moyse, D; Simon, A, 2001) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "These results indicate that insulin sensitivity was not modified significantly by nebivolol, whereas it was reduced by atenolol, although blood pressure was decreased to the same extent by both drugs." | 5.09 | Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. ( Cléroux, J; Lacourcière, Y; Nadeau, A; Poirier, L, 2001) |
| "Eighty-six patients with hypertension were randomized to double-blind treatment with either the angiotensin II type 1 receptor antagonist irbesartan or the beta1 adrenergic receptor blocker atenolol and followed for 3 months." | 5.09 | Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2001) |
| "Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period." | 5.09 | Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. ( Hägg, A; Kahan, T; Lind, L; Millgård, J; von zur Mühlen, B, 2001) |
| " In retrospective analyses of the Veterans Affairs Single-Drug Therapy for Hypertension Study, we compared changes in pulse pressure with 6 classes of antihypertensive agents: 1292 men with diastolic blood pressure of 95 to 109 mm Hg on placebo were randomized to receive hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem, prazosin, or placebo." | 5.09 | Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. ( Cushman, WC; Materson, BJ; Reda, DJ; Williams, DW, 2001) |
| "To compare the efficacy of native carvedilol(Cv) with native atenolol(At), we treated 80 cases of essential hypertension(stage I-II) for 4 weeks, using both open-test and double blind randomized imitative methods." | 5.09 | [Efficacy of native carvedilol in patients with essential hypertension]. ( Jia, Z; Lin, S; Peng, Y; Yang, T; Zhang, Z, 1999) |
| "The effects of MPC-1304, a new calcium channel blocker, on blood pressure, serum lipoproteins, and carbohydrate metabolism were compared with those of atenolol in a group of patients with mild to moderate essential hypertension." | 5.08 | Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension. ( Arakawa, K; Kajiyama, G; Kusukawa, R; Mashiba, H; Nonaka, K; Sasaki, J; Shichiri, M; Sunaga, T; Tanaka, N, 1995) |
| "The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension." | 5.08 | Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. ( Dahlöf, B; Goldberg, AI; Keller, SE; Lim, NY; Makris, L; Sweet, CS, 1995) |
| "The effect of treatment with two different antihypertensive agents on the function of small arteries from 17 patients with essential hypertension randomly assigned to receive either the angiotensin I-converting enzyme inhibitor cilazapril or the beta-blocker atenolol was investigated." | 5.08 | Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. ( Deng, LY; Schiffrin, EL, 1995) |
| "The effects of isradipine and atenolol on platelet function and fibrinolytic activity were studied in 10 male patients with mild untreated hypertension." | 5.08 | Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? ( Gleerup, G; Mehlsen, J; Winther, K, 1995) |
| "We conducted this study to compare the effects of fosinopril versus atenolol on peripheral blood pressure, central arterial wave reflection, and left ventricular mass in a group of patients with essential hypertension." | 5.08 | Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. ( Chang, MS; Chen, CH; Chou, P; Hsu, TL; Lin, SJ; Siu, CO; Ting, CT; Wang, SP; Yin, FC, 1995) |
| "The primary objective in this multicentre, double-blind randomised, parallel study was to compare the metabolic effects of 12 months of treatment with an ACE inhibitor (enalapril) with those of a selective beta-blocker (atenolol) in patients with mild hypertension." | 5.08 | Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group. ( Aberg, H; Lithell, H; Mörlin, C, 1995) |
| "The efficacy and tolerability of controlled-release metoprolol (metoprolol CR/ZOK), 100-200 mg, and atenolol, 50-100 mg, once daily was compared in Chinese patients with mild to moderate essential hypertension." | 5.08 | A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. ( Chen, MF; Chen, WJ; Lee, CM; Lee, YT; Liau, CS; Wu, CC; Yang, CY, 1995) |
| "The hemodynamic effects of celiprolol (CAS 56980-93-9), a betablocker with beta 1 antagonist and beta 2 agonist properties, were compared with those of atenolol (CAS 29122-68-7) in 12 patients with mild to moderately severe hypertension (diastolic BP 95-110 mmHg)." | 5.08 | Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. ( Mahler, F; Saner, H; Seiler, A, 1995) |
| "This 12-week, open-label study was conducted to gain experience with losartan potassium, an angiotensin II receptor antagonist, in patients with severe hypertension." | 5.08 | Losartan potassium as initial therapy in patients with severe hypertension. ( Chrysant, S; Dunlay, MC; Fitzpatrick, V; Francischetti, EA; Goldberg, AI; Sweet, CS, 1995) |
| "We assessed the effects of 6 months of treatment with an angiotensin-converting enzyme (ACE) inhibitor (cilazapril) or a beta 1-adrenergic blocker (atenolol) on aortic stiffness in essential hypertension." | 5.08 | Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension. ( Hekali, P; Keto, P; Kupari, M; Poutanen, VP; Rames, A; Savolainen, A; Standertskjöld-Nordenstam, CG, 1996) |
| " In a recent prospective, randomized, double blind trial in 257 patients with essential hypertension, the loss of GFR, determined with 51Cr-EDTA clearance, was significantly less with an ACE inhibitor (cilazapril) than with a beta-adrenoceptor blocker (atenolol) during the first year of treatment." | 5.08 | Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. ( Furängen, A; Hansson, BG; Hansson, L; Hedstrand, H; Himmelmann, A; Ohrvik, J; Skogström, K, 1996) |
| "To compare the effects of the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol (Uniloc) on insulin sensitivity and glucose and lipid homeostasis in patients with type-2 diabetes and hypertension." | 5.08 | Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. ( Eriksson, JW; Foley, K; Jansson, PA; Lithell, H, 1996) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 5.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "5 mg lisinopril/hydrochlorothiazide and placebo in patients with essential hypertension." | 5.08 | Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. ( de Leeuw, PW; Notter, T; Zilles, P, 1997) |
| "A randomized double-blind trial was conducted in hypertensive subjects with hypercholesterolemia treated with pravastatin in order to compare the effects of captopril and atenolol on lipid metabolism." | 5.08 | [Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial]. ( Arsenescu, I; Provendier, O; Witchitz, S, 1996) |
| " In this randomized, double-blind, placebo-controlled, crossover study of 39 physically active men with uncomplicated essential hypertension, we compared the effects of atenolol and enalapril on cardiovascular fitness and serum lipids." | 5.08 | Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. ( Duncan, JJ; Gordon, NF; Scott, CB, 1997) |
| "Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial." | 5.08 | Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Anderson, RJ; Gottdiener, JS; Massie, BM; Materson, BJ; Reda, DJ; Williams, DW, 1997) |
| "To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension." | 5.08 | Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. ( Acampora, R; D'Onofrio, F; De Angelis, L; De Rosa, N; Giugliano, D; Marfella, R; Ragone, R; Ziccardi, P, 1997) |
| "Thirty-seven patients with mild to moderate hypertension were randomized in a double-blind, parallell-group study to receive either 6 mg of spirapril or 50 mg of atenolol." | 5.08 | Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. ( Hakamäki, T; Lehtonen, A, 1997) |
| "In older persons with isolated systolic hypertension, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in preventing heart failure." | 5.08 | Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. ( Applegate, WB; Berge, KG; Berkson, DM; Black, HR; Blaufox, MD; Cohen, JD; Curb, JD; Cutler, J; Davis, BR; Grimm, RH; Kostis, JB; Lacy, CR; McDonald, R; Perry, HM; Schron, E; Smith, WM; Wassertheil-Smoller, S, 1997) |
| "To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension." | 5.08 | Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. ( Anlauf, M; Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1997) |
| "Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks." | 5.08 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension. ( Chern, MS; Lin, FC; Wu, D, 1997) |
| "The blood pressure lowering effect and tolerability of the angiotensin-converting enzyme inhibitor enalapril combined with a very low dose of hydrochlorothiazide (HCTZ) were compared with the selective betareceptor blocker atenolol in patients with mild-to-moderate hypertension." | 5.08 | Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group. ( Dollerup, J; Hotnes, T; Mogensen, CE; Os, I, 1997) |
| "The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM)." | 5.08 | Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. ( Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Van Nueten, L; Vertommen, C; Zoppi, A, 1997) |
| " We identified 43 subjects from general practice with uncomplicated mild to moderate hypertension to compare the effects of the calcium antagonist isradipine with that of the beta-blocker atenolol on platelet function, plasma beta-thromboglobulin levels, fibrinolysis, and serum lipids in a randomised double-blind parallel group study." | 5.08 | Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects. ( Carney, S; Gillies, A; Mason, A; McPherson, J; Smith, A; Taylor, M, 1997) |
| "A double-blind, randomised, parallel-group trial was conducted in patients with essential hypertension in British general practices, of nebivolol 5 mg, atenolol 50 mg, and placebo each given once daily." | 5.08 | Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. ( Robertson, JI; Taylor, FR; Van Nueten, L, 1998) |
| "To compare the effect of four drug groups on the ambulatory circadian blood pressure (BP) pattern, amiloride hydrochlorothiazide, atenolol, nifedipine, and perindopril (5/50 mg/d, 100 mg/d, 40 mg/d, and 4 mg/d respectively, for 14 days) were alternated in each of 20 essential hypertension patients." | 5.08 | Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study. ( Moulopoulos, S; Stamatelopoulos, S; Zakopoulos, N, 1997) |
| "5 mg; diuretic, hydrochlorothiazide [HCTZ] 25 mg; and angiotension converting enzyme-inhibitor, spirapril 6 mg) on obese patients with sleep disordered breathing and hypertension were compared by the ambulatory blood pressure measurement (ABPM)." | 5.08 | Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. ( Hietanen, EK; Kantola, IM; Kataja, MJ; Pelttari, LH; Salo, TT, 1998) |
| "In this multicenter, double-blind study, the antihypertensive efficacy and safety of irbesartan were compared with those of atenolol in patients with mild-to-moderate hypertension." | 5.08 | Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. ( Haworth, D; Hoglund, C; Kassler-Taub, K; Kerwin, L; Martin, A; Masson, C; Osbakken, M; Simon, T; Stumpe, KO, 1998) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 5.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "In this multicenter, double-blind, active-controlled, randomized, parallel-group comparison, 66 patients with mild-to-moderate hypertension (sitting diastolic blood pressure, SDBP, 95-114 mm Hg) and LV mass index > 102 g/m2 for males and > 88 g/m2 for females were randomized to an initial treatment with 50 mg of either mibefradil or atenolol for 4 weeks." | 5.08 | A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. ( Cifkova, R; Höglund, C; Lindberg, E; Mimran, A; Tenczer, J; Watt, A; Wilkins, MR, 1998) |
| "The aim of this study was to evaluate the efficacy and tolerability of valsartan, a new angiotensin II receptor antagonist, versus atenolol in the treatment of severe primary hypertension." | 5.08 | Valsartan and atenolol in patients with severe essential hypertension. ( Botteri, F; Cifkova, R; Hradec, J; Oddou-Stock, P; Peleska, J; Pintérová, E; Rosolová, H; Thirlwell, J; Zeman, K, 1998) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 5.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension." | 5.08 | Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. ( Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA, 1998) |
| "The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)." | 5.08 | Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. ( Koch, B; Stimpel, M; Weber, MA, 1998) |
| "To evaluate cardiac responses to norepinephrine and epinephrine in heart transplant patients compared with patients with mild essential hypertension and to evaluate the contribution of beta2-receptors versus beta1-receptors to the cardiac responses by assessing the effects of the 2 agonists after treatment with placebo compared with the beta1-selective blocker atenolol and the nonselective blocker nadolol." | 5.08 | Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. ( Davies, RA; Fourney, A; Leenen, FH, 1998) |
| "-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension." | 5.08 | Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Hedner, T; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Wedel, H, 1998) |
| "1 We have utilised a non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensation volume flow (ACVF), to assess the cardiovascular effects of amlodipine and atenolol over 3 months in 24 patients with essential hypertension." | 5.07 | Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. ( Guy, S; Herity, N; Silke, B; Tham, TC, 1993) |
| "5 mg/day) on regression of left ventricular hypertrophy (LVH), an independent predictor of poor prognosis in hypertension, was compared by echocardiography to that of nifedipine (NFD, 40 mg/day), enalapril (ENL, 20 mg/day), atenolol (ATL, 100 mg/day), and hydrochlorothiazide (HCTZ, 25 mg/day) in four parallel double-blind studies in 151 hypertensive patients with a diastolic blood pressure between 95 and 120 mm Hg and a raised left ventricular mass index (LVMI) (mg/m2) (Devereux)." | 5.07 | Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. ( Amabile, G; Bory, M; De Luca, N; Denis, B; Imbs, JL; Lahiri, A; Marchegiano, R; Raftery, EB; Senior, R; Zannad, F, 1993) |
| "The acute and short-term responses to bisoprolol and to atenolol on systemic and renal hemodynamics and on ambulatory blood pressure (BP) were compared in a randomized double-blind cross-over study including 14 patients with mild to moderate essential hypertension." | 5.07 | Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. ( Collart, F; Degaute, JP; Leeman, M; Mélot, C; Peeters, L; van de Borne, P; Vandenhoven, G, 1993) |
| " Sixteen sedentary patients with essential hypertension underwent a randomized, double-blind, cross-over study comparing atenolol and diltiazem sustained-release 300 mg, each administered during 6 weeks, after a 15-day run-in placebo period." | 5.07 | Cardiopulmonary response during exercise of a beta 1-selective beta-blocker (atenolol) and a calcium-channel blocker (diltiazem) in untrained subjects with hypertension. ( Baleynaud, S; Cohen-Solal, A; Gourgon, R; Laperche, T; Sebag, C, 1993) |
| "The effects of monotherapy with atenolol or diltiazem-SR on blood pressure, 24-h blood pressure (BP) load, and exercise capacity were tested in patients with mild to moderate (stages I and II) essential hypertension." | 5.07 | Effects of atenolol and diltiazem-SR on exercise and pressure load in hypertensive patients. ( Chrysant, SG; Miller, E, 1994) |
| " The aim of this study was to compare the safety and antihypertensive efficacy of 25 to 50 mg carvedilol once daily with 50 to 100 mg atenolol once daily in patients with mild to moderate essential hypertension." | 5.07 | Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. ( Ruilope, LM, 1994) |
| "This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)." | 5.07 | Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994) |
| "Central nervous system (CNS)-related symptoms and quality of life during treatment with controlled-release (CR) metoprolol and a standard formulation of atenolol were compared in a double-blind crossover study in 60 patients with mild to moderate hypertension." | 5.07 | Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. ( Albrektsen, T; Dimenäs, E; Olofsson, B; Walle, PO; Westergren, G, 1994) |
| "Fifty patients with mild to moderate essential hypertension were randomized to receive either 20 mg fosinopril daily for 16 weeks or placebo for 4 weeks followed by 12 weeks of 50 mg atenolol daily." | 5.07 | Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. ( Andersson, PE; Haenni, A; Lithell, H; Reneland, R, 1994) |
| "The central role of insulin resistance in patients with essential hypertension was the impetus for the present study, in which carbohydrate and lipid metabolism were examined before and after three months treatment with doxazosin (n = 14) and atenolol (n = 15)." | 5.07 | Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. ( Andersson, PE; Berne, C; Johansson, J; Lithell, H, 1994) |
| "A randomized double-blind trial comparing the alpha-adrenergic blocker doxazosin and the beta-adrenergic blocker atenolol was completed by 131 patients with mild to moderate hypertension." | 5.07 | Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. ( Carruthers, SG; Huff, MW; Newman, C; Rabkin, SW; Sim, D, 1994) |
| " In the present study, the antihypertensive and negative chronotropic effects of 5 and 10 mg once-daily nebivolol were compared to those of 50 and 100 mg once-daily atenolol in 25 white, male subjects with essential hypertension, using a double-blind, crossover design, and a parallel placebo-treated group of subjects (N = 7)." | 5.07 | Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. ( Johnson, ML; Simon, G, 1993) |
| " The aim of this randomised, double-blind four way crossover study was to assess the interaction between the new calcium antagonist, lacidipine and atenolol, in patients with mild to moderate hypertension." | 5.07 | An assessment of lacidipine and atenolol in mild to moderate hypertension. ( Fowler, G; Hall, ST; Lyons, D; Petrie, JC; Webster, J, 1994) |
| "Atenolol and bisoprolol, two beta-1-selective blockers, were compared in patients with mild and medium severe hypertension." | 5.07 | [Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension]. ( Prásek, J; Soucek, M; Spinarová, L, 1993) |
| "5 mg and atenolol 50 mg (C-A) in adult black patients with mild to moderate hypertension (a resting supine diastolic blood pressure (DBP) between 95 and 115 mmHg after a two week placebo washout period)." | 5.07 | Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. ( Maharaj, B; van der Byl, K, 1993) |
| "Adverse alterations in lipid profile suggesting higher atherogenicity were observed following 12 weeks treatment with atenolol in patients of hypertension." | 5.07 | Effect of atenolol and labetalol on serum lipids. ( Dahiya, SS; Seth, RK; Seth, S; Sharma, D; Siwach, SB, 1993) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "The authors compared the relative safety and efficacy of changing treatment from once-daily atenolol to metoprolol in patients with essential hypertension." | 5.07 | A comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring. ( Brady, EM; Feig, PU; Kriegman, AG; May, S; Rutan, GH, 1993) |
| " They were randomized to a usual diet (n = 296) or to a weight loss diet (n = 291) and within each diet group to placebo, chlorthalidone, 25 mg/d, or atenolol, 50 mg/d." | 5.07 | Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. ( Blaufox, MD; Cutler, JA; Davis, BR; Kirchner, K; Langford, HG; Oberman, A; Wassertheil-Smoller, S; Zimbaldi, N, 1993) |
| " Forty patients with moderate to severe hypertension and daytime ambulatory diastolic blood pressure > or = 90 mm Hg were randomized double-blind to once-daily treatment with either quinapril up to 20 mg (n = 20) or atenolol up to 100 mg (n = 20) as single drugs or in combination with hydrochlorothiazide 25 mg over a period of 12 weeks." | 5.07 | Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring. ( Lacourcière, Y; Lefebvre, J; Poirier, L; Provencher, P, 1993) |
| "The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension." | 5.07 | Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. ( Doi, Y; Kagimoto, M; Kato, K; Kawasaki, K; Koga, S; Sakai, K; Sakaue, A; Sasaki, J; Takada, K; Takii, M, 1993) |
| "The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy." | 5.07 | Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993) |
| "The effects of six weeks of treatment with the selective peripheral alpha 1-adrenoceptor blocker terazosin, or the selective beta 1-adrenoceptor blocker atenolol on blood pressure, exercise performance and blood lipid profile were compared in a single-blind, randomized, crossover study of 17 patients with mild-to-moderate essential hypertension." | 5.07 | A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. ( Cleland, J; Coles, SJ; Humphreys, J; Ligueros, M; Unwin, R; Wilkins, MR, 1992) |
| "Terazosin is a selective alpha 1-adrenoceptor antagonist; its actions on the serum lipoprotein profile were compared with those of the cardioselective beta-adrenoceptor antagonist atenolol in 40 patients with mild to moderate hypertension." | 5.07 | Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension. ( Guy, S; Humphreys, JE; Silke, B, 1992) |
| "This study used 2D Doppler flowmetry to assess the effects on peripheral hemodynamics of effective treatment with nicardipine or atenolol in 40 patients with mild or moderate essential hypertension." | 5.07 | Large artery compliance in essential hypertension. Effects of calcium antagonism and beta-blocking. ( Andriani, A; De Cesaris, R; Filitti, V; Ranieri, G, 1992) |
| " Perindopril's effectiveness in mild to moderate hypertension was evaluated in three studies." | 5.07 | Clinical efficacy of perindopril in hypertension. ( Anderson, A; Morgan, T, 1992) |
| "5 mg, 5 mg, or 10 mg) once daily was compared with atenolol (50 mg to 100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992) |
| "Twenty-four patients with mild to moderate essential hypertension and no contraindications to atenolol participated in the study." | 5.07 | Classic conditioning and placebo effects in crossover studies. ( Ader, R; Suchman, AL, 1992) |
| "We prospectively measured UAE prior to and 4 and 8 weeks after treatment with enalapril, nitrendipine, atenolol, or a diuretic in 48 patients with essential hypertension and microalbuminuria." | 5.07 | Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. ( Baldari, G; Bianchi, S; Bigazzi, R; Campese, VM, 1992) |
| "A multicenter, randomized double-blind study of 6 months' duration was performed in 540 patients (average age 54 years, 57% male) with mild-to-moderate essential hypertension to determine the relative effects on quality of life of cilazapril, atenolol, and nifedipine retard." | 5.07 | Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. ( Bulpitt, CJ; Chase, DM; Collins, WC; Fletcher, AE; Furberg, CD; Goggin, TK; Hewett, AJ; Neiss, AM, 1992) |
| "Subjects were randomly assigned to usual, weight loss, or low sodium/high potassium diet and then randomly assigned to receive placebo, chlorthalidone, or atenolol." | 5.07 | Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. ( Blaufox, MD; Davis, B; Langford, H; Lee, HB; Oberman, A; Wassertheil-Smoller, S, 1992) |
| " The Trial of Antihypertensive Interventions and Management studied 878 mildly hypertensive individuals randomly assigned, in a 3 x 3 design, to no diet change, weight loss, or a low sodium-high potassium diet and to placebo, 25 mg chlorthalidone, or 50 mg atenolol." | 5.07 | Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. ( Blaufox, MD; Cutler, JA; Davis, BR; Hawkins, CM; Langford, HG; Oberman, A; Wassertheil-Smoller, S; Zimbaldi, N, 1992) |
| "A 3-month double-blind multicenter trial compared the efficacy and safety of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor, with atenolol in mild-to-moderate essential hypertension." | 5.07 | Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. ( Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992) |
| "29 women with pregnancy induced hypertension in the third trimester, 13 randomised to atenolol and 16 to pindolol." | 5.07 | Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. ( Ingemarsson, I; Marsál, K; Montan, S; Sjöberg, NO, 1992) |
| "A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block." | 5.07 | Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992) |
| "In a double-blind, crossover study, five white men with mild-to-moderate hypertension received placebo and fixed doses of atenolol, metoprolol, chlorthalidone, verapamil, and the combination of atenolol and chlorthalidone in a quasi-random order." | 5.07 | Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. ( Durel, LA; Hayashi, PJ; Schneiderman, N; Weidler, DJ, 1992) |
| "In a multicenter, parallel, double-blind study, lisinopril, a new converting enzyme inhibitor, was compared with atenolol in the treatment of mild to moderate essential hypertension." | 5.07 | Lisinopril versus atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition. ( Darne, B; Fouchard, M; Garabedian, VG; Madonna, O; Pannier, BE; Safar, ME, 1991) |
| "The immediate and short-term (2 week) hemodynamic and humoral effects of the beta-1 antagonist, beta-2 agonist, celiprolol, were compared with those of more prolonged atenolol therapy in 12 patients with essential hypertension." | 5.07 | Hemodynamic effects of celiprolol in essential hypertension. ( Frohlich, ED; Kaesser, UR; Ketelhut, R; Losem, CJ; Messerli, FH, 1991) |
| "This was a double-blind multicenter study to compare the efficacy, tolerability and effects on the quality of life with isradipine and atenolol in the treatment of essential hypertension." | 5.07 | Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group. ( Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Kullman, S; Scherstén, B; Sivertsson, R; Sörensen, S, 1991) |
| "Carvedilol is a novel treatment for hypertension, having a balanced pharmacology of vasodilation and beta-receptor blockade." | 5.07 | A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. ( Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI, 1991) |
| "This study was designed to compare the antihypertensive efficacy of nitrendipine and atenolol in young and middle-aged patients with mild or moderate essential hypertension and to assess treatment effects on plasma lipids and potential changes in left ventricular mass (LVM)." | 5.07 | Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass. ( Arocha, I; Arreaza, MR; Barrios, YE; Corral, JL; Galué, GA; Giralt, J; López, NC; Rincón, LA, 1991) |
| "Six double-blind studies were designed to assess the efficacy, tolerance, and safety of the angiotensin-converting enzyme inhibitor ramipril in patients with mild-to-moderate essential hypertension." | 5.07 | Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis. ( Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C, 1991) |
| "This study assessed the effectiveness of atenolol in the treatment of moderate and severe hypertension during pregnancy." | 5.07 | Effectiveness of atenolol in the treatment of hypertension during pregnancy. ( Alvarez, L; Baglivo, HP; Cerrato, C; Drisaldi, S; Esper, RJ; Fabregues, G; Moschettoni, C; Pituelo, D; Varas Juri, P, 1992) |
| "The antihypertensive and metabolic effects of placebo (PL), a fixed combination of hydrochlorothiazide (25 mg) and triamterene (50 mg) (HCTZ/TRI), atenolol (25 mg) (Atc-25), atenolol (50 mg) (Ate-50) and their combination with HCTZ/TRI given once daily, were tested on 256 patients with mild-to-moderate essential-hypertension." | 5.07 | Antihypertensive and metabolic effects of single and combined atenolol regimens. ( Chappel, C; Chrysant, SG; Farnham, DJ; Levin, B; Lueg, M; McCluskey, D; Steiner, C, 1992) |
| " Maximal aerobic exercise capacity, submaximal endurance exercise performance, and exercise haemodynamics have been studied in sixteen patients with mild to moderate essential hypertension during treatment with captopril and atenolol." | 5.07 | Exercise performance during captopril and atenolol treatment in hypertensive patients. ( Koene, FM; Tan, ES; Van Baak, MA; Verstappen, FT, 1991) |
| "The short-term effects of atenolol and nifedipine on plasma levels of atrial natriuretic peptide (ANP), plasma renin activity (PRA), and plasma aldosterone (PA) were studied in two groups of patients with uncomplicated essential hypertension." | 5.07 | Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. ( Bucci, V; Casale, R; Colantonio, D; Desiati, P; Giandomenico, G; Pasqualetti, P, 1991) |
| "The antihypertensive effects and safety profiles of lisinopril (10 to 40 mg) and atenolol (50 to 100 mg) were compared in a randomized, double-blind, parallel group trial in 144 patients with essential hypertension." | 5.07 | Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. ( Admani, K; Angell-James, JE; Beevers, DG; Blackwood, RA; Feely, M; Garnham, S; Husaini, MH; Kumar, S; Mehrzad, AA; Watson, M, 1991) |
| "In this randomised double-blind parallel study, we compared the efficacy of labetalol and atenolol in a group of black (n = 33) and white (n = 34) hypertensives with uncomplicated essential hypertension after obtaining pretreatment renin profiles." | 5.07 | Renin profile, race, and antihypertensive efficacy with atenolol and labetalol. ( DiPette, DJ; Goodman, RP; McKenney, JM; Townsend, R; Wright, JT, 1991) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 5.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 125 patients (116 of whom had not previously used antihypertensive drugs) with a five times elevated diastolic pressure (DP) of between 95 and 130 mmHg were randomized and treated daily either with atenolol 50 mg o." | 5.07 | Captopril compared to atenolol in mild to moderate hypertension in a randomized double-blind controlled trial. ( Havinga, TK; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1991) |
| "Various aspects of carbohydrate and lipid metabolism have been studied in two groups of patients with mild hypertension before and after four months of treatment with either nifedipine (n = 12) or atenolol (n = 12)." | 5.07 | Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. ( Chen, YD; Hoffman, B; Reaven, GM; Sheu, WH; Swislocki, AL, 1991) |
| "In persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%, with 5-year absolute benefit of 30 events per 1000 participants." | 5.07 | Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. ( , 1991) |
| "To evaluate differences in efficacy, safety, and quality of life, 394 male patients with mild-to-moderate hypertension were randomized to receive 20 weeks of either atenolol or nifedipine gastrointestinal therapeutic system (GITS) in a multicenter double-blind trial." | 5.07 | Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. ( Anderson, RB; Hollenberg, NK; Testa, MA; Williams, GH, 1991) |
| "In 15 patients with mild to moderate essential hypertension, the effects of diltiazem (120 mg twice daily) were compared with those of atenolol (50 mg once daily), the two drugs in combination, and placebo in a randomized double-blind cross-over study with treatment phases of 4 weeks duration." | 5.06 | Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. ( Bune, AJ; Cain, MD; Chalmers, J; Morris, MJ; Russell, AE; Tonkin, AL; West, MJ; Wing, LM, 1990) |
| "Carvedilol has been shown to be effective and safe in patients with essential hypertension when given as monotherapy." | 5.06 | Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; van der Does, R; Widmann, L, 1990) |
| ") as an adjunct to pre-existing hydrochlorothiazide (HCTZ) monotherapy in patients with mild to moderate hypertension [diastolic blood pressure (DBP), 100-115 mm Hg]." | 5.06 | Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. ( Hörrmann, M; Machwirth, M; Stienen, U; Uberbacher, HJ; van der Does, R; Widmann, L, 1990) |
| "This study was performed to assess the effect of a calcium channel blocker (nifedipine) and beta-blockade (atenolol) on left ventricular early diastolic function and filling in essential hypertension (WHO stage I, II; HT)." | 5.06 | [Effects of calcium antagonists or beta-blockade on left ventricular diastolic function in essential hypertension]. ( Arita, M; Fujiwara, S; Masuyama, Y; Nakamura, N; Nakamura, Y; Nakatsu, C; Nishio, I; Ohshika, H; Shiotani, M; Ueno, Y, 1990) |
| "Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension." | 5.06 | Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. ( Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990) |
| "The efficacy and tolerability of doxazosin and atenolol in the management of mild and moderate hypertension were compared in a multicentre, parallel study, the first year of which was randomized and double-blind." | 5.06 | A long-term study of atenolol and doxazosin in mild and moderate hypertension. ( Daae, L; Talseth, T; Westlie, L, 1990) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 5.06 | Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1990) |
| " The influence of long-acting propranolol and of atenolol on the circadian rhythm of heart rate was assessed using 24 h electrocardiographic recordings in elderly patients with essential hypertension." | 5.06 | Influences of propranolol and atenolol on the circadian rhythm of heart rate in elderly patients with essential hypertension. ( Sakata, S; Shimamoto, H; Shimamoto, Y, 1990) |
| "A randomized double-blind study lasting 2 months was performed with either 25 mg captopril twice a day or 50 mg atenolol once a day in 125 patients with established diastolic hypertension (diastolic blood pressure greater than 95 mmHg) identified during a population screening programme of subjects aged less than 65 years." | 5.06 | Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of captopril and atenolol. ( Bulpitt, CJ; Fletcher, AE; Havinga, TK; Hawkins, CM; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1990) |
| "In a double-blind study with parallel groups, the clinical bioequivalence of the antihypertensive effect of metoprolol CR/ZOK (controlled release formulation) 50 mg and atenolol 50 mg in ordinary tablets given once daily for uncomplicated hypertension was investigated." | 5.06 | A double-blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension. ( Berger, J; Klein, G; Menzel, T; Olsson, G, 1990) |
| " The aim of the study was to compare the efficacy and the tolerability of treatment with atenolol (50-100 mg once daily), nitrendipine (20-40 mg once daily) and their combination (atenolol 50 mg + nitrendipine 20 mg) once daily in patients with mild to moderate essential hypertension." | 5.06 | Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. ( Coulson, RR; Fitzsimons, TJ; Irvine, N; Lewis, R; Maclean, D; McDevitt, DG; McEwen, J; McLay, JS; Mitchell, ET; Slater, ND, 1990) |
| "The study objective was to determine the effects of monotherapy with clonidine and atenolol versus placebo on serum lipids, apolipoproteins, and blood pressure in patients with mild primary hypertension." | 5.06 | The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. ( Bradley, CA; Burger, C; Hays, JT; Houston, MC; Nadeau, J; Olafsson, L; Swift, L, 1990) |
| "This randomized, double-blind parallel study compared the effects of atenolol, captopril, enalapril and propranolol in 360 men with mild-to-moderate essential hypertension." | 5.06 | Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. ( Friedhoff, AJ; Santo, JP; Steiner, SS; Wecker, JR; Wilson, BL, 1990) |
| " In this double-blind randomized study, after a 4-weeks placebo period, 18 patients with mild to moderate primary hypertension were assigned to treatment with either dilevalol (n = 9) daily or atenolol (n = 9) over a period of 3 months." | 5.06 | Comparative effects of dilevalol and atenolol on lung function and airway response to methacholine in hypertensive subjects. ( Boulet, LP; Lacourcière, Y; Lampron, N; Milot, J, 1990) |
| "A double-blind, positively controlled, forced dose titration study comparing the efficacy and safety of atenolol, captopril, and verapamil sustained release as single agents in the treatment of black patients with mild to moderate hypertension (diastolic blood pressure, 95 to 114 mm Hg) was conducted." | 5.06 | A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. ( Curry, C; Gray, J; Hollifield, J; Kong, BW; Saunders, E; Schoenberger, J; Sowers, JR; Vertes, V; Weir, MR; Zemel, MB, 1990) |
| "A multicenter, randomized double-blind clinical trial was conducted among 306 black men and women with mild to moderate hypertension to determine effects of atenolol, captopril, and verapamil SR on measures of quality of life." | 5.06 | Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. ( Baume, RM; Croog, SH; Kong, BW; Levine, S; Saunders, E; Weir, MR, 1990) |
| "The effect of enalapril was evaluated in 67 patients with essential hypertension, and its therapeutic efficacy was compared with atenolol in a placebo run-in, single-blind, cross-over trial." | 5.06 | Efficacy of enalapril in essential hypertension and its comparison with atenolol. ( Basha, A; Bolya, YK; el Mangoush, M; Gamati, A; Gupta, BS; Kumar, S; Singh, NK, 1990) |
| "The cardioselective beta-blocker atenolol and the angiotensin-converting enzyme inhibitor enalapril were compared for efficacy, safety, and quality-of-life factors in 30 patients with hypertension whose hypertension was inadequately controlled with diuretic alone." | 5.06 | Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril. ( Blumenthal, JA; Ekelund, LG; Emery, CF, 1990) |
| "To determine the effect of atenolol on the outcome of pregnancy in women with essential hypertension." | 5.06 | Atenolol in essential hypertension during pregnancy. ( Butters, L; Kennedy, S; Rubin, PC, 1990) |
| "The purpose of this multicenter investigation was to determine the efficacy and safety of the alpha/beta-blocker labetalol versus the beta 1-selective beta-blocker atenolol in white and black patients with essential hypertension." | 5.06 | Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. ( Blumfield, D; Cronin, R; DiPette, DJ; Goodman, R; Gradman, A; Katz, LA; McCarthy, EP; Sopko, G; Townsend, RR, 1990) |
| "Twenty-eight patients with mild to moderate essential hypertension well controlled by atenolol entered a five-week, double-blind, placebo-controlled trial of the effects of sulindac and naproxen on blood pressure (BP) control." | 5.06 | Effect of naproxen and sulindac on blood pressure response to atenolol. ( Abate, MA; D'Alessandri, R; Layne, RD; Neely, JL, 1990) |
| "A multicentre randomised double-blind trial was performed in order to compare the therapeutic efficacy and acceptability of the angiotensin converting enzyme (ACE) inhibitor perindopril with those of atenolol in mild to moderate hypertension." | 5.06 | A double blind comparison of perindopril and atenolol in essential hypertension. ( Brown, CL; Creytens, G; Mimran, A; Rorive, G; Santoni, JP; Thurston, H; Zanchetti, A, 1990) |
| "Forty-one elderly patients with mild to moderate hypertension (resting diastolic blood pressure 100-130 mmHg after an eight week placebo run-in phase) were randomised to a double-blind parallel group comparison of nifedipine retard 10 mg twice daily or atenolol 50 mg once daily." | 5.06 | Comparative trial of nifedipine retard and atenolol in the treatment of elderly patients with mild to moderate hypertension. ( Clamp, M; Holmes, B; Wilcox, R, 1990) |
| "Dilevalol (100 mg) or atenolol (50 mg) was given orally in 13 subjects with essential hypertension." | 5.06 | Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects. ( Ebihara, A; Fujimura, A; Kotegawa, T, 1990) |
| "We studied the effect of phenylpropanolamine on blood pressures in seven patients whose hypertension was controlled with beta blockers." | 5.06 | The effect of single-dose phenylpropanolamine on blood pressure in patients with hypertension controlled by beta blockers. ( Gross, CR; O'Connell, MB, 1990) |
| "A new non-imaging echo-Doppler cardiac output device that works on the principle of attenuated compensation volume flow (ACVF), has been used to assess the cardiovascular effects of atenolol and dilevalol in 24 patients with essential hypertension." | 5.06 | Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension. ( Silke, B; Taylor, SH; Tham, TC, 1990) |
| "Left ventricular diastolic filling was investigated in 12 black and 15 white subjects before and after double-blinded randomized treatment of mild to moderate hypertension with combined alpha- and beta-adrenergic receptor blockade (labetalol) and beta-blockade alone (atenolol)." | 5.06 | Left ventricular filling in hypertensive blacks and whites following adrenergic blockade. ( Cornman, C; Dianzumba, SB; DiPette, D; Joyner, CR; Mauro, K; Theobald, T; Townsend, R; Weber, E, 1990) |
| " In two, randomized, placebo-controlled, 5-way crossover trials, the pulmonary effects of celiprolol 200 and 400 mg, propranolol 40 mg and atenolol 100 mg were compared in 34 asthmatic patients." | 5.06 | Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. ( Applin, WJ; Brown, R; Caruso, FS; Doshan, HD; Rosenthal, RR; Slutsky, A, 1986) |
| "The antihypertensive effects of equivalent beta-blocking doses of atenolol and celiprolol were compared in 55 patients with mild to moderate hypertension." | 5.06 | A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension. ( Rosenthal, F; Silke, B; Taylor, S, 1986) |
| "Forty-two patients (28 men, 14 women, age range 27-65 years) with newly discovered mild to moderate hypertension were randomly allocated to treatment with either bisoprolol or atenolol for a double-blind comparison of these two beta 1-adrenoceptor blocking drugs." | 5.06 | A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure. ( Lithell, H; Selinus, I; Vessby, B; Weiner, L, 1986) |
| "In a multicenter, parallel, double-blind study, lisinopril was compared with atenolol in the treatment of mild to moderate essential hypertension." | 5.06 | The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. ( Arriaga, J; Bernal, R; Bernardes, H; Bolzano, K; Calderon, JL; Debruyn, J; Dienstl, F; Drayer, J; Goodfriend, TL; Gross, W, 1987) |
| "The antihypertensive effect and safety of doxazosin once-daily was compared with that of atenolol once-daily in 40 patients with mild to moderate hypertension." | 5.06 | Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1988) |
| "Once-daily administration of amlodipine, a long-acting dihydropyridine calcium-channel blocker, and atenolol, a cardioselective beta-adrenoceptor blocking agent, were compared in patients with mild to moderate hypertension in a multicenter placebo-controlled trial." | 5.06 | Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. ( Cocco, G; de Bruijn, B; Tyler, HM, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with placebo and atenolol in 125 patients with mild to moderate systemic hypertension [supine diastolic blood pressure (DBP) 90-114 mm Hg]." | 5.06 | A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1988) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 5.06 | Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Lissens, W; Staessen, J, 1989) |
| "60 Patients with primary hypertension (diastolic blood pressure when resting supine 95-119 mm Hg on at least two occasions during four to six weeks of treatment with placebo) randomised to receive either metoprolol (n = 30) or atenolol (n = 30) during the first treatment period." | 5.06 | Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. ( Berne, C; Lithell, H; Pollare, T; Selinus, I, 1989) |
| "The effects of once-daily therapy with doxazosin (1 to 8 mg/day) on exercise capacity, left ventricular performance and hemodynamics (radionuclide ventriculography) were compared with those of atenolol (50 to 100 mg/day) and placebo in a randomized, double-blind crossover trial in 16 patients (9 men) with mild hypertension." | 5.06 | Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function. ( Bautovich, GJ; Fletcher, PJ; Gillin, AG; Horvath, JS; Hutton, BF; Tiller, DJ, 1989) |
| "A total of 152 patients with essential hypertension (World Health Organization classification I/II) entered a multicenter randomized study to assess the safety and efficacy of isradipine compared with, and in combination with, the beta-blocker atenolol." | 5.06 | A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group. ( , 1989) |
| "In a double-blind parallel-group randomized study, 28 patients with essential hypertension (World Health Organization class I/II) were allocated in equal numbers to one of two groups for treatment with either isradipine 5 to 20 mg twice daily or atenolol 50 to 100 mg once daily." | 5.06 | Differential effects of isradipine and atenolol on peripheral hemodynamics and arterial compliance. ( Jespersen, LT; Krusell, LR; Pedersen, OL; Sihm, I, 1989) |
| "We compared the effects of transdermal clonidine and oral atenolol on acute exercise performance and on conditioning response to an 8-week program of regular aerobic exercise in young, otherwise healthy subjects with mild hypertension." | 5.06 | Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension. ( Davidman, M; Davies, SF; Graif, JL; Husebye, DG; Iber, C; Maddy, MM; McArthur, CD; O'Connell, MB; Path, MJ, 1989) |
| "The effects of two cardioselective beta-adrenergic blocking agents--celiprolol (claimed to have bronchodilator properties) and atenolol (without such claims)--on respiratory function and control of asthma were studied in ten asthmatic patients with mild to moderate essential hypertension." | 5.06 | Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. ( Bateman, ED; Jennings, AA; Opie, LH; van Zyl, AI, 1989) |
| "Fifty milligrams of carvedilol and 100 mg atenolol were administered in a random order once a day for 2 months to 43 patients with mild to moderate hypertension, in a double-blind crossover study." | 5.06 | Carvedilol and atenolol once daily in the treatment of hypertension. ( Härkönen, R; Hilden, M; Icen, R; Kohvakka, A; Linna, M; Lukkala, K; Luurila, OJ; Sillanpää, J; Vänskä, O, 1989) |
| "M-mode echocardiography was used in 80 patients with essential hypertension to study changes in the index of left ventricular mass during treatment over 3 years with reserpine, prazosin, indapamide and atenolol, separately or in combination." | 5.06 | The effect of chronic antihypertensive therapy on the index of left ventricular mass in patients with essential hypertension. ( Duman, EL; Komsuoğlu, B; Komsuoğlu, SS; Ozgür, O, 1989) |
| "In a double-blind, randomized, cross-over study in 23 diabetic patients, insulin treated (N = 11) or noninsulin treated (N = 12), with mild to moderate hypertension, the hypotensive effects of captopril and atenolol were compared." | 5.06 | A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. ( de Nobel, E; Elving, LD; Thien, T; van Lier, HJ, 1989) |
| "The antihypertensive effects of nisoldipine, a calcium channel blocker, and atenolol, a beta-adrenergic blocker, were compared in patients with mild or moderate essential hypertension." | 5.06 | Comparison of nisoldipine and atenolol in the treatment of essential hypertension. ( Fukuyama, M; Okabayashi, H; Takahashi, H; Yoneda, S; Yoshimura, M, 1989) |
| "Sixty patients, with mild to moderate essential hypertension, were considered for a double-blind trial comparing the effects of ketanserin and atenolol." | 5.06 | A double-blind comparative study of ketanserin with atenolol in essential hypertension. ( Andreoni, A; Antonicelli, R; Gambini, C; Paciaroni, E; Saccomanno, G, 1989) |
| "The antihypertensive efficacy and tolerability of the 5HT2-receptor antagonist ketanserin was investigated in 188 patients aged 41 to 82 years with mild to moderate essential hypertension." | 5.06 | [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy]. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Reutter, F; Vallotton, MB, 1989) |
| " Aim of this work was to evaluate the influence of obesity on the kinetics and the antihypertensive effect of two Beta-blockers with different solubility such as: the water-soluble, atenolol and the liposoluble, metoprolol." | 5.06 | Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. ( Fasano, ML; Ferrara, LA; Galletti, F; Groppi, A; Mancini, M; Montagna, M, 1989) |
| "The effects of ketanserin on blood pressure and well-being were investigated in 188 patients, aged 41-82 years, with mild to moderate essential hypertension." | 5.06 | Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin. ( Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Heer, K; Reutter, F; Vallotton, MB, 1989) |
| " After a washout period, 58 patients with essential hypertension received either 20 mg of enalapril or 50 mg of atenolol." | 5.06 | The neglected time factor and antihypertensive therapy. A pitfall in evaluating side effects in a cross-over study. ( Baumgart, P; Edmonds, D; Greminger, P; Vetter, H; Vetter, W, 1988) |
| "In order to assess whether blood pressure reduction with atenolol or enalapril is associated with changes in renal prostaglandin (PG) synthesis, we studied the effects of 10 weeks therapy in 20 subjects with mild or moderate hypertension." | 5.06 | Effects of atenolol and enalapril on blood pressure, plasma renin activity and urinary prostanoids. ( Wilson, TW, 1988) |
| "Atenolol (A) and enalapril (E), two agents widely used as first-line monotherapy in arterial hypertension, have never been compared in their potency and duration of action by using 24-h ambulatory blood pressure monitoring (ABPM)." | 5.06 | Duration of the antihypertensive action of atenolol, enalapril and placebo: a randomized within-patient study using ambulatory blood pressure monitoring. ( Benemio, G; Boldrini, F; Gatteschi, C; Guerrieri, M; Porcellati, C; Verdecchia, P, 1988) |
| "In an international, randomized, double-blind trial involving 229 patients, 400 mg of bevantolol was compared with 100 mg of atenolol (both in single daily doses) in the management of mild to moderate hypertension (diastolic blood pressure [BP] 95 to 115 mm Hg after a 4-week placebo washout period)." | 5.06 | Comparison of bevantolol and atenolol for systemic hypertension. ( Fairhurst, GJ, 1986) |
| "1 Eight men with primary hypertension were treated for 3 weeks with placebo, epanolol (200 mg or 400 mg), or atenolol 100 mg in a randomised cross-over study." | 5.06 | Post-exercise hypotension: the effects of epanolol or atenolol on some hormonal and cardiovascular variables in hypertensive men. ( Baylis, PH; Bennett, T; Broughton Pipkin, F; Macdonald, IA; Wilcox, RG, 1987) |
| "1 To compare the haemodynamic effects of secondary characteristics of beta-adrenoceptor blockers with an angiotensin converting enzyme inhibitor forty patients with previously untreated mild to moderate hypertension were prescribed either atenolol 50-100 mg day-1, labetalol 200-800 mg day-1, pindolol 10-30 mg day-1 or captopril 25-100 mg day-1 and observed for 6 months." | 5.06 | Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function. ( Breckenridge, AM; Grimmer, SF; Orme, ML; Roberts, DH; Tsao, Y; Winstanley, PA, 1987) |
| "In a six month placebo-controlled cross-over trial twenty patients with hypertension and peripheral arterial disease were randomised to captopril 25 mg twice daily, atenolol 100 mg once daily, labetalol 200 mg twice daily, or pindolol 10 mg twice daily for one month." | 5.06 | Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. ( Breckenridge, A; McLoughlin, GA; Roberts, DH; Tsao, Y, 1987) |
| "Sixteen patients with mild to moderate hypertension were randomized to receive either atenolol 100 mg a day (group A: 2 females, 6 males, mean age 42." | 5.06 | [Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension]. ( Amiel, A; Boutaud, P; Ciber, MA; Demange, J; Herpin, D, 1987) |
| "A randomised double blind parallel group study was performed to compare the efficacy and acceptability of slow release nifedipine (maximum dose 40 mg twice a day) with those of atenolol (maximum dose 100 mg once a day) as single agents for the treatment of essential hypertension." | 5.06 | Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee. ( , 1988) |
| "Twenty-four men with mild essential hypertension were assigned randomly to receive propranolol (n = 9), atenolol (n = 7), or a placebo (n = 8)." | 5.06 | Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. ( Blumenthal, JA; Ekelund, LG; Madden, DJ, 1988) |
| "The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension." | 5.06 | Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988) |
| "0, range 37-61 years; eight females) with mild essential hypertension (DBP greater than 90 mm Hg on placebo) completed a randomised, double-blind placebo controlled crossover study comparing the hypotensive effects of bisoprolol (10-20 mg) and atenolol (50-100 mg) each taken once daily." | 5.06 | A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ( Ioannides, C; Johnston, A; Lewis, R; Maclean, D; McDevitt, DG, 1988) |
| "Fourteen male patients (mean age +/- SD, 52 +/- 11 years) with a history of hypertension (systolic blood pressure, 148 +/- 10 mm Hg; diastolic blood pressure, 99 +/- 2 mm Hg) were enrolled in a cross-over trial of prazosin and atenolol, with a minimum of eight weeks of treatment with each drug." | 5.06 | Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. ( Krauss, RM; Superko, HR; Wood, PD, 1989) |
| "The efficacy and tolerability of the alpha-blocker prazosin was compared with that of atenolol, a beta-blocker, in the long-term treatment of uncomplicated, essential hypertension." | 5.06 | The long-term antihypertensive effects of prazosin and atenolol. ( Itskovitz, HD; Khoury, S; Krug, K; Mollura, JL, 1989) |
| "The effects on plasma lipids and apoproteins A-I and B of oral administration of doxazosin and atenolol over a 20-week period were studied in 42 patients with mild to moderate essential hypertension." | 5.06 | Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. ( Himanen, P; Lehtonen, A; Marniemi, J; Niittymäki, K; Saraste, M, 1986) |
| "Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist which has been shown to be effective and well tolerated in the treatment of hypertension given in once-daily doses as monotherapy for up to 1 year or as an adjunct to thiazide or beta-adrenoceptor blockers." | 5.06 | The antihypertensive effects of doxazosin: a clinical overview. ( Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986) |
| "The pharmacodynamics of doxazosin and atenolol were compared on single study days in 39 patients with mild to moderate hypertension receiving long-term double-blind treatment." | 5.06 | The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment. ( Faulkner, JK; Himanen, P; Karjalainen, U; Saraste, M, 1987) |
| "Patients with moderate to severe essential hypertension (mean untreated supine blood pressure 190/112 mm Hg) received once daily enalapril 20-40 mg or atenolol 50-100 mg, supplemented if required by hydrochlorothiazide 25-100 mg, in a randomized observer-blind trial." | 5.06 | Enalapril in moderate to severe hypertension: a comparison with atenolol. ( Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986) |
| "The effects of lisinopril (MK-521; MSD) and atenolol in the treatment of mild-to-moderate essential hypertension were compared in a double-blind, parallel, controlled study, with 24 patients randomly assigned to lisinopril and 12 to atenolol." | 5.06 | A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension. ( Parag, KB; Seedat, YK, 1987) |
| "The aim of the present double-blind crossover study was to compare the antihypertensive efficacy and tolerability of enalapril and atenolol in 48 patients with mild to moderate essential hypertension." | 5.06 | Enalapril as a first-step agent in essential hypertension: a comparative study with atenolol. ( Edmonds, D; Greminger, P; Knorr, M; Locher, R; Vetter, H; Vetter, W, 1986) |
| "In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic)." | 5.06 | Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. ( Curry, RC; Schwartz, KM; Urban, PL, 1988) |
| "The anti-hypertensive and tolerance of penbutolol, a non-selective beta-blocker of long duration and endowed with an ISA effect were compared with those of atenolol, a cardioselective beta-blocker without ISA effect, in two groups of 20 patients each suffering from slight-to-moderate essential primary hypertension selected on the basis of a clinico-experimental design of open randomised type." | 5.06 | [Treatment of essential mild-to-moderate arterial hypertension with once-daily penbutolol. Controlled clinical study vs atenolol]. ( Bianchini, C; Gennari, C; Martinelli, M; Nami, R, 1988) |
| "The efficacy, tolerance and effect on serum lipids of acebutolol were compared with those of atenolol over a 6-month period in a large group of patients with mild arterial hypertension." | 5.06 | Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension. ( De Backer, G, 1988) |
| " Twenty-six adult men with mild essential hypertension received either a placebo or a beta blocker (atenolol or propranolol) for 2 weeks." | 5.06 | Memory performance by mild hypertensives following beta-adrenergic blockade. ( Blumenthal, JA; Ekelund, LG; Krantz, DS; Light, KC; Madden, DJ; McKee, DC, 1986) |
| "Atenolol and metoprolol are the two most widely used beta 1-adrenoceptor antagonists in the treatment of essential hypertension." | 5.06 | No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. ( Almkvist, G; Dahlöf, C; Dimenäs, E; Jern, S; Johansson, B; Larsson, C; Lorentzon, S; Nilsson, D; Nygaard-Pedersen, L, 1988) |
| "The safety and efficacy of once-daily terazosin hydrochloride administered concomitantly with once-daily atenolol for the treatment of essential hypertension were evaluated in this double-blind, multiclinic, placebo-controlled study." | 5.06 | Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. ( Holtzman, JL; Kaihlanen, PM; Lewin, AJ; Oberlin, JA; Rider, JA; Spindler, JS, 1988) |
| "In this randomised, double-blind, crossover trial, the efficacy in hypertension of atenolol and nifedipine as single agents or in combination was compared." | 5.06 | Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study. ( Anderton, JL; Crowe, PF; Mittra, B; Perks, WH; Stanley, NN; Vallance, BD, 1988) |
| "This randomised, double-blind, crossover study investigated the haemodynamic effects of a beta-blocker (atenolol 50mg) and a calcium antagonist (sustained release nifedipine 20mg) given either separately or in combination in 3 groups of patients with mild to moderate essential hypertension." | 5.06 | Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension. ( Heath, ID; Larkin, H; Stanley, NN; Thirkettle, JL; Varma, MP, 1988) |
| "We compared the relative effects of relaxation therapy, conventional hygienic techniques, and a beta-receptor blocker, atenolol, on control of arterial pressure, left ventricular mass, and diastolic function in patients with mild primary hypertension." | 5.06 | Behavioral vs beta-blocker therapy in patients with primary hypertension: effects on blood pressure, left ventricular function and mass, and the pressor surge of social stress anger. ( Aleman, E; Allen, J; Davison, G; DeQuattro, V; Kimura, S; Konugres, G; Lee, DD, 1988) |
| "A randomized, double-blind study was undertaken to compare atenolol and captopril as second-step agents in the treatment of essential hypertension resistant to 5 mg bendrofluazide daily." | 5.06 | Comparative efficacy of captopril and atenolol in moderately severe essential hypertension. ( Blake, S; Carey, M, 1986) |
| "To compare the effects of prazosin and atenolol on plasma lipid concentrations, 60 patients with arterial hypertension (diastolic 90 to 120 mm Hg, systolic 160 to 200 mm Hg) were allocated at random to one of two treatment groups." | 5.06 | Effects of two antihypertensive agents on lipids, lipoproteins, and apoproteins A and B. Comparison of prazosin and atenolol. ( Jaillard, J; Rouffy, J, 1986) |
| "The effects of prazosin and atenolol monotherapy on plasma lipid concentrations were compared in 51 patients with mild to moderate essential hypertension." | 5.06 | Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension. ( Lowenstein, J; Neusy, AJ, 1986) |
| "Three therapies were used to treat 35 patients with mild to moderate systemic hypertension: (1) the cardioselective beta-adrenoceptor blocker atenolol, (2) the calcium antagonist nifedipine and (3) combination therapy for those who failed to reach the target diastolic blood pressure (BP) of less than 90 mm Hg with monotherapy." | 5.06 | Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone. ( Daniels, AR; Opie, LH, 1986) |
| "After a run-in period on placebo, 26 patients with essential hypertension were prescribed single-blind tibalosine, 150 mg daily." | 5.06 | Chronic treatment with tibalosine in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; M'Buyamba-Kabangu, JR; Staessen, J, 1986) |
| "In a double-blind study 19 patients with mild and uncomplicated arterial hypertension were randomized to treatment with either pindolol 10 mg or atenolol 100 mg once daily for 4 weeks." | 5.06 | Changes in blood pressure, heart rate and thyroid hormones after sudden withdrawal of pindolol and atenolol in hypertensive patients. ( Friis, T; Jespersen, CM; Jørgensen, PH; Krogsgaard, AR, 1986) |
| "The influence of hydrochlorothiazide and atenolol on serum lipoproteins was investigated in a randomized, prospective study on 68 men with essential hypertension." | 5.06 | Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial. ( Holzgreve, H; Middeke, M; Schwandt, P; Weisweiler, P, 1987) |
| "The effects of graded doses of verapamil were compared with those of a combination of atenolol and hydralazine in a double-blind, randomised, crossover trial in 16 patients with essential hypertension." | 5.06 | Verapamil in essential hypertension: a comparison with atenolol plus hydralazine. ( Bailey, BP; Duggin, GG; Fletcher, PJ; Hall, B; Horvath, JS; Tiller, D, 1987) |
| " All patients were treated in the same hypertension clinic with the beta 1-selective agent atenolol, administered either alone or more usually with a diuretic with or without a vasodilator or other agents." | 5.06 | Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. ( Cruickshank, JM; Pennert, K; Sörman, AE; Thorp, JM; Zacharias, FJ; Zacharias, FM, 1987) |
| "In 93 patients with hypertension uncontrolled by bendrofluazide 5 mg plus atenolol 100 mg daily, the effects of adding nifedipine (up to 60 mg/day, n = 31), prazosin (up to 20 mg/day, n = 31), or hydralazine (up to 200 mg/day, n = 31) were compared in a 6 month open random parallel group study." | 5.06 | Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker. ( Parnell, L; Ramsay, LE; Waller, PC, 1987) |
| " Seven patients with intermittent claudication were randomly allocated to treatment with atenolol 100 mg or pindolol 10 mg." | 5.06 | The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication. ( Boström, PA; Janzon, L; Ohlsson, O; Westergren, A, 1986) |
| "The pharmacodynamic effects of single oral doses of atenolol (100 mg), labetalol (300 mg), and propranolol (80 mg) were compared with those of placebo in a randomized, double-blind, Latin square design in 12 patients with hypertension." | 5.06 | The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function. ( Berry, DA; Finley, D; Holtzman, JL; Johnson, B; Sirgo, MA, 1986) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "The efficacy and tolerability of the new ACE-inhibitor enalapril (MK 421) and the beta 1-selective adrenoceptor blocker atenolol for the treatment of primary hypertension were compared in a double blind parallel study." | 5.05 | Enalapril and atenolol in primary hypertension--a comparative study of blood pressure lowering and hormonal effects. ( Karlberg, BE; Ohman, KP, 1984) |
| "Twenty-five patients with moderate essential hypertension (standing diastolic blood pressure 100-125 mmHg, phase 5) completed a single-blind placebo-controlled cross-over study comparing four week periods of treatment with atenolol 100 mg, metoprolol 100 mg, metoprolol durules 200 mg, slow-release oxprenolol 160 mg, and slow-release oxprenolol 320 mg respectively." | 5.05 | Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. ( Hampton, JR; Wilcox, RG, 1981) |
| "The mechanisms of the changes in plasma lipids concentrations observed after beta-blockade were examined in 53 patients with hypertension receiving treatment with atenolol, metoprolol, propranolol, and oxprenolol in a randomised cross-over trial." | 5.05 | Adrenergic mechanisms in control of plasma lipid concentrations. ( Day, JL; Metcalfe, J; Simpson, CN, 1982) |
| "1 The effects of 4 week treatment periods of once-daily atenolol 100 mg, nadolol 80 mg, nadolol 160 mg and placebo on resting and exercise heart rate and blood pressure were compared in a single-blind crossover trial in fifteen patients with essential hypertension." | 5.05 | Comparison between atenolol and nadolol in essential hypertension at rest and on exercise. ( Hampton, JR; Wilcox, RG, 1982) |
| "In 19 healthy men aged 50 with untreated mild essential hypertension (WHO group I classification) randomized into two groups, treatment (18 weeks) with oxprenolol (n = 10) lowered HDL cholesterol by 11." | 5.05 | The effect on HDL cholesterol of oxprenolol and atenolol. ( Eide, I; Eriksen, IL; Foss, OP; Holme, I; Kjeldsen, SE; Leren, P, 1982) |
| "Atenolol was compared with placebo in a randomised and double-blind prospective study of 120 women with mild to moderate pregnancy-associated hypertension who were also initially managed conventionally by bed rest." | 5.05 | Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. ( Butters, L; Clark, DM; Low, RA; Reid, JL; Reynolds, B; Rubin, PC; Steedman, D; Sumner, DJ, 1983) |
| "The efficacy of once-daily bopindolol, a nonselective beta-adrenoceptor blocking agent with partial agonist activity, and of pindolol and atenolol in the treatment of essential hypertension has been compared." | 5.05 | Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. ( Gugler, R; Schiess, W; Welzel, D, 1984) |
| " Seventeen male patients with essential hypertension were studied after 4 weeks of placebo and after 8 weeks of beta-adrenoceptor-blockade therapy with atenolol (100 mg/kg)." | 5.05 | Factors influencing cardiac hypertrophy in hypertensive patients. ( Ibrahim, MM; Madkour, MA; Mossallam, R, 1981) |
| "Atenolol 100 mg once daily and metoprolol SA 200 mg once daily were compared in 20 patients with mild to moderate hypertension, in a randomised, double-blind cross-over trial." | 5.05 | A comparison of once daily atenolol and metoprolol SA in mild to moderate hypertension. ( Cavalcanti, C; Morley, CA; Perrins, EJ; Sutton, R, 1983) |
| "The relationship between the oral dosage and plasma concentration of the long-acting cardioselective beta-adrenoceptor blocker atenolol and the antihypertensive response to the the degree of beta-adrenoceptor blockade and change in plasma renin activity (PRA) was evaluated in patients with mild-to-moderate essential hypertension in a double-blind, randomized, between-patient, dose-ranging (25, 50 or 100 mg once daily for 4 weeks) study." | 5.05 | A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. ( Ishizaki, T; Nakaya, H; Oyama, Y; Sasaki, T; Sato, T; Shibuya, T; Suganuma, T, 1983) |
| "In a randomized controlled, double-blind clinical trial with 45 patients with moderate hypertension atenolol 100 mg and penbutolol 40 mg were equally effective in lowering the blood pressure." | 5.05 | A comparative study of atenolol and penbutolol in hypertensive patients. ( Houtzagers, JJ; Lameijer, LD; Voermans, LA, 1983) |
| "Fifteen out-patients with moderate hypertension were randomly and sequentially treated with atenolol, indapamide and a combination of the two drugs after a wash-out period of at least 1 week and a 2-week placebo run-in period." | 5.05 | Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study. ( De Divitiis, O; Di Somma, S; Fazio, S; Ligouri, V; Petitto, M, 1983) |
| "In a cross-over study of 52 middle-aged patients with mild to moderate essential hypertension, we have compared the effect and tolerability of 100 mg atenolol and 100 mg metoprolol given once daily." | 5.05 | Influence of time and physical activity on blood pressure and heart rate during treatment with beta-blocking agents once daily. ( Danielson, M; Kjellberg, J; Kuylenstierna, J; Lundkvist, L; Svensson, O, 1983) |
| "Twenty-five patients with essential hypertension were randomly assigned to treatment with either captopril or atenolol." | 5.05 | Captopril or atenolol in essential hypertension. ( Andrén, L; Hansson, L; Svensson, A, 1983) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 119 patients with a diastolic pressure (DP) between 95 and 120 mmHg were randomised and treated either with 50 mg hydrochlorothiazide (n = 59) or 100 mg atenolol (n = 60)." | 5.05 | Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1984) |
| "The obstetric implications of the use of the beta-adrenoceptor antagonist atenolol have been evaluated in a prospective, randomized, double-blind, and placebo-controlled study involving 120 women with pregnancy-associated hypertension." | 5.05 | Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. ( Belfield, A; Butters, L; Clark, D; Low, RA; Pledger, D; Reid, JL; Rubin, PC; Sumner, D, 1984) |
| "The effects of once daily dosage of the two cardioselective beta-adrenoceptor blocking agents, atenolol and metoprolol, were studied in 26 patients with primary hypertension." | 5.05 | A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives. ( Atterhög, JH; Castenfors, J; Jorfelt, L; Karlberg, BE; Nilsson, OR; Ohman, KP; Thulin, T; Tolagen, K; Wettre, S, 1984) |
| "A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension." | 5.05 | A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients. ( Born, A; Emanueli, A; Lavezzari, M, 1984) |
| "We describe the results of a prospective study in which 120 women who developed hypertension in the last trimester of pregnancy were randomly allocated in double blind manner to atenolol or placebo." | 5.05 | First year of life after the use of atenolol in pregnancy associated hypertension. ( Adams, T; Butters, L; Evans, J; Reynolds, B; Rubin, PC, 1984) |
| "A double-blind, crossover comparison of once-daily acebutolol (400 mg) and once-daily atenolol (100 mg) was carried out in 33 patients with mild to moderate essential hypertension." | 5.05 | Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension. ( Brocklehurst, JC; Turner, AS, 1983) |
| "In 19 men aged 50 with essential hypertension, 18 weeks' treatment with atenolol (n = 9) or oxprenolol (n = 10) increased supine plasma free dopamine concentrations by 78% (p less than 0." | 5.05 | Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension. ( Aakesson, I; Amundsen, R; Eide, I; Eriksen, IL; Kjeldsen, SE; Leren, P, 1983) |
| "Fourteen patients with established hypertension followed a double-blind crossover-styled trial to study the effects of 100 mg/day atenolol compared to placebo." | 5.05 | Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. ( Aviram, M; Brook, JG; Levy, Y; Markel, A; Youdim, MB, 1983) |
| "1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol." | 5.05 | Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. ( Andrén, L; Asplund, J; Hansson, L; Karlberg, B; Ohman, P; Svensson, A, 1982) |
| "The behaviour of active (AR) and inactive (IR) renin was studied in 48 hypertensive patients (37 with uncomplicated essential hypertension and 11 with reno-vascular hypertension) treated with indomethacin alone or with AR stimulating (bumetanide, tienilic acid, captopril) and inhibiting (atenolol) drugs before and after indomethacin addition." | 5.05 | Effects of prostaglandins inhibition on changes in active and inactive renin induced by antihypertensive drugs. ( Arzilli, F; Pedrinelli, R; Salvetti, A; Sassano, P; Turini, F, 1982) |
| "Thirty-two patients with primary hypertension were studied in a double-blind cross-over comparison between the cardioselective beta 1-blocking agent atenolol and the combined alpha- and beta-blocking agent labetalol." | 5.05 | Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension. ( Henningsen, NC; Karlberg, BE; Nilsson, OR; Thulin, T, 1982) |
| "The effect of once-daily dosage of the two most widely prescribed cardioselective beta-adrenoceptor antagonists used to treat hypertension--namely, atenolol and metoprolol--was studied in nine carefully selected hypertensive outpatients." | 5.05 | Atenolol and metoprolol once daily in hypertension. ( Hawksworth, GM; Lovell, HG; Petrie, JC; Rigby, JW; Scott, AK; Webster, J, 1982) |
| "Intra-arterial ambulatory blood pressure was measured over 24 hours, in 34 patients with newly diagnosed hypertension, both before and after double-blind randomisation to treatment with atenolol (n=9), metoprolol (n=9), pindolol (n=9), or propranolol in its slow-release form (n=7)." | 5.05 | Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol. ( Floras, JS; Hassan, MO; Jones, JV; Sleight, P, 1982) |
| "1 The effects of atenolol (100 mg), a cardioselective beta-adrenoceptor blocking agent, and labetalol (300 mg), a combined alpha- and non-selective beta-adrenoceptor blocking agent given in single doses were examined in a double-blind placebo controlled study in 11 asthmatic patients with hypertension." | 5.05 | Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. ( Beevers, DG; Jackson, SH, 1983) |
| "1 The effects of propranolol and atenolol given in random order in a cross-over study to fifteen patients with essential hypertension have been studied." | 5.05 | A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. ( Harry, JD; Hawkins, T; Kerr, DN; Pickering, M; Robson, V; Stevens, IM; Wilkinson, R, 1980) |
| "Twenty-four black patients (Zulus) with hypertension participated in a double-blind, placebo-controlled cross-over trial of the efficacy of a beta-blocking agent (atenolol) 100 mg once daily as compared with chlorthalidone 25 mg once daily." | 5.05 | Trial of atenolol and chlorthalidone for hypertension in black South Africans. ( Seedat, YK, 1980) |
| "A double-blind, within-patient study was carried out in 23 newly diagnosed patients with mild to moderate hypertension (diastolic blood pressure of at least 100 mmHg) to compare the antihypertensive effects of atenolol (100 mg) and chlorthalidone (25 mg) given in free and fixed combination." | 5.05 | Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. ( Nissinen, A; Tuomilehto, J, 1980) |
| "In a double-blind cross-over multicentre study lasting for 16 weeks, the antihypertensive effect of atenolol (100 mg once a day) was compared with that of methyldopa (250 mg thrice a day) in 48 patients with mild to moderately severe hypertension." | 5.05 | Antihypertensive effect of atenolol (100 mg once a day) and methyldopa (250 mg thrice a day). A double-blind cross-over multicentre study. ( Brøns, M; Christensen, CK; Geday, E; Jacobsen, FK; Jensen, SN; Kristensen, BO; Linde, NC, 1981) |
| "A double-blind within-patient study was carried out on Zimbabwean Blacks to investigate the effect of once-daily atenolol on hypertension in doses of 100 and 200 mg/d." | 5.05 | Once-daily atenolol in hypertensive Zimbabwean blacks. A double-blind trial using two different doses. ( Abson, CP; Eyherabide, G; Levy, LM, 1981) |
| "Atenolol, Pindolol and Propranolol in single daily doses administered to 18 selected patients with mild essential hypertension achieved adequate control of blood pressure." | 5.05 | Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol. ( England, JD, 1981) |
| "Atenolol 100 mg and penbutolol 40 mg given once a day were both effective in controlling moderate hypertension, as judged by a randomised controlled, double-blind trial in 45 patients treated for six weeks." | 5.05 | Use of fixed doses of beta blocking drugs in the treatment of hypertension. Randomised study of atenolol and penbutolol. ( Chadha, DR; Houtzagers, JJ; Lameijer, LD; Voermans, LA, 1981) |
| "1 In an open, randomized cross-over investigation of thirteen patients (nine and four women, aged 37-67 years) with mild or moderate essential hypertension a comparison between atenolol and metoprolol was carried out in order to study the effects of 50, 100 and 200 mg given once daily on blood pressure and heart rate at rest and during exercise." | 5.05 | A comparative study of atenolol and metoprolol in the treatment of hypertension. ( Arnung, K; Eskildsen, PC; Nielsen, PE; Rasmussen, S, 1981) |
| "A randomized cross-over trial was undertaken on 21 occupationally active persons who had a stable mild or moderate hypertension with the purpose of comparing the effect of a beta-adreno-receptor blocking agent (atenolol) with that of a calcium channel inhibitor (nifedipine)." | 5.05 | Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist. ( Green, KA; Lange Andersen, K; Ottmann, W; Piatkowski, W, 1985) |
| "This open randomised parallel trial compared the antihypertensive efficacy of enalapril and atenolol given alone once a day or with hydrochlorothiazide in 20 patients with moderate to severe hypertension." | 5.05 | Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension. ( Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 5.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "Fifty patients with mild or moderate essential hypertension were randomized (double-blindly) to treatment with either captopril (n = 26) or atenolol (n = 24)." | 5.05 | Long-term effects of captopril and atenolol in essential hypertension. ( Andrén, L; Hansson, L; Karlberg, BE; Nilsson, OR; Ohman, P; Svensson, A, 1985) |
| "In order to investigate comparatively the effects of prazosin and atenolol on plasma lipid concentrations, 60 patients from two centres, presenting with arterial hypertension (diastolic 90-120 mmHg, systolic 160-200 mmHg), were allocated at random to one or the other of these drugs." | 5.05 | [Comparative study of the effects of prazosin and atenolol on plasma lipids of hypertensive patients]. ( Jaillard, J; Rouffy, J, 1985) |
| "In a 12-week double-blind randomised study the efficacy of atenolol and a new longer-acting formulation of trimazosin were compared when given once daily in patients with mild to moderate hypertension." | 5.05 | A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension. ( Hutcheson, MJ; Lorimer, AR; Murray, GD; Robertson, JI; Robertson, MP; Webb, DJ, 1985) |
| "The treatments of mild hypertension with atenolol and prazosin in occupationally active men and women were compared in a double blind cross-over with placebo." | 5.05 | Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication. ( Green, KA; Lange Andersen, K; Ottmann, W; Piatkowski, W, 1985) |
| "After screening two local populations in the northern part of The Netherlands for hypertension, patients with a diastolic pressure (DP) between 95 and 120 mmHg were treated daily either with 50 mg hydrochlorothiazide or 100 mg atenolol." | 5.05 | A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "In 20 patients with long-standing essential hypertension, a comparison was made in a randomized cross-over study of the effect of once and twice daily prazosin administration on blood pressure levels." | 5.05 | Prazosin once or twice daily? ( Hengeveld, WL; Schouten, JA; Westerman, RF, 1985) |
| "Acebutolol was compared to atenolol in 33 patients with mild to moderate essential hypertension (diastolic blood pressure greater than 95 mm Hg) with the use of a double-blind crossover study design." | 5.05 | Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison. ( Brocklehurst, JC; Napier, RN; Turner, AS, 1985) |
| "Eleven physically active men with systemic hypertension were studied after 5 weeks of treatment with placebo, atenolol or propranolol." | 5.05 | Effect of beta 1-selective and nonselective beta blockade on blood pressure relative to physical performance in men with systemic hypertension. ( Eliasson, K; Hylander, B; Kaijser, L; Kaiser, P, 1985) |
| "After screening a local population in the northern part of The Netherlands for hypertension, 59 patients with a diastolic pressure (DP) between 95 and 130 mmHg were randomized and treated either with 50 mg atenolol (n = 29) or 100 mg atenolol (n = 30) for 1 month." | 5.05 | Comparison of atenolol 50 mg and 100 mg as initial treatment in uncomplicated mild to moderate hypertension. ( Donker, AJ; May, JF; Schuurman, FH; ten Berge, BS; van der Veur, E; Wesseling, H, 1985) |
| "Fifty-five patients with mild to moderate, renal or essential hypertension were admitted to a double blind cross-over trial of 18 weeks, involving treatment periods with placebo, the thiazide bendrofluazide (15 mg daily) and the beta blocker atenolol (600 mg daily)." | 5.04 | Relative value of beta blockers and thiazides for initiating antihypertensive therapy. Beta blockers or thiazides in hypertension. ( Amery, A; De Plaen, JF; Fagard, R; Lijnen, P; Missotten, A, 1976) |
| "Atenolol was compared with five other beta-blockers and a thiazide diuretic in a randomised cross-over trial of once-daily treatment of essential hypertension." | 5.04 | Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. ( Wilcox, RG, 1978) |
| "The object of this study was to establish whether cardioselectivity of atenolol confers any advantage over noncardioselective beta-blockade in the treatment of hypertension." | 5.04 | Atenolol and three nonselective beta-blockers in hypertension. ( Waal-Manning, HJ, 1979) |
| "The antihypertensive effect of atenolol, a new beta-1-receptor blocking agent, was studied in a double-blind trial in which 45 patients with essential hypertension were randomly assigned to placebo or atenolol treatment." | 5.04 | Controlled study of atenolol in treatment of hypertension. ( Aberg, H; Hansson, L; Karlberg, BE; Westerlund, A, 1975) |
| "1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction." | 5.04 | Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. ( Chatterjee, SS; Croxson, RS; Cruickshank, JM; Perks, WH, 1978) |
| "A double-blind, crossover, multicentre study of 98 previously untreated patients with mild to moderate essential hypertension was carried out in general practice to assess the effect of 50 mg, 100 mg, and 200 mg atenolol, given once daily, compared with that of placebo over a period of 4 weeks each." | 5.04 | A dose-response study of atenolol in mild to moderate hypertension in general practice. ( Barmer, NP; Gostick, NK; Ingram, DF; Mayhew, SR; Million, R; Sagar, D; Suxena, SR, 1977) |
| "A double-blind crossover trial was completed in 15 patients with moderate hypertension and the effects of propranolol (Inderal) 80 mg twice a day and atenolol (Tenormin) 100 mg twice a day were assessed on blood pressure, pulse rate and plasma renin activity (PRA), while patients were maintained on 1 cyclopenthiazide tablet (Navidrex K) per day." | 5.04 | Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension. ( Epstein, SE; LUbbe, WF, 1977) |
| "The antihypertensive effect of atenolol, a new beta 1 receptor blocking agent, was studied in a double blind non cross-over trial in 40 patients (pts) affected by mild to moderately severe essential hypertension with normal plasma renin activity." | 5.04 | [Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)]. ( Bonaduce, D; Chiariello, M; Condorelli, M; Ferrara, N; Petretta, M; Rengo, F; Trimarco, B, 1978) |
| "082 (atenolol or Tenormin), alone or in combination with other drugs for treatment of hypertension in a total of 104 patients, including 15 with a chronic obstructive lung disease." | 5.04 | Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system. ( Henningsen, NC; Mattiasson, I, 1979) |
| "The antihypertensive effect of atenolol, with and without chlorthalidone, on hypertension was assessed in an outpatient as well as in an inpatient study." | 5.04 | Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Teeuw, AH, 1979) |
| "In 15 patients with moderate to severe hypertension (WHO II--III) atenolol was evaluated against a thiazide diuretic (bendrofluazide) in a single blind crossover study." | 5.04 | [Atenelol and bendrofluazide in the treatment of medium and severe hypertension (preliminary report)]. ( Braendli, B; Bucher, HJ; Nager, F; Truniger, B, 1978) |
| "Twenty-seven patients with mild to moderate arterial hypertension were treated "double-blind" with either atenolol of oxprenolol." | 5.04 | Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison. ( Brocklehurst, JE; Turner, AS; Watson, OF, 1979) |
| "Systemic BP reduction, calf blood flow and vascular resistance in the calf were determined in forty-two previously untreated patients with mild to moderate essential hypertension (WHO I-WHO II) before and after 6 weeks, 6 months and 18 months of BP-lowering treatment with mefruside (25 mg daily) or atenolol (100--400 mg daily)." | 5.04 | Blood pressure reduction and vascular adaptation. A study on long-term effects of treatment with mefruside or atenolol. ( Andersson, O; Hansson, L; Sivertsson, R, 1979) |
| "The antihypertensive effects of atenolol and propranolol were compared in a double-blind crossover study of 19 patients with essential hypertension (World Health Organization, I and II) who were receiving long-term diuretic treatment (chlorthalidone, 50 mg daily) during the study." | 5.04 | Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Rooijen, GJ, 1979) |
| "The antihypertensive effect on the selective beta-1-adrenoceptor blocking agent, atenolol, given in doses of 100 and 200 mg once daily, was evaluated in 37 patients with primary hypertension." | 5.04 | Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. ( Karlberg, BE; Nilsson, OR; Ohlsson, O; Thulin, T; Tolagen, K, 1979) |
| "Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily." | 5.04 | Once-daily dosing with Atenolol in patients with mild or moderate hypertension. ( Cruickshank, JM; Douglas-Jones, AP, 1976) |
| "The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been investigated." | 5.04 | Atenolol in essential hypertension. ( Dollery, CT; Lewis, GR; Myers, MG; Steiner, J, 1976) |
| "Propranolol was given to 30 patients with essential hypertension following randomised, double-blind administration of either placebo or a new cardioselective beta-adrenergic receptor antagonist, atenolol (Tenormin, ICI 66 082)." | 5.04 | A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol. ( Aberg, H; Hansson, L; Karlberg, BE; Westerlund, A, 1976) |
| "The comparative potency of two beta-blockers, propranolol and atenolol, in the inhibition of exercise tachycardia and isoproterenol-tachycardia has been studied in two groups of hypertensive patients, using oral doses which were increased weekly." | 5.04 | Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man. ( Amery, A; De Plaen, JF; Reybrouck, T, 1976) |
| " The beta1-adrenoreceptor-blocking agent atenolol was studied in the treatment of twelve out-patients with essential hypertension." | 5.04 | Clinical and haemodynamic study of atenolol (Tenormin) in essential hypertension. ( Jensen, HA; Mosbaek, N; Rasmussen, K, 1976) |
| "This meta-analysis of randomized parallel controlled trials was designed to compare the efficacy of atenolol with angiotensin-converting enzyme inhibitors (ACEIs) in changing pulse wave velocity (PWV), peripheral blood pressure and heart rate (HR) among patients with essential hypertension." | 4.95 | A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients. ( Luo, G; Peng, F; Xie, H; Xie, L; Zheng, Y, 2017) |
| "A MEDLINE literature search (1966-May 2013) was performed using the following key terms: hypertension, β-blockers, atenolol, carvedilol, metoprolol tartrate, metoprolol succinate, nebivolol, pharmacology, pharmacodynamics, pharmacokinetics, blood pressure, metabolic, lipid, central aortic pressure, diabetes, and insulin resistance." | 4.90 | β-blockers: a review of their pharmacological and physiological diversity in hypertension. ( Ripley, TL; Saseen, JJ, 2014) |
| " Twenty-one hypertension trials with data on 145,811 participants were identified: 15 used atenolol, 7 were placebo-controlled trials, and 14 were active comparator trials." | 4.90 | Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. ( Khan, NA; Kuyper, LM, 2014) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| " This case-based review describes the risk and benefits of prescribing antithrombotic therapy for a hypothetical 80-year-old man who has atrial fibrillation and hypertension, and it offers practical advice on managing warfarin therapy." | 4.81 | Warfarin therapy for an octogenarian who has atrial fibrillation. ( Fihn, SD; Gage, BF; White, RH, 2001) |
| "Nifedipine, as most calcium-antagonist drugs, is widely used for the treatment of angina pectoris and primary hypertension." | 4.80 | [Edema and skin ulcers of the lower limbs as a collateral effect of nifedipine. A clinical case report]. ( Luca, S; Romeo, S, 1999) |
| " In a long-term (4 weeks) double-blind cross-over study in essential hypertension, rilmenidine was well tolerated and had similar effects to those of atenolol on erect and supine blood pressure." | 4.79 | Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol. ( Elliott, HL; MacPhee, G; Panfilov, V; Reid, JL, 1995) |
| "In view of the important impact of small-artery structural and functional abnormalities on complications of hypertension and recent data suggesting that some antihypertensive agents may correct some of these abnormalities, a study of resistance artery structure and function in 20 well-controlled essential hypertensive patients who had received for a prolonged period of time monotherapy with the once-a-day extended release formulation of the calcium channel antagonist nifedipine (nidefipine GITS) or with the beta-blocker atenolol is reviewed." | 4.79 | Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine. ( Schiffrin, EL, 1997) |
| "Nifedipine and atenolol are first choice drugs in the treatment of arterial hypertension and angina pectoris." | 4.78 | [Pharmacology and clinical use of a fixed combination of nifedipine and slow release atenolol (Niften) in the treatment of arterial hypertension and angina pectoris]. ( Verdecchia, P, 1993) |
| " In the first part of the eighties two prospective multi-center randomised trials were conducted to determine the effect of captopril in comparison to methyldopa or an unselective beta-blocker on the quality of life in patients with mild to moderate hypertension (Hill et al." | 4.78 | ACE-inhibitors and quality of life. ( Herlitz, H, 1990) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| "An amlodipine-based BP regimen reduced the long-term incidence of stroke compared with an atenolol-based regimen but had no measurable effect on dementia." | 4.02 | Long-Term Incidence of Stroke and Dementia in ASCOT. ( Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN, 2021) |
| "Amlodipine lowered long-term gout risk compared with lisinopril or chlorthalidone." | 3.96 | The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Beach, JL; Davis, BR; Ishak, A; Juraschek, SP; Mukamal, KJ; Shmerling, RH; Simpson, LM, 2020) |
| "001), a sub-analysis on those with hypertension diagnosis confirmed that only the hypertensive population taking atenolol had a significantly larger population of obese individuals (BMI ≥25) compared with those who took metoprolol (58." | 3.96 | Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis. ( Bajorek, B; Fong, W; Freedman, B; Lee, VWY; Leung, KL, 2020) |
| "The present study aimed to analyze and compare the interaction of passive cigarette smoking and hypertension on epinephrine and felypressin blood pressure effects after intravascular injection." | 3.96 | Passive Cigarette Smoking Impact on Blood Pressure Response to Epinephrine and Felypressin in 1K1C Hypertensive Rats Treated or not with Atenolol. ( Almeida, EPM; Amaral, SL; Calvo, AM; Dionisio, TJ; Faria, FAC; Fleury, CA; Oliveira, GM; Santos, CF, 2020) |
| "Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners." | 3.94 | Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. ( Atkins, E; Bennett, A; Burke, M; Chalmers, J; Chou, M; Chow, CK; Dehbi, HM; Hillis, G; Hilmer, S; Krum, H; Neal, B; Nelson, M; Patel, A; Peiris, D; Reid, CM; Rodgers, A; Rogers, K; Salam, A; Thakkar, J; Thom, S; Usherwood, T; Vo, K; Webster, R; Woodward, M, 2017) |
| "To investigate the effect and mechanism of nebivolol on aortic remodeling in N-nitro-l-arginine methyl ester (l-NAME)-induced hypertension." | 3.85 | Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats. ( Li, Z; Liu, Y; Pang, X; Wang, Y; Wei, Z; Yin, S; Zhang, F, 2017) |
| "Risk of incident stroke was examined in relation to abnormal PTFV1 on a baseline ECG in 7778 hypertensive patients with ECG left ventricular hypertrophy, no history of atrial fibrillation, in sinus rhythm on their baseline ECG with no incident atrial fibrillation during follow-up, who were randomly assigned to losartan-based or atenolol-based treatment." | 3.83 | Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. ( Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM, 2016) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "Genome-wide association analysis of BP response to atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension in the pharmacogenomic evaluation of antihypertensive responses study." | 3.81 | PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Curry, RW; Donner, KM; El Rouby, N; Gong, Y; Gums, JG; Hall, K; Hiltunen, TP; Johnson, JA; Kontula, KK; Kubo, M; Langaee, TY; McDonough, CW; O'Connell, JR; Padmanabhan, S; Pepine, CJ; Schmidt, SO; Takahashi, A; Tanaka, T; Turner, ST, 2015) |
| "Patients with echocardiographic left ventricular hypertrophy at baseline (n = 124) showed greater reduction of left ventricular mass index with Per/Ind (-11." | 3.80 | [Arterial stiffness, wave reflections and myocardial protection: the REASON project]. ( London, GM, 2003) |
| " We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension." | 3.79 | Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. ( Birnbaum, Y; Castillo, AC; Chen, X; Ling, S; Long, B; Perez-Polo, JR; Qian, J; Thomas, B; Ye, H; Ye, Y, 2013) |
| "We sought to identify novel pharmacogenomic markers for HDL-C response to atenolol in participants with mild to moderate hypertension." | 3.79 | Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. ( Alsultan, A; Buford, TW; Chang, SW; Chapman, AB; Cooper-DeHoff, RM; El Rouby, NM; Gillis, NK; Gong, Y; Gums, JG; Johnson, JA; Kawaguchi-Suzuki, M; Lang, JE; Langaee, TY; McDonough, CW; Sá, AC; Shahin, MH; Turner, ST, 2013) |
| " Metabolic dysregulation is a major contributor to coronary disease; therefore, we assessed LXRA in International Verapamil Sustained Release SR Trandolapril Study Genetic Substudy (INVEST-GENES), a genetic-substudy of a large clinical trial in patients with hypertension and coronary artery disease." | 3.77 | Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. ( Cooper-DeHoff, RM; Johnson, JA; Martin, MA; Pacanowski, MA; Pepine, CJ; Price, ET; Zineh, I, 2011) |
| "Metabolic syndrome patients with hypertension (n=28) and a control group (n=20) were given atenolol (50 mg/day) for 4 weeks." | 3.77 | The enhanced effect of atenolol on hypertension in metabolic syndrome. ( Satou, Y; Ueno, N, 2011) |
| "Although most guidelines committees historically recommended initial diuretics and/or β blockers for uncomplicated hypertension, clinical trial outcomes analyzed in the last 5 to 7 years have been suboptimal with atenolol, the world's most popular β blocker." | 3.77 | Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? ( Childers, WK; Elliott, WJ, 2011) |
| "1." | 3.77 | Angiotensin-converting enzyme inhibition as first-line treatment for hypertension. ( Thurston, H, 1992) |
| "Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes." | 3.76 | Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2010) |
| "In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.76 | Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010) |
| "In this salt-sensitive genetic hypertension model, losartan protects from hypertension- and high dietary salt-related vascular oxidative stress, exceeding the benefits of BP reduction." | 3.76 | Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol. ( de Cavanagh, EM; Ferder, LF; Ferder, MD; Inserra, F; Stella, IY; Toblli, JE, 2010) |
| "Celiprolol hydrochloride is a highly cardioselective beta1-adrenergic antagonist with a unique pharmacologic profile." | 3.76 | Safety profile of celiprolol. ( Lamon, KD, 1988) |
| "To assess the cost effectiveness of four alternative treatment strategies in patients with hypertension and three or more cardiovascular risk factors in the UK (from the UK NHS perspective) or Sweden (from the societal perspective): amlodipine-based plus atorvastatin, atenolol-based plus atorvastatin, amlodipine-based alone and atenolol-based alone." | 3.75 | The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| " She had received atenolol for hypertension for 3 years prior to surgery and it was reintroduced at a dose of 100 mg/day because of recurrence of hypertension." | 3.75 | Atenolol hepatotoxicity: report of a complicated case. ( Boillot, O; Dumortier, J; Gouraud, A; Guillaud, O; Pittau, G; Scoazec, JY; Vial, T, 2009) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| "beta-Adrenergic blockers, particularly atenolol, are often recommended for the tachycardia and hypertension that accompany hyperthyroidism; however, the effects of monotherapy with atenolol on both systolic blood pressure (SBP) and heart rate (HR) have not been reported." | 3.74 | Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats. ( Dolson, MK; Henik, RA; Stepien, RL; Wenholz, LJ, 2008) |
| "To determine whether diabetes leads to retinal neuronal dysfunction in hypertensive transgenic (mRen-2)27 rats (Ren-2), and whether the effect can be prevented by treatment of hypertension with either the angiotensin-1 receptor blocker (AT1-RB) valsartan or the beta1-adrenergic receptor antagonist atenolol." | 3.74 | Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. ( Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL, 2007) |
| " Published comparisons of the beta-adrenergic blocker atenolol and non-atenolol beta-adrenergic blockers indicate different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis post myocardial infarction, all in disfavor of atenolol." | 3.74 | Does atenolol differ from other beta-adrenergic blockers? ( Aursnes, I; Gåsemyr, J; Natvig, B; Osnes, JB; Tvete, IF, 2007) |
| "The role of atenolol in the management of patients with hypertension is currently under scrutiny." | 3.74 | Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. ( Blackburn, DF; Blackburn, JL; Dobson, RT; Eurich, DT; Johnson, JA; Lamb, DA; Wilson, TW, 2007) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 3.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "The salivary activity in pups of spontaneously hypertensive rats (SHR) and Wistar (W) rats treated with atenolol during pregnancy, and lactation was evaluated." | 3.74 | Atenolol reduces salivary activity in pups of spontaneously hypertensive and normotensive rats treated during pregnancy and lactation. ( Antoniali, C; Delbem, AC; Elias, GP; Sassaki, KT, 2008) |
| "In the Losartan Intervention For End-point reduction in hypertension (LIFE) study, we evaluated the impact of antihypertensive treatment on change of PP/SVi as raw indicator of systemic arterial stiffness, and further explored the impact of the change in PP/SVi on the change in LV mass and RWT." | 3.74 | Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. ( Bella, JN; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Palmieri, V; Papademetriou, V; Wachtell, K, 2008) |
| "8 years losartan- or atenolol-based treatment in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 3.74 | Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). ( Cramariuc, D; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Wachtell, K, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 3.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 3.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "To understand the effects of single- and multiple-drug combinations for hypertension on the risk of adverse clinical outcomes, the authors analyzed data from the International Verapamil SR/Trandolapril Study (INVEST)." | 3.73 | A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. ( Cooper-DeHoff, R; Elliott, WJ; Hewkin, AC; Kupfer, S; Pepine, CJ, 2005) |
| "The study showed that L-NAME-induced hypertension has differential effects on endothelial connexins, which respond variously to carvedilol and atenolol." | 3.73 | Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. ( Ko, YS; Lee, PY; Su, CH; Tian, TY; Tsai, CH; Yeh, HI, 2006) |
| "In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.73 | Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006) |
| "To describe a case of atenolol-induced breast pain and swelling in a patient receiving atenolol." | 3.73 | Atenolol-induced breast pain in a woman with hypertension. ( Kelleher, JA, 2006) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| " A verapamil SR strategy is an alternative to an atenolol strategy for the treatment of Hispanic patients with hypertension and CAD and can reduce the risk of new-onset diabetes." | 3.73 | Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). ( Aranda, JM; Cangiano, JL; Conti, CR; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Hewkin, A; Pepine, CJ, 2006) |
| "The purpose of this analysis was to evaluate the cost-effectiveness of losartan compared with atenolol for the treatment of hypertension, both from the point of view of society and from that of the health care sector, based on data from the LIFE study." | 3.73 | [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark]. ( Burke, T; Carides, GW; Hildebrandt, P; Keiding, H, 2006) |
| "In a prospective follow-up study we screened 970 hypertensive patients of Caucasian descent for the Gly16Arg, Gln27Glu, and Thr164Ile beta(2)AR polymorphisms and left ventricular echocardiographic hypertrophy and assigned selected patients to enalapril or atenolol to assess left ventricular hypertrophy regression after 2-year follow-up." | 3.73 | Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. ( Cipolletta, E; De Luca, N; Di Renzo, G; Iaccarino, G; Iovino, GL; Izzo, R; Lanni, F; Priante, O; Rozza, F; Sorriento, D; Trimarco, B; Trimarco, V, 2006) |
| " The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases." | 3.72 | New strategies for prevention of ischemic stroke: the LIFE study. ( Adams, HP, 2003) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system." | 3.72 | Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective. ( Burnier, M; Erne, P; Szucs, TD, 2004) |
| "Atenolol taken at the time of conception and/or during the first trimester of pregnancy was associated with low birth weight." | 3.71 | Anti-hypertensive drugs in pregnancy and fetal growth: evidence for "pharmacological programming" in the first trimester? ( Bayliss, H; Beevers, DG; Beevers, M; Churchill, D, 2002) |
| "The effects of propranolol and atenolol were investigated on arterial hypertension, cardiomyocyte hypertrophy, and ventricular ischaemic lesions induced by an 8-week treatment with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat per day) in Wistar rats." | 3.71 | Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. ( Antunes, E; de Azevedo, AP; De Luca, IM; De Nucci, G; De Oliveira, CF; Pacca, SR, 2002) |
| "To investigate whether chronic selective beta1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol." | 3.71 | Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. ( Bonetti, S; Cosentino, F; Eto, M; Lüscher, TF; Rehorik, R; Volpe, M; Werner-Felmayer, G, 2002) |
| " At similar blood pressure control, losartan, as compared to atenolol, reduced the relative risk of primary cardiovascular event (death, myocardial infarction, or stroke) by 13% (p = 0." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| "Oral combinations of nifedipine and atenolol are widely used in the treatment of hypertension, proving particularly effective when the atenolol is released immediately and the nifedipine is released in a sustained manner." | 3.70 | Development of tablets for controlled joint release of nifedipine and atenolol. ( Concheiro, A; Gómez-Amoza, JL; Iglesias, R; Martínez-Pacheco, R; Souto, C; Taboada, C, 1998) |
| "Two groups of drugs commonly used for the treatment of hypertension are atenolol and amlodipine." | 3.70 | A study of pulmonary profile of hypertensive patients--comparison of atenolol vs amlodipine. ( Chaswal, M; Shankar, N; Singh, S; Tandon, OP, 1998) |
| "Fifty patients with stable slight and moderate uncomplicated essential hypertension, treated by ramipril, atenolol, or isradipine, were examined." | 3.70 | [Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]. ( Betekhtina, VA; Rakov, SS, 2000) |
| "We assessed the renal hemodynamic response to L-arginine infusion (30 g within 60 minutes) in normotensive subjects, patients with never-treated essential hypertension, and hypertensive patients controlled by long-term (more than 2 years) treatment with or without an angiotensin-converting enzyme inhibitor." | 3.69 | Contrasting effect of antihypertensive treatment on the renal response to L-arginine. ( DuCailar, G; Mimran, A; Ribstein, J, 1995) |
| "To investigate the possible harmful effects of early antihypertensive drug therapy with atenolol versus other therapies on pregnancy outcome, we reviewed the records of 398 women referred to our antenatal hypertension clinic between 1980 and 1995." | 3.69 | Effect of atenolol on birth weight. ( Beevers, DG; Beevers, M; Churchill, D; Lip, GY; Shaffer, LM, 1997) |
| "In this study we examined the effects of long-term treatment of 19 patients with primary hypertension with the beta 1-adrenoceptor antagonist atenolol on norepinephrine and epinephrine kinetics, at rest and during sympathoadrenal stimulation by lower body negative pressure." | 3.69 | Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension. ( Jacobs, MC; Lenders, JW; Smits, P; Tack, C; Thien, T; Willemsen, JJ, 1997) |
| " At this time the remission of spinal anaesthesia was nearly complete, and the patient had received his daily dose of 150 mg atenolol because of a current hypertension 80 minutes earlier." | 3.69 | [Syncope with postoperative beta blocker medication after spinal anesthesia--case report]. ( Seitz, W; Selhorst-Kiss, S, 1997) |
| "This study compares the antihypertensive and lipid modifying effects of treatment of mild to moderate hypertension with celiprolol or atenolol." | 3.69 | A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. ( Jackson, RT; Milne, RJ; Vander Hoorn, S, 1997) |
| "The present study was designed to investigate the role of the autonomic nervous system in experimental hypertension induced by chronic administration of N-nitro-L-arginine methyl ester (L-NAME) in the drinking water (1 mg/mL) over 6 days." | 3.68 | Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. ( Cabral, AM; Cunha, RS; Vasquez, EC, 1993) |
| "Twenty-one patients with previously untreated essential hypertension were treated with a low dose combination of 50 mg of atenolol and 10 mg of enalapril once daily for 39 months." | 3.68 | Preserved ventricular pump function after a marked reduction of left ventricular mass. ( Behr, U; Franz, IW; Ketelhut, R; Messerli, FH; Toennesmann, U, 1992) |
| "The antihypertensive and hemodynamic effects of lisinopril and atenolol were evaluated in 21 patients with mild-to-moderate essential hypertension." | 3.68 | Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications. ( Boucher, CA; Christensen, DM; Higgins, J; Zusman, RM, 1992) |
| "Haemodynamic changes in the carotid and brachial arteries produced by single doses of four anti-hypertensive drugs (nicardipine, enalapril, atenolol, and urapidil) have been studied in 12 patients with essential hypertension." | 3.68 | Changes in the haemodynamics of large arteries induced by single doses of nicardipine, enalapril, atenolol and urapidil. ( Arosio, E; Lechi, A; Pancera, P; Priante, F; Ribul, M; Talamini, G; Zannoni, M, 1992) |
| "A study was made of the influence of atenolol on the sinocarotid and cardiopulmonary baroreceptor reflexes (BR) in patients with essential hypertension." | 3.68 | [The relationship between the effect of atenolol on the baroreceptor reflex and its hypotensive action in hypertension patients]. ( Tsyrlin, VA; Zverev, OG, 1991) |
| "In the present study, 20 patients with both hypertension and stabile angina pectoris were treated twice daily for 6 months with 50 mg atenolol and 20 mg retard-formulation nifedipine." | 3.68 | [Therapy of hypertensive coronary patients. Open long-term study with a combination of atenolol and nifedipine]. ( Lindner, UK, 1991) |
| " Doxazosin, a new selective alpha 1-inhibitor used in the treatment of hypertension, is compared with the established beta-blocker, atenolol." | 3.68 | The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden. ( Lindgren, B, 1990) |
| " Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension." | 3.68 | Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990) |
| "The myocardial effects of a daily oral dose of atenolol were studied by radionuclide multi-triggered ventriculogram in 10 patients (7 men and 3 women) with mild to moderate essential hypertension, aged 29 to 53 years (mean 43) at rest and during exercise." | 3.68 | Analysis of left ventricular function by radionuclide ventriculogram in hypertensive patients treated with atenolol. ( Degrossi, O; Dopico, AM; Marcó, EJ; Otero, F; Ramírez, AJ; Sánchez, RA, 1990) |
| "In this study the clinical, biological, radiologic, electrocardiographic, and hormonal characteristics of 80 patients with slight or moderate essential arterial hypertension in whom the treatment with atenolol alone or associated with chlorthalidone or with a third agent normalized the arterial pressure during a period of one year, are revised." | 3.68 | [The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension]. ( Aguilera, MT; Coca, A; de la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 3.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "The hemodynamic effects of nitrendipine have been studied at rest and during exercise in eight patients with mild to moderate essential hypertension." | 3.67 | Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension. ( Detry, JM; Lavenne, F; Melin, JA; Nannan, ME; Vanbutsele, RJ, 1984) |
| "We assessed the effects on renal haemodynamics in 18 black patients with essential hypertension of acute and chronic beta-adrenergic blockade with three agents having different properties: atenolol, nadolol or propranolol." | 3.67 | Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives. ( Anderson, S; Brater, DC; Kaplan, NM; Ram, CV, 1984) |
| "5 mg chlorthalidone (Tenoretic Mite, TM) was studied in 37 patients with arterial hypertension, aged 61-80 years (mean, 70." | 3.67 | Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients. ( Fogari, R; Zoppi, A, 1984) |
| "The authors conducted a clinical investigation in twenty-five patients affected with essential hypertension of mild or moderate grade associated with type II diabetes mellitus, the purpose being to assess the effect of 8 weeks of combined treatment with atenolol (100 mg) and chlorthalidone (25 mg) on arterial blood pressure, heart rate, and glycaemia." | 3.67 | Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics. ( Coltorti, M; Gentile, S, 1984) |
| "Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months." | 3.67 | Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984) |
| "In patients with mild hypertension, flurbiprofen in a dose of 100 mg daily for 7 days attenuated the hypotensive effect of a single dose of propranolol 80 mg but not of atenolol 100 mg." | 3.67 | Flurbiprofen interaction with single doses of atenolol and propranolol. ( Hawksworth, GM; McLean, I; Petrie, JC; Webster, J, 1984) |
| "The transfer of atenolol and metoprolol to human breast milk was studied in 7 lactating women with hypertension." | 3.67 | Atenolol and metoprolol. A comparison of their excretion into human breast milk. ( Kulas, J; Lunell, NO; Rane, A; Rosing, U; Stéen, B, 1984) |
| "Forty term patients with pregnancy-induced hypertension were treated with the beta 1-adrenoceptor blocker atenolol (Tenormin R; ICI) for at least 7 days prior to parturition." | 3.67 | Influence of the beta 1-adrenoceptor blocker atenolol on antenatal cardiotocography. ( Montan, S; Sjöberg, NO; Solum, T, 1984) |
| "To assess the problem of continuing atenolol in a breast-feeding mother with hypertension associated with thyrotoxicosis, studies were performed to determine simultaneous plasma and breast milk concentrations of atenolol after a single dose of 50 mg and on continuous therapy of varying weekly dosages." | 3.67 | Atenolol in human plasma and breast milk. ( Andreoli, JW; Cohn, RD; White, WB; Wong, SH, 1984) |
| " Therefore, M-mode and Doppler techniques were used to assess changes in LV hypertrophy after 10, 30 and 50 weeks of atenolol therapy (50 or 100 mg once daily) in 19 patients with essential hypertension." | 3.67 | Effects of atenolol on left ventricular hypertrophy and early left ventricular function in essential hypertension. ( Allen, JW; Kaiser, PJ; Montenegro, A, 1989) |
| "We compared the antihypertensive effects of the beta-blocker atenolol and the converting enzyme inhibitor lisinopril during 12 weeks of treatment in patients with mild to moderate essential hypertension." | 3.67 | Comparison of antihypertensive therapies by noninvasive techniques. ( Cheung, DG; Graettinger, WF; Klein, RC; Lipson, JL; Weber, MA, 1989) |
| "A study has been performed in thirteen patients with essential hypertension, WHO Class I-II, and a diastolic blood pressure greater than or equal to 95 mmHg, on beta-blocker (metoprolol or atenolol) monotherapy, who were also given felodipine 10 mg b." | 3.67 | Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol. ( Bengtsson-Hasselgren, B; Elmfeldt, D; Moberg, L; Rönn, O, 1989) |
| "In 13 patients, affected by hypertrophic obstructive cardiomyopathy (HOCM) and essential hypertension, antihypertensive-efficacy and effects of a new calcium-channel blocker (gallopamil) associated with a diuretic agent (chlorthalidone) on left ventricular systolic and diastolic performance assessed by phonocardiographic methods." | 3.67 | [Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle ( Brandini, V; Chieppa, S; De Simone, R; Giuliani, F; Iarussi, D; Langella, S; Lobascio, C, 1989) |
| "In 16 patients with essential hypertension the effects of enalapril 20 mg once daily were compared with those of atenolol 50 mg once daily, with the two drugs in combination and with placebo using a double-blind cross-over design with allocation of treatment order by randomised Latin squares." | 3.67 | Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. ( Bune, AJ; Cain, MD; Chalmers, JP; Morris, MJ; Russell, AE; Southgate, DO; West, MJ; Wing, LM, 1988) |
| "Six elderly patients with established hypertension and six young healthy subjects were studied after 8 days of treatment with atenolol 50 mg day-1, metoprolol 50 mg day-1, oxprenolol 80 mg day-1 and propranolol 80 mg day-1." | 3.67 | A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. ( Hawksworth, GM; Petrie, JC; Rigby, JW; Scott, AK, 1985) |
| "The aim of this study was a comparison between the hypotensive effects of two fixed combinations (atenolol + chlorthalidone and labetalol + chlorthalidone) in patients suffering from untreated mild to moderate hypertension." | 3.67 | Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone. ( Cumetti, C; De Cristofaro, A; Montanari, C; Roja, M; Vergani, A, 1985) |
| "To investigate whether the lower the blood pressure (BP) the better the prognosis for the patient with moderate-to-severe hypertension, an assessment was made of 902 patients who received the beta 1-selective beta-blocker atenolol (median dose 100 mg a day), either alone or with other antihypertensive agents, for up to 10 years (mean 6." | 3.67 | Benefits and potential harm of lowering high blood pressure. ( Cruickshank, JM; Thorp, JM; Zacharias, FJ, 1987) |
| " We obtained echocardiograms at baseline and serially (on seven occasions) during a 1 year treatment period with the beta-adrenergic receptor inhibitor atenolol in 12 patients with previously untreated essential hypertension." | 3.67 | Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. ( Dunn, FG; Frohlich, ED; Kobrin, I; Messerli, FH; Ventura, HO, 1987) |
| "In eight patients with essential hypertension the effect of 50 mg atenolol, once daily for 6 months, on vasodilation during epinephrine infusion and submaximal dynamic exercise was studied." | 3.67 | Impaired vasodilation during long-term beta 1-selective beta-blockade in hypertensive patients. ( de Boo, T; Lemmens, WA; Lenders, JW; Reyenga, J; Thien, T, 1988) |
| "Slow-release nifedipine has been used in the treatment of severe hypertension in 23 pregnant women." | 3.67 | Nifedipine as a second line antihypertensive drug in pregnancy. ( Beevers, DG; Constantine, G; Luesley, DM; Reynolds, AL, 1987) |
| "Nifedipine has been used in the management of hypertension in 36 consecutive patients who could not tolerate, or were not controlled by, atenolol and thiazide diuretics." | 3.67 | Use of nifedipine as the drug of third choice in management of hypertension. ( Muir, AL; Roulston, JE; Wathen, CG, 1986) |
| "Fetal circulation was studied by means of combined real-time and pulsed Doppler ultrasound in 14 women with pregnancy-associated hypertension before and during the first and third days of treatment with the beta 1-selective blocker, atenolol; in seven of the women the maternal uterine arcuate blood velocity waveform was also studied." | 3.67 | Fetal and uteroplacental haemodynamics during short-term atenolol treatment of hypertension in pregnancy. ( Liedholm, H; Lingman, G; Marsál, K; Montan, S; Sjöberg, NO; Solum, T, 1987) |
| "An elderly, mildly demented, hypertensive male patient developed hypersomnolence on administration of propranolol for treatment of hypertension; no other cause for hypersomnolence was detected." | 3.67 | Hypersomnolence with beta-adrenergic blockers. ( Kochar, MS; Thachil, J; Zeller, JR, 1987) |
| "Nine patients who had been treated for hypertension for many years with atenolol in a dose of 100 mg/day took part in this 18-month study, during which the dosage alternated between 50 and 100 mg/day for two-month periods." | 3.67 | A comparison of the hypotensive and metabolic effects of 50 and 100 mg atenolol per day. ( Aberg, H; Lithell, H; Selinus, I, 1986) |
| "We report the first case of an illness resembling idiopathic lupus erythematosus, with fever, pleuropericarditis, antinuclear antibodies and antidenaturated DNA antibodies after 18 months of treatment with atenolol for hypertension." | 3.67 | Atenolol induced systemic lupus erythematosus syndrome. ( Aucouturier, P; Gouet, D; Marechaud, R; Preud'homme, JL; Sudre, Y; Touchard, G, 1986) |
| "Short-term treatment with 1-(p-carbamoyl-methylphenoxy)-3-isopropylamino)-2-propanol (atenolol, Tenormin) (100 mg/d for 5 days) was conducted in 12 patients with labile essential hypertension." | 3.67 | Mechanism of antihypertensive effect of atenolol in patients with borderline hypertension during short-term treatment. A comprehensive study. ( Abe, K; Imai, Y; Kasai, Y; Nihei, M; Omata, K; Sasaki, S; Sato, K; Sato, M; Sekino, H; Yoshinaga, K, 1986) |
| "Minoxidil was given to 16 men with hypertension of various degrees of severity, in conjunction with a diuretic and atenolol." | 3.67 | Once-a-day triple therapy with low-dose minoxidil for moderate hypertension. ( Boner, G; Johnsen, AM; McDonald, RH; Rosenfeld, JB; Shapiro, AP; Traub, YM, 1986) |
| "This study was undertaken to determine the chronic effects of a long-acting calcium-channel blocker (nitrendipine) on resting left ventricular filling abnormalities in ten patients with essential hypertension." | 3.67 | Alteration of left ventricular diastolic filling in hypertensive patients: effects of nitrendipine and atenolol. ( Beckers, C; De Kock, M; Detry, JM; Lavenne, F; Melin, JA; Nannan, ME; Robert, A, 1986) |
| " Pretreatment with either N-methylatropine or atenolol intra-arterially reduced the 5-HT-induced bradycardia in normotensive rats; the reduction was enhanced when both antagonists were given in combination." | 3.67 | The cardiovascular effects of centrally administered 5-hydroxytryptamine in the conscious normotensive and hypertensive rat. ( Dalton, DW, 1986) |
| "In 16 people with essential hypertension, heart rate (HR), blood pressure (BP) and relative cardiac volumes were measured at rest and during submaximal upright exercise before and after 10 mg of sublingual nifedipine using radionuclide ventriculography." | 3.67 | Afterload reduction by nifedipine--the acute haemodynamic response to exercise in hypertensive subjects. ( Hannan, WJ; Muir, AL; Turnbull, LW; Wathen, CG, 1985) |
| "Abrupt withdrawal of the centrally-acting antihypertensive agent, clonidine, is associated with a high incidence of rebound hypertension and tachycardia, with symptoms of sympathetic overactivity and increased catecholamine excretion." | 3.67 | Regimen for the control of blood pressure and symptoms during clonidine withdrawal. ( Campbell, BC; Reid, JL, 1985) |
| "Hemodynamic (systemic and regional), metabolic and cardiovascular reflexive variables were measured before and after 4 weeks of beta blockade with atenolol in 10 patients with mild essential hypertension." | 3.66 | Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension. ( Dreslinski, GR; Dunn, FG; Frohlich, ED; Messerli, FH; Reisin, E; Suarez, DH, 1982) |
| "The calcium-channel blocker, nifedipine, was used as additional oral therapy to beta-adrenergic receptor blockade by the cardioselective agent, atenolol, in the therapy of 31 patients with hypertension." | 3.66 | Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. ( Jee, L; Opie, LH; White, D, 1982) |
| "Heart rate (HR), blood pressure and systolic time intervals (STI), including total electromechanical systole (QS2), left ventricular ejection time (LVETc), pre-ejection period (PEPc), the PEP/LVET index and the time to the peak of carotid upstroke (Ut), were measured in 24 patients with moderate essential hypertension after 15 days of treatment with oral furosemide (F), hydrochlorothiazide (H), propranolol (P), atenolol (A), furosemide + propranolol (F + P) and hydrochlorothiazide + propranolol (H + P)." | 3.66 | Modification of blood pressure and systolic time intervals by diuretics and beta-blockers in essential hypertension. ( Gamio Capestany, F; García-Barreto, D; González-Gómez, A; Hernández-Cañero, A, 1983) |
| "The urinary excretion of prostaglandins (PG) E2 and F2 alpha was measured by radioimmunoassay in 15 patients with essential hypertension, before and after 2 and 4 weeks of treatment with the selective beta 1-adrenergic blocker, atenolol." | 3.66 | Effect of atenolol treatment on urinary prostaglandins E2 and F2 alpha in essential hypertension. ( Bernheim, J; Magen, A; Rath-Wolfson, L; Rathaus, M; Shapira, J, 1983) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 3.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| " The effects of 3 wk of treatment with two selective beta 1 blockers, metoprolol and atenolol, were observed in 54 patients with mild or moderate essential hypertension." | 3.66 | Predictability of antihypertensive efficacy of selective beta 1 blockers. ( Condorelli, M; Cuocolo, A; De Luca, N; Ricciardelli, B; Trimarco, B; Veniero, AM; Volpe, M, 1983) |
| "This study reports the results that were obtained in 56 cases of arterial hypertension in pregnancy solely by beta-blocking with Atenolol or Labetalol." | 3.66 | [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. ( Beauséjour, B; Blazquez, G; Faurie, C; Flouvat, B; Gérard, J; Lardoux, H; Rousset, D, 1983) |
| "Plasma renin activity (PRA) and systolic time intervals (STI), including total electromechanical systole (QS2), left ventricular ejection time (LVET), pre-ejection period (PEP) and isovolumetric contraction time (ICT), were measured in patients with borderline hypertension (n = 23) before and after oral treatment with atenolol and propranolol." | 3.66 | Effects of propranolol and atenolol on plasma renin activity and systolic time intervals in borderline hypertension. ( Fong Chi, S; Gamio Capestany, F; García-Barreto, D; González-Gómez, A; Hernández-Cañero, A, 1982) |
| "Cardioselective beta-blocking agent tenormin (atenolol) was used in 55 patients with essential hypertension, Stage II; in 20 of those, central, intracardiac and regional hemodynamics were assessed echocardiographically and rheographically." | 3.66 | [Therapeutic effect of the cardioselective beta-blocking agent tenormin and its action on the indices of systemic, intracardiac and regional hemodynamics in patients with hypertension]. ( Charyev, KhE; Erina, EV; Oshchepkova, EV, 1983) |
| "The effects of propranolol (100 mg/kg), atenolol (200 mg/kg) and acebutolol (1000 mg/kg) administered daily by gavage to spontaneously hypertensive rats (SHRs) from their 6th to 20th weeks of age were investigated on genetic hypertension development (GHD) and at regular intervals on heart rate (HR), cardiac output (CO), stroke volume (SV), peripheral resistence (PR), plasma renin concentration (PRC) and heart weight/body weight ratio (HW/BW)." | 3.66 | beta-Adrenoreceptor blockage and genetic hypertension development in rats. ( Boissier, JR; Giudicelli, JF; Richer, C; Venturini-Souto, N, 1980) |
| "Captopril (100mg/kg) administered daily by gavage to young spontaneously hypertensive rats (SHRs) from their 6th to 20th weeks of age almost completely inhibited genetic hypertension development (GHD)." | 3.66 | Captopril and hypertension development in the SHR. ( Freslon, JL; Giudicelli, JF; Glasson, S; Richer, C, 1980) |
| "Atenolol has been studied prospectively in the management of ten patients with essential hypertension during pregnancy." | 3.66 | Atenolol in the treatment of essential hypertension during pregnancy. ( Butters, L; Low, RA; Reid, JL; Rubin, PC, 1982) |
| "16 patients suffering from hypertension and angina pectoris (class II according to the NYHA) are treated with 100 mg atenolol once daily for three weeks." | 3.66 | [Effects of therapy with a association of nifedipine and atenolol in patients with systemic arterial hypertension and angina pectoris]. ( Attisano, N; Grenci, G; Martelli, G; Sarica, G; Schirripa, V, 1982) |
| "Atenolol, a cardioselective beta-adrenergic blocking agent, was given as the sole hypotensive drug for 8-12 weeks to 20 patients with hypertension of varying degrees of severity." | 3.66 | Clinical evaluation of atenolol in hypertensive patients. ( Ibrahim, MM; Mossallam, R, 1981) |
| "A 30 year-old male patient with accelerated arterial hypertension relatively resistent to diazoxide received a single oral dose of 100 mg of atenolol, following which hypotension of more than 24 hours duration and acute renal failure ensued." | 3.66 | [Prolonged hypotension after the first dose of atenolol (author's transl)]. ( Botey, A; Darnell, A; Montoliu, J; Revert, L, 1981) |
| "1 The pharmacological properties of atenolol suggest its possible usefulness in pregnancy-induced hypertension." | 3.66 | Atenolol in the treatment of pregnancy-induced hypertension. ( Cruickshank, JM; McAinsh, J; Thorley, KJ, 1981) |
| "In 14 patients with essential hypertension, left ventricular function was assessed echocardiographically before and after 4 and 8 weeks of treatment with the betablocking agent atenolol." | 3.66 | [Left ventricular function in hypertension treated with beta blockers]. ( Gonzenbach, R; Jenni, R; Krayenbühl, HP; Satz, N; Vetter, W, 1978) |
| " Sixteen patients (11 male, five female), median age 41 years, with essential hypertension insufficiently controlled by hydrochlorothiazide (75 mg/day; diastolic blood pressure greater than or equal to 100 mmHg), were studied." | 3.66 | Angiotensin II blockade during combined thiazide-beta-adrenoreceptor-blocker treatment. ( Giese, J; Ibsen, H; Leth, A; McNair, A, 1979) |
| "The effects on arterial pressure of saralasin and short-term (seven days) administration of the cardioselective beta-blocker atenolol were compared in 21 patients with various forms of hypertension." | 3.66 | The renin-angiotensin system and the antihypertensive effect of atenolol in man. ( Barjon, P; Deschodt, G; Fourcade, J; Mimran, A, 1979) |
| "The antihypertensive effect of atenolol, a cardioselective beta-blocker, was examined in 8 patients with essential hypertension." | 3.66 | [Haemodynamic response to antihypertensive treatment with atenolol in patients with hypertension (author's transl]. ( Glogar, D; Leisch, F; Niederberger, M; Steinbach, K; Uhlir, H; Zilcher, H, 1978) |
| "After acute beta-adrenergic blockade (5 mg atenolol intravenously) in 11 patients with essential hypertension but no heart failure arterial blood pressure and inotropic state fell slightly (-5." | 3.66 | [The hypertensive heart. VII. Effect of atenolol on the function, coronary haemodynamics and oxygen uptake of the left ventricle (author's transl)]. ( Strauer, BE, 1978) |
| "1 Thirteen men with untreated essential hypertension in WHO stage I were studied on an outpatient basis to evaluate the haemodynamic long-tern effect of a new beta-adrenoceptor blocker, atenolol." | 3.65 | Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension. ( Lund-Johansen, P, 1976) |
| "Atenolol was used in PEAR and INVEST, and metoprolol was used in PEAR-2." | 2.90 | β ( Beitelshees, AL; Boerwinkle, E; Chapman, A; Conrado, DJ; Cooper-DeHoff, RM; Gong, Y; Gonzalez, D; Gums, JG; Johnson, JA; Lobmeyer, MT; Pepine, CJ; Rouby, NE; Shahin, MH; Turner, ST, 2019) |
| "Only enalapril was able to significantly reduce LVMI (47±12 vs 39." | 2.82 | Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation. ( Baldini, L; Berrino, L; Calabrò, R; Castaldi, B; D'Aiello, FA; Del Gaizo, F; Di Salvo, G; Fadel, BM; Gala, S; Keating, S; Mormile, A; Pacileo, G; Perna, A; Rea, A; Russo, MG; Scognamiglio, G, 2016) |
| "In long-term hemodialysis patients, treating hypertension using home BP measurements may improve well-being." | 2.82 | Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess. ( Agarwal, R, 2016) |
| "A significant white coat hypertension was noticed in both the arms." | 2.78 | A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension. ( Avasthi, R; Dastidaro, DG; Guha, S; Majumdar, D; Mani, S; Mitra, M; Mondal, MM; Mookerjee, S; Narain, VS; Rajendiran, C; Ray, S; Saha, J, 2013) |
| "Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date." | 2.76 | Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. ( Chang, CL; Dahlöf, B; Gupta, AK; Nasothimiou, EG; Poulter, NR; Sever, PS, 2011) |
| "Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group." | 2.75 | Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. ( Andersson, J; Boman, JH; Boman, K; Dahlöf, B; Olofsson, M, 2010) |
| "Patients received atenolol therapy for at least 8 weeks, with 5 of those weeks at a dosage of 100 mg/day, and then underwent a 2-hour oral glucose tolerance test during a pharmacokinetic study visit." | 2.75 | Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. ( Cooper-Dehoff, RM; Frye, RF; Hall, K; Johnson, JA; Navare, HA; Schmidt, SO; Shuster, JJ; Turner, ST, 2010) |
| "Treatment with perindopril/indapamide improves endothelium-dependent vasodilation in comparison with atenolol." | 2.74 | Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. ( Ghiadoni, L; Kardasz, I; Magagna, A; Salvetti, A; Taddei, S, 2009) |
| "Isolated systolic hypertension is an important risk factor for cardiovascular disease and results primarily from elastic artery stiffening." | 2.74 | Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. ( Brown, MJ; Cockcroft, JR; Dhakam, Z; Mackenzie, IS; McEniery, CM; Wilkinson, IB, 2009) |
| "Amlodipine-based treatment was associated with a smaller arteriolar length:diameter ratio than atenolol-based treatment (13." | 2.74 | Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. ( Allemann, S; Chaturvedi, N; Hughes, A; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Stanton, A; Stettler, C; Tapp, R; Thom, S; Witt, N, 2009) |
| "Patients with hypertension and left ventricular hypertrophy (LVH) are at increased risk of cardiovascular complications and the current guidelines recommend echocardiography for determination of left ventricular mass." | 2.74 | [Echocardiography of left ventricular mass in patients with essential hypertension]. ( Buus, NH; Christensen, KL; Fenger-Grøn, M, 2009) |
| "Here, we test whether pharmacological treatment of hypertension normalizes regional cerebral blood flow responses and whether it does so differentially according to drug class." | 2.73 | Cerebrovascular support for cognitive processing in hypertensive patients is altered by blood pressure treatment. ( Christie, IC; Jennings, JR; Meltzer, CC; Muldoon, MF; Price, J, 2008) |
| "5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks." | 2.73 | Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report. ( Feely, J; Mahmud, A, 2007) |
| "In atenolol-treated patients, the arterial wall became stiffer, whereas in the eplerenone-treated patients, it became less stiff and similar to that of a normotensive control group." | 2.73 | Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. ( Amiri, F; Savoia, C; Schiffrin, EL; Touyz, RM, 2008) |
| "Atenolol and metoprolol succinate, dosed once daily, have different pharmacokinetic profiles." | 2.73 | Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. ( Bakris, GL; Basta, E; Bogojevic, Z; Kirstner, E; Sarafidis, P, 2008) |
| "We randomized 40 subjects with untreated hypertension (mean +/- s." | 2.73 | Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. ( Feely, J; Mahmud, A, 2008) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| "Atenolol treatment did not induce significant changes in any test score, whereas losartan significantly increased the score of both the word list memory (+2." | 2.71 | Influence of losartan and atenolol on memory function in very elderly hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Zoppi, A, 2003) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 2.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "Hypertension is a major risk factor for morbidity and mortality." | 2.71 | Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K, 2004) |
| "Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation." | 2.71 | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA ( Brändström, H; Kahan, T; Kindmark, A; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; öHman, KP; Stiger, F, 2004) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 2.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "Hypertension is associated with reduced coronary vasodilatory capacity, possibly caused by structural changes in the coronary resistance vessels." | 2.71 | Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. ( Buus, NH; Bøttcher, M; Christensen, KL; Jørgensen, CG; Mulvany, MJ; Nielsen, TT; Thygesen, K, 2004) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 2.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 2.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear." | 2.70 | Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Bella, JN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Papademetriou, V; Rokkedal, J; Smith, G; Wachtell, K, 2002) |
| "Hypertensive patients (n = 758) with Type 2 diabetes (mean age 56 years, mean blood pressure 159/94 mmHg), 400 of whom were allocated to the angiotensin converting enzyme inhibitor captopril and 358 to the beta blocker atenolol." | 2.70 | An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). ( Adler, A; Clarke, P; Cull, C; Gray, A; Holman, R; Neil, A; Raikou, M; Stevens, R; Stratton, I, 2001) |
| "Essential hypertension is associated with impaired endothelium-dependent vasodilation caused by oxygen free radical-induced nitric oxide (NO) breakdown." | 2.70 | Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. ( Cominacini, L; Garbin, U; Ghiadoni, L; Magagna, A; Pasini, AF; Salvetti, A; Taddei, S; Virdis, A, 2001) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "1148 hypertensive patients with type 2 diabetes from UK prospective diabetes study randomised to tight control of blood pressure (n=758) or less tight control (n=390)." | 2.69 | Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. ( , 1998) |
| "Concern based on the reported short-term adverse effects of antihypertensive agents on plasma lipid and lipoprotein profiles (PLPPs) has complicated the therapy for hypertension." | 2.69 | Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Cushman, WC; Freis, ED; Lakshman, MR; Materson, BJ; Reda, DJ, 1999) |
| "To elucidate the effect on blood pressure and blood lipids of an angiotensin converting enzyme inhibitor (captopril), and a beta-receptor blocking agent (atenolol), given alone or in combination with a cholesterol reducing drug, the beta-hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin, in patients who were also encouraged to improve their lifestyle." | 2.69 | Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. ( Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L, 1999) |
| "Atenolol or enalapril was the mandatory second-line drug." | 2.69 | Influence of diabetes and type of hypertension on response to antihypertensive treatment. ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM, 2000) |
| "When diagnosing or evaluating treatment in hypertension, this may have implications." | 2.69 | Difference in blood pressure, but not in heart rate, between measurements performed at a health centre and at a hospital by one and the same physician. ( Enström, I; Lindholm, LH; Pennert, K, 2000) |
| "Treatment with atenolol reduced the incidence of preeclampsia from 5 of 28 (18%) to 1 of 28 (3." | 2.69 | Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. ( Brateng, D; Brown, Z; Easterling, TR; Millard, SP; Schmucker, B, 1999) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system, predisposing to a procoagulant state." | 2.69 | Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. ( Hatzizacharias, AN; Krespi, PG; Kyriakidis, MK; Makris, TK; Stavroulakis, GA; Triposkiadis, FK; Tsoukala, CG; Votteas, VV, 2000) |
| "Treatment with prazosin GITS resulted in a favourable effect on the serum lipid profile at the end of 24 weeks (p = 0." | 2.69 | Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group. ( Jaguste, V; Joglekar, SJ; Nanivadekar, AS, 1998) |
| "Atenolol is a cardioselective beta-blocker." | 2.68 | A comparison of antihypertensive effects between two formulations of atenolol: tenolol and tenormin. ( Chen, CY; Chiang, HT; Hou, ZY; Lee, DK; Wu, TL, 1995) |
| "Losartan was shown to have a smooth antihypertensive profile throughout the 24 h period following dosing, which mirrors the diurnal variability of blood pressure." | 2.68 | Efficacy and safety of losartan. ( Goldberg, A; Sweet, C, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Perindopril treatment caused an increase in small artery diameter (231 +/- 14 to 274 +/- 13 microns, P < ." | 2.68 | Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. ( Aalkjaer, C; Cooper, A; Heagerty, AM; Mulvany, MJ; Stephens, N; Thybo, NK, 1995) |
| "Left ventricular hypertrophy is very frequent when determined by echocardiography and all three drugs produced regression of left ventricular hypertrophy in a different way with respect to left ventricle geometry, an effect which could have potential therapeutic implications." | 2.68 | [Effect of 3 hypertensive++ agents on ventricular geometry and function]. ( Gómez Pajuelo, C; Gómez Sánchez, MA; Lombera Romero, F; Marín Ruiz, R; Sáenz de la Calzada, C; Sanz Julve, M; Tascón Pérez, J, 1995) |
| " Heart rate (EHR) after 5 min of exercise by bicycle ergometry (constant 75W), and parameters of renal function were assessed before (baseline) and during concomitant dosing of atenolol and tenoxicam." | 2.68 | Study on the possible interaction between tenoxicam and atenolol in hypertensive patients. ( Güzelhan, C; Hartmann, D; Horsch, AK; Lingenfelder, M; Stief, G, 1995) |
| "Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups." | 2.68 | Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. ( Goyal, RK; Satia, MC; Shukla, ML, 1995) |
| "Atenolol treatment had neutral properties in some metabolic aspects, but deleterious effects on lipid status." | 2.68 | Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. ( Haenni, A; Lithell, H, 1996) |
| "Orlistat was given in doses of 50 mg 3 times daily mid-meal for 7 (nifedipine and captopril) or 8 days (atenolol and furosemide)." | 2.68 | Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. ( Jonkmann, JH; Schmidtke-Schrezenmeier, G; Tam, YK; van Brummelen, P; Weber, C, 1996) |
| "The captopril treated patients exhibited favorable changes in several aspects of quality of life: sleep-related, gastrointestinal, and physical activity-related symptoms improved from baseline to end of follow-up." | 2.68 | The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. ( Anson, O; Neumann, L; Paran, E, 1996) |
| "Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect." | 2.68 | Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997) |
| " The type and incidence of adverse events seen with both drugs are characteristic of the dihydropyridine class of drugs and were mainly due to pharmacologically induced vasodilation, but lacidipine caused a significantly lower incidence of ankle edema than nifedipine SR." | 2.67 | A long-term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data. ( Leonetti, G; Salvi, S, 1994) |
| "Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0." | 2.67 | Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. ( Biscione, F; Lanza, GA; Manzoli, A; Natale, A; Santarelli, P, 1994) |
| "If atenolol was contraindicated, 0." | 2.67 | Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. ( Applegate, WB; Camel, GH; Greenlick, MR; Hadley, E; Luhr, J; Moye, L; Perry, HM; Pressel, S; Shekelle, RB; Wittes, J, 1994) |
| "100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l." | 2.67 | Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. ( Chanard, J; Durand, D; el Esper, N; Fournier, A; Godin, M; Goldfarb, B; Hannedouche, T; Landais, P; Mignon, F; Suo, JM, 1994) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 2.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| " After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached." | 2.67 | Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. ( Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994) |
| "Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function." | 2.67 | Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994) |
| "Isolated systolic hypertension has a higher prevalence with age and an associated excess cardiovascular risk." | 2.67 | Conclusions and implications of the systolic hypertension in the elderly program. ( Davis, BR; Hawkins, CM; Moyé, LA; Probstfield, JL, 1993) |
| " During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study." | 2.67 | Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. ( Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994) |
| " No significant difference was observed in the elimination half-life between the two trials." | 2.67 | Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects. ( Ebihara, A; Fujimura, A; Ohashi, K; Shiga, T; Tateishi, T, 1993) |
| " Office BPs were recorded at the end of the 24-hour dosing interval (trough)." | 2.67 | Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. ( Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 2.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent)." | 2.67 | Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. ( Cushman, WC; Freis, ED; Fye, C; Gottdiener, J; Hamburger, RJ; Kochar, MS; Lakshman, R; Massie, BM; Materson, BJ; Reda, DJ, 1993) |
| "The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials." | 2.67 | Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. ( , 1993) |
| "Nisoldipine, which has a higher coronary vascular selectivity and less negative inotropism than nifedipine, is as effective and as well tolerated as nifedipine in patients whose hypertension is inadequately controlled on atenolol." | 2.67 | Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol. ( Earle, KA; Hoffbrand, BI; Nievel, JG; Restrick, LJ; Simmonds, NJ, 1993) |
| "Bisoprolol and atenolol were similar in the black (10 +/- 5/9 +/- 3 mm Hg [n = 22] and 10 +/- 6/6 +/- 3 mm Hg [n = 13], respectively) and young (15 +/- 1/11 +/- 1 mm Hg [n = 84] and 16 +/- 2/10 +/- 1 mm Hg [n = 66], respectively) groups." | 2.67 | Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. ( Kazempour, MK; Lefkowitz, MP; Neutel, JM; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "It is now recognized that left ventricular hypertrophy (LVH), often associated with hypertension, is itself a risk factor for coronary disease in the elderly." | 2.67 | Left ventricular mass regression in elderly hypertensives. ( Gerstenblith, G, 1992) |
| "Atenolol and Ni were equally effective in reducing sphygmomanometric brachial artery blood pressure (BP)." | 2.67 | Effects of antihypertensive agents on carotid pulse contour in humans. ( Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, BM; Safar, M, 1992) |
| "Atenolol did not enhance the effect of physical training upon blood pressure and had little if any effect upon the training-induced increase in exercise tolerance." | 2.67 | Effects of mild physical activity, atenolol and the combination on ambulatory blood pressure in hypertensive subjects. ( Adamopoulos, S; Casadei, B; Clark, SJ; Coats, AJ; Meyer, TE; Piepoli, M; Pipilis, A; Radaelli, A, 1992) |
| " This suggests that some were apparent non-responders due to too low dosing of atenolol rather than true non-responders." | 2.67 | Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men. ( Erikssen, J; Froeland, G; Otterstad, JE; Saltvedt, E; Soeyland, AK, 1992) |
| "and enalapril 20 mg o." | 2.67 | Ambulatory blood pressure monitoring. A tool for more comprehensive assessment. ( Enström-Granath, I, 1992) |
| "The efficacy and safety of carvedilol, a beta-blocker with vasodilating properties, were compared at a dosage of 25 to 50 mg once daily with those of atenolol at a dosage of 50-100 mg once daily in a double-blind, randomized, parallel-group, multicenter study." | 2.67 | A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group. ( Young, PH, 1992) |
| " Corresponding values for the rate of absorption were in the mean 102." | 2.67 | Bioequivalence of a new atenolol formulation. ( Günzel, R; Rostock, G; Stulich, M; Vogel, I, 1992) |
| "Perindopril (4 mg) was compared to atenolol (50 mg), captopril (25 mg b." | 2.67 | Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs. ( Desche, P; Thurston, H, 1991) |
| " The incidence of adverse events was also similar for both drugs, and serious adverse events were rare and thought to be unrelated to the study drug therapy." | 2.67 | A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group. ( , 1991) |
| "This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients." | 2.67 | The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. ( Blaufox, MD; Davis, BR; Langford, HG; Oberman, AS; Wassertheil-Smoller, S; Wylie-Rosett, J, 1992) |
| " The mean dosage in the isradipine group was 7." | 2.67 | Effect of isradipine and atenolol on lung function in patients with mild essential hypertension. ( Meisner, W; Reiterer, W, 1991) |
| "This randomised, double-blind, crossover study compared enalapril 5 mg, and atenolol 50 mg, each dosed once daily for 4 weeks, and investigated casual and diurnal BP changes using 24 hour ambulatory BP monitoring." | 2.67 | Effect of atenolol or enalapril on diurnal changes of blood pressure in Japanese mild to moderate hypertensives: a double-blind, randomised, crossover trial. ( Hara, H; Ishida, Y; Kobayashi, K; Nakamura, S; Ohta, H; Takabatake, T; Takakuwa, H; Yamamoto, Y, 1991) |
| " The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs." | 2.67 | A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ( Dixon, MS; Sheridan, DJ; Thomas, P, 1990) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| " Each drug was given separately in a random fashion in fixed dosage for 4 weeks with a washout period of 2 weeks in between the drugs." | 2.67 | The effects of antihypertensive agents on the quality of life in Indian hypertensives. ( Kumar, K; Rajan, AG; Somani, PN; Sundar, S, 1991) |
| "Atenolol did not produce a reduction in the left-ventricular-mass index (109 +/- 9 g per square meter before treatment vs." | 2.67 | The effects of antihypertensive therapy on left ventricular mass in elderly patients. ( Becker, LC; Gerstenblith, G; Gottlieb, SO; Schulman, SP; Weisfeldt, ML; Weiss, JL; Woodruff, KM, 1990) |
| " Sitting (and standing) blood pressure and heart rate one to four hours after dosing were recorded at entry (191/95 mmHg) and at the end of the run-in period (186/93 mmHg)." | 2.67 | Hypertension in the elderly: a study of a combination of atenolol and nifedipine. ( Cheadle, B; Duckett, GK, 1990) |
| " More specifically, a comparison of the two drugs during the final 6 hours (3 AM to 9 AM) of the dosing interval showed that the mean decrease in diastolic BP of 10." | 2.67 | Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. ( Cheung, DG; Graettinger, WF; Neutel, JM; Schnaper, H; Weber, MA, 1990) |
| "Nifedipine did not cause significant changes in systolic or diastolic variability; a small but nonsignificant decrease in diastolic variability was seen with atenolol and the combination of atenolol and nifedipine." | 2.66 | Effect of calcium antagonists on ambulatory blood pressure and its variations. ( Clement, DL; De Pue, NY; Packet, L, 1987) |
| "Nitrendipine is a dihydropyridine calcium antagonist suggested to be a new drug for first-line antihypertensive therapy, possibly active in once-daily administration." | 2.66 | Long-term hypotensive treatment with nitrendipine in mild to moderate essential hypertension: preliminary results of a placebo-controlled study versus atenolol. ( Fommei, E; Genovesi-Ebert, A; Ghione, S; Giaconi, S; Giuliano, G; Marabotti, C; Mezzasalma, L; Palombo, C, 1987) |
| " The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)." | 2.66 | [Perindopril: first-line treatment of arterial hypertension]. ( Desche, P; Zanchetti, A, 1989) |
| "Indenolol was as effective and safe as atenolol in long-term antihypertensive therapy." | 2.66 | Comparison of a vasodilating beta-blocker and a cardioselective beta-blocker in long-term treatment of hypertension: a European multicentre study. ( Ambrosioni, E; Birkenhäger, W; Dal Palù, C; De Leeuw, PW; Demanet, JC; Groothold, G; Libretti, A; Mailland, F; Malacco, E; Poli, A, 1989) |
| "Enalapril and atenolol were also equally effective, but in combination their hypotensive effects were less than fully additive, with attenuation of the potential additive response by 30-50%." | 2.66 | Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions. ( Bune, AJ; Chalmers, JP; Elliott, JM; Morris, MJ; Russell, AE; West, MJ; Wing, LM, 1987) |
| "After the treatment of hypertension with the ACE inhibitor the responses to exercise were less restrictive than those after treatment with the cardioselective beta-blocker." | 2.66 | Effects of angiotensin converting enzyme inhibition and beta-blockade on exercise responses in hypertensive patients. ( Goodman, C; Radford, HM; Rogers, GG; Rosendorff, C, 1988) |
| "Treatment with labetalol, on the other hand, led to an improvement in respiratory function." | 2.66 | Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease. ( Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986) |
| "Atenolol was significantly more effective than relaxation in reducing both systolic and diastolic pressure." | 2.66 | Relaxation therapy for hypertension. Comparison of effects with concomitant placebo, diuretic, and beta-blocker. ( Coburn, PC; Jacob, RG; Johnsen, AM; McDonald, RH; Reeves, RA; Shapiro, AP, 1986) |
| "Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels." | 2.66 | A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. ( Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ, 1987) |
| "Celiprolol is a new generation beta blocker with a novel profile of activity that includes a high degree of cardioselectivity, partial beta 2-agonist activity, and possibly a degree of direct peripheral vasodilation." | 2.66 | Antihypertensive therapy with celiprolol: a new cardioselective beta blocker. ( Norris, RJ, 1988) |
| " After a placebo run-in period the patients received increasing dosages of medication every 2 weeks until the target diastolic blood pressure of 90 mm Hg or less was achieved on two consecutive visits, the maximum dosage was reached, or the patient withdrew because of adverse effects." | 2.66 | Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group. ( , 1987) |
| "Atenolol treatment generally resulted in performance levels that did not differ from those observed with placebo." | 2.66 | Impact of beta-blockade on complex cognitive functioning. ( DePadova, A; McGlynn, T; Piasecki, M; Pogash, R; Streufert, S, 1988) |
| "Prazosin was better tolerated by the subjects and was preferred by 10 of the men." | 2.66 | Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers. ( Cullinane, EM; Nugent, AM; Sady, MA; Sady, SP; Thompson, PD, 1989) |
| " Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension." | 2.66 | Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. ( Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987) |
| "A randomised trial of the treatment of hypertension in 884 patients aged 60 to 79 years at the onset showed a reduction of 18/11 mm Hg in blood pressure over a mean follow up period of 4." | 2.66 | Randomised trial of treatment of hypertension in elderly patients in primary care. ( Coope, J; Warrender, TS, 1986) |
| "The daily administration of 240 to 360 mg of diltiazem lowered blood pressure in a dose-related pattern similar to that seen in patients taking a daily dosage of 50 to 100 mg of atenolol." | 2.66 | Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. ( Giard, MJ; Josselson, J; Lam, YW; Posner, JN; Saunders, E; Warren, JB; Weir, MR; Zaske, DE, 1987) |
| " The mean supine BP 24 hours post dosing were 177/110 mmHg (placebo), 173/109 mmHg (propranolol) and 164/100 mmHg (atenolol)." | 2.66 | Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide. ( Lovell, HG; Petrie, JC; Robb, OJ; Webster, J; Witte, K, 1987) |
| "Atenolol did not cause any significant change in the total cholesterol but increased HDL cholesterol by 7% at 1 month, the change being due to rise of the HDL3." | 2.66 | Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol. ( Harno, K; Maass, L; Nikkilä, EA; Välimäki, M, 1986) |
| " Dosage was a single tablet per day given in the morning." | 2.66 | Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial. ( Backhouse, CI; Edwards, KG; Hosie, J; Tweed, JA, 1985) |
| "Labetalol and atenolol were equivalent in control of blood pressure at rest, exercise tolerance and use of nitroglycerin; however, heart rates at rest and during exercise were higher with labetalol (p less than 0." | 2.66 | Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris. ( Jee, LD; Opie, LH, 1985) |
| " Blood pressure and heart rate were measured 22 hours after the last tablet of a 2-week dosing period." | 2.66 | Comparison of the duration of antihypertensive action of atenolol and metoprolol over a 24-hour period. ( Crowe, PF; Ferguson, RJ, 1985) |
| " Twenty-four hours after dosing only atenolol treatment was consistently associated with a reduction in both exercise heart rate (P less than 0." | 2.66 | Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients. ( Freestone, S; Lennard, MS; Ramsay, LE; Silas, JH, 1985) |
| "Propranolol was the only drug that significantly increased airways obstruction (FEV1, specific airways resistance)." | 2.65 | Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. ( Adam, WR; Barter, CE; Meagher, EJ, 1982) |
| "Atenolol is an alternative drug in the treatment of PVC in patients with coronary heart disease." | 2.65 | [Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)]. ( Brandes, JW; Körst, HA; Lembcke, HJ; Littmann, KP, 1981) |
| "Atenolol was withdrawn in those allocated to labetalol and minoxidil was given only to men." | 2.65 | The 'third drug' trial: a comparative study of anti-hypertensive agents added to treatment when blood pressure is uncontrolled by a beta-blocker plus thiazide diuretic. ( Latham, L; Lorimer, AR; McAreavey, D; McLaren, D; Ramsay, LE; Reid, JL; Robertson, JI; Robertson, MP; Weir, RJ, 1983) |
| "Atenolol was withdrawn in those allocated to labetalol, and minoxidil was given only to men." | 2.65 | "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. ( Latham, L; Lorimer, AR; McAreavey, D; McLaren, AD; Ramsey, LE; Reid, JL; Robertson, JI; Robertson, MP; Weir, RJ, 1984) |
| " Patients who responded (diastolic BP less than 95 mmHg) continued on the initial dosage regimen." | 2.65 | Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents. ( Lyngstam, O; Rydén, L, 1981) |
| "Atenolol, 100 mg/day, was given to 12 hypertensive patients for 8 weeks, and its effects on mean arterial pressure (MAP), cardiac index (CI) and ejection indexes of myocardial performance were examined by echocardiography." | 2.65 | Effect of atenolol on left ventricular function in hypertensive patients. ( Ibrahim, MM; Madkour, MA; Mossallam, R, 1980) |
| "1." | 2.65 | Effect of atenolol on left ventricular function in hypertensive patients. ( Ibrahim, MM; Madkour, MA; Mossallam, R, 1980) |
| "1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients." | 2.65 | Atenolol and chlorthalidone in combination for hypertension. ( Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979) |
| "Prazosin appears to be a potent and appropriate third agent." | 2.64 | Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. ( Barritt, DW; Heaton, ST; Marshall, AJ; Pocock, J, 1977) |
| "5." | 2.64 | Clinical evaluation of atenolol in hypertension. ( Aberg, H; Hansson, L; Henningsen, NC; Jameson, S; Karlberg, BE; Westerlund, A, 1976) |
| "Atenolol was the beta-blocker most used." | 2.55 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Opie, LH; Volmink, J; Wiysonge, CS, 2017) |
| "Initiating treatment of hypertension with beta-blockers leads to modest reductions in cardiovascular disease and no significant effects on mortality." | 2.48 | Beta-blockers for hypertension. ( Bradley, HA; Mayosi, BM; Mbewu, A; Opie, LH; Volmink, J; Wiysonge, CS, 2012) |
| "Beta-blockers have been used to treat hypertension for decades, either as monotherapy or combined with other antihypertensive agents, primarily diuretics, often as fixed-dose combination products." | 2.44 | Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. ( Black, HR; Sica, DA, 2008) |
| "Beta-blockers have been widely used to treat hypertension and are still recommended as first-line drugs in guidelines." | 2.44 | Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome? ( Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2007) |
| "Beta blockers used for the treatment of hypertension may be associated with increased risk for new-onset diabetes mellitus (DM)." | 2.44 | A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. ( Bangalore, S; Grossman, E; Messerli, FH; Parkar, S, 2007) |
| "Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications." | 2.44 | Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. ( Feihl, F; Gojanovic, B; Liaudet, L; Waeber, B, 2008) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "Blood pressure and proteinuria are important determinants of progressive renal failure in patients with renal diseases." | 2.41 | [Intensive treatment of blood pressure in patients with kidney disease and proteinuria]. ( Huysmans, FT; Wetzels, JF, 2000) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| " In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug." | 2.40 | [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy]. ( Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999) |
| "1%) were the most commonly reported clinical adverse experiences in patients treated with losartan." | 2.39 | Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Heart failure is characterized by the inability of the myocardium to shorten sufficiently or to eject an adequate stroke volume to maintain normal perfusion of both the cardiac and the extracardiac organs." | 2.38 | Beta-blocking agents in heart failure: modern concepts and overview. ( Strauer, BE, 1990) |
| "Hypertension is an asymptomatic conditions which can be life threatening." | 2.38 | Beta blockers and quality of life. ( Cruikshank, JM; McAinsh, J, 1992) |
| "Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours." | 2.38 | Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. ( Brogden, RN; Murdoch, D; Wadworth, AN, 1991) |
| "The chronic use of propranolol is characterized by 10%-20% decrements of renal plasma flow (RPF) and glomerular filtration rate (GFR)." | 2.37 | Beta blockers and renal function: a reappraisal. ( Epstein, M; Oster, JR, 1985) |
| "Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity." | 2.36 | Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1979) |
| "Midlife hypertension is an important risk factor for cognitive impairment and dementia, including Alzheimer's disease." | 1.91 | Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats. ( Bakker, ENTP; Coolen, BF; de Vos, J; Heijst, JA; Jongenelen, CAM; Naessens, DMP; Richard, E; Scholl, ER; Strijkers, GJ; Teunissen, CE; van der Wel, NN; VanBavel, E; Wilhelmus, MMM, 2023) |
| "Hypertension was induced by oral administration of nitric oxide synthase inhibitor, N-nitro L-arginine-methyl-ester (L-NAME), at 40 mg/kg body weight to the male Wistar rats for 14 consecutive days." | 1.51 | Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats. ( Adedara, IA; Adeyemo, MO; Ajibade, TO; Alake, SE; Farombi, EO; Olajide, LO, 2019) |
| "Enalapril was the most commonly prescribed drug." | 1.48 | Drug utilization among hypertensive patients in the outpatient department of medicine in a tertiary care hospital: A cross-sectional study. ( Paradkar, SG; Sinha, SR, 2018) |
| "Hypertension was confirmed prior to treatment with HCTZ (148 blacks and 218 whites) or with atenolol (146 blacks and 221 whites)." | 1.43 | Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. ( Bailey, KR; Chapman, AB; Cooper-Dehoff, RM; Gharaibeh, KA; Gums, JG; Hamadah, AM; Johnson, JA; Schwartz, GL; Turner, ST, 2016) |
| "Atenolol use was related to increased mortality in community-dwelling hypertensive Older adults." | 1.40 | Atenolol use is associated with long-term mortality in community-dwelling older adults with hypertension. ( Abete, P; Bonaduce, D; Cacciatore, F; Della-Morte, D; Galizia, G; Gargiulo, G; Mastrobuoni, C; Mazzella, F; Rengo, F; Testa, G, 2014) |
| " The pharmacokinetic study illustrated that the fast absorption and increased oral bioavailability of atorvastatin as well as therapeutic concentration of atenolol in blood were made available through adoption of formulation strategy of bilayer tablets." | 1.40 | Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release. ( Chattopadhyay, S; Dey, S; Mazumder, B, 2014) |
| "Hippadine is an alkaloid isolated from Crinum macowanii." | 1.40 | Effects of hippadine on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats. ( Dietrich, D; Green, I; Mugabo, P; Philander, A; Raji, I, 2014) |
| "Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase." | 1.38 | An economic evaluation of antihypertensive therapies based on clinical trials. ( Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL, 2012) |
| "Metoprolol and atenolol were generally well tolerated except at higher doses such as metoprolol >100 mg daily." | 1.38 | Cardioselective beta-blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks? ( Self, TH; Soberman, JE; Wallace, JL, 2012) |
| "Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0." | 1.37 | Beta blockers and breast cancer mortality: a population- based study. ( Barron, TI; Bennett, K; Connolly, RM; Sharp, L; Visvanathan, K, 2011) |
| "In 1112 never-treated essential hypertension patients and 203 normotensive controls, tightly linked SNPs of beta-adrenergic receptors (ADRB1 - Ser49Gly and Arg389Gly; ADRB2 - Cys19Arg, Gly16Arg and Gln27Glu) and the G-protein beta3-subunit (GNB3 - A3882C, G5249A and C825T) were genotyped." | 1.36 | Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. ( Argiolas, G; Bulla, E; Bulla, P; Degortes, S; Filigheddu, F; Frau, F; Glorioso, N; Pitzoi, S; Troffa, C; Zaninello, R, 2010) |
| "Atenolol was effective in both reducing systolic BP maximum values and mitigating BP increase during resistance exercise performed at different intensities in hypertensive subjects." | 1.36 | Atenolol blunts blood pressure increase during dynamic resistance exercise in hypertensives. ( Costa, LA; Fernandes, JR; Forjaz, CL; Gomides, RS; Junior, DM; Ortega, KC; Queiroz, AC; Souza, DR; Tinucci, T, 2010) |
| " Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<." | 1.35 | Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. ( Ferdinand, KC; Khan, BV; Merchant, N; Pandian, A; Rahman, ST; Searles, CD; Umpierrez, GE, 2009) |
| "Hypertension is present in nearly 80% of dialysis patients yet adequately controlled in less than half." | 1.34 | ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. ( Coyne, DW; Nath, V; Zheng, S, 2007) |
| " The effects of nebivolol on the bioavailability of NO and ONOO, indicators of endothelial function and dysfunction, respectively, were measured in vitro using nanosensors placed in mesenteric arteries." | 1.33 | Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. ( Boychuk, B; Jacob, RF; Kubant, R; Malinski, T; Mason, RP; Walter, MF, 2006) |
| "Atenolol presented lower LF and higher HF of PI." | 1.33 | Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. ( Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC, 2006) |
| "Treatment with atenolol did not change PIP and KLV in either subgroup of hypertensives." | 1.32 | The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. ( Beloqui, O; Díez, J; González, A; Laviades, C; López, B; Mayor, G; Orbe, J; Páramo, JA; Zalba, G, 2003) |
| "Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%." | 1.32 | Hypertension and insulin resistance are not directly related in obese dogs. ( Gokee, A; Rocchini, AP; Yang, JQ, 2004) |
| "Pretreatment with terazosin (10 mg/kg ip) significantly reduced the initial increase in MAP to 12 +/- 6 mmHg, whereas MAP for the last 45 min was superimposable on control values." | 1.32 | Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice. ( Brands, MW; Lee, DL; Webb, RC, 2004) |
| "Hypertension is the most common." | 1.32 | Abdominal coarctation in a hypertensive female collegiate basketball player. ( Simons, S; Sloan, B; Stromwall, A, 2004) |
| "Losartan therapy was associated with more benefits in stroke risk reduction and in the development of new cases of diabetes." | 1.31 | [Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study]. ( González-Juanatey, JR, 2002) |
| "Atenolol was started on an alternate day, 37." | 1.31 | Long-term control of hypertension in dialysis patients by low dose atenolol. ( Hadjiconstantinou, VE; Hadjiyannakos, DK; Karras, SM; Mentzikof, DG; Noussias, CV; Vlassopoulos, DA, 2002) |
| " Changes in RVR were inversely related to changes in CLi and Curic acid, suggesting unopposed alfa-adrenergic stimulation to be implicated in the renal counterregulation at a proximal tubular site following long-term administration of atenolol in essential hypertension." | 1.30 | Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol. ( Christensen, CK; Jespersen, LT; Krusell, LR; Pedersen, OL; Thomsen, K, 1997) |
| "In conclusion, ESRD patients taking atenolol or captopril are needed to be frequently monitored for blood potassium levels and it would be advisable to avoid these drugs to control hypertension in ESRD patients, especially, when scheduled for renal transplantation." | 1.30 | Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study. ( Gaur, A; Kaushik, S; Kher, V; Tripathi, M, 1997) |
| "Indications for treatment were hypertension (75%), coronary artery disease with (12%) or without (3%) hypertension, or unknown (10%)." | 1.30 | Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. ( Danser, AH; Hense, HW; Holmer, SR; Mayer, B; Riegger, GA; Schunkert, H, 1998) |
| " Chronic administration of propranolol (5 or 50 mg." | 1.29 | Effects of propranolol and atenolol on immobilization stress-induced hypertension and down-regulation of central beta-adrenoceptors in rats. ( Kigoshi, S; Muramatsu, I; Oda, Y; Takita, M, 1995) |
| "Neuropeptide Y (NPY) has been recently characterised as a circulating vasoconstrictor peptide which is co-stored with noradrenaline (NA) in sympathetic neurons." | 1.29 | Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. ( Hänze, J; Lang, RE; Lettgen, B; Rascher, W; Wagner, S, 1994) |
| "The ECG test showed sinus tachycardia (heart rate > 100/min) but an otherwise normal function in group A." | 1.29 | Hyperdynamic beta-adrenergic syndrome among Croatian soldiers engaged in battle. ( Bergovec, M; Beslin, MB; Eremić, Z; Gopcević, A; Heitzler, VN; Mihatov, S; Prpić, H; Seni, B; Stancić, V; Tomljenović, M, 1993) |
| "4." | 1.29 | Response of the rat mesenteric vasculature to chronic treatment with nitrendipine alone and in combination with atenolol: evidence of a significant drug interaction. ( Draper, AJ; Kingsbury, MP; Redfern, PH; Todd, MH, 1993) |
| "Observed numbers of cancers in clinic patients were compared with expected numbers derived from cancer rates in two control populations adjusted for age, sex, and time period of data collection." | 1.29 | Incidence of and mortality from cancer in hypertensive patients. ( Gillis, CR; Hawthorne, VM; Hole, DJ; Isles, CG; Lever, AF; McGhee, SM; Robertson, JW; Wapshaw, JA, 1993) |
| "Atenolol was initiated in 7." | 1.29 | Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system. ( Aron, DC; Aucott, JN; Dombrowski, R; Fuehrer, SM; Laich, J; Pelecanos, E, 1996) |
| " The author assumes that in addition to the effectiveness of the administered drug the marked improvement of the patients is due to better collaboration of the patients and adherence to the prescribed dosage and lifestyle." | 1.29 | [Corotenol, its effectiveness and tolerance in light of new studies]. ( Uhlír, O, 1996) |
| "The effects of the chronic administration of bopindolol on the binding characteristics of [3H]CGP12177 and [3H]prazosin to cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes of spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) were compared with those of two other beta-blockers, atenolol and propranolol." | 1.29 | Effects of chronic administration of bopindolol on the binding characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes in cardiac muscles of spontaneously hypertensive rats (SHR). ( Hattori, K; Hosohata, Y; Maruyama, K; Nagatomo, T; Ohnuki, T; Sasaki, K; Suzuki, J; Watanabe, K, 1996) |
| "Betaxolol is a new beta-blocker that has been reported to have beta 1-selectivity, and it is devoid of both membrane stabilizing action and intrinsic sympathomimetic action." | 1.28 | Regional hemodynamic effects of betaxolol, a new selective beta 1-blocker, and atenolol in conscious spontaneously hypertensive rats. ( Abe, Y; Aki, Y; Fujisawa, Y; He, H; Horiuchi, K; Iwao, H; Kiyomoto, H; Nishiyama, A; Shoji, T; Tamaki, T, 1992) |
| "The recently published MRC-trial on treatment of hypertension in older adults showed generally beneficial effects." | 1.28 | [Treatment of hypertension in the elderly--diuretics/atenolol?]. ( Osnes, JB, 1992) |
| "1." | 1.28 | Effects of chronic administration of atenolol on the in situ perfused mesentery of normotensive and hypertensive rats. ( Draper, AJ; Kingsbury, MP; Redfern, PH; Todd, MH, 1992) |
| " Prereduction dosage of atenolol was 100 mg in 26 and 50 mg in 15 patients." | 1.28 | [Effect of halving the dosage of atenolol in essential hypertension]. ( Brack, T; Edmonds, D; Greminger, P; Grüne, S; Vetter, W, 1992) |
| "4." | 1.28 | Stimulating effects of atenolol on vasodepressor prostaglandin generation in spontaneously hypertensive rats. ( Hirawa, N; Ikeda, T; Ishii, M; Matsuoka, H; Numabe, A; Sugimoto, T; Takada, S; Uehara, Y; Yagi, S, 1991) |
| "Cromakalim was generally well tolerated in both normotensive and hypertensive subjects." | 1.28 | Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1990) |
| "A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome." | 1.28 | Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome. ( Friedler, A; Mor, F; Shapira, Y; Weinberger, A; Wysenbeek, AJ, 1990) |
| "The pseudolymphoma syndrome is a reversible reactive condition consisting of fever, lymphadenopathy and generalized rash." | 1.28 | Atenolol-induced pseudolymphoma. ( Henderson, CA; Shamy, HK, 1990) |
| "Atenolol was injected subcutaneously (20 mg/kg) twice daily commencing in four-week-old rats." | 1.27 | The effects of beta adrenoceptor blockade with atenolol on myocardial cellular and subcellular hypertrophy in spontaneously hypertensive rats. ( Lauva, IK; Tomanek, RJ, 1983) |
| "Indomethacin and sulindac were used as tools to study the role of renal and/or systemic prostaglandins in the pharmacological response to atenolol." | 1.27 | The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. ( Abdel-Haq, B; Alberici, P; Magagna, A; Pedrinelli, R; Salvetti, A, 1984) |
| "Atenolol was orally given to 10 patients with essential hypertension once a day and changes in various parameters were observed through 24 hours." | 1.27 | Acute effect of atenolol on hemodynamic, plasma renin activity and plasma aldosterone concentration in the once daily oral administration. ( Arakawa, K; Sasaki, Y, 1984) |
| " The average daily dosage was 144." | 1.27 | Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. ( Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983) |
| " In these patients, the doubling of diuretic dose (hydrochlorothiazide 50 mg + amiloride 5 mg) in combination with atenolol resulted in a further drop in systolic pressure (to 142." | 1.27 | Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients. ( Bentivoglio, M; Corea, L; Verdecchia, P, 1983) |
| " If standard doses of some beta-blockers are used in poor metabolizers, these patients may be susceptible to concentration-related adverse reactions and they may also require lower and less frequent dosing for control of angina pectoris." | 1.27 | Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. ( Lennard, MS; Silas, JH; Tucker, GT; Woods, HF, 1986) |
| " Patients were treated with propranolol 40 to 160 mg bid for 8 weeks, followed by atenolol 50 to 100 mg given once daily for 8 weeks, and then rechallenged with the required dosage of propranolol for 8 weeks." | 1.27 | A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension. ( Chockalingam, A; Drover, A; Fifield, F; Fodor, JG; Pauls, CJ, 1987) |
| "DOCA-salt hypertension was associated with hyporeninemia and mild hypokalemia, without consistent changes in heart rate or plasma catecholamines." | 1.27 | Production and reversal of DOCA-salt hypertension in baboons. ( Goldstein, DS; Turkkan, JS, 1987) |
| " No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects." | 1.27 | A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. ( Adam, HK; Castleden, CM; Fitzsimons, TJ; Ryan, J; Sabanathan, K, 1987) |
| "Atenolol is a beta-blocker antihypertensive agent that reportedly has little central nervous system action." | 1.27 | Severe confusion in a patient receiving electroconvulsive therapy and atenolol. ( Kramer, BA, 1986) |
| " Full dose-response curves for isoproterenol were constructed in BP and HR." | 1.26 | The ratio of cardiac to vascular beta-receptor blockade of atenolol and propranolol in spontaneously hypertensive rats in vivo. ( Kudo, Y; Sokabe, H, 1982) |
| "Atenolol treatment abolished almost completely these hemodynamic changes." | 1.26 | [Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient]. ( Cannella, G; Cesura, AM; Giambelli, A; Maiorca, R; Picotti, GB; Scolari, F; Tosoni, S, 1982) |
| "Pindolol was 71." | 1.26 | The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. ( Taylor, EA; Turner, P, 1981) |
| "Labetalol, which is a combined alpha- and beta-blocking agent, reduces mean blood pressure levels at all times." | 1.26 | Effects of treatment on circadian rhythms of blood pressure. ( Balasubramanian, V; Mann, S; Millar-Craig, MW; Raftery, EB, 1981) |
| " 3 No significant differences in the pharmacokinetic profile of atenolol were evident between the values obtained following chronic dosing and an acute single-dose study." | 1.26 | Withdrawal of long-term therapy with atenolol in hypertensive patients. ( Barber, HE; Hawksworth, GM; Jeffers, TA; Petrie, JC; Webster, J, 1981) |
| " This difference may be because chronic administration of the drug caused saturation of red cell binding." | 1.26 | Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. ( Bastain, W; Farina, PL; McAinsh, J; Riva, E; Sega, R; Tognoni, G, 1980) |
| "The authors describe a simple method of fluorimetric estimation of atenolol, applicable to blood and urine, sufficiently sensitive to permit a pharmacokinetic study." | 1.26 | [Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)]. ( Bazin, M; Flouvat, B; Guedon, J; Lucsko, M; Roux, A, 1978) |
| "3." | 1.26 | Prevention and reversal of isolation-induced systolic arterial hypertension in rats by treatment with beta-adrenoceptor antagonists. ( Bennett, T; Gardiner, SM, 1979) |
| "Chronic hypertension was induced in Wistar rats with intact kidneys by subcutaneous implantation of 50 mg of deoxycorticosterone acetate (DOCA) in wax and addition of sodium chloride (9 g/l) to the drinking water." | 1.26 | Dependence of deoxycorticosterone/salt hypertension in the rat on the activity of adrenergic cardiac nerves. ( Bell, C; McLachlan, EM, 1979) |
| " The simple dosage regime, combined with proven effectiveness and a relative lack of side-effects makes atenolol a useful treatment for the hypertensive patient." | 1.26 | Multicentre general practitioner assessment of 'Tenormin' and methyldopa. ( Mason, B; Sleigh, R; Tweed, JA, 1979) |
| " In patients with normal renal function the atenolol half-life was calculated to be about six hours following single 100 mg oral doses." | 1.26 | Pharmacokinetics of atenolol in patients with renal impairment. ( Legheand, J; McAinsh, J; Pozet, N; Sassard, J; Zech, P, 1977) |
| "Treatment with atenolol markedly inhibited the onset of genetic hypertension, reduced HR and PRC from the outset and diminished the heart weight/body weight ratio." | 1.26 | Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. ( Boissier, JR; Giudicelli, JF; Richer, C, 1978) |
| "Propranolol was given to 15 patients and I." | 1.25 | Dopamine-beta-hydroxylase after treatment with beta-blockers in hypertension. ( Aberg, H; Hedstrand, H; Ross, SB; Wetterberg, L, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 662 (37.23) | 18.7374 |
| 1990's | 447 (25.14) | 18.2507 |
| 2000's | 489 (27.50) | 29.6817 |
| 2010's | 163 (9.17) | 24.3611 |
| 2020's | 17 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Majid, A | 1 |
| Javed, A | 1 |
| Hussain, M | 1 |
| Faisal, Z | 1 |
| Elahi, A | 1 |
| Akhtar, L | 1 |
| Behera, G | 1 |
| Nagaraj, GA | 1 |
| Thirunavukarasu, SC | 1 |
| Jayaraman, R | 1 |
| Murugesan, R | 1 |
| Subramanian, A | 1 |
| Mitsuboshi, S | 1 |
| Niimura, T | 1 |
| Aizawa, F | 1 |
| Goda, M | 1 |
| Zamami, Y | 1 |
| Ishizawa, K | 1 |
| Esler, M | 1 |
| Kjeldsen, SE | 80 |
| Pathak, A | 1 |
| Grassi, G | 3 |
| Kreutz, R | 1 |
| Mancia, G | 24 |
| Naessens, DMP | 1 |
| de Vos, J | 1 |
| Richard, E | 1 |
| Wilhelmus, MMM | 1 |
| Jongenelen, CAM | 1 |
| Scholl, ER | 1 |
| van der Wel, NN | 1 |
| Heijst, JA | 1 |
| Teunissen, CE | 1 |
| Strijkers, GJ | 1 |
| Coolen, BF | 1 |
| VanBavel, E | 1 |
| Bakker, ENTP | 1 |
| Feinberg, JB | 1 |
| Nielsen, EE | 1 |
| Devereux, RB | 96 |
| Gerdts, E | 25 |
| Wachtell, K | 59 |
| Olsen, MH | 34 |
| Singh, S | 5 |
| Warren, HR | 1 |
| Hiltunen, TP | 3 |
| McDonough, CW | 8 |
| El Rouby, N | 2 |
| Salvi, E | 1 |
| Wang, Z | 3 |
| Garofalidou, T | 1 |
| Fyhrquist, F | 25 |
| Kontula, KK | 2 |
| Glorioso, V | 1 |
| Zaninello, R | 2 |
| Glorioso, N | 3 |
| Pepine, CJ | 23 |
| Munroe, PB | 1 |
| Turner, ST | 20 |
| Chapman, AB | 17 |
| Boerwinkle, E | 17 |
| Johnson, JA | 27 |
| Gong, Y | 23 |
| Cooper-DeHoff, RM | 33 |
| Georgianos, PI | 2 |
| Agarwal, R | 6 |
| Juraschek, SP | 2 |
| Simpson, LM | 2 |
| Davis, BR | 17 |
| Beach, JL | 2 |
| Ishak, A | 2 |
| Mukamal, KJ | 2 |
| Shmerling, RH | 1 |
| Leung, KL | 1 |
| Fong, W | 1 |
| Freedman, B | 1 |
| Bajorek, B | 1 |
| Lee, VWY | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Fleury, CA | 2 |
| Almeida, EPM | 1 |
| Dionisio, TJ | 2 |
| Calvo, AM | 1 |
| Oliveira, GM | 1 |
| Amaral, SL | 2 |
| Santos, CF | 3 |
| Faria, FAC | 1 |
| Tucci, PJF | 1 |
| Elias, GP | 2 |
| Araujo, HC | 1 |
| Sassaki, KT | 2 |
| Delbem, ACB | 1 |
| Antoniali, C | 2 |
| Katsuda, SI | 1 |
| Fujikura, Y | 1 |
| Horikoshi, Y | 1 |
| Hazama, A | 1 |
| Shimizu, T | 1 |
| Shirai, K | 1 |
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Santander Plantamura, Y | 1 |
| Allo, MA | 1 |
| Parola, L | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| Bin, EP | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Berg, G | 1 |
| Taira, CA | 2 |
| Donato, M | 1 |
| Chiappetta, DA | 1 |
| Polizio, AH | 1 |
| Höcht, C | 2 |
| Chan You, S | 1 |
| Krumholz, HM | 1 |
| Suchard, MA | 1 |
| Schuemie, MJ | 1 |
| Hripcsak, G | 1 |
| Chen, R | 1 |
| Shea, S | 1 |
| Duke, J | 1 |
| Pratt, N | 1 |
| Reich, CG | 1 |
| Madigan, D | 1 |
| Ryan, PB | 1 |
| Woong Park, R | 1 |
| Park, S | 1 |
| Dasa, O | 1 |
| Smith, SM | 3 |
| Howard, G | 1 |
| Handberg, E | 2 |
| Whiteley, WN | 1 |
| Gupta, AK | 4 |
| Godec, T | 2 |
| Rostamian, S | 1 |
| Whitehouse, A | 2 |
| Mackay, J | 2 |
| Sever, PS | 15 |
| Yousefpour, A | 1 |
| Modarress, H | 1 |
| Goharpey, F | 1 |
| Amjad-Iranagh, S | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Xie, H | 1 |
| Luo, G | 1 |
| Zheng, Y | 1 |
| Peng, F | 1 |
| Xie, L | 1 |
| Wang, Y | 4 |
| Zhang, F | 1 |
| Liu, Y | 1 |
| Yin, S | 1 |
| Pang, X | 1 |
| Li, Z | 2 |
| Wei, Z | 1 |
| Jani, SM | 1 |
| Nallamothu, BK | 1 |
| Cooper, LT | 1 |
| Smith, A | 2 |
| Fazel, R | 1 |
| Zhang, Y | 2 |
| Sun, N | 1 |
| Jiang, X | 1 |
| Xi, Y | 1 |
| Paradkar, SG | 1 |
| Sinha, SR | 1 |
| Magvanjav, O | 1 |
| Gums, JG | 18 |
| Bailey, KR | 11 |
| Beitelshees, AL | 17 |
| Tanaka, T | 2 |
| Kubo, M | 2 |
| Okin, PM | 40 |
| Hille, DA | 18 |
| Hejazi, MM | 1 |
| Bacha, AO | 1 |
| Kaleemuddin, M | 1 |
| Al-Abassi, FA | 1 |
| Al-Alsieni, AI | 1 |
| Kazmi, I | 1 |
| Anwar, F | 1 |
| Choi, MH | 1 |
| Lee, JS | 1 |
| Lee, SE | 1 |
| Lee, SJ | 1 |
| Yoon, D | 1 |
| Park, RW | 1 |
| Hong, JM | 1 |
| Eibel, B | 1 |
| Kristochek, M | 1 |
| Peres, TR | 1 |
| Dias, LD | 1 |
| Dartora, DR | 1 |
| Casali, KR | 1 |
| Kalil, RAK | 1 |
| Lehnen, AM | 1 |
| Irigoyen, MC | 1 |
| Markoski, MM | 1 |
| Adedara, IA | 1 |
| Alake, SE | 1 |
| Olajide, LO | 1 |
| Adeyemo, MO | 1 |
| Ajibade, TO | 1 |
| Farombi, EO | 1 |
| de Moura Leão, MF | 1 |
| Duarte, JA | 1 |
| Sauzen, PD | 1 |
| Piccoli, JDCE | 1 |
| de Oliveira, LFS | 1 |
| Machado, MM | 1 |
| Gupta, A | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Poulter, N | 2 |
| Sever, P | 4 |
| Egan, B | 1 |
| Flack, J | 1 |
| Patel, M | 1 |
| Lombera, S | 1 |
| Shahin, MH | 5 |
| Langaee, TY | 8 |
| Scherer, S | 1 |
| Solayman, MH | 1 |
| El-Hamamsy, M | 1 |
| El-Wakeel, L | 1 |
| Badary, OA | 1 |
| Bombelli, M | 1 |
| Macchiarulo, M | 1 |
| Facchetti, R | 2 |
| Maggiolini, D | 1 |
| Cuspidi, C | 3 |
| Parati, G | 5 |
| Rouby, NE | 1 |
| Conrado, DJ | 1 |
| Gonzalez, D | 1 |
| Lobmeyer, MT | 2 |
| Chapman, A | 3 |
| Ye, H | 1 |
| Ling, S | 2 |
| Castillo, AC | 2 |
| Thomas, B | 2 |
| Long, B | 1 |
| Qian, J | 2 |
| Perez-Polo, JR | 1 |
| Ye, Y | 2 |
| Chen, X | 2 |
| Birnbaum, Y | 1 |
| Chugh, PK | 1 |
| Gupta, M | 1 |
| Agarwal, M | 1 |
| Tekur, U | 1 |
| Santos, SH | 1 |
| Ferreira, AV | 1 |
| Botion, LM | 1 |
| Santos, RA | 1 |
| Campagnole-Santos, MJ | 1 |
| Wikoff, WR | 2 |
| Frye, RF | 3 |
| Zhu, H | 2 |
| Boyle, S | 1 |
| Churchill, E | 1 |
| Fiehn, O | 2 |
| Kaddurah-Daouk, R | 2 |
| Testa, G | 1 |
| Cacciatore, F | 1 |
| Della-Morte, D | 1 |
| Mazzella, F | 1 |
| Mastrobuoni, C | 1 |
| Galizia, G | 1 |
| Gargiulo, G | 1 |
| Rengo, F | 2 |
| Bonaduce, D | 2 |
| Abete, P | 1 |
| Wiik, BP | 2 |
| Lindholm, LH | 46 |
| Dahlöf, B | 108 |
| O'Connell, JR | 3 |
| Schwartz, GL | 5 |
| Padmanabhan, S | 2 |
| Citterio, L | 1 |
| Donner, KM | 2 |
| Hedner, T | 8 |
| Lanzani, C | 1 |
| Melander, O | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Wahlstrand, B | 1 |
| Manunta, P | 1 |
| Kontula, K | 2 |
| Dominiczak, AF | 1 |
| Cotsonis, G | 1 |
| Parekh, V | 2 |
| Cooper-DeHoff, R | 3 |
| Zhou, WJ | 1 |
| Wang, RY | 1 |
| Li, Y | 2 |
| Chen, DR | 1 |
| Chen, EZ | 1 |
| Zhu, DL | 1 |
| Gao, PJ | 1 |
| Redón, J | 3 |
| Pascual-Izuel, JM | 1 |
| Rodilla, E | 1 |
| Vicente, A | 1 |
| Oliván, J | 1 |
| Bonet, J | 1 |
| Torguet, JP | 1 |
| Calaforra, O | 1 |
| Almirall, J | 1 |
| Jekell, A | 1 |
| Malmqvist, K | 22 |
| Wallén, NH | 1 |
| Mörtsell, D | 2 |
| Kahan, T | 29 |
| Kujala, SM | 1 |
| Pöyhönen-Alho, M | 1 |
| Kaaja, RJ | 2 |
| Gillis, NK | 1 |
| Alsultan, A | 1 |
| Chang, SW | 1 |
| Kawaguchi-Suzuki, M | 1 |
| Lang, JE | 1 |
| Buford, TW | 1 |
| El Rouby, NM | 1 |
| Sá, AC | 1 |
| Karnes, JH | 1 |
| Nanhwan, M | 1 |
| Kodakandla, M | 1 |
| Liu, H | 1 |
| Boutouyrie, P | 2 |
| Beaussier, H | 1 |
| Achouba, A | 2 |
| Laurent, S | 3 |
| Kostis, JB | 6 |
| Sedjro, JE | 2 |
| Cabrera, J | 2 |
| Cosgrove, NM | 2 |
| Pantazopoulos, JS | 1 |
| Kostis, WJ | 2 |
| Pressel, SL | 2 |
| Messerli, FH | 17 |
| Cheng, JQ | 1 |
| Swerdel, JN | 1 |
| Deng, Y | 1 |
| Sinha, AD | 1 |
| Pappas, MK | 1 |
| Abraham, TN | 1 |
| Tegegne, GG | 1 |
| Takase, B | 1 |
| Hattori, H | 1 |
| Tanaka, Y | 1 |
| Nagata, M | 1 |
| Ishihara, M | 1 |
| Dey, S | 1 |
| Chattopadhyay, S | 1 |
| Mazumder, B | 1 |
| Mancusi, C | 2 |
| De Simone, G | 6 |
| Abdelhai, YM | 1 |
| Lønnebakken, MT | 4 |
| Boman, K | 16 |
| Zoccali, C | 1 |
| Mallamaci, F | 1 |
| Hou, W | 3 |
| Weng, L | 1 |
| Baillie, RA | 1 |
| Boyle, SH | 1 |
| Patel, A | 2 |
| Cass, A | 1 |
| Peiris, D | 2 |
| Usherwood, T | 2 |
| Brown, A | 1 |
| Jan, S | 1 |
| Neal, B | 2 |
| Hillis, GS | 1 |
| Rafter, N | 1 |
| Tonkin, A | 1 |
| Webster, R | 2 |
| Billot, L | 1 |
| Bompoint, S | 1 |
| Burch, C | 1 |
| Burke, H | 1 |
| Hayman, N | 1 |
| Molanus, B | 1 |
| Reid, CM | 3 |
| Shiel, L | 1 |
| Togni, S | 1 |
| Rodgers, A | 2 |
| Wang, JG | 2 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Ripley, TL | 1 |
| Saseen, JJ | 1 |
| Bang, CN | 2 |
| Aurigemma, GP | 2 |
| Køber, L | 1 |
| Kuyper, LM | 1 |
| Khan, NA | 2 |
| Andreo, VC | 1 |
| Lomba, PC | 1 |
| Faria, FA | 1 |
| Guha, S | 1 |
| Avasthi, R | 2 |
| Narain, VS | 1 |
| Rajendiran, C | 1 |
| Mitra, M | 1 |
| Ray, S | 1 |
| Majumdar, D | 1 |
| Mondal, MM | 1 |
| Mani, S | 1 |
| Mookerjee, S | 1 |
| Saha, J | 1 |
| Dastidaro, DG | 1 |
| Kiselev, AR | 1 |
| Gridnev, VI | 1 |
| Prokhorov, MD | 1 |
| Karavaev, AS | 1 |
| Posnenkova, OM | 1 |
| Ponomarenko, VI | 1 |
| Bezruchko, BP | 1 |
| Stawowy, P | 1 |
| Moore, MJ | 1 |
| Hall, K | 4 |
| Schmidt, SO | 3 |
| Curry, RW | 2 |
| Bailey, K | 2 |
| Mugabo, P | 1 |
| Philander, A | 1 |
| Raji, I | 1 |
| Dietrich, D | 1 |
| Green, I | 1 |
| Lin, LL | 1 |
| Wang, D | 1 |
| Wang, W | 1 |
| Cheng, YQ | 1 |
| Su, DF | 8 |
| Liu, AJ | 1 |
| Li, M | 1 |
| Jiang, D | 1 |
| Yu, S | 1 |
| Kuyper, L | 1 |
| Aparicio, LS | 1 |
| Alfie, J | 1 |
| Barochiner, J | 1 |
| Cuffaro, PE | 1 |
| Giunta, DH | 1 |
| Elizondo, CM | 1 |
| Tortella, JJ | 1 |
| Morales, MS | 1 |
| Rada, MA | 1 |
| Waisman, GD | 1 |
| Denardo, SJ | 1 |
| Farsang, C | 2 |
| Keltai, M | 2 |
| Szirmai, L | 1 |
| Bavry, AA | 1 |
| Handberg, EM | 4 |
| Larstorp, AC | 5 |
| Di Salvo, G | 1 |
| Castaldi, B | 1 |
| Gala, S | 1 |
| Baldini, L | 1 |
| Del Gaizo, F | 1 |
| D'Aiello, FA | 1 |
| Mormile, A | 1 |
| Rea, A | 1 |
| Scognamiglio, G | 1 |
| Pacileo, G | 1 |
| Keating, S | 1 |
| Fadel, BM | 1 |
| Berrino, L | 1 |
| Perna, A | 1 |
| Russo, MG | 1 |
| Calabrò, R | 1 |
| Vishram, JK | 1 |
| Ibsen, H | 50 |
| Rothwell, PM | 2 |
| Roman, MJ | 2 |
| Palmieri, V | 12 |
| Nieminen, MS | 47 |
| Papademetriou, V | 12 |
| Takahashi, A | 1 |
| Choi, YJ | 1 |
| Ah, YM | 1 |
| Kong, J | 1 |
| Choi, KH | 1 |
| Kim, B | 1 |
| Han, N | 1 |
| Yu, YM | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Lee, HY | 1 |
| Lee, JY | 1 |
| Goupil, R | 1 |
| Dupuis, D | 1 |
| Troyanov, S | 1 |
| Madore, F | 1 |
| Agharazii, M | 1 |
| Kamel, H | 1 |
| Holzgreve, H | 6 |
| Gharaibeh, KA | 1 |
| Hamadah, AM | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Midtbø, H | 1 |
| Damian, DJ | 1 |
| McNamee, R | 1 |
| Carr, M | 1 |
| Wiysonge, CS | 2 |
| Bradley, HA | 2 |
| Volmink, J | 3 |
| Mayosi, BM | 2 |
| Opie, LH | 9 |
| Chow, CK | 1 |
| Thakkar, J | 1 |
| Bennett, A | 1 |
| Hillis, G | 1 |
| Burke, M | 1 |
| Vo, K | 1 |
| Rogers, K | 1 |
| Atkins, E | 1 |
| Chou, M | 1 |
| Dehbi, HM | 1 |
| Salam, A | 1 |
| Krum, H | 1 |
| Chalmers, J | 3 |
| Nelson, M | 1 |
| Woodward, M | 1 |
| Hilmer, S | 1 |
| Thom, S | 4 |
| Jennings, JR | 3 |
| Muldoon, MF | 3 |
| Price, J | 2 |
| Christie, IC | 2 |
| Meltzer, CC | 3 |
| Tuncer, M | 3 |
| Guntekin, U | 3 |
| Gunes, Y | 3 |
| Gumrukcuoglu, HA | 2 |
| Eryonucu, B | 3 |
| Schneider, GS | 1 |
| Pacanowski, MA | 3 |
| Schork, NJ | 1 |
| Shriver, MD | 1 |
| Sica, DA | 2 |
| Black, HR | 3 |
| Waeber, B | 5 |
| Mourad, JJ | 2 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Bangalore, S | 4 |
| Cohen, JD | 4 |
| Bacher, PH | 1 |
| Sleight, P | 9 |
| Kowey, P | 2 |
| Zhou, Q | 5 |
| Champion, A | 7 |
| Mehlsen, J | 5 |
| Pasini, AF | 3 |
| Garbin, U | 5 |
| Stranieri, C | 3 |
| Boccioletti, V | 2 |
| Mozzini, C | 1 |
| Manfro, S | 1 |
| Pasini, A | 1 |
| Cominacini, M | 1 |
| Cominacini, L | 5 |
| Goldberg, AI | 4 |
| Dunlay, MC | 3 |
| Sweet, CS | 4 |
| Matsui, Y | 2 |
| Eguchi, K | 2 |
| Shibasaki, S | 2 |
| Ishikawa, J | 2 |
| Hoshide, S | 2 |
| Pickering, TG | 1 |
| Shimada, K | 2 |
| Kario, K | 2 |
| Ostergren, J | 3 |
| Poulter, NR | 14 |
| Wedel, H | 27 |
| Beevers, G | 16 |
| Caulfield, M | 4 |
| Collins, R | 2 |
| Kristinsson, A | 1 |
| McInnes, GT | 3 |
| Nieminen, M | 3 |
| O'Brien, E | 9 |
| Henik, RA | 1 |
| Stepien, RL | 1 |
| Wenholz, LJ | 1 |
| Dolson, MK | 1 |
| Dietz, R | 1 |
| Dechend, R | 1 |
| Yu, CM | 2 |
| Bheda, M | 1 |
| Ford, J | 1 |
| Prescott, MF | 1 |
| Keefe, DL | 1 |
| Whyte, EM | 1 |
| Scanlon, J | 1 |
| Shafi, T | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Klag, MJ | 1 |
| Parekh, RS | 1 |
| Hausberg, M | 3 |
| Hillebrand, U | 1 |
| Kisters, K | 1 |
| Pöyhönen-Alho, MK | 1 |
| Manhem, K | 4 |
| Katzman, P | 2 |
| Kibarskis, A | 2 |
| Antikainen, RL | 1 |
| Erkkola, RU | 1 |
| Tuomilehto, JO | 1 |
| Ebeling, PE | 1 |
| Fan, X | 1 |
| Han, Y | 1 |
| Sun, K | 1 |
| Xin, Y | 1 |
| Bai, Y | 1 |
| Li, W | 1 |
| Yang, T | 2 |
| Song, X | 1 |
| Wang, H | 2 |
| Fu, C | 1 |
| Chen, J | 1 |
| Shi, Y | 1 |
| Zhou, X | 1 |
| Wu, H | 1 |
| Hui, R | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Han, SH | 1 |
| Lee, Y | 1 |
| Kim, SJ | 1 |
| Koh, Y | 1 |
| Shin, EK | 1 |
| de Faire, U | 22 |
| Lederballe-Pedersen, O | 20 |
| Narayan, P | 1 |
| Omvik, P | 23 |
| Oparil, S | 25 |
| Wald, DS | 1 |
| Law, M | 1 |
| Mills, S | 1 |
| Bestwick, JP | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Stumpe, KO | 8 |
| Agabiti-Rosei, E | 3 |
| Zielinski, T | 1 |
| Schremmer, D | 1 |
| Scholze, J | 2 |
| Laeis, P | 1 |
| Schwandt, P | 2 |
| Ludwig, M | 4 |
| Lazebnik, LB | 1 |
| Mikheeva, OM | 1 |
| Drozdov, VN | 1 |
| Petrakov, AV | 1 |
| Sil'vestrova, SIu | 1 |
| Protogerou, A | 2 |
| Blacher, J | 1 |
| Stergiou, GS | 1 |
| Achimastos, A | 2 |
| Safar, ME | 14 |
| Han, P | 1 |
| Shen, FM | 4 |
| Xie, HH | 5 |
| Chen, YY | 2 |
| Miao, CY | 6 |
| Mehta, JL | 1 |
| Sassard, J | 6 |
| Mastorantonakis, S | 1 |
| Chang, CL | 2 |
| Ghiadoni, L | 2 |
| Magagna, A | 4 |
| Kardasz, I | 1 |
| Taddei, S | 3 |
| Salvetti, A | 8 |
| Escobar, C | 2 |
| Barrios, V | 3 |
| Oikarinen, L | 10 |
| Viitasalo, M | 7 |
| Toivonen, L | 7 |
| Edelman, JM | 20 |
| Franklin, SS | 2 |
| Lindgren, P | 2 |
| Buxton, M | 2 |
| Jönsson, B | 3 |
| Zineh, I | 3 |
| Aursnes, I | 2 |
| Osnes, JB | 3 |
| Cockcroft, JR | 4 |
| Liljedahl, S | 1 |
| Lind, L | 18 |
| Arnlöv, J | 1 |
| Mackenzie, IS | 1 |
| McEniery, CM | 4 |
| Dhakam, Z | 3 |
| Brown, MJ | 6 |
| Wilkinson, IB | 4 |
| Dolan, E | 3 |
| Stanton, AV | 1 |
| Atkins, N | 1 |
| McInnes, G | 1 |
| Collier, D | 3 |
| Dicker, P | 1 |
| Stettler, C | 1 |
| Stanton, A | 3 |
| Witt, N | 1 |
| Tapp, R | 1 |
| Chaturvedi, N | 1 |
| Allemann, S | 1 |
| Mayet, J | 2 |
| Hughes, A | 2 |
| Ara, N | 1 |
| Rashid, M | 1 |
| Amran, MS | 1 |
| Franklin, S | 2 |
| Rieck, A | 1 |
| Campbell, K | 1 |
| Schmidt, S | 1 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Giordano, U | 1 |
| Cifra, B | 1 |
| Giannico, S | 1 |
| Turchetta, A | 1 |
| Calzolari, A | 1 |
| Morin, DP | 1 |
| John, M | 1 |
| Manisty, CH | 1 |
| Zambanini, A | 2 |
| Parker, KH | 1 |
| Davies, JE | 1 |
| Francis, DP | 1 |
| McG Thom, SA | 1 |
| Hughes, AD | 2 |
| Gerhard, T | 1 |
| Ried, LD | 1 |
| Dobson, JE | 2 |
| Campbell, NR | 1 |
| Pavithran, P | 1 |
| Prakash, ES | 1 |
| Dutta, TK | 1 |
| Madanmohan, T | 1 |
| Dumortier, J | 1 |
| Guillaud, O | 1 |
| Gouraud, A | 1 |
| Pittau, G | 1 |
| Vial, T | 1 |
| Boillot, O | 1 |
| Scoazec, JY | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Julius, S | 36 |
| Harrison, JL | 1 |
| Hildreth, CM | 1 |
| Callahan, SM | 1 |
| Goodchild, AK | 1 |
| Phillips, JK | 1 |
| Boman, JH | 1 |
| Andersson, J | 1 |
| Olofsson, M | 1 |
| Bakris, GL | 5 |
| Kupfer, S | 4 |
| Morozova, TE | 1 |
| Andrushchishina, TB | 1 |
| Christensen, KL | 2 |
| Fenger-Grøn, M | 1 |
| Buus, NH | 2 |
| Legler, UF | 1 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 2 |
| Wen, S | 1 |
| Télez, M | 2 |
| Ortiz-Lastra, E | 2 |
| Gonzalez, AJ | 1 |
| Flores, P | 2 |
| Huerta, I | 1 |
| Ramírez, JM | 1 |
| Barasoain, M | 1 |
| Criado, B | 2 |
| Arrieta, I | 2 |
| Warmack, TS | 1 |
| Estes, MA | 1 |
| Heldenbrand, S | 1 |
| Franks, AM | 1 |
| Ghuman, N | 1 |
| Tendler, B | 1 |
| Gjertson, CK | 1 |
| Kaur, M | 1 |
| Moskowitz, H | 1 |
| White, WB | 7 |
| Lyle, PA | 11 |
| Snapinn, SM | 10 |
| El-Haddad, B | 1 |
| Hammoud, D | 1 |
| Shaver, T | 1 |
| Shahouri, S | 1 |
| Merchant, N | 1 |
| Searles, CD | 1 |
| Pandian, A | 1 |
| Rahman, ST | 1 |
| Ferdinand, KC | 1 |
| Umpierrez, GE | 1 |
| Khan, BV | 1 |
| Sawicki, PT | 1 |
| Anlauf, M | 2 |
| Haller, H | 1 |
| Palatini, P | 5 |
| Hegde, HV | 1 |
| Puri, GD | 1 |
| Fiehn, A | 1 |
| Howard, SC | 1 |
| Filigheddu, F | 1 |
| Argiolas, G | 1 |
| Degortes, S | 1 |
| Frau, F | 1 |
| Pitzoi, S | 1 |
| Bulla, E | 1 |
| Bulla, P | 1 |
| Troffa, C | 1 |
| Trunet, P | 1 |
| Søraas, CL | 1 |
| Tønnessen, T | 1 |
| Høieggen, A | 5 |
| Lindholm, L | 4 |
| Rokkedal, JE | 1 |
| Polónia, J | 1 |
| Barbosa, L | 1 |
| Silva, JA | 1 |
| Bertoquini, S | 1 |
| Salinas, AM | 1 |
| Ryan, CM | 1 |
| Price, JC | 1 |
| de Cavanagh, EM | 1 |
| Ferder, LF | 1 |
| Ferder, MD | 1 |
| Stella, IY | 1 |
| Toblli, JE | 2 |
| Inserra, F | 1 |
| Dobson, J | 2 |
| Eldridge, S | 2 |
| Cappuccio, FP | 3 |
| Cruickshank, JK | 1 |
| Feder, G | 1 |
| Navare, HA | 1 |
| Shuster, JJ | 1 |
| Gogin, EE | 1 |
| Weber, MA | 8 |
| Gomides, RS | 1 |
| Costa, LA | 1 |
| Souza, DR | 1 |
| Queiroz, AC | 1 |
| Fernandes, JR | 1 |
| Ortega, KC | 3 |
| Junior, DM | 1 |
| Tinucci, T | 1 |
| Forjaz, CL | 1 |
| Gusmão, JL | 1 |
| Pierin, AM | 1 |
| Nishiura, JL | 1 |
| Ignez, EC | 1 |
| Segre, CA | 1 |
| Ventura, CG | 1 |
| Mano, GP | 1 |
| Fontes, V | 1 |
| Cunha, FM | 1 |
| Mion, D | 1 |
| Durand, Mde T | 1 |
| Castania, JA | 1 |
| Fazan, R | 2 |
| Salgado, MC | 1 |
| Salgado, HC | 2 |
| Jin, Y | 1 |
| Thijs, L | 1 |
| Richart, T | 1 |
| Staessen, JA | 1 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 4 |
| Heffernan, KS | 1 |
| Suryadevara, R | 1 |
| Patvardhan, EA | 1 |
| Mooney, P | 1 |
| Karas, RH | 1 |
| Kuvin, JT | 1 |
| Collier, DJ | 2 |
| Buch, J | 1 |
| Caulfield, MJ | 1 |
| Nemati, F | 1 |
| Rahbar-Roshandel, N | 1 |
| Hosseini, F | 1 |
| Mahmoudian, M | 1 |
| Shafiei, M | 1 |
| Uusimaa, P | 2 |
| Peuhkurinen, S | 1 |
| Ylitalo, A | 2 |
| Vuolteenaho, O | 2 |
| Risteli, J | 2 |
| Peuhkurinen, K | 2 |
| Price, ET | 1 |
| Martin, MA | 1 |
| Ganz, PA | 1 |
| Cole, SW | 1 |
| Barron, TI | 1 |
| Connolly, RM | 1 |
| Sharp, L | 1 |
| Bennett, K | 1 |
| Visvanathan, K | 1 |
| Ueno, N | 1 |
| Satou, Y | 1 |
| Gupta, R | 1 |
| Kirby, S | 1 |
| Lawler, F | 1 |
| Welborn, TL | 1 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Os, I | 6 |
| Yan, W | 1 |
| Shan, Z | 1 |
| Wang, Q | 1 |
| Huang, Y | 1 |
| Wang, C | 1 |
| Yan, K | 1 |
| Nasothimiou, EG | 1 |
| Elliott, WJ | 4 |
| Childers, WK | 1 |
| Amr, YM | 1 |
| Amin, SM | 1 |
| Lee, T | 2 |
| Ariansen, I | 2 |
| Reims, HM | 5 |
| Gjesdal, K | 2 |
| Igase, M | 2 |
| Yokoyama, H | 2 |
| Ferrario, CM | 3 |
| Shah, NK | 1 |
| Nichols, WW | 1 |
| Lo, MC | 1 |
| Ashfaq, U | 1 |
| Satish, P | 1 |
| Epstein, BJ | 1 |
| DiNicolantonio, JJ | 1 |
| Hackam, DG | 1 |
| Tsuji, RL | 1 |
| Silva, GV | 1 |
| Berwanger, O | 1 |
| Mion Júnior, D | 1 |
| Duarte, JD | 1 |
| Tran, B | 1 |
| Signorovitch, JE | 1 |
| Samuelson, TM | 1 |
| Ramakrishnan, K | 1 |
| Marynchenko, M | 1 |
| Wu, EQ | 1 |
| Blum, SI | 1 |
| Ramasamy, A | 1 |
| Chen, S | 1 |
| Rodenas, M | 1 |
| Kumar, S | 3 |
| Freund, KB | 1 |
| Moallem, J | 1 |
| Stears, AJ | 1 |
| Woods, SH | 1 |
| Watts, MM | 1 |
| Burton, TJ | 1 |
| Graggaber, J | 1 |
| Mir, FA | 1 |
| Poirier, L | 3 |
| Lacourcière, Y | 6 |
| Greve, AM | 1 |
| Bella, JN | 8 |
| Zanchetti, A | 18 |
| Yusuf, S | 1 |
| Pais, P | 1 |
| Sigamani, A | 1 |
| Xavier, D | 1 |
| Afzal, R | 1 |
| Gao, P | 1 |
| Teo, KK | 1 |
| Gugssa, SA | 1 |
| Johnston, JC | 1 |
| Vandell, AG | 1 |
| Gawronski, BE | 1 |
| Liggett, SB | 1 |
| Self, TH | 1 |
| Wallace, JL | 1 |
| Soberman, JE | 1 |
| Velayutham, PK | 1 |
| Adhikary, SD | 1 |
| Babu, SK | 1 |
| Vedantam, R | 1 |
| Korula, G | 1 |
| Ramachandran, A | 1 |
| Mbewu, A | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Nyström, F | 13 |
| Ohman, KP | 13 |
| Bayliss, H | 1 |
| Churchill, D | 2 |
| Beevers, M | 3 |
| Beevers, DG | 11 |
| Stapff, M | 1 |
| Ribeiro, A | 1 |
| Fritschka, E | 1 |
| Tholl, U | 1 |
| Smith, RD | 4 |
| Arosio, E | 3 |
| De Marchi, S | 2 |
| Prior, M | 1 |
| Zannoni, M | 2 |
| Lechi, A | 4 |
| Diez, J | 5 |
| Nicholls, MG | 2 |
| Aurup, P | 8 |
| Johansson, M | 1 |
| Borch-Johnsen, K | 6 |
| Kristianson, K | 13 |
| Snapinn, S | 7 |
| Malik, RA | 1 |
| Böhm, S | 1 |
| Borer, KT | 1 |
| Cornelissen, G | 1 |
| Halberg, F | 1 |
| Brook, R | 1 |
| Rajagopalan, S | 1 |
| Fay, W | 1 |
| González-Juanatey, JR | 3 |
| Edelman, J | 2 |
| Jha, A | 1 |
| Tomar, R | 1 |
| Hallberg, P | 7 |
| Karlsson, J | 9 |
| Kurland, L | 13 |
| Melhus, H | 13 |
| Van Brabandt, H | 1 |
| Vandenbroucke, JP | 2 |
| Dominiak, P | 1 |
| Zidek, W | 3 |
| Pannier, B | 2 |
| Guérin, A | 1 |
| London, G | 1 |
| Asmar, R | 2 |
| Safar, M | 7 |
| Doskina, EV | 1 |
| Bond, MG | 5 |
| Hennig, M | 8 |
| Neiss, A | 3 |
| Dal Palù, C | 9 |
| Hansson, L | 21 |
| Magnani, B | 6 |
| Rahn, KH | 8 |
| Reid, JL | 14 |
| Rodicio, J | 2 |
| Eckes, L | 3 |
| Rizzini, P | 1 |
| Edner, M | 6 |
| Bergfeldt, L | 2 |
| Rokicki, W | 1 |
| Rokicka, A | 1 |
| Bur, A | 1 |
| Woisetschläger, C | 1 |
| Herkner, H | 1 |
| Derhaschnig, U | 1 |
| Quehenberger, P | 1 |
| Hirschl, MM | 1 |
| Quiñones-Galvan, A | 2 |
| Pucciarelli, A | 2 |
| Ciociaro, D | 1 |
| Masoni, A | 1 |
| Franzoni, F | 2 |
| Natali, A | 2 |
| Ferrannini, E | 2 |
| Resnick, LM | 1 |
| Lester, MH | 1 |
| Liu, JG | 1 |
| Damron, DP | 1 |
| Mulatero, P | 1 |
| Rabbia, F | 1 |
| Milan, A | 1 |
| Paglieri, C | 1 |
| Morello, F | 1 |
| Chiandussi, L | 1 |
| Veglio, F | 1 |
| Rokkedal, J | 9 |
| Smith, G | 3 |
| Kirichenko, AA | 1 |
| Ebzeeva, EIu | 1 |
| Karpov, IuA | 2 |
| Glezer, MG | 1 |
| Abil'dinova, AZh | 1 |
| Adams, HP | 1 |
| Morgan, TO | 4 |
| Anderson, A | 2 |
| Ruzicka, M | 1 |
| Leenen, FH | 4 |
| Schmieder, RE | 3 |
| Schneider, MP | 3 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 1 |
| Sourgens, H | 1 |
| Schmidt, J | 1 |
| Derendorf, H | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 1 |
| Werkö, L | 3 |
| Grossman, E | 2 |
| Fournier, A | 5 |
| Oprisiu, R | 1 |
| Andrejak, M | 3 |
| Fernandez, L | 1 |
| Achard, JM | 1 |
| Pedersen, OL | 4 |
| Kjeldsen, S | 2 |
| Michaëlsson, K | 5 |
| Cruickshank, JM | 12 |
| London, GM | 8 |
| Marchais, SJ | 3 |
| Guerin, AP | 3 |
| Metivier, F | 2 |
| Adda, H | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Fujino, T | 1 |
| Hasebe, N | 1 |
| Kawabe, J | 1 |
| Fujita, M | 1 |
| Fukuzawa, J | 1 |
| Tobise, K | 1 |
| Kikuchi, K | 2 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 7 |
| Ajayi, AA | 2 |
| Sofowora, GG | 2 |
| Adigun, AQ | 2 |
| Asiyanbola, B | 2 |
| Schunkert, H | 2 |
| Liebson, PR | 1 |
| Nakov, R | 1 |
| Beck, K | 1 |
| Janka, HU | 1 |
| Jern, S | 12 |
| Rizos, E | 1 |
| Bairaktari, E | 1 |
| Kostoula, A | 1 |
| Hasiotis, G | 1 |
| Ganotakis, E | 1 |
| Elisaf, M | 1 |
| Mikhailidis, DP | 2 |
| Felmeden, DC | 2 |
| Blann, AD | 3 |
| Spencer, CG | 3 |
| Persson, M | 1 |
| Alaupovic, P | 2 |
| Carlberg, B | 1 |
| Svensson, A | 4 |
| Samuelsson, O | 3 |
| Yao, XY | 1 |
| Fan, WH | 1 |
| Chen, JZ | 1 |
| Zhu, JH | 1 |
| Chen, BX | 1 |
| Liu, XJ | 1 |
| Kamp, O | 1 |
| Sieswerda, GT | 1 |
| Visser, CA | 1 |
| Helle Berg, S | 1 |
| Talbert, RL | 1 |
| Pieper, JA | 1 |
| Ito, MK | 1 |
| Aronow, WS | 1 |
| Baumgart, P | 6 |
| Diener, HC | 2 |
| Tham, TC | 2 |
| Herity, N | 1 |
| Guy, S | 2 |
| Silke, B | 5 |
| Sidorenko, BA | 2 |
| Ugriumova, MO | 1 |
| Liljedahl, U | 7 |
| Syvänen, AC | 7 |
| Morato, M | 1 |
| Sousa, T | 1 |
| Guimarães, S | 1 |
| Moura, D | 1 |
| Albino-Teixeira, A | 1 |
| Kukes, VG | 1 |
| Ostroumova, OD | 1 |
| Mamaev, VI | 1 |
| Batutina, AM | 1 |
| Abakumov, IuE | 1 |
| Zykova, AA | 1 |
| van Dijk, MA | 1 |
| Breuning, MH | 1 |
| Duiser, R | 1 |
| van Es, LA | 1 |
| Westendorp, RG | 1 |
| Minami, N | 3 |
| Yoshikawa, T | 1 |
| Kataoka, H | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Kanazawa, M | 1 |
| Kohzuki, M | 1 |
| Fogari, R | 18 |
| Mugellini, A | 8 |
| Zoppi, A | 15 |
| Derosa, G | 3 |
| Pasotti, C | 5 |
| Fogari, E | 2 |
| Preti, P | 6 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Opezzo, JA | 1 |
| Laviades, C | 1 |
| Orbe, J | 1 |
| Zalba, G | 1 |
| López, B | 4 |
| González, A | 4 |
| Mayor, G | 1 |
| Páramo, JA | 1 |
| Beloqui, O | 1 |
| Chen, C | 1 |
| Nodari, S | 1 |
| Metra, M | 1 |
| Dei Cas, L | 1 |
| Hamidian Jahromi, AR | 1 |
| Jahromi, AR | 1 |
| Raissjalali, GA | 1 |
| Marks, RG | 1 |
| Cangiano, JL | 2 |
| Garcia-Barreto, D | 8 |
| Erdine, S | 2 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Parmley, WW | 1 |
| Tepliakov, AT | 2 |
| Gavrilova, NV | 1 |
| Garganeeva, AA | 1 |
| Corradi, L | 6 |
| Rinaldi, A | 3 |
| Asmar, RG | 3 |
| O'Rourke, MF | 7 |
| Xu, LP | 2 |
| Shu, H | 1 |
| Jiang, YY | 4 |
| Trevano, FQ | 1 |
| Facchini, A | 1 |
| Toutouzas, T | 1 |
| Chanu, B | 1 |
| Mallion, JM | 5 |
| Chamontin, B | 2 |
| De Leeuw, PW | 7 |
| Duprez, D | 2 |
| Romero, R | 2 |
| Battegay, E | 2 |
| Hitzenberger, G | 2 |
| Rocchini, AP | 1 |
| Yang, JQ | 1 |
| Gokee, A | 1 |
| Alderman, MH | 1 |
| Douglas, JG | 1 |
| Harris, KE | 10 |
| Nesbitt, S | 1 |
| Randall, OS | 1 |
| Wright, JT | 4 |
| Burke, TA | 2 |
| Krobot, K | 1 |
| Carides, GW | 4 |
| Bratland, B | 1 |
| Gerhardsen, G | 1 |
| Gisholt, K | 2 |
| Risanger, T | 1 |
| Smedsrud, T | 1 |
| Liu, JE | 2 |
| Koren, MJ | 1 |
| Zabalgoitia, M | 1 |
| Billberger, K | 1 |
| Fossum, E | 8 |
| Brady, WE | 3 |
| Kaaja, R | 2 |
| Tuomilehto, J | 3 |
| Tang, R | 4 |
| Hollweck, R | 2 |
| Micheli, D | 1 |
| Klingbeil, AU | 2 |
| Delles, C | 2 |
| Kolloch, RE | 3 |
| Krekler, M | 2 |
| Brändström, H | 1 |
| Stiger, F | 1 |
| Kindmark, A | 1 |
| Tuxen, C | 4 |
| Bang, LE | 4 |
| Hall, C | 3 |
| Hildebrandt, P | 3 |
| de Luca, N | 7 |
| Ciulla, MM | 2 |
| Paliotti, R | 2 |
| Esposito, A | 1 |
| Gilles, L | 1 |
| Magrini, F | 2 |
| Lee, DL | 1 |
| Webb, RC | 1 |
| Brands, MW | 1 |
| Mogensen, CE | 4 |
| Wan, Y | 4 |
| Trimarco, B | 6 |
| Lee, RT | 1 |
| Bøttcher, M | 1 |
| Jørgensen, CG | 1 |
| Thygesen, K | 2 |
| Nielsen, TT | 1 |
| Mulvany, MJ | 2 |
| Burns, J | 1 |
| Mary, DA | 1 |
| Mackintosh, AF | 1 |
| Ball, SG | 2 |
| Greenwood, JP | 1 |
| Sáez, GT | 1 |
| Tormos, C | 1 |
| Giner, V | 1 |
| Chaves, J | 1 |
| Lozano, JV | 1 |
| Iradi, A | 1 |
| Gaxiola, E | 3 |
| Sloan, B | 1 |
| Simons, S | 1 |
| Stromwall, A | 1 |
| Berglund, L | 1 |
| Darcie, S | 1 |
| Leone, CR | 1 |
| Calil, VM | 1 |
| Prescinotti, EP | 1 |
| Kahhale, S | 1 |
| Zugaib, M | 1 |
| Harris, K | 1 |
| Kizer, JR | 3 |
| Alcocer, L | 1 |
| Fernández-Bonetti, P | 1 |
| Campos, E | 1 |
| Olvera Ruiz, R | 1 |
| Bahena, J | 1 |
| de la Fuente, JJ | 1 |
| Segovia-Ayala, C | 1 |
| Dominguez-Henkel, R | 1 |
| Huffman, JC | 1 |
| Wulsin, LR | 1 |
| Stern, TA | 1 |
| Enkvist, C | 1 |
| Pulcrano, M | 1 |
| Palmieri, EA | 1 |
| Pagano, L | 1 |
| Tauchmanova, L | 1 |
| Rossi, A | 1 |
| Fazio, S | 3 |
| Lombardi, G | 1 |
| Biondi, B | 1 |
| Hirata, K | 1 |
| Vlachopoulos, C | 1 |
| Adji, A | 1 |
| Giannattasio, C | 1 |
| Failla, M | 1 |
| Reid, J | 3 |
| Bond, G | 2 |
| Fratta Pasini, A | 1 |
| Nava, MC | 2 |
| Davoli, A | 1 |
| Sawamura, T | 1 |
| Lo Cascio, V | 2 |
| Müller-Brunotte, R | 4 |
| Szucs, TD | 1 |
| Burnier, M | 3 |
| Erne, P | 1 |
| Stepacheva, TA | 1 |
| Ivannikova, OA | 1 |
| Pushnikova, EIu | 1 |
| Kaliuzhin, VV | 1 |
| Malakhovich, EV | 1 |
| Makushkin, EV | 1 |
| Zenevich, MV | 1 |
| Hornestam, B | 2 |
| Lehto, M | 2 |
| Slotwiner, DJ | 1 |
| Bourassa, MG | 1 |
| Lazzari, P | 3 |
| Hjerkinn, E | 1 |
| Nesbitt, SD | 1 |
| Andersen, UB | 1 |
| Phillips, RA | 1 |
| Gaboury, CL | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Schrader, J | 1 |
| Kulschewski, A | 1 |
| Strawn, WB | 1 |
| Gallagher, PE | 1 |
| Geary, RL | 1 |
| Hildebrandt, PR | 3 |
| Muiesan, ML | 2 |
| Baurecht, H | 3 |
| Punda, A | 1 |
| Polić, S | 1 |
| Rumboldt, Z | 1 |
| Bagatin, J | 1 |
| Marković, V | 1 |
| Lukin, A | 1 |
| Dasbach, EJ | 1 |
| Amar, J | 1 |
| Ruidavets, JB | 1 |
| Peyrieux, JC | 1 |
| Ferrières, J | 1 |
| Asai, T | 1 |
| Kushiro, T | 1 |
| Fujita, H | 1 |
| Kanmatsuse, K | 1 |
| Iaccarino, G | 2 |
| Trimarco, V | 2 |
| Lanni, F | 2 |
| Cipolletta, E | 2 |
| Izzo, R | 2 |
| Arcucci, O | 1 |
| Di Renzo, G | 2 |
| Shi, ZW | 1 |
| Neland, K | 1 |
| Dige-Petersen, H | 1 |
| Averill, DB | 1 |
| Brosnihan, KB | 1 |
| Schiffrin, EL | 18 |
| Penmetsa, S | 1 |
| Simmons, M | 1 |
| Daugird, A | 1 |
| Grant, RW | 1 |
| Singer, DE | 1 |
| Meigs, JB | 1 |
| van den Born, BJ | 1 |
| Brewster, LM | 1 |
| Koopmans, RP | 1 |
| van Montfrans, GA | 1 |
| Moan, A | 1 |
| Beyan, C | 1 |
| Kaptan, K | 1 |
| Ifran, A | 1 |
| Gapon, LI | 1 |
| Prilepova, AA | 1 |
| Tsygol'nik, MD | 1 |
| Nattel, S | 1 |
| Jordan, J | 2 |
| Engeli, S | 2 |
| Boschmann, M | 2 |
| Weidinger, G | 4 |
| Luft, FC | 2 |
| Sharma, AM | 2 |
| Kreuzberg, U | 2 |
| Hewkin, AC | 3 |
| Dieterle, W | 1 |
| Corynen, S | 1 |
| Vaidyanathan, S | 1 |
| Mann, J | 1 |
| Carr, AA | 1 |
| Kowey, PR | 2 |
| Brenner, BM | 1 |
| Zhang, Z | 2 |
| Shahinfar, S | 1 |
| Fomin, VV | 1 |
| Moiseev, SV | 1 |
| Füessl, HS | 1 |
| Bilous, R | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 2 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Filipovský, J | 1 |
| Yeh, HI | 1 |
| Lee, PY | 1 |
| Su, CH | 1 |
| Tian, TY | 1 |
| Ko, YS | 1 |
| Tsai, CH | 1 |
| Saloranta, C | 1 |
| Tuomi, T | 1 |
| Benetos, A | 3 |
| Coca, A | 3 |
| Conti, CR | 3 |
| Tavazzi, L | 1 |
| Williams, B | 1 |
| Lacy, PS | 1 |
| Thom, SM | 1 |
| Cruickshank, K | 1 |
| Thurston, H | 5 |
| O'Rourke, M | 2 |
| Chern, CM | 1 |
| Hsu, HY | 1 |
| Hu, HH | 1 |
| Hsu, LC | 1 |
| Chao, AC | 1 |
| Osadchii, O | 1 |
| Woodiwiss, A | 1 |
| Deftereos, D | 1 |
| Norton, G | 1 |
| Davies, J | 1 |
| Carr, E | 1 |
| Band, M | 1 |
| Morris, A | 1 |
| Struthers, A | 1 |
| Konrady, AO | 1 |
| Kasherininov, YR | 1 |
| Shavarov, AA | 1 |
| Shavarova, EK | 1 |
| Vachrameeva, NV | 1 |
| Krutikov, AN | 1 |
| Smirnova, EV | 1 |
| Shlyakhto, EV | 1 |
| Kelleher, JA | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Aranda, JM | 1 |
| Hewkin, A | 1 |
| Piller, LB | 2 |
| Cutler, JA | 5 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Adams, F | 1 |
| Franke, G | 1 |
| Klaua, S | 1 |
| Savoia, C | 3 |
| Touyz, RM | 4 |
| Endemann, DH | 1 |
| Pu, Q | 3 |
| Ko, EA | 1 |
| De Ciuceis, C | 1 |
| Kolloch, R | 3 |
| Zwiers, WJ | 1 |
| Blodgett, TM | 1 |
| Vallejo, MC | 1 |
| Finegold, H | 1 |
| Zhang, XF | 1 |
| Kozlovskiĭ, IV | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Nielsen, OW | 1 |
| Wergeland, R | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 3 |
| Ariff, B | 1 |
| Vamadeva, S | 1 |
| Barratt, D | 1 |
| Xu, Y | 1 |
| Mason, RP | 1 |
| Kubant, R | 1 |
| Jacob, RF | 1 |
| Walter, MF | 1 |
| Boychuk, B | 1 |
| Malinski, T | 1 |
| Ishibashi, S | 1 |
| Laville, M | 1 |
| Ring, M | 1 |
| Sankar, D | 1 |
| Rao, MR | 1 |
| Sambandam, G | 1 |
| Pugalendi, KV | 1 |
| Pechère, A | 1 |
| Nobre, F | 1 |
| da Silva, CA | 1 |
| Coelho, EB | 1 |
| Dart, AM | 2 |
| Gatzka, CD | 2 |
| Kingwell, B | 1 |
| Nieminen, T | 1 |
| Kähönen, M | 2 |
| Kööbi, T | 1 |
| Cameron, JD | 2 |
| Meredith, IT | 1 |
| Hope, SA | 1 |
| Gullu, H | 1 |
| Erdogan, D | 1 |
| Caliskan, M | 1 |
| Tok, D | 1 |
| Yildirim, I | 1 |
| Sezgin, AT | 1 |
| Muderrisoglu, H | 1 |
| Keiding, H | 1 |
| Burke, T | 1 |
| Christensen, MK | 1 |
| Wiinberg, N | 2 |
| Volpe, M | 3 |
| Cohen, DL | 1 |
| Townsend, RR | 3 |
| Sorriento, D | 1 |
| Iovino, GL | 1 |
| Rozza, F | 1 |
| Priante, O | 1 |
| Mahmud, A | 2 |
| Feely, J | 2 |
| Otterstad, JE | 6 |
| Phipps, JA | 1 |
| Wilkinson-Berka, JL | 1 |
| Fletcher, EL | 1 |
| Karagiannis, A | 1 |
| Kakafika, AI | 1 |
| Tziomalos, K | 1 |
| Athyros, VG | 1 |
| Grana, D | 1 |
| Cao, G | 1 |
| Milei, J | 1 |
| Flammer, AJ | 1 |
| Hermann, F | 1 |
| Wiesli, P | 1 |
| Schwegler, B | 1 |
| Chenevard, R | 1 |
| Hürlimann, D | 1 |
| Sudano, I | 1 |
| Gay, S | 1 |
| Neidhart, M | 1 |
| Riesen, W | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 2 |
| Noll, G | 1 |
| Lehmann, R | 1 |
| Pellegrini, M | 1 |
| Luchetta, ML | 1 |
| Fabrizzi, P | 1 |
| Sontheimer, D | 1 |
| Hitchcock, K | 1 |
| Saseen, J | 1 |
| Bilo, G | 1 |
| Maronati, A | 1 |
| Omboni, S | 2 |
| Held, C | 2 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Willson, K | 1 |
| Liang, YL | 1 |
| Berry, KL | 1 |
| Wing, LM | 4 |
| Ryan, P | 1 |
| Beilin, LJ | 2 |
| Jennings, GL | 1 |
| Johnston, CI | 1 |
| McNeil, JJ | 3 |
| Macdonald, GJ | 2 |
| West, MJ | 4 |
| Kingwell, BA | 1 |
| Narkiewicz, K | 2 |
| Tvete, IF | 1 |
| Gåsemyr, J | 1 |
| Natvig, B | 1 |
| Blackburn, DF | 1 |
| Lamb, DA | 1 |
| Eurich, DT | 1 |
| Wilson, TW | 2 |
| Dobson, RT | 1 |
| Blackburn, JL | 1 |
| Boersma, C | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Postma, MJ | 1 |
| Zheng, S | 1 |
| Nath, V | 1 |
| Coyne, DW | 1 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Flaa, A | 1 |
| Chattopadhyay, A | 1 |
| Kujala, S | 1 |
| Antikainen, R | 1 |
| Ylihärsilä, H | 1 |
| Erkkola, R | 1 |
| Castellano, JM | 1 |
| Barba, J | 1 |
| Margolis, KL | 1 |
| Ford, CE | 1 |
| Henriquez, MA | 1 |
| Cushman, WC | 4 |
| Einhorn, PT | 1 |
| Colon, PJ | 1 |
| Vidt, DG | 2 |
| Christian, R | 1 |
| Wong, ND | 1 |
| Goff, DC | 1 |
| Gleim, GW | 1 |
| Benz, K | 1 |
| Amann, K | 1 |
| Dittrich, K | 1 |
| Dötsch, J | 1 |
| Uretsky, S | 1 |
| Parkar, S | 1 |
| Ural, E | 1 |
| Kozdag, G | 1 |
| Kilic, T | 1 |
| Ural, D | 1 |
| Sahin, T | 1 |
| Celebi, O | 1 |
| Komsuoglu, B | 2 |
| Carugo, S | 1 |
| Gould, S | 1 |
| Westwood, FR | 1 |
| Curwen, JO | 1 |
| Ashton, SE | 1 |
| Roberts, DW | 1 |
| Lovick, SC | 1 |
| Ryan, AJ | 1 |
| Nilsson, P | 2 |
| Larsen, J | 1 |
| Resstel, LB | 1 |
| Corrêa, FM | 1 |
| Burton, T | 1 |
| Amiri, F | 1 |
| Cramariuc, D | 2 |
| Franco, V | 1 |
| Sarafidis, P | 1 |
| Bogojevic, Z | 1 |
| Basta, E | 1 |
| Kirstner, E | 1 |
| Alekseeva, IuM | 1 |
| Malkina, TA | 1 |
| Sokolov, SF | 1 |
| Laguna, C | 1 |
| Pérez-Ferriols, A | 1 |
| Alegre, V | 1 |
| Delbem, AC | 1 |
| Ajala, AM | 1 |
| Goodwin, JA | 1 |
| Goodwin, SR | 1 |
| Josephson, GD | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Su, DH | 1 |
| Ang, PS | 1 |
| Tow, SL | 1 |
| Vagaonescu, TD | 1 |
| Wilson, AC | 1 |
| Gojanovic, B | 1 |
| Feihl, F | 1 |
| Liaudet, L | 1 |
| Sabino, B | 1 |
| Lessa, MA | 1 |
| Nascimento, AR | 1 |
| Rodrigues, CA | 1 |
| Henriques, Md | 1 |
| Garzoni, LR | 1 |
| Levy, BI | 1 |
| Tibiriçá, E | 1 |
| Fettser, DV | 1 |
| Batyraliev, TA | 1 |
| Gumrukchuoglu, KhA | 1 |
| Guler, N | 1 |
| Hashemi, N | 1 |
| Pareek, A | 1 |
| Karnik, N | 1 |
| Salagre, SB | 1 |
| Zawar, SD | 1 |
| Joglekar, VK | 1 |
| Chandurkar, N | 1 |
| Naik, GS | 1 |
| Nannan, ME | 2 |
| Melin, JA | 2 |
| Vanbutsele, RJ | 1 |
| Lavenne, F | 2 |
| Detry, JM | 2 |
| Karlberg, BE | 11 |
| Piantanelli, L | 1 |
| Giunta, S | 1 |
| Basso, A | 1 |
| Cognini, G | 1 |
| Andreoni, A | 2 |
| Paciaroni, E | 2 |
| Lilja, M | 3 |
| Jounela, AJ | 3 |
| Juustila, H | 1 |
| Mattila, MJ | 3 |
| Coenen, CH | 1 |
| Zonderland, M | 1 |
| Maas, AH | 1 |
| Jack, DB | 1 |
| Dean, S | 2 |
| Laugher, S | 1 |
| Coope, JR | 1 |
| Dolce, E | 1 |
| Misceo, N | 2 |
| Partipilo, N | 1 |
| Pirrelli, A | 3 |
| Koch-Weser, J | 1 |
| Frishman, WH | 7 |
| Ohlsson, O | 3 |
| Lindell, SE | 1 |
| Hardin, JM | 1 |
| Makdassi, R | 1 |
| Gherbrand, JD | 1 |
| Fievet, P | 1 |
| Schmit, JL | 1 |
| Roger, JC | 1 |
| Harichaux, P | 1 |
| Kassouf, J | 1 |
| Wilcox, RG | 5 |
| Hampton, JR | 2 |
| McLeod, AA | 1 |
| Shand, DG | 1 |
| Maiorano, G | 3 |
| Loiacono, N | 2 |
| Castelnuovo, F | 1 |
| Altomare, E | 1 |
| Di Bello, V | 1 |
| Albano, O | 1 |
| Day, JL | 2 |
| Metcalfe, J | 2 |
| Simpson, CN | 1 |
| Dreslinski, GR | 1 |
| Dunn, FG | 2 |
| Suarez, DH | 1 |
| Reisin, E | 1 |
| Frohlich, ED | 3 |
| Schamroth, CL | 1 |
| Davidoff, R | 1 |
| Schamroth, JM | 1 |
| Myburgh, DP | 3 |
| Mattioli, G | 1 |
| Ricci, S | 1 |
| Menozzi, A | 1 |
| Teglio, V | 1 |
| Fuerst, M | 1 |
| Dubois, D | 1 |
| Petitcolas, J | 1 |
| Temperville, B | 1 |
| Klepper, A | 1 |
| Catherine, P | 1 |
| Madeddu, P | 1 |
| Dessì Fulgheri, P | 1 |
| Sanna, G | 1 |
| Fiori, C | 1 |
| Dettori, S | 1 |
| Cocco, F | 1 |
| Rappelli, A | 2 |
| Juustila, HJ | 1 |
| Paalzow, L | 1 |
| Jee, L | 1 |
| White, D | 1 |
| Adam, WR | 1 |
| Meagher, EJ | 1 |
| Barter, CE | 1 |
| Di Veroli, C | 1 |
| Compagno, S | 1 |
| Bai, TR | 1 |
| Webb, D | 1 |
| Hamilton, M | 1 |
| de Bos, R | 1 |
| van Soest, GA | 2 |
| Willemse, PJ | 1 |
| Birkenhäger, WH | 2 |
| Marchesi, E | 1 |
| Bellomo, G | 1 |
| Parini, A | 1 |
| Eide, I | 3 |
| Leren, P | 4 |
| Foss, OP | 2 |
| Holme, I | 2 |
| Eriksen, IL | 2 |
| Rubin, PC | 7 |
| Butters, L | 5 |
| Clark, DM | 1 |
| Reynolds, B | 2 |
| Sumner, DJ | 1 |
| Steedman, D | 1 |
| Low, RA | 3 |
| Tsukiyama, H | 1 |
| Otsuka, K | 1 |
| Horii, M | 1 |
| Yoshii, Y | 1 |
| Hatori, Y | 1 |
| Nakamura, Y | 3 |
| Nemoto, E | 1 |
| Yamato, T | 1 |
| Sakai, T | 1 |
| Yamamoto, Y | 2 |
| Smith, AM | 1 |
| Walker, H | 1 |
| Bonduelle, M | 1 |
| Greer, I | 1 |
| Calder, AA | 1 |
| Lund-Johansen, P | 3 |
| O'Callaghan, WG | 1 |
| Laher, MS | 1 |
| McGarry, K | 1 |
| O'Malley, K | 1 |
| Erina, EV | 3 |
| Charyev, KhE | 4 |
| González-Gómez, A | 5 |
| Gamio Capestany, F | 2 |
| Hernández-Cañero, A | 5 |
| Lardoux, H | 3 |
| Gerard, J | 3 |
| Blazquez, G | 3 |
| Flouvat, B | 4 |
| Kudo, Y | 2 |
| Sokabe, H | 2 |
| Kawashima, K | 1 |
| Middeke, M | 3 |
| Lauva, IK | 1 |
| Tomanek, RJ | 1 |
| Luque Otero, M | 1 |
| Fernandez Pinilla, C | 1 |
| Escriba Polo, A | 1 |
| Rodriguez Vazquez, M | 1 |
| Martell Claros, N | 1 |
| Fernandez-Cruz, A | 1 |
| Jackson, EA | 1 |
| Sullman, SA | 1 |
| Tötterman, K | 1 |
| Groop, L | 1 |
| Groop, PH | 1 |
| Kala, R | 1 |
| Tolppanen, EM | 1 |
| Tucker, DC | 3 |
| Johnson, AK | 2 |
| Bhatnagar, RK | 1 |
| Ingemarsson, I | 2 |
| Liedholm, H | 2 |
| Montan, S | 5 |
| Westgren, M | 1 |
| Melander, A | 1 |
| Johns, VJ | 1 |
| François, B | 1 |
| Cahen, R | 1 |
| Gravejat, MF | 1 |
| Estrade, M | 1 |
| Furberg, CD | 4 |
| Friedewald, WT | 1 |
| Ziegler, MG | 1 |
| Woodson, LC | 1 |
| Schiess, W | 1 |
| Welzel, D | 1 |
| Gugler, R | 1 |
| Abetel, G | 1 |
| Mérier, G | 1 |
| Karly, M | 1 |
| Genoud, A | 1 |
| Bousquet, JC | 1 |
| Kaiser, P | 2 |
| Brater, DC | 1 |
| Anderson, S | 1 |
| Kaplan, NM | 4 |
| Ram, CV | 4 |
| Yamori, Y | 1 |
| Tarazi, RC | 1 |
| Ooshima, A | 1 |
| Körst, HA | 1 |
| Brandes, JW | 1 |
| Lembcke, HJ | 1 |
| Littmann, KP | 1 |
| Shkhvatsabaia, IK | 2 |
| Huang, ZQ | 1 |
| Liu, LH | 1 |
| Xue, SH | 1 |
| Zheng, DY | 1 |
| Loaldi, A | 1 |
| Pepi, M | 1 |
| Agostoni, PG | 1 |
| Fiorentini, C | 1 |
| Grazi, S | 1 |
| Della Bella, P | 1 |
| Guazzi, MD | 1 |
| Gawkrodger, DJ | 1 |
| Beveridge, GW | 1 |
| Shen, JQ | 2 |
| Wang, LD | 1 |
| Carnovali, M | 1 |
| Crespi, E | 1 |
| Banderali, G | 1 |
| Missaglia, A | 1 |
| Ponti, GB | 1 |
| Brandstetter, G | 1 |
| Hoffmann, H | 1 |
| Ibrahim, MM | 4 |
| Madkour, MA | 3 |
| Mossallam, R | 4 |
| Cabrera, R | 1 |
| Toruncha, A | 1 |
| Morley, CA | 1 |
| Cavalcanti, C | 1 |
| Perrins, EJ | 1 |
| Sutton, R | 1 |
| Ishizaki, T | 1 |
| Oyama, Y | 1 |
| Suganuma, T | 1 |
| Sasaki, T | 1 |
| Nakaya, H | 1 |
| Shibuya, T | 1 |
| Sato, T | 1 |
| Lameijer, LD | 2 |
| Houtzagers, JJ | 3 |
| Voermans, LA | 2 |
| De Divitiis, O | 2 |
| Di Somma, S | 2 |
| Petitto, M | 2 |
| Ligouri, V | 1 |
| Zech, PY | 4 |
| Pozet, N | 5 |
| Cuisinaud, G | 1 |
| Vincent, M | 2 |
| Danielson, M | 2 |
| Kjellberg, J | 1 |
| Kuylenstierna, J | 1 |
| Lundkvist, L | 1 |
| Svensson, O | 1 |
| Skjøtø, J | 2 |
| Aakesson, I | 3 |
| Andrén, L | 3 |
| Weiner, L | 3 |
| Rössner, S | 3 |
| van der Veur, E | 6 |
| ten Berge, BS | 6 |
| Donker, AJ | 3 |
| May, JF | 5 |
| Schuurman, FH | 5 |
| Wesseling, H | 6 |
| Pedrinelli, R | 2 |
| Alberici, P | 1 |
| Abdel-Haq, B | 2 |
| Sasaki, Y | 1 |
| Arakawa, K | 2 |
| Clark, D | 1 |
| Sumner, D | 1 |
| Belfield, A | 1 |
| Pledger, D | 1 |
| Nilsson, OR | 4 |
| Atterhög, JH | 1 |
| Castenfors, J | 1 |
| Jorfelt, L | 1 |
| Thulin, T | 5 |
| Tolagen, K | 2 |
| Wettre, S | 1 |
| Emanueli, A | 1 |
| Born, A | 1 |
| Lavezzari, M | 1 |
| Marshall, AJ | 5 |
| Barritt, DW | 5 |
| Grell, GA | 3 |
| Forrester, TE | 1 |
| Alleyne, GA | 2 |
| Evans, J | 1 |
| Adams, T | 1 |
| Bass, C | 1 |
| Misra, NP | 1 |
| Bahadur, MM | 1 |
| da Costa, PS | 1 |
| de Moraes, LB | 1 |
| Costa, AG | 1 |
| McAreavey, D | 2 |
| Ramsay, LE | 4 |
| Latham, L | 2 |
| Lorimer, AR | 5 |
| McLaren, D | 1 |
| Robertson, JI | 4 |
| Robertson, MP | 4 |
| Weir, RJ | 3 |
| Ramsey, LE | 1 |
| McLaren, AD | 1 |
| Haider, Z | 1 |
| Bano, KA | 1 |
| Giudicelli, JF | 4 |
| Freslon, JL | 2 |
| Richer, C | 4 |
| Roudaut, R | 1 |
| Wicker, P | 1 |
| Junca, F | 1 |
| Clementy, J | 3 |
| Dallocchio, M | 3 |
| Gentile, S | 2 |
| Coltorti, M | 1 |
| Krauss, S | 1 |
| Spitz, E | 1 |
| Krauss, A | 1 |
| Grizotzki, B | 1 |
| Clement, S | 1 |
| Miranda, B | 1 |
| Ruilope, L | 1 |
| Mancheño, E | 1 |
| Arribas, F | 1 |
| García-Robles, R | 1 |
| Alcázar, JM | 1 |
| Nieto, J | 1 |
| Sancho, J | 1 |
| Rodicio, JL | 2 |
| Fagard, R | 16 |
| Reybrouck, T | 9 |
| Vanhees, L | 2 |
| Cattaert, A | 1 |
| Vanmeenen, T | 1 |
| Grauwels, R | 1 |
| Amery, A | 19 |
| Webster, J | 16 |
| Petrie, JC | 16 |
| McLean, I | 1 |
| Hawksworth, GM | 4 |
| Zhao, GS | 1 |
| Andersen, GS | 3 |
| Oppenheim, G | 1 |
| Rathaus, M | 1 |
| Magen, A | 1 |
| Rath-Wolfson, L | 1 |
| Shapira, J | 1 |
| Bernheim, J | 2 |
| Kulas, J | 1 |
| Lunell, NO | 1 |
| Rosing, U | 1 |
| Stéen, B | 1 |
| Rane, A | 1 |
| Solum, T | 2 |
| Sjöberg, NO | 4 |
| Wang, ZH | 1 |
| Viadero, JJ | 1 |
| Wong, SH | 2 |
| Robinson, BF | 1 |
| Dobbs, RJ | 1 |
| Phillips, RJ | 1 |
| Orlandi, C | 3 |
| Schmieder, R | 3 |
| Friedrich, G | 3 |
| Neus, H | 3 |
| Rüdel, H | 1 |
| von Eiff, AW | 3 |
| Iurenev, AP | 2 |
| Ricciardelli, B | 2 |
| Cuocolo, A | 2 |
| Veniero, AM | 1 |
| Condorelli, M | 3 |
| Strocchi, E | 2 |
| Costa, FV | 5 |
| Caldari, R | 1 |
| Malini, PL | 3 |
| Marata, AM | 2 |
| Parini, J | 3 |
| Ambrosioni, E | 8 |
| Kirk, CA | 1 |
| Cove-Smith, R | 1 |
| Guevara, F | 1 |
| Rüddel, H | 2 |
| Schulte, W | 1 |
| Turner, AS | 3 |
| Brocklehurst, JC | 2 |
| Sala, G | 1 |
| Bignotti, GC | 1 |
| Ratti, G | 1 |
| Mascaretti, L | 1 |
| Teruzzi, L | 1 |
| Ronchi, E | 1 |
| Franzini, P | 1 |
| Girelli, A | 1 |
| Pilotti, A | 1 |
| Santambrogio, C | 1 |
| Amundsen, R | 1 |
| Markel, A | 1 |
| Brook, JG | 2 |
| Levy, Y | 1 |
| Aviram, M | 2 |
| Youdim, MB | 1 |
| Chouty, F | 1 |
| Chia, BL | 1 |
| Feng, PH | 1 |
| Teo, SK | 1 |
| Beauséjour, B | 1 |
| Faurie, C | 1 |
| Rousset, D | 1 |
| Corea, L | 1 |
| Bentivoglio, M | 1 |
| Groth, H | 1 |
| Foerster, EC | 2 |
| Neyses, L | 1 |
| Kulhmann, U | 1 |
| Vetter, H | 9 |
| Vetter, W | 10 |
| Andreoli, JA | 1 |
| Andreoli, JW | 1 |
| Cohn, RD | 1 |
| Rouffy, J | 4 |
| Jaillard, J | 3 |
| Fowler, MB | 1 |
| Brudenell, M | 1 |
| Jackson, G | 2 |
| Holt, DW | 1 |
| Karlberg, B | 1 |
| Ohman, P | 4 |
| Asplund, J | 1 |
| Beloev, I | 1 |
| Popiliev, I | 1 |
| Tŭrnovska, R | 1 |
| Pelov, R | 1 |
| Trafford, JA | 1 |
| McGonigle, R | 1 |
| Bowles, J | 1 |
| O'Neal, H | 1 |
| Bennet-Jones, DN | 1 |
| Halford, L | 1 |
| Sassano, P | 1 |
| Arzilli, F | 1 |
| Turini, F | 1 |
| Henningsen, NC | 6 |
| Rasmussen, S | 2 |
| Arnung, K | 2 |
| Eskildsen, PC | 2 |
| Nielsen, PE | 2 |
| Demczuk, M | 2 |
| Marszal-Marciniak, M | 2 |
| Rafalska, K | 2 |
| Krzemińska-Pakuła, M | 2 |
| Cannella, G | 1 |
| Picotti, GB | 2 |
| Giambelli, A | 1 |
| Scolari, F | 1 |
| Cesura, AM | 1 |
| Tosoni, S | 1 |
| Maiorca, R | 1 |
| Fong Chi, S | 1 |
| Mazzari, M | 2 |
| Coppola, E | 2 |
| Montenero, AS | 2 |
| Schiavoni, G | 2 |
| Domenichelli, B | 2 |
| Mongiardo, R | 2 |
| Pennestrì, F | 2 |
| Hiemstra, S | 2 |
| Ziegler, E | 1 |
| Coope, J | 2 |
| Hausen, T | 1 |
| Scott, AK | 3 |
| Rigby, JW | 2 |
| Lovell, HG | 2 |
| Woods, DL | 1 |
| Morrell, DF | 1 |
| Wocial, B | 1 |
| Januszewicz, W | 1 |
| Sznajderman, M | 2 |
| Feltynowski, T | 1 |
| Thorley, KJ | 2 |
| Ilyas, M | 1 |
| Haidry, JG | 1 |
| Hassan, MS | 1 |
| Floras, JS | 5 |
| Jones, JV | 7 |
| Hassan, MO | 6 |
| Karastanev, I | 1 |
| Valkov, Y | 1 |
| Tzvetkova, Z | 1 |
| Fránquiz, JM | 1 |
| Mellini, M | 1 |
| Robutti, A | 1 |
| Mattiauda, C | 1 |
| Cavazzana, G | 1 |
| Roych, C | 1 |
| Sanfelici, D | 1 |
| Baccino, M | 1 |
| Reforzo, F | 1 |
| Jackson, SH | 2 |
| Indovina, I | 1 |
| Salerno, L | 1 |
| Licata, G | 1 |
| Pepe, S | 1 |
| Custro, N | 2 |
| Oshchepkova, EV | 1 |
| Sterkowicz, W | 1 |
| Sterkowicz, S | 1 |
| Landolina, R | 1 |
| Di Salvo, M | 1 |
| Salerno, M | 1 |
| Battaglia, G | 1 |
| Pinizzotto, G | 1 |
| Pollina, D | 1 |
| Vaccaro, F | 1 |
| Sau, F | 3 |
| Seguro, C | 3 |
| Pisano, MR | 2 |
| Pirisi, R | 2 |
| Raffo, M | 2 |
| Cherchi, A | 3 |
| Frewin, DB | 2 |
| Penhall, RK | 1 |
| Leonello, PP | 1 |
| Clapp, RJ | 1 |
| Lundbäck, M | 1 |
| Waal-Manning, HJ | 3 |
| Bolli, P | 2 |
| Wilkinson, R | 3 |
| Stevens, IM | 1 |
| Pickering, M | 1 |
| Robson, V | 1 |
| Hawkins, T | 1 |
| Kerr, DN | 1 |
| Harry, JD | 5 |
| Velasco, M | 2 |
| Guevara, J | 2 |
| Morillo, J | 2 |
| Ramírez, A | 2 |
| Urbina-Quintana, A | 2 |
| Hernández-Pieretti, O | 2 |
| Leary, WP | 2 |
| Asmal, AC | 1 |
| Brayshaw, P | 1 |
| Williams, P | 1 |
| Venturini-Souto, N | 1 |
| Boissier, JR | 2 |
| Adams-Strump, BJ | 1 |
| Hayes, J | 1 |
| Barber, JH | 2 |
| Jeffers, TA | 7 |
| Robb, OJ | 4 |
| Seedat, YK | 2 |
| Leonetti, G | 6 |
| Terzoli, L | 2 |
| Bianchini, C | 2 |
| Sala, C | 1 |
| Glasson, S | 1 |
| Nissinen, A | 1 |
| Asbury, MJ | 1 |
| Wells, FO | 1 |
| Barker, NP | 7 |
| Lyngstam, O | 2 |
| Rydén, L | 2 |
| Kristensen, BO | 1 |
| Brøns, M | 1 |
| Christensen, CK | 3 |
| Geday, E | 1 |
| Jacobsen, FK | 1 |
| Jensen, SN | 1 |
| Linde, NC | 1 |
| Aärynen, M | 1 |
| Mäkelä, M | 1 |
| Hämeenaho, P | 1 |
| Abson, CP | 1 |
| Levy, LM | 1 |
| Eyherabide, G | 1 |
| England, JD | 1 |
| Pieri, R | 1 |
| Martinez, R | 1 |
| Saponaro, A | 1 |
| Dragagna, G | 1 |
| Forcinella, M | 1 |
| Di Fusco, W | 1 |
| Russo, R | 1 |
| Lijnen, P | 13 |
| Trotta, P | 1 |
| Labeeuw, M | 3 |
| Ellis, ME | 1 |
| Sahay, JN | 1 |
| Chatterjee, SS | 2 |
| Ellis, SH | 1 |
| Chadha, DR | 2 |
| Otter, HP | 1 |
| Takeda, K | 1 |
| Nakagawa, Y | 1 |
| Chin, WP | 1 |
| Imai, S | 1 |
| Polak, BC | 1 |
| Henkes, HE | 1 |
| McNeil, GN | 1 |
| Shaw, PK | 1 |
| Dock, DS | 1 |
| Schirripa, V | 1 |
| Attisano, N | 1 |
| Sarica, G | 1 |
| Grenci, G | 1 |
| Martelli, G | 1 |
| Allegri, M | 1 |
| Magni, S | 1 |
| Freggiaro, V | 1 |
| Stirace, T | 1 |
| Greminger, P | 8 |
| Boerlin, HJ | 1 |
| Havelka, J | 1 |
| Walger, P | 2 |
| Lüscher, T | 1 |
| Siegenthaler, W | 3 |
| Anania, V | 1 |
| Bartoli, E | 1 |
| Desole, MS | 1 |
| Faedda, R | 1 |
| Miele, E | 1 |
| Olmeo, NA | 1 |
| Satta, A | 1 |
| Soggia, G | 1 |
| Vacca, R | 1 |
| Montoliu, J | 1 |
| Botey, A | 1 |
| Darnell, A | 1 |
| Revert, L | 1 |
| Gotzen, R | 1 |
| Halawa, B | 1 |
| Mazurek, W | 1 |
| Centritto, V | 1 |
| Kirch, W | 1 |
| Schäfer-Korting, M | 1 |
| Axthelm, T | 1 |
| Köhler, H | 2 |
| Mutschler, E | 1 |
| Eliasson, K | 3 |
| Lins, LE | 1 |
| Ezra, D | 3 |
| Rosenthal, T | 4 |
| Molho, M | 2 |
| Lidgy, M | 1 |
| Pauchant, A | 1 |
| Robinson, HM | 1 |
| Anderson, M | 1 |
| Taylor, EA | 1 |
| Turner, P | 2 |
| Raftery, EB | 4 |
| Millar-Craig, MW | 1 |
| Mann, S | 2 |
| Balasubramanian, V | 2 |
| Barber, HE | 1 |
| Davy, M | 1 |
| Lindenbaum, A | 1 |
| Cohen, Y | 1 |
| Wepierre, J | 1 |
| McAinsh, J | 6 |
| Brandão, AP | 1 |
| Oigman, W | 1 |
| Albanesi Filho, FM | 1 |
| Montebugnoli, L | 1 |
| Rosati, G | 1 |
| Johnson, JN | 1 |
| McFarland, J | 1 |
| Pessina, AC | 4 |
| Semplicini, A | 1 |
| Moramio, P | 1 |
| Casiglia, E | 2 |
| Gavin, MJ | 1 |
| Castle, WM | 1 |
| Waycott, JA | 1 |
| Riva, E | 1 |
| Farina, PL | 1 |
| Sega, R | 1 |
| Tognoni, G | 2 |
| Bastain, W | 1 |
| Steiner, JM | 1 |
| White, DA | 1 |
| Mhlongo, SW | 1 |
| Jensen, HA | 2 |
| Rasmussen, K | 2 |
| Mosbaek, N | 2 |
| Morel, Y | 1 |
| Gadient, A | 1 |
| Keller, U | 1 |
| Vadas, L | 1 |
| Golay, A | 1 |
| Mimran, A | 5 |
| Ribstein, J | 1 |
| DuCailar, G | 1 |
| Senior, R | 1 |
| Imbs, JL | 1 |
| Bory, M | 2 |
| Amabile, G | 1 |
| Denis, B | 1 |
| Zannad, F | 1 |
| Marchegiano, R | 1 |
| Lahiri, A | 1 |
| Leeman, M | 1 |
| van de Borne, P | 1 |
| Collart, F | 1 |
| Vandenhoven, G | 1 |
| Peeters, L | 1 |
| Mélot, C | 1 |
| Degaute, JP | 1 |
| Harasawa, Y | 1 |
| Imaizumi, T | 1 |
| Ando, S | 1 |
| Masaki, H | 1 |
| Harada, S | 1 |
| Momohara, M | 1 |
| Takeshita, A | 1 |
| Sasaki, H | 1 |
| Naka, K | 1 |
| Kishi, Y | 1 |
| Ohoshi, T | 1 |
| Hagihara, T | 1 |
| Matsuo, H | 1 |
| Sowa, R | 1 |
| Matsumoto, G | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Rubio-Luengo, MA | 1 |
| Maldonado-Martín, A | 1 |
| Gil-Extremera, B | 1 |
| González-Gómez, L | 1 |
| Luna del Castillo, JD | 1 |
| Sasaki, J | 2 |
| Kajiyama, G | 1 |
| Kusukawa, R | 1 |
| Shichiri, M | 1 |
| Sunaga, T | 1 |
| Mashiba, H | 1 |
| Tanaka, N | 1 |
| Nonaka, K | 1 |
| Jamieson, MJ | 1 |
| Garbutt-Sculli, L | 1 |
| Shepherd, AM | 4 |
| Himmelmann, A | 2 |
| Hansson, BG | 2 |
| Hedstrand, H | 3 |
| Skogström, K | 2 |
| Ohrvik, J | 2 |
| Furängen, A | 2 |
| Salvi, S | 1 |
| Chiang, HT | 1 |
| Hou, ZY | 1 |
| Lee, DK | 1 |
| Wu, TL | 1 |
| Chen, CY | 1 |
| Wheeldon, NM | 1 |
| MacDonald, TM | 3 |
| Prasad, N | 1 |
| Maclean, D | 6 |
| Peebles, L | 1 |
| McDevitt, DG | 5 |
| Keller, SE | 1 |
| Makris, L | 1 |
| Lim, NY | 1 |
| Goldberg, A | 1 |
| Sweet, C | 1 |
| Malamani, GD | 1 |
| Marasi, G | 2 |
| Vanasia, A | 1 |
| Villa, G | 3 |
| Panfilov, V | 3 |
| MacPhee, G | 1 |
| Elliott, HL | 2 |
| Cohen-Solal, A | 1 |
| Baleynaud, S | 1 |
| Laperche, T | 1 |
| Sebag, C | 1 |
| Gourgon, R | 1 |
| Pose Reino, A | 1 |
| Amaro Cendón, A | 2 |
| García Acuña, JM | 2 |
| Castelo Fuentes, V | 1 |
| Calvo Gómez, C | 2 |
| de la Peña, MG | 1 |
| Deng, LY | 6 |
| Larochelle, P | 4 |
| Danchin, N | 1 |
| Genton, P | 1 |
| Atlas, P | 1 |
| Anconina, J | 1 |
| Leclere, J | 1 |
| Cherrier, F | 1 |
| González Maqueda, I | 2 |
| Thybo, NK | 1 |
| Stephens, N | 1 |
| Cooper, A | 1 |
| Aalkjaer, C | 1 |
| Heagerty, AM | 2 |
| Gleerup, G | 2 |
| Winther, K | 2 |
| Gómez Pajuelo, C | 1 |
| Gómez Sánchez, MA | 1 |
| Marín Ruiz, R | 1 |
| Lombera Romero, F | 1 |
| Sanz Julve, M | 1 |
| Tascón Pérez, J | 1 |
| Sáenz de la Calzada, C | 1 |
| Chen, CH | 1 |
| Ting, CT | 1 |
| Lin, SJ | 1 |
| Hsu, TL | 1 |
| Yin, FC | 1 |
| Siu, CO | 1 |
| Chou, P | 1 |
| Wang, SP | 1 |
| Chang, MS | 1 |
| Kochar, MS | 3 |
| Trottier, D | 1 |
| Kotecki, G | 1 |
| Forbes, M | 1 |
| Bamrah, VS | 1 |
| Takita, M | 1 |
| Oda, Y | 1 |
| Kigoshi, S | 1 |
| Muramatsu, I | 1 |
| Aberg, H | 10 |
| Mörlin, C | 2 |
| Lithell, H | 15 |
| Hartmann, D | 1 |
| Stief, G | 1 |
| Lingenfelder, M | 1 |
| Güzelhan, C | 1 |
| Horsch, AK | 1 |
| Oberman, A | 7 |
| Blaufox, MD | 8 |
| Wassertheil-Smoller, S | 8 |
| Zimbaldi, N | 4 |
| Kirchner, K | 2 |
| Wylie-Rosett, J | 3 |
| Langford, HG | 5 |
| Spolaore, P | 1 |
| Mazza, A | 1 |
| Ginocchio, G | 1 |
| Colangeli, G | 1 |
| Onesto, C | 1 |
| Di Menza, G | 1 |
| Pegoraro, L | 1 |
| Ambrosio, GB | 1 |
| Fahrenbach, MC | 1 |
| Yurgalevitch, SM | 1 |
| Zmuda, JM | 1 |
| Thompson, PD | 2 |
| Santarelli, P | 1 |
| Biscione, F | 1 |
| Natale, A | 1 |
| Manzoli, A | 1 |
| Lanza, GA | 1 |
| Cholley, BP | 1 |
| Shroff, SG | 1 |
| Sandelski, J | 1 |
| Korcarz, C | 1 |
| Balasia, BA | 1 |
| Jain, S | 1 |
| Berger, DS | 1 |
| Murphy, MB | 1 |
| Marcus, RH | 1 |
| Lang, RM | 1 |
| Attwood, S | 1 |
| Bird, R | 1 |
| Burch, K | 1 |
| Casadei, B | 2 |
| Coats, A | 1 |
| Conway, J | 2 |
| Dawes, M | 1 |
| Ebbs, D | 1 |
| Farmer, A | 1 |
| Robinson, J | 1 |
| Agarwal, DK | 1 |
| Barthwal, SP | 1 |
| Tandon, S | 1 |
| Agarwal, RL | 1 |
| Chrysant, SG | 3 |
| Miller, E | 1 |
| Cunha, RS | 1 |
| Cabral, AM | 1 |
| Vasquez, EC | 1 |
| Ruilope, LM | 3 |
| Reder, S | 1 |
| Bauer, K | 1 |
| Kaik, G | 1 |
| Kaik, B | 1 |
| Cléroux, J | 3 |
| Beaulieu, M | 2 |
| Kouamé, N | 1 |
| Mäkynen, H | 1 |
| Arvola, P | 1 |
| Pörsti, I | 1 |
| Walle, PO | 1 |
| Westergren, G | 2 |
| Dimenäs, E | 3 |
| Olofsson, B | 1 |
| Albrektsen, T | 1 |
| Applegate, WB | 12 |
| Pressel, S | 2 |
| Wittes, J | 2 |
| Luhr, J | 1 |
| Shekelle, RB | 1 |
| Camel, GH | 1 |
| Greenlick, MR | 1 |
| Hadley, E | 1 |
| Moye, L | 1 |
| Perry, HM | 5 |
| Hannedouche, T | 1 |
| Landais, P | 1 |
| Goldfarb, B | 1 |
| el Esper, N | 1 |
| Godin, M | 1 |
| Durand, D | 1 |
| Chanard, J | 1 |
| Mignon, F | 1 |
| Suo, JM | 1 |
| Reneland, R | 4 |
| Andersson, PE | 4 |
| Haenni, A | 4 |
| Ishimitsu, T | 1 |
| Ono, H | 1 |
| Ogawa, Y | 3 |
| Tsukada, H | 1 |
| Oka, K | 1 |
| Yagi, S | 2 |
| Rueckert, PA | 1 |
| Slane, PR | 1 |
| Hanson, P | 1 |
| Deckert, J | 1 |
| Przuntek, H | 1 |
| Gleiter, CH | 1 |
| Ames, RP | 1 |
| Burris, JF | 3 |
| Davidov, ME | 1 |
| Mroczek, WJ | 2 |
| Avanzini, F | 1 |
| Alli, C | 1 |
| Bettelli, G | 1 |
| Corso, R | 1 |
| Colombo, F | 1 |
| Mariotti, G | 1 |
| Radice, M | 1 |
| Torri, V | 1 |
| Johansson, J | 1 |
| Berne, C | 3 |
| Croog, SH | 2 |
| Elias, MF | 1 |
| Colton, T | 1 |
| Baume, RM | 2 |
| Leiblum, SR | 1 |
| Jenkins, CD | 1 |
| Hall, WD | 3 |
| Lucini, D | 3 |
| Pagani, M | 4 |
| Mela, GS | 1 |
| Malliani, A | 4 |
| Rabkin, SW | 1 |
| Huff, MW | 1 |
| Newman, C | 2 |
| Sim, D | 2 |
| Carruthers, SG | 1 |
| Lettgen, B | 1 |
| Wagner, S | 1 |
| Hänze, J | 1 |
| Lang, RE | 1 |
| Rascher, W | 1 |
| Nielsen, FS | 2 |
| Rossing, P | 2 |
| Gall, MA | 2 |
| Skøtt, P | 1 |
| Smidt, UM | 2 |
| Parving, HH | 2 |
| Simon, G | 1 |
| Johnson, ML | 1 |
| Prattichizzo, FA | 1 |
| Galetta, F | 2 |
| Lyons, D | 1 |
| Fowler, G | 1 |
| Hall, ST | 1 |
| Ranieri, G | 3 |
| Filitti, V | 4 |
| Andriani, A | 2 |
| Bonfantino, MV | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 3 |
| Lemieux, SC | 1 |
| Soucek, M | 1 |
| Prásek, J | 1 |
| Spinarová, L | 1 |
| Cacciapuoti, F | 1 |
| Perrone, N | 1 |
| Diaspro, R | 1 |
| Galzerano, D | 1 |
| Lapiello, B | 1 |
| Dujovne, CA | 1 |
| Eff, J | 1 |
| Ferraro, L | 1 |
| Goldstein, RJ | 2 |
| Gotto, AM | 1 |
| Harris, WS | 1 |
| Held, SJ | 1 |
| Herd, A | 1 |
| Hunninghake, DB | 1 |
| Arad, M | 1 |
| Solomon, A | 1 |
| Roth, A | 1 |
| Atsmon, J | 1 |
| Rabinowitz, B | 1 |
| Maharaj, B | 2 |
| van der Byl, K | 1 |
| Moyé, LA | 1 |
| Hawkins, CM | 5 |
| Probstfield, JL | 3 |
| Lever, AF | 2 |
| Brennan, PJ | 1 |
| Carmona, J | 1 |
| Amado, P | 1 |
| Castanheira, J | 1 |
| Nazaré, J | 1 |
| Araújo, V | 1 |
| Siwach, SB | 1 |
| Dahiya, SS | 1 |
| Seth, S | 1 |
| Seth, RK | 1 |
| Sharma, D | 1 |
| Benz, JR | 1 |
| Bartels, DW | 1 |
| Due, DL | 1 |
| Peng, A | 1 |
| Sirgo, M | 1 |
| Heitzler, VN | 1 |
| Bergovec, M | 1 |
| Prpić, H | 1 |
| Tomljenović, M | 1 |
| Stancić, V | 1 |
| Gopcević, A | 1 |
| Mihatov, S | 1 |
| Seni, B | 1 |
| Beslin, MB | 1 |
| Eremić, Z | 1 |
| Brobyn, R | 3 |
| Brown, RD | 3 |
| Johnson, BF | 3 |
| Reeves, RL | 4 |
| Wombolt, DG | 3 |
| Pancera, P | 2 |
| Priante, F | 2 |
| Ribul, M | 2 |
| Leiva, F | 1 |
| Bosch, M | 1 |
| Delgadillo, J | 1 |
| Rutan, GH | 3 |
| Feig, PU | 1 |
| May, S | 1 |
| Kriegman, AG | 1 |
| Brady, EM | 1 |
| el-Yazigi, A | 1 |
| Bouchama, A | 1 |
| al-Abdely, H | 1 |
| Yusuf, A | 1 |
| Sieck, JO | 1 |
| Draper, AJ | 2 |
| Kingsbury, MP | 2 |
| Redfern, PH | 2 |
| Todd, MH | 2 |
| Shiga, T | 1 |
| Fujimura, A | 2 |
| Tateishi, T | 1 |
| Ohashi, K | 1 |
| Ebihara, A | 2 |
| Neutel, JM | 4 |
| Smith, DH | 3 |
| Fagan, TC | 1 |
| Lefkowitz, MP | 2 |
| Kazempour, MK | 2 |
| Kotamäki, M | 1 |
| Manninen, V | 1 |
| Laustiola, KE | 1 |
| Carruthers, G | 1 |
| Dessain, P | 1 |
| Fodor, G | 1 |
| Palmer, W | 1 |
| Lefebvre, J | 1 |
| Provencher, P | 1 |
| Materson, BJ | 4 |
| Reda, DJ | 4 |
| Massie, BM | 2 |
| Freis, ED | 2 |
| Hamburger, RJ | 1 |
| Fye, C | 1 |
| Lakshman, R | 1 |
| Gottdiener, J | 1 |
| Bevan, EG | 1 |
| Pringle, SD | 2 |
| Waller, PC | 3 |
| Herrick, AL | 3 |
| Findlay, JG | 2 |
| Murray, GD | 3 |
| Carmichael, HA | 1 |
| Jennings, S | 1 |
| Hataway, H | 1 |
| Stern, J | 1 |
| Koga, S | 1 |
| Kato, K | 1 |
| Takii, M | 1 |
| Sakai, K | 1 |
| Kawasaki, K | 1 |
| Kagimoto, M | 1 |
| Doi, Y | 1 |
| Takada, K | 1 |
| Sakaue, A | 1 |
| Hole, DJ | 1 |
| Hawthorne, VM | 1 |
| Isles, CG | 1 |
| McGhee, SM | 1 |
| Robertson, JW | 1 |
| Gillis, CR | 1 |
| Wapshaw, JA | 1 |
| Fletcher, AE | 4 |
| Bulpitt, CJ | 5 |
| Coles, EC | 1 |
| Dollery, CT | 4 |
| Ledingham, JG | 1 |
| Palmer, AJ | 2 |
| Haedersdal, C | 1 |
| Froeland, G | 5 |
| Erikssen, J | 2 |
| Morrissette, DL | 1 |
| Skinner, MH | 2 |
| Hoffman, BB | 2 |
| Levine, RE | 1 |
| Davidson, JM | 1 |
| Derman, WE | 1 |
| Ernotte, D | 1 |
| Noakes, TD | 1 |
| Grüne, S | 3 |
| Weisser, B | 2 |
| Kraft, K | 3 |
| Del Bufalo, A | 2 |
| Binswanger, B | 2 |
| Mengden, T | 3 |
| Spühler, T | 2 |
| Moccetti, T | 1 |
| Hoffbrand, BI | 1 |
| Earle, KA | 1 |
| Nievel, JG | 1 |
| Restrick, LJ | 1 |
| Simmonds, NJ | 1 |
| Schubiger, JL | 1 |
| Wohler, D | 1 |
| Araque, A | 1 |
| Lahera, V | 1 |
| Suarez, C | 1 |
| Chen, MF | 1 |
| Yang, CY | 1 |
| Chen, WJ | 1 |
| Lee, CM | 1 |
| Wu, CC | 1 |
| Liau, CS | 1 |
| Lee, YT | 1 |
| Haneda, T | 2 |
| Okamoto, K | 1 |
| Hiroshima, T | 1 |
| Kashiwagi, Y | 1 |
| Miyata, S | 1 |
| Ohi, S | 1 |
| Osaki, J | 1 |
| Hirayama, T | 1 |
| Satia, MC | 1 |
| Shukla, ML | 1 |
| Goyal, RK | 1 |
| Kumagai, K | 1 |
| Suzuki, H | 2 |
| Ichikawa, M | 1 |
| Jimbo, M | 1 |
| Nishizawa, M | 1 |
| Ryuzaki, M | 1 |
| Saruta, T | 2 |
| Saner, H | 1 |
| Seiler, A | 1 |
| Mahler, F | 1 |
| Fitzpatrick, V | 1 |
| Chrysant, S | 1 |
| Francischetti, EA | 1 |
| Murphy, CA | 1 |
| McCarty, R | 2 |
| Maritz, FJ | 1 |
| Weich, HF | 1 |
| Schoeman, HS | 1 |
| Antonios, TF | 1 |
| Markandu, ND | 2 |
| Sagnella, GA | 1 |
| MacGregor, GA | 2 |
| Morris, AD | 2 |
| Donnelly, R | 3 |
| Heinrich, U | 1 |
| Bolte, J | 1 |
| Aschenberg, W | 1 |
| Savolainen, A | 1 |
| Keto, P | 1 |
| Poutanen, VP | 1 |
| Hekali, P | 1 |
| Standertskjöld-Nordenstam, CG | 1 |
| Rames, A | 1 |
| Kupari, M | 1 |
| Aucott, JN | 1 |
| Pelecanos, E | 1 |
| Dombrowski, R | 1 |
| Fuehrer, SM | 1 |
| Laich, J | 1 |
| Aron, DC | 1 |
| Uhlír, O | 1 |
| Scemama, M | 1 |
| Prince, M | 1 |
| Lewis, G | 1 |
| Bird, A | 1 |
| Blizard, R | 1 |
| Mann, A | 1 |
| Lazar, AI | 1 |
| van Jaarsveld, BC | 1 |
| Derkx, FH | 1 |
| Krijnen, P | 1 |
| Pieterman, H | 1 |
| Man in't Veld, AJ | 1 |
| Woittiez, AJ | 1 |
| Dees, A | 1 |
| Postma, CT | 1 |
| Schalekamp, MA | 2 |
| Nederfors, T | 1 |
| Cleophas, TJ | 3 |
| van der Mey, N | 1 |
| van der Meulen, J | 1 |
| Niemeyer, MG | 2 |
| Hosohata, Y | 1 |
| Sasaki, K | 1 |
| Maruyama, K | 1 |
| Ohnuki, T | 1 |
| Hattori, K | 2 |
| Suzuki, J | 1 |
| Watanabe, K | 1 |
| Nagatomo, T | 1 |
| Mercuri, M | 1 |
| Rangemark, C | 1 |
| Lind, H | 1 |
| Weber, C | 1 |
| Tam, YK | 1 |
| Schmidtke-Schrezenmeier, G | 1 |
| Jonkmann, JH | 1 |
| van Brummelen, P | 2 |
| Schiessl, S | 1 |
| Chi, VX | 1 |
| Chau, NP | 1 |
| Ramanathan, M | 1 |
| Curb, JD | 3 |
| Savage, PJ | 1 |
| Black, H | 2 |
| Camel, G | 1 |
| Frost, PH | 2 |
| Gonzalez, N | 1 |
| Guthrie, G | 1 |
| Stamler, J | 3 |
| Paran, E | 2 |
| Anson, O | 1 |
| Neumann, L | 2 |
| Schmitz, G | 1 |
| Herrmann, W | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Foley, K | 1 |
| Berge, KG | 3 |
| Probstfield, J | 1 |
| Notter, T | 1 |
| Zilles, P | 1 |
| Mangrum, A | 1 |
| Copley, JB | 1 |
| Vicknair, N | 1 |
| Sadler, R | 1 |
| Apperloo, AJ | 1 |
| de Zeeuw, D | 1 |
| de Jong, PE | 1 |
| Rendell, MS | 1 |
| Shehan, MA | 1 |
| Kahler, K | 1 |
| Bailey, KL | 1 |
| Eckermann, AJ | 1 |
| Witchitz, S | 2 |
| Provendier, O | 1 |
| Arsenescu, I | 1 |
| Zadionchenko, VS | 2 |
| Bagatyrova, KM | 1 |
| Adasheva, TV | 1 |
| Timofeeva, NIu | 1 |
| Zaporozhets, TP | 1 |
| Gordon, NF | 2 |
| Scott, CB | 1 |
| Duncan, JJ | 1 |
| Gottdiener, JS | 2 |
| Williams, DW | 2 |
| Anderson, RJ | 1 |
| Bönner, G | 1 |
| Chrosch, R | 1 |
| Legssyer, AK | 1 |
| Hove-Madsen, L | 1 |
| Hoerter, J | 1 |
| Fischmeister, R | 1 |
| Shaffer, LM | 1 |
| Krusell, LR | 4 |
| Jespersen, LT | 2 |
| Thomsen, K | 1 |
| Giugliano, D | 1 |
| Acampora, R | 1 |
| Marfella, R | 1 |
| De Rosa, N | 1 |
| Ziccardi, P | 1 |
| Ragone, R | 1 |
| De Angelis, L | 1 |
| D'Onofrio, F | 1 |
| Elijovich, F | 1 |
| Laffer, CL | 1 |
| Hakamäki, T | 1 |
| Lehtonen, A | 4 |
| Cutler, J | 1 |
| Grimm, RH | 2 |
| Lacy, CR | 1 |
| Schron, E | 1 |
| Berkson, DM | 1 |
| Smith, WM | 1 |
| McDonald, R | 1 |
| Devereux, R | 1 |
| Philipp, T | 4 |
| Distler, A | 5 |
| Michaelis, J | 1 |
| Wellek, S | 1 |
| Chern, MS | 1 |
| Lin, FC | 2 |
| Wu, D | 2 |
| Hotnes, T | 1 |
| Dollerup, J | 1 |
| Chazan, R | 1 |
| Chen, JW | 1 |
| Sato, A | 1 |
| Sierakowski, B | 1 |
| Püchler, K | 1 |
| Witte, PU | 1 |
| Renneisen, K | 1 |
| Delius, W | 1 |
| Gralec, M | 1 |
| Piusińska-Macoch, A | 1 |
| Cholewa, M | 1 |
| Sułek, K | 1 |
| Mandal, AK | 1 |
| Miller, WG | 1 |
| Saklayen, MG | 1 |
| Markert, RJ | 1 |
| Jacobs, MC | 1 |
| Lenders, JW | 2 |
| Smits, P | 1 |
| Willemsen, JJ | 1 |
| Tack, C | 1 |
| Thien, T | 3 |
| Selhorst-Kiss, S | 1 |
| Seitz, W | 1 |
| Lusardi, P | 3 |
| Van Nueten, L | 2 |
| Vertommen, C | 1 |
| Johnston, GD | 1 |
| Wilson, R | 1 |
| McDermott, BJ | 1 |
| Conroy, C | 1 |
| Agewall, S | 1 |
| Kendall, M | 1 |
| McPherson, J | 1 |
| Taylor, M | 1 |
| Mason, A | 1 |
| Carney, S | 1 |
| Gillies, A | 1 |
| Taylor, FR | 1 |
| Ofili, EO | 1 |
| St Vrain, JA | 1 |
| Pearson, A | 1 |
| Martin, TJ | 1 |
| Uy, ND | 1 |
| Castello, R | 1 |
| Labovitz, AJ | 1 |
| Zakopoulos, N | 1 |
| Stamatelopoulos, S | 1 |
| Moulopoulos, S | 1 |
| Pelttari, LH | 1 |
| Hietanen, EK | 1 |
| Salo, TT | 1 |
| Kataja, MJ | 1 |
| Kantola, IM | 1 |
| Haworth, D | 1 |
| Hoglund, C | 2 |
| Kerwin, L | 1 |
| Martin, A | 1 |
| Simon, T | 1 |
| Masson, C | 1 |
| Kassler-Taub, K | 1 |
| Osbakken, M | 1 |
| Daae, LN | 2 |
| Westlie, L | 5 |
| Tripathi, M | 1 |
| Kaushik, S | 1 |
| Gaur, A | 1 |
| Kher, V | 1 |
| Andersen, P | 2 |
| Seljeflot, I | 2 |
| Herzog, A | 1 |
| Arnesen, H | 2 |
| Hjermann, I | 2 |
| Makris, T | 1 |
| Krespi, P | 1 |
| Triposkiadis, F | 1 |
| Votteas, V | 1 |
| Hatzizaharias, A | 1 |
| Kyriakidis, M | 1 |
| Pierdomenico, SD | 1 |
| Bucci, A | 1 |
| Costantini, F | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Cifkova, R | 2 |
| Tenczer, J | 1 |
| Watt, A | 1 |
| Wilkins, MR | 2 |
| Lindberg, E | 1 |
| Vogt, T | 1 |
| Burlando, A | 1 |
| Cohen, J | 1 |
| Wilson, A | 1 |
| Brass, LM | 1 |
| Frishman, W | 2 |
| Price, T | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Williams, G | 1 |
| Fakouhi, TD | 1 |
| Troisi, E | 1 |
| Attanasio, A | 1 |
| Matteis, M | 1 |
| Bragoni, M | 1 |
| Monaldo, BC | 1 |
| Caltagirone, C | 1 |
| Silvestrini, M | 1 |
| Peleska, J | 1 |
| Hradec, J | 1 |
| Rosolová, H | 1 |
| Pintérová, E | 1 |
| Zeman, K | 1 |
| Oddou-Stock, P | 1 |
| Thirlwell, J | 1 |
| Botteri, F | 1 |
| Holmer, SR | 1 |
| Hense, HW | 1 |
| Danser, AH | 1 |
| Mayer, B | 1 |
| Riegger, GA | 1 |
| Ravinetto, R | 1 |
| Poletti, L | 3 |
| Thürmann, PA | 2 |
| Kenedi, P | 1 |
| Harder, S | 1 |
| Rietbrock, N | 1 |
| Krivitzky, A | 1 |
| Nguyen, G | 1 |
| Gaudouen, Y | 1 |
| Legrand, M | 1 |
| Cohen, R | 1 |
| Stimpel, M | 1 |
| Koch, B | 1 |
| Davies, RA | 1 |
| Fourney, A | 1 |
| Miser, WF | 1 |
| Patel, V | 1 |
| Rassam, SM | 1 |
| Chen, HC | 1 |
| Jones, M | 1 |
| Kohner, EM | 1 |
| Iglesias, R | 1 |
| Taboada, C | 1 |
| Souto, C | 1 |
| Martínez-Pacheco, R | 1 |
| Gómez-Amoza, JL | 1 |
| Concheiro, A | 1 |
| Dahlöf, C | 3 |
| Nilsson-Ehle, P | 1 |
| Engqvist, L | 1 |
| Lagerstedt, C | 1 |
| Berglund, E | 1 |
| Soma, J | 1 |
| Aakhus, S | 1 |
| Dahl, K | 1 |
| Widerøe, TE | 1 |
| Skjaerpe, T | 1 |
| Barenbrock, M | 1 |
| Hohage, H | 2 |
| Müller, S | 1 |
| Heidenreich, S | 1 |
| Lakshman, MR | 1 |
| Singer, RB | 1 |
| Milne, RJ | 1 |
| Vander Hoorn, S | 1 |
| Jackson, RT | 1 |
| Pastori, C | 1 |
| Delva, P | 1 |
| Degan, M | 1 |
| Lydakis, C | 1 |
| Salo, TM | 1 |
| Kantola, I | 1 |
| Voipio-Pulkki, LM | 1 |
| Pelttari, L | 1 |
| Viikari, JS | 1 |
| Andrén, B | 1 |
| vd Mey, N | 1 |
| Meulen, J | 1 |
| Pesant, Y | 1 |
| Marc-Aurèle, J | 1 |
| Bielmann, P | 1 |
| Cartier, P | 1 |
| Bichet, D | 1 |
| Thibault, G | 1 |
| Lupien, PJ | 1 |
| de la Sierra, A | 2 |
| Graff-Iversen, S | 1 |
| Istad, H | 1 |
| Søyland, E | 2 |
| Tjeldflaat, L | 1 |
| Graving, B | 1 |
| Aspelin, T | 1 |
| Kierulf, P | 1 |
| Pastore, L | 1 |
| Tessitore, A | 1 |
| Martinotti, S | 1 |
| Toniato, E | 1 |
| Alesse, E | 1 |
| Bravi, MC | 1 |
| Ferri, C | 1 |
| Desideri, G | 1 |
| Gulino, A | 1 |
| Santucci, A | 1 |
| Luca, S | 1 |
| Romeo, S | 1 |
| Robles, NR | 1 |
| Gómez Guindal, JA | 1 |
| González Lama, I | 1 |
| Martin, ME | 1 |
| Chaswal, M | 2 |
| Shankar, N | 2 |
| Lim, PO | 2 |
| Donnan, PT | 1 |
| Chastang, C | 1 |
| Unger, P | 1 |
| Alvarez, E | 1 |
| Byberg, L | 1 |
| Andrawis, NS | 1 |
| Battle, MM | 1 |
| Klamerus, KJ | 1 |
| Burghart, PH | 1 |
| Neefe, L | 1 |
| Weinryb, I | 1 |
| Mayer, P | 1 |
| Abernethy, DR | 1 |
| Park, JB | 3 |
| Intengan, HD | 1 |
| Martínez, B | 1 |
| Lostao, CM | 1 |
| Penagarikano, O | 1 |
| Ortega, B | 1 |
| Alonso, RM | 1 |
| Jiménez, RM | 1 |
| Lee, TH | 2 |
| Kraiczi, H | 1 |
| Hedner, J | 2 |
| Peker, Y | 1 |
| Grote, L | 1 |
| Castaigne, A | 1 |
| Palmer, CR | 1 |
| Hollenberg, NK | 2 |
| Williams, GH | 2 |
| Anderson, R | 1 |
| Garcia-Puig, J | 1 |
| Niegowska, J | 2 |
| Baiz, AQ | 1 |
| Vrijens, F | 1 |
| Bortman, G | 1 |
| Tandon, OP | 1 |
| Enström, I | 3 |
| Pennert, K | 5 |
| Glasser, SP | 2 |
| Stone, P | 1 |
| Johnson, MF | 1 |
| Price, TR | 1 |
| Fields, WS | 1 |
| Guralnik, JM | 2 |
| Kuller, L | 1 |
| Easterling, TR | 2 |
| Brateng, D | 1 |
| Schmucker, B | 1 |
| Brown, Z | 1 |
| Millard, SP | 1 |
| Makris, TK | 1 |
| Stavroulakis, GA | 1 |
| Krespi, PG | 1 |
| Hatzizacharias, AN | 1 |
| Triposkiadis, FK | 1 |
| Tsoukala, CG | 1 |
| Votteas, VV | 1 |
| Kyriakidis, MK | 1 |
| Franse, LV | 2 |
| Pahor, M | 3 |
| Di Bari, M | 2 |
| Shorr, RI | 2 |
| Wan, JY | 2 |
| Somes, GW | 2 |
| Kähkönen, S | 1 |
| Kaartinen, M | 1 |
| Juhela, P | 1 |
| Bakir, S | 1 |
| Rakov, SS | 1 |
| Betekhtina, VA | 1 |
| Greenfield, JR | 1 |
| Chisholm, DJ | 1 |
| Suwelack, B | 1 |
| Gerhardt, U | 1 |
| Kato, J | 1 |
| Matsuhashi, H | 1 |
| Morimoto, H | 1 |
| Honda, H | 1 |
| Takenaka, T | 1 |
| Tanazawa, S | 1 |
| Kataoka, R | 1 |
| Head, GA | 2 |
| Kuperstein, R | 1 |
| Sasson, Z | 1 |
| Mettimano, M | 1 |
| Pichetti, F | 1 |
| Fazzari, L | 1 |
| Migneco, A | 1 |
| Specchia, L | 1 |
| Romano Spica, V | 1 |
| Savi, L | 1 |
| Huysmans, FT | 1 |
| Wetzels, JF | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Bertram, M | 1 |
| Girard, A | 1 |
| Holand, S | 1 |
| Laude, D | 1 |
| Elghozi, JL | 1 |
| Ferrucci, L | 2 |
| Freytag, F | 1 |
| Schelling, A | 1 |
| Meinicke, T | 1 |
| Deichsel, G | 1 |
| Shekhtman, MM | 1 |
| Elokhina, TB | 1 |
| Petrova, SB | 1 |
| Sokolova, MIu | 1 |
| Patki, KC | 1 |
| Joglekar, SJ | 2 |
| Kamat, SK | 1 |
| Thatte, UM | 1 |
| Yeolekar, ME | 1 |
| Rege, NN | 1 |
| Dahanukar, SA | 1 |
| Nanivadekar, AS | 2 |
| Kelkar, PN | 1 |
| Jaguste, V | 1 |
| Gage, BF | 1 |
| Fihn, SD | 1 |
| White, RH | 1 |
| Cervera Barba, EJ | 1 |
| García de Vinuesa, S | 1 |
| Luño, J | 1 |
| Gómez-Campderá, F | 1 |
| Ridao, N | 1 |
| Sánchez, M | 2 |
| Dall'Anese, C | 1 |
| Valderrábano, F | 1 |
| Khazine, F | 1 |
| Simons, O | 1 |
| Hägg, A | 5 |
| Osbakken, MD | 1 |
| Ostergern, J | 1 |
| Simon, A | 4 |
| Gariépy, J | 1 |
| Moyse, D | 1 |
| Levenson, J | 3 |
| Ball, KJ | 1 |
| Williams, PA | 1 |
| Novo, S | 3 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 3 |
| Barbagallo, M | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Brown, CA | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Hall, JE | 1 |
| Gray, A | 1 |
| Clarke, P | 1 |
| Raikou, M | 1 |
| Adler, A | 1 |
| Stevens, R | 1 |
| Neil, A | 1 |
| Cull, C | 1 |
| Stratton, I | 1 |
| Holman, R | 1 |
| Tzemos, N | 1 |
| Einecke, D | 2 |
| Virdis, A | 1 |
| Nadeau, A | 1 |
| Strauer, BE | 3 |
| Laurent, SA | 1 |
| Wikstrand, J | 1 |
| Fratta-Pasini, A | 1 |
| von zur Mühlen, B | 1 |
| Millgård, J | 1 |
| Penninx, BW | 1 |
| DiBari, M | 1 |
| Williamson, JD | 1 |
| Chen, JG | 1 |
| Perk, G | 1 |
| Ghanem, J | 1 |
| Aamar, S | 1 |
| Ben-Ishay, D | 1 |
| Bursztyn, M | 1 |
| O'Rourke, ME | 1 |
| Tokola, H | 1 |
| Ruskoaho, H | 1 |
| Kirby, PL | 1 |
| Caulfield, MC | 1 |
| Griffiths, CG | 1 |
| Hemingway, H | 1 |
| Feder, GS | 1 |
| Diamond, JA | 1 |
| Armentano, RL | 1 |
| Graf, S | 1 |
| Ramírez, AJ | 2 |
| Espinosa, JD | 1 |
| Brandani, L | 1 |
| Baglivo, H | 1 |
| Sánchez, R | 1 |
| Pertusa Martínez, S | 1 |
| Soriano, R | 1 |
| Llopis, J | 1 |
| Pacca, SR | 1 |
| de Azevedo, AP | 1 |
| De Oliveira, CF | 1 |
| De Luca, IM | 1 |
| De Nucci, G | 1 |
| Antunes, E | 1 |
| Björnstad, H | 1 |
| Giles, TD | 1 |
| Fleĭshman, AN | 1 |
| Filimonov, SN | 1 |
| Klimina, NV | 1 |
| Cosentino, F | 1 |
| Bonetti, S | 1 |
| Rehorik, R | 1 |
| Eto, M | 1 |
| Werner-Felmayer, G | 1 |
| Aalto, T | 1 |
| Bovet, P | 1 |
| Madeleine, G | 1 |
| Paccaud, F | 1 |
| Rovira, E | 1 |
| Miralles, A | 1 |
| Julve, R | 1 |
| Pascual, JM | 1 |
| Rollins, G | 1 |
| Pannier, BM | 2 |
| Kristiansson, K | 2 |
| Jia, Z | 1 |
| Lin, S | 1 |
| Peng, Y | 1 |
| Vlassopoulos, DA | 1 |
| Mentzikof, DG | 1 |
| Hadjiyannakos, DK | 1 |
| Noussias, CV | 1 |
| Karras, SM | 1 |
| Hadjiconstantinou, VE | 1 |
| Heinzl, S | 1 |
| Serkova, VK | 1 |
| Sheverda, NV | 1 |
| Rapi, J | 1 |
| Scheen, AJ | 1 |
| Komai, N | 1 |
| Ohishi, M | 1 |
| Morishita, R | 1 |
| Moriguchi, A | 1 |
| Kaibe, M | 1 |
| Matsumoto, K | 1 |
| Rakugi, H | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Fuchs, FD | 1 |
| Gurney, D | 1 |
| Westerlund, A | 6 |
| Jameson, S | 4 |
| Besterman, E | 1 |
| Yates, RA | 1 |
| Roberts, CJ | 1 |
| Zech, P | 2 |
| Pellet, M | 1 |
| Traeger, J | 1 |
| Galloway, DB | 3 |
| De Plaen, JF | 3 |
| Missotten, A | 3 |
| Comerford, MB | 1 |
| Besterman, EM | 1 |
| Keim, HJ | 1 |
| Cordes, U | 2 |
| Wolff, HP | 1 |
| Dany, F | 2 |
| Gonzenbach, R | 1 |
| Satz, N | 1 |
| Jenni, R | 1 |
| Krayenbühl, HP | 1 |
| Bazin, M | 1 |
| Lucsko, M | 1 |
| Roux, A | 1 |
| Guedon, J | 1 |
| Bennett, T | 2 |
| Gardiner, SM | 1 |
| Gudbrandsson, T | 1 |
| Heel, RC | 1 |
| Brogden, RN | 2 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Bell, C | 1 |
| McLachlan, EM | 1 |
| Knapp, MF | 1 |
| Linden, RJ | 1 |
| Stoker, JB | 1 |
| Newcombe, C | 1 |
| Lagrée, S | 1 |
| Prague, Y | 1 |
| Salamon, R | 1 |
| Louis, WJ | 2 |
| Pocock, J | 1 |
| Heaton, ST | 1 |
| Lehner, JP | 1 |
| Kehder, A | 1 |
| Weiss, Y | 2 |
| Tzincoca, C | 1 |
| Meekers, J | 1 |
| Demuynck, D | 1 |
| Harvengt, C | 2 |
| Pas, P | 1 |
| Billiet, L | 4 |
| Balansard, P | 1 |
| Chabrillat, Y | 1 |
| Paulin, R | 1 |
| Libes, M | 1 |
| Gérard, R | 1 |
| Zacharias, FJ | 6 |
| Cowen, KJ | 2 |
| Hayes, PJ | 1 |
| Wilson, C | 1 |
| Scott, ME | 1 |
| Abdel-Mohsen, A | 1 |
| Basker, MA | 1 |
| Tweed, JA | 5 |
| Castleden, CM | 2 |
| Dathan, JR | 1 |
| George, CF | 1 |
| Perks, WH | 2 |
| Croxson, RS | 1 |
| Gostick, NK | 1 |
| Mayhew, SR | 1 |
| Million, R | 1 |
| Sagar, D | 1 |
| Suxena, SR | 1 |
| Ingram, DF | 2 |
| Barmer, NP | 1 |
| Jones, BP | 1 |
| Mason, B | 2 |
| Epstein, SE | 1 |
| LUbbe, WF | 1 |
| Petretta, M | 1 |
| Ferrara, N | 1 |
| Chiariello, M | 1 |
| Reid, B | 1 |
| Okanga, JB | 1 |
| Mattiasson, I | 1 |
| Teeuw, AH | 1 |
| Geyskes, GG | 2 |
| Boer, P | 2 |
| Braendli, B | 1 |
| Bucher, HJ | 1 |
| Nager, F | 1 |
| Truniger, B | 1 |
| Hellström, PE | 1 |
| Salonen, T | 1 |
| Cilliers, AJ | 1 |
| Bateman, DN | 1 |
| Dean, CR | 1 |
| Mucklow, JC | 1 |
| Pitkäjärvi, T | 5 |
| Watson, OF | 1 |
| Brocklehurst, JE | 1 |
| McGrath, BP | 2 |
| Schofield, T | 1 |
| Benedict, CR | 1 |
| Cooper, R | 1 |
| Heaton, S | 1 |
| Brym, E | 1 |
| Cybulska, I | 1 |
| Czerniewska, E | 1 |
| Leth, A | 1 |
| McNair, A | 1 |
| Giese, J | 1 |
| Magelli, C | 1 |
| Agosta, R | 1 |
| Craig, MW | 1 |
| Kenny, D | 1 |
| Knapp, MS | 2 |
| Floras, J | 1 |
| Littler, WA | 1 |
| Watson, RD | 1 |
| Yen, TT | 1 |
| Pearson, DV | 1 |
| Watkins, J | 1 |
| Dargie, HJ | 2 |
| Bune, A | 1 |
| Sivertsson, R | 2 |
| Andersson, O | 1 |
| Ylitalo, P | 2 |
| Metsä-Ketelä, T | 1 |
| Vapaatalo, H | 2 |
| van Rooijen, GJ | 1 |
| Dorhout Mees, EJ | 1 |
| Sleigh, R | 1 |
| Deschodt, G | 1 |
| Fourcade, J | 1 |
| Barjon, P | 1 |
| Pérez-Medina, T | 2 |
| Gamio-Capestany, F | 1 |
| Fox, P | 1 |
| Turner, KL | 1 |
| Cerasola, GA | 1 |
| Botta, RM | 1 |
| Riolo, A | 1 |
| Amico, LM | 1 |
| Legheand, J | 1 |
| Kawecka-Jaszcz, K | 3 |
| Kocemba, J | 2 |
| Caesar, K | 1 |
| Saborowski, F | 1 |
| Lang, R | 3 |
| Meurer, KA | 1 |
| Kaufmann, W | 1 |
| Trevi, P | 1 |
| Benussi, P | 1 |
| Veronese, P | 3 |
| Hlede, M | 1 |
| Ardigò, A | 2 |
| Woolfson, AM | 1 |
| Zilcher, H | 1 |
| Glogar, D | 1 |
| Uhlir, H | 1 |
| Leisch, F | 1 |
| Niederberger, M | 1 |
| Steinbach, K | 1 |
| Hall, D | 1 |
| Charocopos, F | 1 |
| Froer, KL | 1 |
| Rudolph, W | 1 |
| Simpson, N | 1 |
| Page, RL | 1 |
| Boel, A | 1 |
| Willems, J | 1 |
| Douglas-Jones, AP | 1 |
| Myers, MG | 1 |
| Lewis, GR | 1 |
| Steiner, J | 1 |
| Deplaen, JF | 1 |
| Clement, DL | 2 |
| Bogaert, MG | 1 |
| Pannier, R | 1 |
| Cuthbertson, PF | 1 |
| Johnson, TB | 1 |
| Prestt, J | 1 |
| Thompson, J | 1 |
| Vickers, J | 1 |
| Simpson, WT | 2 |
| Tuson, R | 1 |
| Hadj-Aissa, A | 1 |
| Grobecker, H | 1 |
| Saavedra, JM | 1 |
| Chiueh, CC | 1 |
| Kopin, IJ | 1 |
| Aström, H | 2 |
| Vallin, H | 1 |
| Harris, AM | 1 |
| Wollard, KV | 1 |
| Walter, B | 1 |
| Walter, U | 1 |
| Beyer, J | 1 |
| Lewis, JA | 1 |
| Wetterberg, L | 2 |
| Ross, SB | 1 |
| McDonald, RH | 4 |
| Kuller, LH | 1 |
| Gerstenblith, G | 4 |
| Ligueros, M | 1 |
| Unwin, R | 1 |
| Humphreys, J | 1 |
| Coles, SJ | 1 |
| Cleland, J | 1 |
| Pozzi, A | 1 |
| De Bernardi, F | 1 |
| Pizzinelli, P | 1 |
| Zhu, QY | 1 |
| Yang, YC | 1 |
| Johannesson, M | 1 |
| Fagerberg, B | 2 |
| Hayoz, D | 1 |
| Tardy, Y | 1 |
| Perret, F | 1 |
| Meister, JJ | 1 |
| Brunner, HR | 4 |
| Soininen, K | 1 |
| Gerlin-Piira, L | 1 |
| Suihkonen, J | 1 |
| Kyllönen, T | 1 |
| Parviainen, R | 1 |
| Kyllönen, E | 1 |
| Hämäläinen, K | 1 |
| Lonka, R | 1 |
| Tikkanen, T | 1 |
| Selonen, R | 1 |
| Radaelli, A | 1 |
| Piepoli, M | 1 |
| Adamopoulos, S | 1 |
| Pipilis, A | 1 |
| Clark, SJ | 1 |
| Meyer, TE | 1 |
| Coats, AJ | 1 |
| Ljungman, S | 1 |
| Herlitz, H | 2 |
| Widgren, B | 1 |
| Rudge, PJ | 1 |
| Andrews, CD | 1 |
| Callaghan, TS | 1 |
| Ekbom, T | 1 |
| Scherstén, B | 3 |
| Wester, PO | 2 |
| Soeyland, AK | 2 |
| Saltvedt, E | 1 |
| Enström-Granath, I | 1 |
| Humphreys, JE | 1 |
| Koshiji, M | 1 |
| Ito, H | 1 |
| Minatoguchi, S | 1 |
| Watanabe, H | 1 |
| Imai, Y | 2 |
| Kakami, M | 1 |
| Hirakawa, S | 1 |
| Cristal, N | 1 |
| Ketelhut, R | 6 |
| Franz, IW | 5 |
| Behr, U | 5 |
| Toennesmann, U | 1 |
| Cruikshank, JM | 1 |
| Ménard, J | 1 |
| Chatellier, G | 1 |
| Young, PH | 2 |
| Zusman, RM | 1 |
| Christensen, DM | 1 |
| Higgins, J | 1 |
| Boucher, CA | 1 |
| Morgan, T | 1 |
| Hauklien, H | 1 |
| Suchman, AL | 1 |
| Ader, R | 1 |
| Silagy, CA | 1 |
| Bianchi, S | 1 |
| Bigazzi, R | 1 |
| Baldari, G | 1 |
| Campese, VM | 1 |
| Rostock, G | 1 |
| Vogel, I | 1 |
| Stulich, M | 1 |
| Günzel, R | 1 |
| Shoji, T | 1 |
| Aki, Y | 1 |
| Horiuchi, K | 1 |
| Tamaki, T | 1 |
| He, H | 1 |
| Nishiyama, A | 1 |
| Kiyomoto, H | 1 |
| Fujisawa, Y | 1 |
| Iwao, H | 1 |
| Abe, Y | 1 |
| Talamini, G | 1 |
| Vega Fernández, M | 1 |
| Virgós Lamela, A | 1 |
| Gil de la Peña, M | 1 |
| Chase, DM | 1 |
| Collins, WC | 1 |
| Goggin, TK | 1 |
| Hewett, AJ | 1 |
| Neiss, AM | 1 |
| Wasenius Soeyland, AK | 1 |
| Knutsen, KM | 1 |
| Ekeli, T | 2 |
| Lee, HB | 1 |
| Davis, B | 2 |
| Langford, H | 2 |
| Michelsen, S | 1 |
| Petrovitch, H | 1 |
| Vogt, TM | 1 |
| Futterman, A | 1 |
| Morrissette, D | 1 |
| Thompson, LW | 1 |
| Blaschke, TF | 1 |
| Dimsdale, JE | 1 |
| Newton, RP | 1 |
| Conway, EL | 1 |
| Bartholomeusz, LC | 1 |
| Anderson, AI | 1 |
| Cameron, DP | 1 |
| Donnelly, T | 1 |
| Hooper, MJ | 1 |
| Marsál, K | 2 |
| Illingworth, JM | 1 |
| Davies, MJ | 1 |
| Dysart, RH | 1 |
| Silbert, BS | 1 |
| Scott, DA | 1 |
| Cook, RJ | 1 |
| Robinson, FO | 1 |
| Johnston, SR | 1 |
| Atkinson, AB | 1 |
| Brack, T | 1 |
| Edmonds, D | 6 |
| Yoshimoto, R | 1 |
| Hashiguchi, Y | 1 |
| Dohmoto, H | 1 |
| Hosono, M | 1 |
| Iida, H | 1 |
| Fujiyoshi, T | 1 |
| Ikeda, K | 1 |
| Hayashi, Y | 1 |
| Brantzeg, S | 1 |
| Durel, LA | 1 |
| Hayashi, PJ | 1 |
| Weidler, DJ | 3 |
| Schneiderman, N | 1 |
| Pannier, BE | 1 |
| Garabedian, VG | 1 |
| Madonna, O | 1 |
| Fouchard, M | 1 |
| Darne, B | 1 |
| Hirawa, N | 1 |
| Uehara, Y | 1 |
| Numabe, A | 1 |
| Takada, S | 1 |
| Matsuoka, H | 1 |
| Ikeda, T | 1 |
| Sugimoto, T | 1 |
| Ishii, M | 1 |
| Turkkan, JS | 2 |
| Goldstein, DS | 2 |
| Vulpis, V | 1 |
| Antonacci, A | 1 |
| Prandi, P | 1 |
| Bokor, D | 1 |
| Kaesser, UR | 1 |
| Losem, CJ | 1 |
| Meredith, PA | 1 |
| Wadworth, AN | 1 |
| Murdoch, D | 1 |
| Kullman, S | 1 |
| Sörensen, S | 1 |
| Eggertsen, R | 1 |
| Hall, S | 1 |
| Prescott, RI | 1 |
| Hallman, RJ | 1 |
| Dixon, S | 1 |
| Harvey, RE | 1 |
| López, NC | 1 |
| Corral, JL | 1 |
| Rincón, LA | 1 |
| Arreaza, MR | 1 |
| Giralt, J | 1 |
| Galué, GA | 1 |
| Barrios, YE | 1 |
| Arocha, I | 1 |
| Lenox-Smith, AJ | 1 |
| Street, RB | 1 |
| Kendall, FD | 1 |
| Erhard, W | 1 |
| Lindner, U | 1 |
| Krall, H | 1 |
| Breitstadt, A | 1 |
| Pfeiffer, C | 1 |
| Desche, P | 3 |
| Oberman, AS | 1 |
| Fabregues, G | 2 |
| Alvarez, L | 1 |
| Varas Juri, P | 1 |
| Drisaldi, S | 1 |
| Cerrato, C | 1 |
| Moschettoni, C | 1 |
| Pituelo, D | 1 |
| Baglivo, HP | 2 |
| Esper, RJ | 2 |
| Chappel, C | 1 |
| Farnham, DJ | 1 |
| Levin, B | 1 |
| Lueg, M | 1 |
| McCluskey, D | 1 |
| Steiner, C | 1 |
| Zverev, OG | 1 |
| Tsyrlin, VA | 1 |
| Van Baak, MA | 2 |
| Koene, FM | 2 |
| Verstappen, FT | 2 |
| Tan, ES | 1 |
| Chenard, A | 1 |
| De Kermadec, JM | 1 |
| Tertrain, F | 1 |
| Abiteboul, M | 1 |
| Deary, IJ | 1 |
| Capewell, S | 1 |
| Hajducka, C | 1 |
| Muir, AL | 4 |
| Ivashkin, VT | 2 |
| Grigor'ev, IuV | 2 |
| Sinopal'nikov, AI | 2 |
| Korneev, NV | 1 |
| Levitskiĭ, DN | 1 |
| Virs, EA | 1 |
| Lawson, M | 1 |
| Talseth, T | 4 |
| Daae, L | 3 |
| Tettamanti, F | 3 |
| Malamani, G | 1 |
| Kohno, M | 1 |
| Yokokawa, K | 1 |
| Yasunari, K | 1 |
| Murakawa, K | 1 |
| Kurihara, N | 1 |
| Takeda, T | 1 |
| Colantonio, D | 1 |
| Casale, R | 1 |
| Desiati, P | 1 |
| Giandomenico, G | 1 |
| Bucci, V | 1 |
| Pasqualetti, P | 1 |
| Reiterer, W | 1 |
| Meisner, W | 1 |
| Lithell, HO | 1 |
| Jansson, JH | 1 |
| Johansson, B | 2 |
| Nilsson, TK | 1 |
| Adams, MA | 1 |
| Bobik, A | 1 |
| Cai, B | 1 |
| Blackwood, RA | 1 |
| Garnham, S | 1 |
| Watson, M | 1 |
| Mehrzad, AA | 1 |
| Admani, K | 1 |
| Angell-James, JE | 1 |
| Feely, M | 1 |
| Husaini, MH | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 2 |
| Bhatia, RS | 1 |
| Nigam, P | 1 |
| Phillips, HL | 1 |
| Schnaper, H | 3 |
| Schocken, D | 1 |
| Luhr, JC | 1 |
| Koch, GG | 1 |
| Park, GD | 1 |
| Lindner, UK | 1 |
| DiPette, DJ | 2 |
| Goodman, RP | 1 |
| Townsend, R | 3 |
| McKenney, JM | 1 |
| Takabatake, T | 1 |
| Ohta, H | 1 |
| Ishida, Y | 1 |
| Hara, H | 1 |
| Nakamura, S | 1 |
| Takakuwa, H | 1 |
| Kobayashi, K | 1 |
| Houston, MC | 2 |
| Olafsson, L | 2 |
| Burger, MC | 1 |
| Tonkin, AL | 1 |
| Russell, AE | 3 |
| Bune, AJ | 3 |
| Morris, MJ | 3 |
| Cain, MD | 2 |
| Lindgren, B | 1 |
| Dixon, MS | 1 |
| Thomas, P | 1 |
| Sheridan, DJ | 1 |
| Widmann, L | 2 |
| van der Does, R | 2 |
| Hörrmann, M | 2 |
| Machwirth, M | 2 |
| Uberbacher, HJ | 1 |
| Stienen, U | 1 |
| Feher, MD | 2 |
| Henderson, AD | 1 |
| Wadsworth, J | 2 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 2 |
| Elkeles, RS | 2 |
| Lecerof, H | 1 |
| Bornmyr, S | 1 |
| Lilja, B | 1 |
| De Pedis, G | 1 |
| Hulthén, UL | 1 |
| Groppelli, A | 1 |
| Rizzardi, G | 1 |
| Fiocchi, G | 1 |
| Jankelow, D | 1 |
| Pretorius, JJ | 1 |
| Lombardi, F | 1 |
| Furlan, R | 1 |
| Guzzetti, S | 1 |
| Cerutti, S | 1 |
| Blake, S | 2 |
| MacDonald, D | 1 |
| Havinga, TK | 2 |
| Sheu, WH | 1 |
| Swislocki, AL | 1 |
| Hoffman, B | 1 |
| Chen, YD | 1 |
| Reaven, GM | 1 |
| Sundar, S | 1 |
| Rajan, AG | 1 |
| Somani, PN | 1 |
| Kumar, K | 1 |
| Sundberg, S | 3 |
| Luurila, OJ | 4 |
| Kohvakka, A | 4 |
| Gordin, A | 1 |
| Testa, MA | 1 |
| Anderson, RB | 1 |
| Shah, PK | 1 |
| Lakhotia, M | 1 |
| Chittora, M | 1 |
| Mehta, S | 2 |
| Vyas, R | 1 |
| Parihar, M | 1 |
| Michaels, RD | 1 |
| Hays, JH | 1 |
| O'Brian, JT | 1 |
| Shakir, KM | 1 |
| Shiotani, M | 1 |
| Arita, M | 1 |
| Nakatsu, C | 1 |
| Nakamura, N | 1 |
| Ohshika, H | 1 |
| Fujiwara, S | 1 |
| Ueno, Y | 1 |
| Nishio, I | 1 |
| Masuyama, Y | 1 |
| Soria, F | 1 |
| Alegría, E | 1 |
| Valdés, M | 1 |
| García, A | 1 |
| Vicente, T | 1 |
| Castello, MJ | 1 |
| Marcó, EJ | 1 |
| Otero, F | 1 |
| Dopico, AM | 1 |
| Degrossi, O | 1 |
| Sánchez, RA | 1 |
| Valtancoli, G | 1 |
| Schulman, SP | 2 |
| Weiss, JL | 1 |
| Becker, LC | 1 |
| Gottlieb, SO | 1 |
| Woodruff, KM | 1 |
| Weisfeldt, ML | 1 |
| Tönnesmann, U | 3 |
| Searle, M | 1 |
| Dathan, R | 1 |
| Christensen, CC | 1 |
| Westheim, A | 3 |
| Staessen, J | 5 |
| Burrieza, HO | 1 |
| Marín, M | 1 |
| Shimamoto, H | 1 |
| Shimamoto, Y | 1 |
| Sakata, S | 1 |
| Niutta, E | 2 |
| Cusi, D | 2 |
| Colombo, R | 2 |
| Pellizzoni, M | 2 |
| Cesana, B | 2 |
| Barlassina, C | 2 |
| Soldati, L | 1 |
| Bianchi, G | 2 |
| Devynck, MA | 1 |
| Pithois-Merli, I | 1 |
| Le Quan Sang, KH | 1 |
| Klein, G | 1 |
| Berger, J | 1 |
| Olsson, G | 1 |
| Menzel, T | 1 |
| Lindvall, K | 1 |
| Rorive, G | 2 |
| Creytens, G | 2 |
| Ruhwiedel, M | 1 |
| Van de Voorde, K | 1 |
| Mitchell, ET | 2 |
| Lewis, R | 2 |
| Irvine, N | 1 |
| McLay, JS | 1 |
| McEwen, J | 1 |
| Coulson, RR | 2 |
| Slater, ND | 1 |
| Fitzsimons, TJ | 3 |
| Pilgaard, S | 1 |
| Palmelund, VO | 1 |
| Svendsen, TL | 1 |
| Fell, PJ | 1 |
| Burger, C | 1 |
| Hays, JT | 1 |
| Nadeau, J | 1 |
| Swift, L | 1 |
| Bradley, CA | 1 |
| Steiner, SS | 1 |
| Friedhoff, AJ | 1 |
| Wilson, BL | 1 |
| Wecker, JR | 1 |
| Santo, JP | 1 |
| Kamlow, F | 1 |
| Neil-Dwyer, G | 1 |
| Dorrance, DE | 1 |
| Hayes, Y | 1 |
| Patel, S | 1 |
| Wainwright, RJ | 1 |
| Boulet, LP | 1 |
| Milot, J | 1 |
| Lampron, N | 1 |
| Saunders, E | 4 |
| Weir, MR | 3 |
| Kong, BW | 2 |
| Hollifield, J | 1 |
| Gray, J | 1 |
| Vertes, V | 1 |
| Zemel, MB | 1 |
| Curry, C | 1 |
| Schoenberger, J | 1 |
| Levine, S | 1 |
| Duckett, GK | 2 |
| Cheadle, B | 2 |
| Mansy, S | 1 |
| Abrahamsen, AM | 1 |
| Digranes, O | 1 |
| Mayhew, S | 1 |
| el Mangoush, M | 1 |
| Singh, NK | 1 |
| Basha, A | 1 |
| Gupta, BS | 1 |
| Bolya, YK | 1 |
| Gamati, A | 1 |
| Blumenthal, JA | 4 |
| Ekelund, LG | 4 |
| Emery, CF | 1 |
| Kavey, RE | 1 |
| Cotton, JL | 1 |
| Blackman, MS | 1 |
| Shapira, Y | 1 |
| Mor, F | 1 |
| Friedler, A | 1 |
| Wysenbeek, AJ | 1 |
| Weinberger, A | 1 |
| Kennedy, S | 1 |
| Cruickshank, DJ | 1 |
| Campbell, DM | 1 |
| Goodman, R | 1 |
| Blumfield, D | 1 |
| Cronin, R | 1 |
| Gradman, A | 1 |
| Katz, LA | 1 |
| McCarthy, EP | 1 |
| Sopko, G | 1 |
| Wing, L | 1 |
| Taylor, S | 2 |
| Huss, R | 1 |
| Jeck, T | 1 |
| Schubert, M | 1 |
| Abate, MA | 1 |
| Layne, RD | 1 |
| Neely, JL | 1 |
| D'Alessandri, R | 1 |
| Sobrino, J | 1 |
| Aguilera, MT | 1 |
| Lluch, MM | 1 |
| Picado, MJ | 1 |
| Urbano-Márquez, A | 1 |
| Brown, CL | 1 |
| Santoni, JP | 1 |
| Clamp, M | 1 |
| Holmes, B | 1 |
| Wilcox, R | 1 |
| Lamey, PJ | 1 |
| Gibson, J | 1 |
| Barclay, SC | 1 |
| Miller, S | 1 |
| Currie, D | 1 |
| Lewis, RV | 2 |
| Nicholson, AN | 1 |
| Wright, NA | 1 |
| Stapper, GJ | 1 |
| Zaeh, D | 1 |
| Haider, B | 1 |
| Brown, P | 1 |
| Silas, E | 1 |
| M'Buyamba-Kabangu, JR | 3 |
| Henderson, CA | 1 |
| Shamy, HK | 1 |
| Kotegawa, T | 1 |
| O'Connell, MB | 2 |
| Gross, CR | 1 |
| Cheung, DG | 2 |
| Graettinger, WF | 2 |
| Taylor, SH | 1 |
| Berglund, A | 1 |
| Holme, E | 1 |
| Wilhelmsen, L | 1 |
| Elmfeldt, D | 2 |
| Dianzumba, SB | 2 |
| DiPette, D | 2 |
| Joyner, CR | 2 |
| Cornman, C | 2 |
| Mauro, K | 2 |
| Weber, E | 2 |
| Theobald, T | 1 |
| Doshan, HD | 1 |
| Rosenthal, RR | 1 |
| Brown, R | 1 |
| Slutsky, A | 1 |
| Applin, WJ | 1 |
| Caruso, FS | 1 |
| Rosenthal, F | 2 |
| Bühler, FR | 3 |
| Berglund, G | 1 |
| Anderson, OK | 1 |
| Scherrer, U | 1 |
| Selinus, I | 5 |
| Vessby, B | 1 |
| Bolzano, K | 1 |
| Arriaga, J | 1 |
| Bernal, R | 1 |
| Bernardes, H | 1 |
| Calderon, JL | 1 |
| Debruyn, J | 1 |
| Dienstl, F | 1 |
| Drayer, J | 1 |
| Goodfriend, TL | 1 |
| Gross, W | 1 |
| De Pue, NY | 1 |
| Packet, L | 1 |
| Palombo, C | 1 |
| Marabotti, C | 1 |
| Genovesi-Ebert, A | 1 |
| Giuliano, G | 1 |
| Giaconi, S | 1 |
| Fommei, E | 1 |
| Mezzasalma, L | 1 |
| Ghione, S | 1 |
| de Bruijn, B | 1 |
| Cocco, G | 1 |
| Tyler, HM | 1 |
| Lissens, W | 1 |
| Sykulski, R | 1 |
| Keller, N | 1 |
| Storm, T | 1 |
| Stokke, O | 1 |
| Myhre, T | 1 |
| Himanen, P | 5 |
| Quitzau, K | 1 |
| Ferreira, IJ | 1 |
| Escosa, L | 1 |
| Casasnovas, JA | 1 |
| Barrios, SJ | 1 |
| Marcos, JM | 1 |
| Pardell, H | 1 |
| Navarro, A | 1 |
| de la Fuente, V | 1 |
| Pollare, T | 3 |
| Lesbre, JP | 1 |
| Morand, P | 1 |
| Raveau-Landon, C | 1 |
| Gillin, AG | 1 |
| Fletcher, PJ | 2 |
| Horvath, JS | 2 |
| Hutton, BF | 1 |
| Bautovich, GJ | 1 |
| Tiller, DJ | 1 |
| Sihm, I | 1 |
| Davies, SF | 1 |
| Graif, JL | 1 |
| Husebye, DG | 1 |
| Maddy, MM | 1 |
| McArthur, CD | 1 |
| Path, MJ | 1 |
| Iber, C | 1 |
| Davidman, M | 1 |
| Allen, JW | 1 |
| Kaiser, PJ | 1 |
| Montenegro, A | 1 |
| Berkin, KE | 1 |
| Callender, JS | 1 |
| Weder, AB | 1 |
| Takiyyuddin, M | 1 |
| Sekkarie, MA | 1 |
| Lipson, JL | 1 |
| Klein, RC | 1 |
| Cherng, WJ | 1 |
| Yeh, SJ | 1 |
| van Zyl, AI | 1 |
| Jennings, AA | 1 |
| Bateman, ED | 1 |
| Strom, JA | 2 |
| Schoenberger, JA | 1 |
| Liebson, P | 1 |
| Poland, MP | 2 |
| Chrysant, C | 1 |
| Bal, IS | 1 |
| Trus, J | 1 |
| Hitchcock, A | 1 |
| Reams, GP | 1 |
| Bauer, JH | 1 |
| Mota, JC | 1 |
| Carrageta, MD | 1 |
| Felix, S | 1 |
| Nunes, AM | 1 |
| Jobbé-Duval, M | 1 |
| Viskoper, RJ | 1 |
| Laszt, A | 1 |
| Oren, S | 1 |
| Hochberg, Y | 1 |
| Villa, Y | 1 |
| Drexler, I | 1 |
| Bregman, L | 1 |
| Mishal, J | 1 |
| Kamenker, ES | 1 |
| Chikvashvili, IA | 1 |
| Pala, AM | 1 |
| Ricciardelli, D | 1 |
| Sanna, A | 1 |
| Vinattieri, MA | 1 |
| Härkönen, R | 2 |
| Hilden, M | 1 |
| Icen, R | 1 |
| Linna, M | 1 |
| Sillanpää, J | 1 |
| Vänskä, O | 1 |
| Lukkala, K | 1 |
| Birkenhäger, W | 1 |
| Demanet, JC | 1 |
| Groothold, G | 1 |
| Libretti, A | 2 |
| Mailland, F | 1 |
| Malacco, E | 1 |
| Poli, A | 1 |
| Bengtsson-Hasselgren, B | 1 |
| Moberg, L | 1 |
| Rönn, O | 1 |
| Chieppa, S | 1 |
| Lobascio, C | 1 |
| Brandini, V | 1 |
| Iarussi, D | 1 |
| Giuliani, F | 1 |
| Langella, S | 1 |
| De Simone, R | 1 |
| Ozgür, O | 1 |
| Duman, EL | 1 |
| Komsuoğlu, SS | 1 |
| Watari, H | 1 |
| Elving, LD | 1 |
| de Nobel, E | 1 |
| van Lier, HJ | 1 |
| Takahashi, H | 1 |
| Fukuyama, M | 1 |
| Yoneda, S | 1 |
| Okabayashi, H | 1 |
| Yoshimura, M | 1 |
| Präntare, H | 1 |
| Hvarfner, A | 1 |
| Ljunghall, S | 1 |
| Borhani, NO | 1 |
| Lakatos, E | 1 |
| Page, LB | 1 |
| Merli, IP | 1 |
| Antonicelli, R | 1 |
| Saccomanno, G | 1 |
| Gambini, C | 1 |
| Beretta-Piccoli, C | 2 |
| Amstein, R | 2 |
| Bertel, O | 2 |
| Follath, F | 2 |
| Reutter, F | 2 |
| Vallotton, MB | 2 |
| Galletti, F | 1 |
| Fasano, ML | 1 |
| Ferrara, LA | 1 |
| Groppi, A | 1 |
| Montagna, M | 1 |
| Mancini, M | 1 |
| Bugni, W | 1 |
| Atkins, J | 1 |
| Fouad-Tarazi, F | 1 |
| Cubbon, J | 1 |
| Kelly, R | 1 |
| Daley, J | 1 |
| Avolio, A | 1 |
| Gómez Marino, MA | 1 |
| Alonso Rodríguez, C | 1 |
| Gayán Laviña, R | 1 |
| Jiménez Ramos, A | 1 |
| Notghi, A | 1 |
| Riemersma, RA | 1 |
| Anderton, JL | 2 |
| Oliver, MF | 1 |
| Slagle, DA | 1 |
| Heer, K | 1 |
| Witte, K | 2 |
| Knorr, M | 2 |
| Frielingsdorf, J | 1 |
| Helgeland, A | 2 |
| Strømmen, R | 2 |
| Hagelund, CH | 2 |
| Tretli, S | 2 |
| Fujimoto, S | 1 |
| Dohi, Y | 1 |
| Aoki, K | 1 |
| Matsuda, T | 1 |
| Chalmers, JP | 2 |
| Southgate, DO | 1 |
| Elliott, JM | 1 |
| Beckman, S | 1 |
| Rogers, GG | 1 |
| Rosendorff, C | 1 |
| Goodman, C | 1 |
| Radford, HM | 1 |
| Gatteschi, C | 1 |
| Benemio, G | 1 |
| Boldrini, F | 1 |
| Guerrieri, M | 1 |
| Porcellati, C | 1 |
| Echeverriá, RF | 1 |
| Camacho, RO | 1 |
| Carbajal, HA | 1 |
| Mileo, HN | 1 |
| Salazar, MR | 1 |
| Riondet, B | 1 |
| Rodrigo, C | 1 |
| Carrageta, MO | 1 |
| Salvadeo, A | 2 |
| Segagni, S | 2 |
| Piazza, V | 1 |
| Picardi, L | 1 |
| Romano, M | 2 |
| Karoff, C | 1 |
| Losse, H | 1 |
| Fehske, KJ | 1 |
| Häcker, W | 1 |
| Frisk-Holmberg, M | 1 |
| Juhlin-Dannfelt, A | 1 |
| Lange Andersen, K | 2 |
| Piatkowski, W | 2 |
| Green, KA | 2 |
| Ottmann, W | 2 |
| Steinrauf, LK | 1 |
| Schulz, AR | 1 |
| Ryder, KW | 1 |
| Brunn, PW | 1 |
| Cook, D | 1 |
| Judy, W | 1 |
| Stumpe, K | 1 |
| Mathieu, M | 1 |
| Capone, P | 2 |
| Skoczeń, M | 1 |
| Jackson, PR | 1 |
| Ghosh, AK | 1 |
| Pupita, F | 1 |
| Ansuini, R | 1 |
| Belogi, M | 1 |
| Pupita, G | 1 |
| Gaggi, S | 1 |
| Lande, K | 1 |
| Frederichsen, P | 1 |
| Eide, IK | 1 |
| Roja, M | 1 |
| Cumetti, C | 1 |
| Vergani, A | 1 |
| Montanari, C | 1 |
| De Cristofaro, A | 1 |
| Epstein, M | 1 |
| Oster, JR | 1 |
| Lennard, MS | 2 |
| Tucker, GT | 1 |
| Silas, JH | 2 |
| Woods, HF | 1 |
| Dal Negro, RW | 1 |
| Zoccatelli, O | 1 |
| Pomari, C | 1 |
| Trevisan, F | 1 |
| Turco, P | 1 |
| Råstam, L | 1 |
| Jacob, RG | 2 |
| Shapiro, AP | 3 |
| Reeves, RA | 1 |
| Johnsen, AM | 2 |
| Coburn, PC | 1 |
| Goldstein, J | 1 |
| Zager, PG | 1 |
| Sutton, JM | 1 |
| Sirgo, MA | 2 |
| Plachetka, JR | 1 |
| Fairhurst, GJ | 1 |
| Thorp, JM | 3 |
| Desager, JP | 1 |
| Heller, F | 1 |
| Hulhoven, R | 1 |
| Frick, MH | 2 |
| Cox, DA | 2 |
| Huttunen, M | 2 |
| Pörsti, P | 2 |
| Pöyhönen, L | 2 |
| Pyykönen, ML | 3 |
| Reinikainen, P | 2 |
| Salmela, P | 2 |
| Ott, P | 1 |
| Storm, TL | 1 |
| Jensen, H | 1 |
| Badskjaer, J | 1 |
| Faergeman, O | 1 |
| Nash, DT | 1 |
| Schonfeld, G | 1 |
| Macdonald, IA | 1 |
| Broughton Pipkin, F | 1 |
| Baylis, PH | 1 |
| Roberts, DH | 2 |
| Tsao, Y | 2 |
| Grimmer, SF | 1 |
| Winstanley, PA | 1 |
| Orme, ML | 1 |
| Breckenridge, AM | 1 |
| Colnago, R | 1 |
| Meregalli, M | 1 |
| Turri, D | 1 |
| Nazzari, M | 1 |
| Fiorella, G | 1 |
| Guffanti, EE | 1 |
| Mazzola, C | 1 |
| McLoughlin, GA | 1 |
| Breckenridge, A | 1 |
| Herpin, D | 2 |
| Boutaud, P | 2 |
| Ciber, MA | 2 |
| Amiel, A | 2 |
| Demange, J | 2 |
| Fodor, JG | 1 |
| Chockalingam, A | 1 |
| Drover, A | 1 |
| Fifield, F | 1 |
| Pauls, CJ | 1 |
| Norris, RJ | 1 |
| Domino, JV | 1 |
| Hogan, LB | 1 |
| Citron, DC | 1 |
| Barker, AH | 1 |
| Stone, JG | 2 |
| Foëx, P | 2 |
| Sear, JW | 2 |
| Johnson, LL | 2 |
| Khambatta, HJ | 2 |
| Triner, L | 2 |
| Madden, DJ | 3 |
| Streufert, S | 1 |
| DePadova, A | 1 |
| McGlynn, T | 1 |
| Pogash, R | 1 |
| Piasecki, M | 1 |
| McLenachan, JM | 1 |
| Henderson, E | 1 |
| Lamon, KD | 1 |
| Vatle, S | 1 |
| Giorgi, G | 1 |
| Legramante, JM | 1 |
| Fioravanti, G | 1 |
| Paies, G | 1 |
| Legramante, A | 1 |
| Ioannides, C | 1 |
| Johnston, A | 1 |
| Contursi, V | 2 |
| Saracino, E | 1 |
| Ricapito, M | 2 |
| Di Lecce, G | 1 |
| Sampieri, L | 1 |
| Rupoli, L | 1 |
| Fruscio, M | 1 |
| Gradnik, R | 1 |
| Benedetti, TJ | 1 |
| Schmucker, BC | 1 |
| Carlson, KL | 1 |
| Cullinane, EM | 1 |
| Nugent, AM | 1 |
| Sady, MA | 1 |
| Sady, SP | 1 |
| Superko, HR | 1 |
| Wood, PD | 1 |
| Krauss, RM | 1 |
| Kwan, CM | 2 |
| Johnson, J | 2 |
| Taylor, WF | 2 |
| Brockway, BA | 1 |
| Itskovitz, HD | 1 |
| Krug, K | 1 |
| Khoury, S | 1 |
| Mollura, JL | 1 |
| Schimmel, MS | 1 |
| Eidelman, AI | 1 |
| Wilschanski, MA | 1 |
| Shaw, D | 1 |
| Ogilvie, RJ | 1 |
| Koren, G | 1 |
| Schmimmel, MS | 1 |
| Eidelman, AJ | 1 |
| Halttunen, P | 1 |
| Baez, MA | 1 |
| Garg, DC | 1 |
| Jallad, NS | 1 |
| Saraste, M | 2 |
| Niittymäki, K | 1 |
| Marniemi, J | 1 |
| Leader, JP | 1 |
| Milson, JA | 1 |
| Singleton, W | 1 |
| Towle, AC | 1 |
| Pettersson, A | 1 |
| Persson, B | 1 |
| Wysocki, M | 1 |
| Andersson, OK | 1 |
| Vogt, M | 1 |
| Ott, B | 1 |
| Rupp, H | 1 |
| Jacob, R | 1 |
| Sen, S | 1 |
| Faulkner, JK | 1 |
| Karjalainen, U | 1 |
| Ventura, HO | 1 |
| Kobrin, I | 1 |
| Mohallen, KL | 1 |
| do Patrocínio, LL | 1 |
| Célnik, D | 1 |
| Kruczan, DD | 1 |
| Pinheiro, L | 1 |
| Weitzel, LH | 1 |
| Bosco, J | 1 |
| Sekeff, JA | 1 |
| Azevedo, Ade C | 1 |
| Lehmann, P | 1 |
| Hölzle, E | 1 |
| Plewig, G | 1 |
| Hanretty, KP | 1 |
| Whittle, MJ | 1 |
| Hosie, J | 2 |
| Frithz, G | 1 |
| Scafidi, V | 1 |
| Fallo, F | 1 |
| Pisani, G | 1 |
| Mantero, F | 1 |
| Pascoe, J | 1 |
| Moon, R | 1 |
| Gray, D | 1 |
| Musgrove, J | 1 |
| Trafford, J | 1 |
| Burgess, J | 1 |
| Richardson, PJ | 2 |
| Davidson, C | 1 |
| Fairhurst, G | 1 |
| Vandenburg, MJ | 1 |
| Cooper, WD | 1 |
| Lichter, I | 1 |
| Wyke, MA | 1 |
| Parag, KB | 1 |
| Alicandri, C | 1 |
| Fariello, R | 1 |
| Boni, E | 1 |
| Zaninelli, A | 1 |
| Muiesan, G | 1 |
| Locher, R | 1 |
| Nakaoka, H | 1 |
| Kitahara, Y | 1 |
| Amano, M | 1 |
| Imataka, K | 1 |
| Fujii, J | 1 |
| Ishibashi, M | 1 |
| Yamaji, T | 1 |
| Török, E | 1 |
| Wagner, M | 1 |
| Podmaniczky, M | 1 |
| van den Meiracker, AH | 1 |
| Man in 't Veld, AJ | 1 |
| van Eck, HJ | 1 |
| Boomsma, F | 1 |
| Stanley, NN | 3 |
| Thirkettle, JL | 2 |
| Varma, MP | 2 |
| Larkin, H | 2 |
| Heath, ID | 2 |
| Chandra, M | 1 |
| Misra, R | 1 |
| Kumar, A | 1 |
| Singh, SP | 1 |
| Pandeya, SN | 1 |
| Curry, RC | 1 |
| Schwartz, KM | 1 |
| Urban, PL | 1 |
| van der Byl, KV | 1 |
| Nami, R | 1 |
| Martinelli, M | 1 |
| Gennari, C | 1 |
| Tripodi, G | 1 |
| Pati, P | 1 |
| Alberghini, E | 1 |
| De Backer, G | 1 |
| Guillard, O | 1 |
| Piriou, A | 1 |
| Krantz, DS | 2 |
| Light, KC | 2 |
| McKee, DC | 2 |
| Warrender, TS | 1 |
| Tominaga, T | 1 |
| Kumagai, H | 1 |
| De Simone, A | 1 |
| Galva, MD | 1 |
| Förster, E | 1 |
| Wehling, M | 2 |
| Galderisi, M | 1 |
| Villari, B | 1 |
| Santomauro, M | 1 |
| Miller, ST | 1 |
| Howard, PJ | 1 |
| Lee, MR | 1 |
| Torrens, DJ | 1 |
| Almkvist, G | 1 |
| Larsson, C | 1 |
| Lorentzon, S | 1 |
| Nilsson, D | 1 |
| Nygaard-Pedersen, L | 1 |
| Trap-Jensen, J | 1 |
| Lepira, B | 1 |
| Tshiani, K | 1 |
| Holtzman, JL | 2 |
| Kaihlanen, PM | 1 |
| Rider, JA | 1 |
| Lewin, AJ | 1 |
| Spindler, JS | 1 |
| Oberlin, JA | 1 |
| Gimeno Gascón, JV | 1 |
| Olague de Ros, J | 1 |
| Ferrer Reig, J | 1 |
| Hernandez Martinez, M | 1 |
| Bordes Siscar, P | 1 |
| Serra Flores, J | 1 |
| Estruch Catala, G | 1 |
| Algarra Vidal, FJ | 1 |
| Gengo, FM | 1 |
| Fagan, SC | 1 |
| de Padova, A | 1 |
| Miller, JK | 1 |
| Kinkel, PR | 1 |
| Vallance, BD | 1 |
| Crowe, PF | 2 |
| Mittra, B | 1 |
| Brismar, K | 1 |
| Hylander, B | 2 |
| Lee, DD | 1 |
| DeQuattro, V | 1 |
| Allen, J | 1 |
| Kimura, S | 1 |
| Aleman, E | 1 |
| Konugres, G | 1 |
| Davison, G | 1 |
| Mahajan, V | 1 |
| Puri, R | 1 |
| Gattani, RK | 1 |
| Chatterji, T | 1 |
| Gröhn, P | 1 |
| Heikkilä, J | 1 |
| Hämäläinen, L | 1 |
| Idänpään-Heikkilä, U | 1 |
| Rytkönen, U | 1 |
| Setälä, M | 1 |
| Carey, M | 1 |
| Josselson, J | 1 |
| Giard, MJ | 1 |
| Warren, JB | 1 |
| Posner, JN | 1 |
| Lam, YW | 1 |
| Zaske, DE | 1 |
| Schamaun, O | 1 |
| Qvigstad, EK | 1 |
| Teisberg, P | 1 |
| Petrella, V | 1 |
| Philip, IG | 1 |
| Qureshi, SM | 1 |
| Richards, HH | 1 |
| Sharma, SK | 1 |
| Wright, FG | 1 |
| Rowley-Jones, D | 1 |
| Potter, JF | 1 |
| Cook, ME | 1 |
| Wallin, JD | 1 |
| Clifton, GG | 1 |
| Poland, M | 1 |
| Simon, J | 1 |
| Fruergaard, P | 1 |
| Rees-Jones, DI | 1 |
| de Boo, T | 1 |
| Lemmens, WA | 1 |
| Reyenga, J | 1 |
| Marler, MR | 1 |
| Lehoczky, JP | 1 |
| Moroni, G | 1 |
| Poggio, F | 1 |
| Toth, PD | 1 |
| Demeter, RJ | 1 |
| Woods, JR | 1 |
| Nyhuis, AW | 1 |
| Judy, WV | 1 |
| Constantine, G | 1 |
| Reynolds, AL | 1 |
| Luesley, DM | 1 |
| Favilla, S | 1 |
| Tucker, FA | 1 |
| Shore, AC | 1 |
| Higgins, TJ | 1 |
| Zacharias, FM | 2 |
| Neusy, AJ | 1 |
| Lowenstein, J | 1 |
| Escudero, J | 1 |
| Hernandez, H | 1 |
| Martinez, F | 1 |
| Capra, A | 2 |
| Daniels, AR | 1 |
| Fiocchi, R | 1 |
| Rowland, M | 1 |
| Adam, G | 1 |
| MacFarlane, E | 1 |
| Jackson, PG | 1 |
| Jespersen, CM | 1 |
| Jørgensen, PH | 1 |
| Krogsgaard, AR | 1 |
| Friis, T | 1 |
| Olofsson, P | 1 |
| Sartor, G | 1 |
| Franchi, F | 1 |
| Bisi, G | 1 |
| Fabbri, G | 1 |
| Pedenovi, P | 1 |
| Lo Sapio, P | 1 |
| Matassi, L | 1 |
| Righi, D | 1 |
| Galanti, G | 1 |
| Weisweiler, P | 1 |
| Lischner, M | 1 |
| Jutrin, I | 2 |
| Ravid, M | 2 |
| Magalhães, LB | 1 |
| Guimarães, AC | 1 |
| Giannola, A | 2 |
| Immordino, R | 2 |
| Roulston, JE | 1 |
| Wathen, CG | 3 |
| Lingman, G | 1 |
| Sabanathan, K | 1 |
| Adam, HK | 1 |
| Ryan, J | 1 |
| Edwards, KG | 2 |
| Saul, PA | 1 |
| Wright, FW | 1 |
| Maxwell, MH | 1 |
| Garrett, BN | 1 |
| Bailey, BP | 1 |
| Duggin, GG | 1 |
| Hall, B | 1 |
| Tiller, D | 1 |
| Theisen, K | 1 |
| Thachil, J | 1 |
| Zeller, JR | 1 |
| Sörman, AE | 1 |
| Parnell, L | 1 |
| Boström, PA | 1 |
| Janzon, L | 1 |
| Westergren, A | 1 |
| Välimäki, M | 1 |
| Maass, L | 1 |
| Harno, K | 1 |
| Nikkilä, EA | 1 |
| Borghi, C | 1 |
| Mussi, A | 1 |
| Petrelli, G | 1 |
| Bovenzi, F | 1 |
| Baker, LH | 1 |
| Gouet, D | 1 |
| Marechaud, R | 1 |
| Aucouturier, P | 1 |
| Touchard, G | 1 |
| Sudre, Y | 1 |
| Preud'homme, JL | 1 |
| Abe, K | 1 |
| Sato, M | 1 |
| Kasai, Y | 1 |
| Sato, K | 1 |
| Omata, K | 1 |
| Sasaki, S | 1 |
| Nihei, M | 1 |
| Sekino, H | 1 |
| Yoshinaga, K | 1 |
| Finley, D | 1 |
| Johnson, B | 1 |
| Berry, DA | 1 |
| Traub, YM | 1 |
| Boner, G | 1 |
| Rosenfeld, JB | 1 |
| Kramer, BA | 1 |
| Rebagliati, M | 1 |
| Sanderson, JE | 1 |
| De Kock, M | 1 |
| Robert, A | 1 |
| Beckers, C | 1 |
| Wu, SC | 1 |
| Secchi, MB | 1 |
| Mancarella, S | 1 |
| Bettazzi, L | 1 |
| Civelli, M | 1 |
| Cirò, A | 1 |
| Oltrona, L | 1 |
| Folli, G | 1 |
| Budriesi, N | 1 |
| Adalio, G | 1 |
| Zamboni, A | 1 |
| Turina, MC | 1 |
| Patterson, JF | 1 |
| La Vecchia, M | 1 |
| Vergara, G | 1 |
| Iannuzzi, G | 1 |
| Simonetti, A | 1 |
| Cimmino, G | 1 |
| Saulino, C | 1 |
| Novelli Genuino, G | 1 |
| Valerio, V | 1 |
| Grimaldi, A | 1 |
| Balestrazzi, M | 1 |
| Chiarappa, R | 1 |
| Avantaggiato, F | 1 |
| Backhouse, CI | 1 |
| Catalano, M | 1 |
| Koh, H | 1 |
| Nambu, S | 1 |
| Ikeda, M | 1 |
| Webb, DJ | 1 |
| Hutcheson, MJ | 1 |
| Nurmi, AK | 1 |
| Seppälä, E | 1 |
| Wojciechowska, M | 1 |
| Delsignore, R | 1 |
| Baroni, MC | 1 |
| Mineo, F | 1 |
| Crotti, G | 1 |
| Butturini, U | 1 |
| Campana, C | 1 |
| Ferrario, M | 1 |
| Tondi, C | 1 |
| Montemartini, C | 1 |
| Ikäheimo, M | 1 |
| Kale, PA | 1 |
| Soman, RN | 1 |
| Hannan, WJ | 2 |
| Jee, LD | 1 |
| Dalton, DW | 1 |
| Westerman, RF | 1 |
| Schouten, JA | 1 |
| Hengeveld, WL | 1 |
| Wouda, AA | 1 |
| Napier, RN | 1 |
| Kaijser, L | 1 |
| McLean, AJ | 1 |
| Knight, R | 1 |
| Harrison, PM | 1 |
| Harper, RW | 1 |
| Gullotti, D | 1 |
| Overlack, A | 1 |
| Ferguson, RJ | 1 |
| Turnbull, LW | 1 |
| Campbell, BC | 1 |
| Freestone, S | 1 |
| Marmur, A | 1 |
| Berkovitch, Y | 1 |
| Cardonne, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension[NCT01762436] | Phase 4 | 109 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Hypertension in Hemodialysis Patients[NCT00582114] | Phase 3 | 200 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Stopped by data safety monitoring board) | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension[NCT00262236] | Phase 3 | 693 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865] | Phase 4 | 50 participants (Actual) | Interventional | 2010-03-31 | Terminated (stopped due to The participants signed an old version of the informed consent.) | ||
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension[NCT00380289] | 66 participants | Interventional | 2006-09-30 | Recruiting | |||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease[NCT01932450] | Phase 2 | 100 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine[NCT00564057] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234] | Phase 4 | 32 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients[NCT01502787] | Phase 4 | 46 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events[NCT03223441] | 543 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Longitudinal Change of Arterial Stiffness Indices in Relation to Ambulatory Aortic and Branchial Pressure in Long Term Peritoneal Dialysis Patients[NCT03607747] | 40 participants (Anticipated) | Observational | 2018-07-18 | Recruiting | |||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries[NCT01480791] | Phase 2 | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn (stopped due to Because of results of Altitude trial, this trial was cancelled.) | ||
| A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension[NCT00147563] | Phase 4 | 34 participants | Interventional | 2003-10-31 | Completed | ||
| Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study[NCT06098300] | 30 participants (Anticipated) | Observational | 2023-09-01 | Recruiting | |||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension[NCT01996449] | Phase 2 | 14 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| A Multicenter Randomized Controlled Trial of Exercise in Aortic Dissection Survivors[NCT05610462] | 126 participants (Anticipated) | Interventional | 2023-01-01 | Active, not recruiting | |||
| Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity[NCT01044693] | 20 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients[NCT01501929] | Phase 4 | 32 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108] | 200 participants (Anticipated) | Observational | 2018-02-24 | Recruiting | |||
| Hypertension Prevalence, Treatment Patterns and Outcomes in Long-Term Care Facilities[NCT03046420] | 139 participants (Actual) | Observational | 2017-01-26 | Completed | |||
| Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial[NCT03015311] | 8,000 participants (Anticipated) | Interventional | 2017-01-15 | Active, not recruiting | |||
| Methodological Improvement in Measuring Efficacy Outcome in Antihypertensive Trials in Children[NCT01070342] | 170 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death. (NCT00582114)
Timeframe: 1 yr
| Intervention | events/100 patient-years (Number) | |||
|---|---|---|---|---|
| Incidence rate, cardiovasular events | Incidence rate, combined MI, stroke, CHF, CV death | Incidence rate, congest heart failure | Incidence rate, all-cause hospitalizations | |
| Atenolol | 24.6 | 13.5 | 6.2 | 89.9 |
| Lisinopril | 58 | 31 | 20.2 | 144.3 |
The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data. (NCT00582114)
Timeframe: Baseline, 6 months, 12 months
| Intervention | g/m^2 (Mean) | |
|---|---|---|
| LVMI Change from baseline, 6 months | LVMI Change from baseline, 12 months | |
| Atenolol | -8.4 | -21.5 |
| Lisinopril | -3.4 | -15.1 |
Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -0.66 |
| Metoprolol | -2.35 |
The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 2.16 |
| Metoprolol | 10.43 |
"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -1.07 |
| Metoprolol | -3.19 |
Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | -8.14 |
| Metoprolol | 8.70 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol < 50 Years Old | 51.55 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: Baseline and Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol <50 Year Old | 51.55 |
| Metoprolol >/= 50 Year Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol >/=50 Years Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: 12 Months
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Nebivolol | 50.07 |
| Metoprolol | 38.13 |
Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 11.47 |
| Metoprolol | -17.27 |
Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -2.65 |
| Metoprolol | -3.88 |
(NCT01502787)
Timeframe: 12 weeks after initiation of metoprolol
| Intervention | mmHg (Mean) |
|---|---|
| Metoprolol | 114 |
| Nebivolol | 113 |
(NCT01502787)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Initial Treatment With Metoprolol | 101 |
| Initial Treatment With Nebivolol | 103 |
(NCT01502787)
Timeframe: 12 weeks after each specified medication
| Intervention | ml/min (Mean) |
|---|---|
| First Intervention Metoprolol: 12 Weeks | 96 |
| Second Intervention Nebivolol: 24 Weeks | 105 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 41 |
| Eplerenone | 43.8 |
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 47 |
| Eplerenone | 51 |
Change from baseline (8 pm) in heart rate at the time of maximal BP-lowering effect (NCT01044693)
Timeframe: 8 pm - 8 am
| Intervention | bpm (Mean) |
|---|---|
| Placebo Capsule | -3 |
| Nebivolol 5 mg | -6 |
| Metoprolol Tartrate 50 mg | -6 |
| Sildenafil 25 mg | 0 |
Nocturnal sodium excretion was defined as the ratio of urinary sodium to urinary creatinine. (NCT01044693)
Timeframe: 8 pm - 8 am
| Intervention | mEq/mg (Mean) |
|---|---|
| Placebo Capsule | 0.145 |
| Nebivolol 5 mg | 0.127 |
| Metoprolol Tartrate 50 mg | 0.139 |
| Sildenafil 25 mg | 0.125 |
Orthostatic tolerance was defined as the area under the curve of standing systolic blood pressure calculated by the trapezoidal rule (upright systolic blood pressure multiplied by standing time) during a 10-minute standing test (NCT01044693)
Timeframe: 10 min standing
| Intervention | mm Hg*min (Mean) |
|---|---|
| Placebo Capsule | 594 |
| Nebivolol 5 mg | 675 |
| Metoprolol Tartrate 50 mg | 696 |
| Sildenafil 25 mg | 575 |
Maximal change from baseline in systolic blood pressure, measured from 8 pm to 8 am, after a single dose of the intervention (NCT01044693)
Timeframe: 8 pm - 8 am
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline supine at 8 pm | Change in systolic BP | |
| Metoprolol Tartrate 50 mg | 157 | -7 |
| Nebivolol 5 mg | 162 | -24 |
| Placebo Capsule | 154 | 1 |
| Sildenafil 25 mg | 158 | -20 |
Endothelial cell (EC) was collected after a 20-guage angiocatheter was inserted into the contralateral forearm vein under sterile conditions. Three J-shaped vascular guidewires (St. Jude, St. Paul, MN) were advanced sequentially into the vein up to 10 cm. Endothelial cells were collected by gentle abrasion and placed into a dissociation buffer (0.5% bovine serum albumin, 2mM EDTA, and 100 ug/ml heparin in PBS). Endothelial cells were recovered from the tips of guide wires by repeated washing into collection tubes and subsequent centrifugation. EC were incubated with monoclonal antibodies against the polyclonal antibodies against NADPH oxidase p47 subunit. The intensity of staining was measured using fluorescence microscopy. (NCT01501929)
Timeframe: 12 weeks
| Intervention | Ratio human to HUVEC p47Phox expression (Mean) |
|---|---|
| Metoprolol | 0.47 |
| Nebivolol | 0.44 |
Microvascular perfusion of skeletal muscle were measured during handgrip at 20 cycle per minute after 12 weeks of metoprolol, and after 12 weeks of nebivolol (NCT01501929)
Timeframe: 12 weeks
| Intervention | video intensity units/ second (Median) |
|---|---|
| Metoprolol | 43.938 |
| Nebivolol | 74.584 |
96 reviews available for atenolol and Blood Pressure, High
| Article | Year |
|---|---|
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Comorbidity | 2022 |
Genome-Wide Meta-Analysis of Blood Pressure Response to β
Topics: ADP-ribosyl Cyclase; Adrenergic beta-1 Receptor Antagonists; Antigens, CD; Atenolol; Bisoprolol; Bla | 2019 |
Systolic and diastolic hypertension among patients on hemodialysis: Musings on volume overload, arterial stiffness, and erythropoietin.
Topics: Atenolol; Diastole; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Humans; Hypertension; I | 2019 |
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Heart R | 2017 |
Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis.
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Atenolol; Coronary Disease; Human | 2017 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
β-blockers: a review of their pharmacological and physiological diversity in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Carbazo | 2014 |
Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Calcium Channel Blockers; Canada; Humans; | 2014 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2017 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Humans; H | 2008 |
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 1995 |
Beta-adrenergic antagonists in hypertension: a review of the evidence.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovasc | 2009 |
[Diagnosis and choice of therapy of arterial hypertension].
Topics: Antihypertensive Agents; Atenolol; Dementia, Vascular; Diagnosis, Differential; Female; Hemodynamics | 2010 |
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Biomarkers; Carbazoles; Car | 2012 |
The evolving role of β-adrenergic receptor blockers in managing hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Cardiac Output; Cardiovascular Dise | 2012 |
Syphilitic aortic aneurysm with spastic paraparesis: a novel presentation and review of the literature.
Topics: Aorta, Thoracic; Aortic Aneurysm, Thoracic; Atenolol; Disease Outbreaks; Disease Progression; Drug T | 2012 |
Beta-blockers for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2012 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Combination therapy as first-line treatment of arterial hypertension.
Topics: Antihypertensive Agents; Atenolol; Captopril; Diltiazem; Drug Therapy, Combination; Humans; Hydrochl | 2002 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
[Arterial stiffness, wave reflections and myocardial protection: the REASON project].
Topics: Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diastole; Drug Combinations; Humans; Hy | 2003 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
[Old or new antihypertensives--which are better?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensi | 2005 |
Clinical inquiries. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diabetic N | 2005 |
[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2005 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Will ASCOT change the form of anti-hypertensive therapy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2006 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
[Low density lipoprotein receptor gene].
Topics: Animals; Atenolol; Humans; Hypertension; Male; Mice; Mice, Knockout; Mutation; Polymorphism, Single | 2006 |
Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Capillaries; Clinic | 2006 |
Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Treatment Outcome | 2007 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Clinical inquiries. Are there big differences among beta-blockers in treating essential hypertension?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Dose-R | 2007 |
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index; Diab | 2007 |
Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blo | 2008 |
beta-Adrenoceptor antagonists: new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Glaucoma; Humans; Hypertension; Kinetics; Me | 1981 |
[Hemodynamic changes caused by beta-blocking agents with and without intrinsic sympathicomimetic activity and with and without cardioselective activity. Comparison of hypertensives at fixed and variable frequencies].
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Hemodynamics; Humans; Hypertension; Male; Metoprolol; | 1982 |
Comparative review of beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Atenolol; Humans; Hypertension; | 1984 |
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
[Course of hypertension and the potentials for regression].
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiomegaly; Diuretics; Heart; Humans; | 1982 |
Type A behaviour: recent developments.
Topics: Amiloride; Atenolol; Behavior Therapy; Benzothiadiazines; Cognition; Coronary Disease; Diuretics; Dr | 1984 |
Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Humans; Hypertension; Kinetics; Propanolamines; Ti | 1982 |
Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor.
Topics: Animals; Atenolol; Cilazapril; Clinical Trials as Topic; Humans; Hypertension; Vascular Resistance | 1995 |
Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Clonidine; Humans; Hypertension; Imidaz | 1995 |
Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
Topics: Adult; Aged; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Vessels; Cilazapril; | 1994 |
[Pharmacology and clinical use of a fixed combination of nifedipine and slow release atenolol (Niften) in the treatment of arterial hypertension and angina pectoris].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Calcium Channel Blockers; Delayed-Action Pre | 1993 |
Managing the older patient with hypertension.
Topics: Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Atenolol; Delayed-Action Preparations; Dilt | 1993 |
[Atresia of the aortic arch. A rare cause of asymmetrical arterial hypertension in adulthood].
Topics: Adrenergic beta-Antagonists; Angiography, Digital Subtraction; Antihypertensive Agents; Aorta, Thora | 1996 |
[Atenolol in treatment of patients with airway obstruction].
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Atenolol; Cardiovascular Diseases; Coronary Disease | 1996 |
Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arterioles; Atenolol; Blood Pressure; Calcium Channel Bloc | 1997 |
Treatment with beta-blockers--the value of an even plasma concentration over 24 h.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure | 1997 |
[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Dose-Respo | 1998 |
Irbesartan treatment in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Ena | 1998 |
[Edema and skin ulcers of the lower limbs as a collateral effect of nifedipine. A clinical case report].
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chronic Disease; | 1999 |
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1999 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Blood Pressure; C | 2000 |
[Intensive treatment of blood pressure in patients with kidney disease and proteinuria].
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Drug; Enalapril; Glom | 2000 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
Warfarin therapy for an octogenarian who has atrial fibrillation.
Topics: Aged; Aged, 80 and over; Analgesics; Anticoagulants; Antihypertensive Agents; Atenolol; Atrial Fibri | 2001 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
Beta-blocking agents in heart failure: modern concepts and overview.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Disease; Heart Failure; Hemodynamics; Human | 1990 |
Beta-blockade and brachial artery hemodynamics in hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Bisoprolol; Brachial Artery; Forearm; Humans; Hypert | 1990 |
Primary prevention with beta-blockade in patients with hypertension: review of results and clinical implications.
Topics: Adrenergic beta-Antagonists; Atenolol; Benzothiadiazines; Clinical Trials as Topic; Data Interpretat | 1990 |
Ask the Doctor. I take a beta blocker called atenolol and an ACE inhibitor every morning for my hypertension. When I get up in the morning, my blood pressure is high, but falls as the day goes on. It seems like it s always pretty good by the time I see my
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure Determin | 2001 |
[Results from the LIFE study: promising effects of new hypertensive agents].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Humans; Hyper | 2002 |
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benz | 2002 |
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Atenolol; Central Nervous System; Hemodynamic | 1979 |
[Cardiac function in hypertension].
Topics: Atenolol; Cardiomegaly; Coronary Disease; Digitalis Glycosides; Heart Function Tests; Heart Valve Di | 1978 |
[The sympathetic nervous system and essential hypertension].
Topics: Atenolol; Catecholamines; Clonidine; Guanethidine; Humans; Hypertension; Methyldopa; Norepinephrine; | 1979 |
Beta blockers and quality of life.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium; Cholinesterase Inhibitors; Humans; Hypertension; Pro | 1992 |
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Dis | 1992 |
Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Systolic hypertension in older persons.
Topics: Aged; Aging; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; | 1992 |
The treatment of moderate to severe hypertension with ACE inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug Therapy, Co | 1990 |
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Drug Evaluation; Humans; Hypertension | 1991 |
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Double-Blind Method; Glucose; Humans; | 1991 |
ACE-inhibitors and quality of life.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Enalapril; Health Status | 1990 |
An atenolol/nifedipine tablet for hypertension--useful or not?
Topics: Atenolol; Drug Combinations; Humans; Hypertension; Nifedipine | 1989 |
Behaviour and hypertension: a pathophysiological puzzle.
Topics: Arousal; Atenolol; Autonomic Nervous System; Blood Pressure; Clonidine; Humans; Hypertension; Muscle | 1989 |
Hypertension and beta-blockers. Are they all the same?
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Labet | 1985 |
[Beta-blockaders in the treatment of hypertension in pregnancy].
Topics: Adrenergic beta-Antagonists; Atenolol; Drug Evaluation; Female; Humans; Hypertension; Metoprolol; Ox | 1985 |
Beta blockers and renal function: a reappraisal.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Urea Nitrogen; Cardiac Output; Creatinine; Dog | 1985 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
[Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension].
Topics: Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Ag | 1988 |
Effects of smoking on the heart and peripheral circulation.
Topics: Atenolol; Blood Pressure; Coronary Circulation; Heart Rate; Humans; Hypertension; Propranolol; Regio | 1988 |
1021 trials available for atenolol and Blood Pressure, High
| Article | Year |
|---|---|
Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension.
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind | 2021 |
Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study.
Topics: Atenolol; Atrial Fibrillation; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2023 |
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aldehyde Dehydrogenase 1 Family; Angiotensin-C | 2017 |
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Humans; Hypertension; Hypertro | 2017 |
The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Humans; Hypertension; Losartan; Mal | 2018 |
Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cerebrovascular Circulation; Double-Bli | 2018 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Fil | 2016 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; | 2018 |
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; | 2019 |
Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Carotid Artery Diseases; Dihydro | 2019 |
β
Topics: Adrenergic beta-Antagonists; Alleles; Atenolol; Black People; Female; Genotype; Heart Rate; Heterotr | 2019 |
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Humans; H | 2014 |
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Blood Pres | 2014 |
A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Atenolol; Baroreflex; Bisoprolol; Essential Hyper | 2013 |
Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Double-Blind Method; Es | 2014 |
Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2013 |
Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
Topics: Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Drug Monitoring; Female; Hot Flashes | 2014 |
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Drug Therapy, | 2014 |
Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hyperten | 2014 |
Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlor | 2014 |
Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; | 2014 |
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Early Termination of Clinical T | 2014 |
Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Brachia | 2014 |
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Female; Humans; | 2014 |
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amino Acids; Atenolol; Blood Glucose; Diabetes | 2014 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme In | 2015 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
A multicentric double blind randomised controlled trial of atenolol versus losartan as first line drug for mild to moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Ambulatory; Double-Blind Method | 2013 |
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Coh | 2014 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
Topics: Adult; Aged; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure Monitoring, Ambulatory; Early | 2015 |
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; E | 2015 |
Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2016 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Treating hypertension in hemodialysis improves symptoms seemingly unrelated to volume excess.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Volume; Body Weight; Female; Humans; Hypert | 2016 |
[No antihypertensive drugs for frail elderly?].
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cause of Death; Ch | 2016 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Fem | 2017 |
Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Aged; Amiloride; Antihypertensive Agents; Ateno | 2016 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Cerebrovascular support for cognitive processing in hypertensive patients is altered by blood pressure treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibi | 2008 |
Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Diastole; Echocardiography, Doppler; Et | 2008 |
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Confidence Intervals; Coronary Disease; Dose-Response R | 2008 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol | 2008 |
Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amidohydrolases; Antihypertensive Agents; Arginine; Atenolol; Ben | 2008 |
Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Biomar | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Atenolol; Blood Pressure; Demography; Dias | 2008 |
Brain imaging findings predict blood pressure response to pharmacological treatment.
Topics: Aging; Antihypertensive Agents; Atenolol; Blood Pressure; Brain; Cerebrovascular Circulation; Cognit | 2008 |
Changes in serum potassium mediate thiazide-induced diabetes.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; | 2008 |
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
Topics: Adiponectin; Antihypertensive Agents; Atenolol; C-Reactive Protein; Double-Blind Method; Female; Fin | 2008 |
Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Asian People; Atenolol; Blood Pressure; Captopril; China; Dela | 2008 |
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
Topics: Adipokines; Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2010 |
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocard | 2009 |
A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Algorithms; Angiotensin-Converting Enzyme Inhi | 2008 |
Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Carotid | 2007 |
[Atenolol and metoprolol differentiated therapy of patients with arterial hypertension complicated by pathology of the digestive tract organs].
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bradycardi | 2008 |
Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study.
Topics: Aged; Antihypertensive Agents; Aortic Diseases; Atenolol; Blood Pressure; Double-Blind Method; Drug | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressur | 2009 |
Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients.
Topics: Adult; Antihypertensive Agents; Atenolol; Brachial Artery; Drug Combinations; Female; Humans; Hypert | 2009 |
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Fem | 2009 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2009 |
The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Comorbidity; Echocardiography, D | 2009 |
Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Arteries; Atenolol; Bendr | 2009 |
Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Topics: Aged; Amlodipine; Atenolol; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female | 2009 |
Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Dose-Response Relation | 2009 |
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Echocardiography; Female; Humans; Hypertens | 2009 |
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Topics: Adult; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Drug Administration Schedule | 2009 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial A | 2009 |
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2009 |
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Europe; | 2009 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2008 |
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Double-Blind M | 2010 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
[An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study].
Topics: Administration, Oral; Adolescent; Adult; Amlodipine; Atenolol; Blood Pressure; Dose-Response Relatio | 2009 |
[Echocardiography of left ventricular mass in patients with essential hypertension].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Double-Blind Met | 2009 |
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Fem | 2009 |
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Press | 2010 |
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood | 2010 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
Brain function, cognition, and the blood pressure response to pharmacological treatment.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brain; Brain Mapping; Cerebrovascular Circulation | 2010 |
Atenolol exposure and risk for development of adverse metabolic effects: a pilot study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Female; Glucose Tolerance | 2010 |
How to avoid discontinuation of antihypertensive treatment: The experience in São Paulo, Brazil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Calcium Channel Blockers | 2010 |
Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery | 2011 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography | 2011 |
Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Boston; C | 2011 |
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug T | 2011 |
Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Biomarkers; Collagen; Coll | 2011 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2011 |
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
Topics: Aged; Algorithms; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Diuretics; Dru | 2011 |
Effects of preoperative oral beta blocker versus intraoperative nitroprusside or esmolol on quality of surgical field during tympanoplasty.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Blood Pressure; Doubl | 2011 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation | 2012 |
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Drug Ther | 2012 |
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Arte | 2011 |
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyd | 2012 |
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2012 |
A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension.
Topics: Adult; Aged; Amiloride; Atenolol; Blood Glucose; Blood Pressure Determination; Cross-Over Studies; D | 2012 |
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hemodynamics; Humans; Hypertension; | 2012 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertens | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Bl | 2012 |
Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blo | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Oxidative stress-associated hypertension in surgically induced brain injury patients: effects of β-blocker and angiotensin-converting enzyme inhibitor.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 2013 |
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Topics: Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Female; Genetic Loci; Genetic Predi | 2012 |
Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Topics: Adult; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Blood Pressure Determi | 2002 |
Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Double-Blind Method; Female; | 2002 |
Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Benzopyrans; Blood Pressure; | 2002 |
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Fema | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Pr | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Adult; Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atenolol; Biphenyl Compounds; B | 2002 |
[Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study].
Topics: Atenolol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemodynamics; Humans; Hyperte | 2002 |
Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2002 |
Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
[Effects of terazosine and atenolol on serum lipids in essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Ate | 2002 |
Metabolic effects of combined antihypertensive treatment in patients with essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Cholesterol; Double-Blind Method; Drug Administrat | 2002 |
Chronic hypertension in pregnancy.
Topics: Atenolol; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; F | 2002 |
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
Topics: Aldosterone; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Confounding Factors, | 2002 |
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular | 2002 |
Different drug classes have variable effects on blood pressure depending on the time of day.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circ | 2003 |
Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Atenolol; Blood Glucose; Blood | 2003 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2003 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2003 |
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
[Arterial stiffness, wave reflections and myocardial protection: the REASON project].
Topics: Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diastole; Drug Combinations; Humans; Hy | 2003 |
Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Doub | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Disease | 2003 |
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2003 |
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atenolol; Benzopyrans; Drug Therapy, Combinat | 2003 |
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Do | 2003 |
A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes T
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Brachial Artery; Card | 2003 |
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Topics: Antihypertensive Agents; Apolipoproteins; Atenolol; Blood Glucose; Blood Pressure; Drug Therapy, Com | 2003 |
[Effects of atenolol and diltiazem-SR on quality of life in the hypertensive patients].
Topics: Adult; Aged; Atenolol; Blood Pressure; Diltiazem; Female; Heart Rate; Humans; Hypertension; Male; Mi | 2003 |
Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzopyrans; Diastole; Double-Blind | 2003 |
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Heart Rate; Hemo | 1993 |
Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
Topics: Adipocytes; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Geno | 2003 |
[Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases].
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambula | 2003 |
No effect of enalapril on progression in autosomal dominant polycystic kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Double-Blind | 2003 |
Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2003 |
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Echocardiography; | 2003 |
Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2003 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertensive Agents; Atenolol; Bipheny | 2004 |
Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Drug Therapy, Combination; Female; Follow-Up Stud | 2004 |
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; | 2003 |
Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Asian People; Atenolol; Black People; Blood Pressu | 2004 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hyperten | 2004 |
[Treatment of hypertension in patients with left ventricular hypertrophy].
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hypertension; Hypertro | 2004 |
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; Heart Ventric | 2004 |
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Genotype; Humans | 2004 |
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Catecholamines; Female; Follow-Up Studie | 2004 |
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography; Electrocardiography; F | 2004 |
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Follow-Up Studies; | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Double-Blind Method; Female; Humans; Hypertension; | 2004 |
Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Aged; Antihypertensive Agents; Atenolol; Carotid Artery Diseases; Carotid Artery, Common; Carotid Ar | 2004 |
Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Endothelin-1; Female; Genotyp | 2004 |
A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Carotid Arteries; Female; Genotype; Glycoproteins; Hum | 2004 |
Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Alleles; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hyperten | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; D | 2004 |
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Drug Therapy, Combi | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2004 |
Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2004 |
Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Atenolol; Be | 2004 |
Glycemia in newborns of hypertensive mothers according to maternal treatment.
Topics: Antihypertensive Agents; Apgar Score; Atenolol; Blood Glucose; Epidemiologic Methods; Female; Fetal | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertens | 2004 |
Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2004 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2005 |
Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Atenolol; Blood Flow | 2005 |
Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Antihypertensive Agents; Arteriosclerosis; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambu | 2005 |
Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation.
Topics: Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Blood Pressure; Blood Proteins; Ethano | 2005 |
Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Echocardiography; Fema | 2005 |
[Antihypertensive and antiischemic effectiveness and safety of the AT1-receptor blocker irbesartranin arterial hypertension in patients with prior myocardial infarction].
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Atenolol; Cross-Over Studies; Diabetes Mellitus, Type | 2005 |
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; F | 2005 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2005 |
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy | 2005 |
Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Adult; Aged; Atenolol; Dihydropyridines; Echocardiography; Female; Humans; Hypertension; Hypertrophy | 2005 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Cross-Over Studies; Female; Humans; Hypertension; Male | 2005 |
Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Carotid Arteries; Carotid Artery Diseases; Dihydropy | 2005 |
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
Topics: Aged; Atenolol; Blood Pressure; Carotid Arteries; Female; Humans; Hypertension; Losartan; Male; Time | 2005 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug | 2005 |
[Effect of nebivolol on parameters of cerebral haemodynamics and 24-hour blood pressure profile in patients with arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Brain; Cerebrovascular Circulation; Female; Hemodynami | 2005 |
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; | 2005 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amides; Atenolol; Celecoxib; Cimetidine; Cross-Over | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
Topics: Acrylates; Antihypertensive Agents; Aorta, Thoracic; Atenolol; Blood Pressure; Cross-Over Studies; D | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Femal | 2006 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-O | 2005 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Area Under Curve; Atenolol; Brachial Artery; E | 2006 |
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2006 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
[Arterial hypertension: problems of maintenance therapy].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood | 2006 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein | 2006 |
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Benzimi | 2006 |
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Block | 2006 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiograp | 2006 |
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Biomarkers; Bl | 2006 |
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2007 |
Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Cross-Over Studies; Diabetes Mel | 2007 |
Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucos | 2007 |
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Blood Pressure Monitoring, Ambul | 2007 |
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2007 |
Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitor | 2007 |
Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2007 |
Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Double-Blind Method; E | 2007 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland | 2007 |
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2007 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2007 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; | 2007 |
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Canada; Chlorthal | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
Topics: Aged; Antihypertensive Agents; Atenolol; Atherosclerosis; Calcium Channel Blockers; Carotid Arteries | 2007 |
Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Fema | 2007 |
A comparison of atenolol and nebivolol in isolated systolic hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Blood Pressure; Cohort Studies; Cross-Over | 2008 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole | 2008 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole | 2008 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole | 2008 |
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Buttocks; Collagen; Diastole | 2008 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diabetic Angiopathies | 2008 |
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Echocardiography, Doppler; Female; Human | 2008 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambul | 2008 |
[Interrelationship between changes of rate and variability of cardiac rhythm under influence of beta-adrenoblockers].
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Dose-Response Relationsh | 2007 |
Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2008 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study.
Topics: Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressu | 2008 |
Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Atenolol; Biphenyl | 2008 |
Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
Topics: Adrenergic beta-Antagonists; Aorta; Atenolol; Benzopyrans; Blood Pressure; Ethanolamines; Female; He | 2008 |
[Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Benzopyra | 2008 |
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Electrocardiography | 2008 |
Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Humans; | 2008 |
Enalapril and atenolol in primary hypertension--a comparative study of blood pressure lowering and hormonal effects.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolo | 1984 |
Interaction of clonidine and beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Atenolol; Blood Pressure; Clinical Trials as Topic; Clo | 1980 |
Hypertension in the over-60s.
Topics: Age Factors; Aged; Atenolol; Bendroflumethiazide; Humans; Hypertension; Middle Aged; Propanolamines | 1980 |
[Control of hypertension and blood lactate during exercise. Comparison of central antihypertensive agents with the cardio-selective beta blockers metoprolol and atenolol].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Female; Humans; Hypertension; Lactates; Male; Metoprol | 1981 |
Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Delayed-Acti | 1981 |
Adrenergic mechanisms in control of plasma lipid concentrations.
Topics: Adrenergic beta-Antagonists; Atenolol; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Fatt | 1982 |
Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Exercise Test; Heart Rate; Humans; Hyp | 1982 |
Beta-blockers may have role in preeclampsia.
Topics: Adrenergic beta-Antagonists; Atenolol; Birth Weight; Clinical Trials as Topic; Female; Humans; Hyper | 1982 |
Labetalol, beta blockers, and acute deterioration of chronic airway obstruction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Ethanolamines; Humans; Hypertension; Labetalol; Lung Di | 1982 |
The effect on HDL cholesterol of oxprenolol and atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, L | 1982 |
Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension.
Topics: Adult; Atenolol; Bed Rest; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1983 |
Antihypertensive therapy in pregnancy.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Labetalol; Ma | 1983 |
Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Blood Pressure; Female; Glomerular Filtration Rate; Hea | 1983 |
[Comparative evaluation of the therapeutic effect of various classes of beta-blockaders in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Echocardiography; Hear | 1983 |
[Blood pressure during isometric and dynamic exercise under long-term antihypertensive treatment with beta receptor blockaders and diuretics].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Diuretics; E | 1983 |
Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; C-Peptide; Double-Blind Method; Erythro | 1984 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double | 1984 |
[Value of a blood pressure profile in evaluating 2 antihypertensive agents].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure Determin | 1984 |
Physical performance and muscle metabolism during beta-adrenergic blockade in man.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Energy Metab | 1984 |
[Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiac Complexes, Premature; Coronary Disease; Double-Blind | 1981 |
[Treatment of hypertensive hyperuricemic patients with a new beta blocker-diuretic combination].
Topics: Adult; Aged; Atenolol; Celiprolol; Chlorthalidone; Drug Combinations; Drug Tolerance; Female; Humans | 1984 |
Factors influencing cardiac hypertrophy in hypertensive patients.
Topics: Adult; Atenolol; Cardiomegaly; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Receptors, Adr | 1981 |
A comparison of once daily atenolol and metoprolol SA in mild to moderate hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double | 1983 |
A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Drug Evaluation; Female; Heart Rate; Humans; H | 1983 |
A comparative study of atenolol and penbutolol in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Diastole; Double-Blind Method; Female; Hu | 1983 |
Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study.
Topics: Adult; Atenolol; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Therapy, Combination | 1983 |
Influence of time and physical activity on blood pressure and heart rate during treatment with beta-blocking agents once daily.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension; | 1983 |
Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension.
Topics: Atenolol; Blood Pressure; Body Weight; Catecholamines; Heart Rate; Humans; Hypertension; Male; Middl | 1984 |
Captopril or atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Drug Synergism; Drug The | 1983 |
Atenolol 50 mg or metoprolol 200 mg - a comparison of antihypertensive efficacy, side effects and lipoprotein changes.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Fatigue; Female; Heart Rate; Humans; Hype | 1983 |
Comparison of hydrochlorothiazide and atenolol as initial treatment in uncomplicated hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Half-Life; Humans; Hydrochlorothi | 1984 |
Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol.
Topics: Atenolol; Clinical Trials as Topic; Delivery, Obstetric; Double-Blind Method; Female; Fetal Heart; F | 1984 |
A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Heart | 1984 |
A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; | 1984 |
Treatment of severe hypertension.
Topics: Atenolol; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Female; Humans; Hypertension; Male | 1984 |
Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthalidone) in black hypertensive patients.
Topics: Adult; Atenolol; Black People; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blin | 1984 |
First year of life after the use of atenolol in pregnancy associated hypertension.
Topics: Atenolol; Body Height; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Humans; H | 1984 |
Atenolol in hypertension.
Topics: Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1984 |
[Comparison of the anti-hypertensive effects of combinations of nifedipine retard with acebutolol or atenolol].
Topics: Acebutolol; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1984 |
The 'third drug' trial: a comparative study of anti-hypertensive agents added to treatment when blood pressure is uncontrolled by a beta-blocker plus thiazide diuretic.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cli | 1983 |
New drugs: beta blockers and sympathomimetics.
Topics: Atenolol; Clinical Trials as Topic; Humans; Hypertension; Metoprolol; Propanolamines; Sleep | 1983 |
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cli | 1984 |
Antihypertensive treatment in elderly patients in general practice (preliminary results).
Topics: Aged; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Female; Humans; Hypert | 1983 |
The influence of beta blockers on cardiovascular reactivity and Type A behavior pattern in hypertensives.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Heart Rate; Humans | 1983 |
Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Dihydralazine; Female; Headache; Heart Rat | 1983 |
A comparison between atenolol and metoprolol in respect of central nervous system side effects.
Topics: Atenolol; Central Nervous System Diseases; Double-Blind Method; Humans; Hypertension; Metoprolol | 1983 |
[The effect of beta receptor blockers and diuretics on blood pressure reactivity].
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochlor | 1983 |
Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension.
Topics: Acebutolol; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middl | 1983 |
Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension.
Topics: Atenolol; Dopamine; Epinephrine; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephri | 1983 |
Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Humans; Hypertension; Male; Middle Aged; Platelet Adhe | 1983 |
Once daily 50 mg Atenolol in the treatment of mild and moderate hypertension.
Topics: Atenolol; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged | 1983 |
Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Drug Therapy, Combination; Female; Heart Rate; Hum | 1982 |
[Clinical use of atenolol (Tenormin) in arterial hypertension].
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Diastole; Female; Humans; Hypertension; Hypertensio | 1982 |
A two year clinical evaluation of atenolol and metoprolol in the treatment of hypertension.
Topics: Adult; Atenolol; Clinical Trials as Topic; Heart Rate; Humans; Hypertension; Metoprolol; Middle Aged | 1982 |
Effects of prostaglandins inhibition on changes in active and inactive renin induced by antihypertensive drugs.
Topics: Adult; Atenolol; Bumetanide; Captopril; Cold Temperature; Diuretics; Enzyme Precursors; Female; Glyc | 1982 |
Antihypertensive and metabolic effects of increasing doses of atenolol and labetalol. A comparative study in primary hypertension.
Topics: Adult; Aged; Aldosterone; Atenolol; Blood Pressure; Double-Blind Method; Drug Evaluation; Ethanolami | 1982 |
[Atenolol and metoprolol in the treatment of slight to moderate hypertension. A comparative study].
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Metoprolol; Mid | 1982 |
[Usefulness of atenolol in the ambulatory treatment of arterial hypertension].
Topics: Adult; Aged; Ambulatory Care; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hy | 1982 |
[Protection of the hypertensive patient: comparative study of atenolol and metoprolol].
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Femal | 1982 |
Adverse reactions to drugs.
Topics: Aged; Atenolol; Humans; Hypertension; Middle Aged; Propanolamines | 1981 |
Atenolol and metoprolol once daily in hypertension.
Topics: Adult; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Fem | 1982 |
Atenolol: side effects in the newborn infant.
Topics: Atenolol; Female; Humans; Hypertension; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Pregnan | 1982 |
Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparat | 1982 |
Atenolol treatment of arterial hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1982 |
Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma.
Topics: Adult; Asthma; Atenolol; Blood Pressure; Ethanolamines; Female; Forced Expiratory Volume; Humans; Hy | 1983 |
Atenolol v placebo in mild hypertension: renal metabolic and stress antipressor effects.
Topics: Atenolol; Blood Pressure; Female; Humans; Hypertension; Kidney; Lipids; Male; Middle Aged; Placebos; | 1980 |
A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Creatinine; Female; Heart Rate; Humans; Hypertension; Kidney; Male; | 1980 |
Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.
Topics: Administration, Oral; Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topi | 1980 |
Antihypertensive effects of sotalol and atenolol given once daily.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Male; Middle Aged; Propanolam | 1980 |
A new approach to drug trials in general practice. Comparison of the antihypertensive efficacy of metoprolol and atenolol.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Family Practice; Female; Heart Rate; Humans; Hyp | 1980 |
Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.
Topics: Adult; Atenolol; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; | 1980 |
Trial of atenolol and chlorthalidone for hypertension in black South Africans.
Topics: Atenolol; Black People; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1980 |
Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Met | 1980 |
Once daily combination therapy for hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Dr | 1980 |
Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Meth | 1981 |
Antihypertensive effect of atenolol (100 mg once a day) and methyldopa (250 mg thrice a day). A double-blind cross-over multicentre study.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Clinical Trials as Topic; Dose-Response Relationship, Dr | 1981 |
Prazosin enhances the antihypertensive effects of beta-blockers during isometric and dynamic exercise.
Topics: Adult; Atenolol; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypertension; | 1981 |
Once-daily atenolol in hypertensive Zimbabwean blacks. A double-blind trial using two different doses.
Topics: Adult; Aged; Atenolol; Black or African American; Black People; Blood Pressure; Clinical Trials as T | 1981 |
Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol.
Topics: Administration, Oral; Adolescent; Adult; Atenolol; Blood Glucose; Blood Pressure Determination; Clin | 1981 |
[Atenolol in essential arterial hypertension: clinical experience].
Topics: Adult; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middle Aged; Propanol | 1981 |
[Clinical trial of atenolol. Study of 20 hypertensive patients].
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension; Male; Mid | 1980 |
Cardioselectivity of atenolol in asthmatic patients.
Topics: Airway Resistance; Asthma; Atenolol; Clinical Trials as Topic; Double-Blind Method; Forced Expirator | 1981 |
Use of fixed doses of beta blocking drugs in the treatment of hypertension. Randomised study of atenolol and penbutolol.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension; | 1981 |
Once-daily penbutolol or atenolol can replace combination therapy in essential hypertension.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1982 |
Effects of beta-blockers on type-A coronary-prone behaviour.
Topics: Amiloride; Atenolol; Blood Pressure; Coronary Disease; Humans; Hydrochlorothiazide; Hypertension; Ma | 1982 |
[Atenolol, pindolol and propranolol in essential hypertension: response rate and tolerance].
Topics: Adult; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; H | 1982 |
A comparative study of atenolol and metoprolol in the treatment of hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Creatinine; Female; Heart Rate; Humans; Hypertension; Male; M | 1981 |
Effect of atenolol on left ventricular function in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Cardiac Output; Echocardiography; Heart Rate; Heart Ventricles; Hum | 1980 |
Double-blind cross-over comparison of hydralazine and prazosin in hypertensive subjects on a beta-adrenoceptor blocking agent (atenolol).
Topics: Atenolol; Double-Blind Method; Drug Therapy, Combination; Humans; Hydralazine; Hypertension; Prazosi | 1980 |
Effect of atenolol on left ventricular function in hypertensive patients.
Topics: Atenolol; Cardiac Output; Heart; Heart Ventricles; Humans; Hypertension; Male; Myocardial Contractio | 1980 |
Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1995 |
Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; France; Humans; Hydro | 1993 |
Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure.
Topics: Adult; Atenolol; Bisoprolol; Blood Pressure; Cardiac Output; Double-Blind Method; Female; Glomerular | 1993 |
Variations in magnesium and zinc in hypertensive patients receiving different treatments.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Cholesterol, HDL; Erythrocytes; | 1995 |
Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoprotein A-II; Apolipoproteins; Atenolol; Blood Glucose; | 1995 |
ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension.
Topics: Aged; Atenolol; Blood Pressure; Cilazapril; Double-Blind Method; Female; Glomerular Filtration Rate; | 1995 |
A long-term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Delayed-Ac | 1994 |
The E.L.S.A. trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Dihydropyridines; Double-Blind Method; Hu | 1994 |
Remodeling of resistance arteries in human hypertension: effects of cilazapril, an angiotensin-I-converting enzyme inhibitor.
Topics: Animals; Atenolol; Cilazapril; Clinical Trials as Topic; Humans; Hypertension; Vascular Resistance | 1995 |
Effects of angiotensin-converting enzyme inhibition versus conventional antihypertensive therapy on the glomerular filtration rate.
Topics: Aged; Atenolol; Blood Pressure; Cilazapril; Double-Blind Method; Female; Follow-Up Studies; Glomerul | 1995 |
A comparison of antihypertensive effects between two formulations of atenolol: tenolol and tenormin.
Topics: Adult; Aged; Atenolol; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Male; | 1995 |
A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension.
Topics: Atenolol; Bisoprolol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; H | 1995 |
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Hum | 1995 |
Efficacy and safety of losartan.
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-R | 1995 |
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressur | 1995 |
Cardiopulmonary response during exercise of a beta 1-selective beta-blocker (atenolol) and a calcium-channel blocker (diltiazem) in untrained subjects with hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Diltiazem; Double-Blind Method; Exercise; Female; Heart; Hear | 1993 |
[The midterm inefficacy of 2 different dosages of chlorthalidone (50 and 25 mg/day) in the regression of left ventricular mass in arterial hypertension].
Topics: Aged; Atenolol; Blood Pressure; Chi-Square Distribution; Chlorthalidone; Enalapril; Follow-Up Studie | 1995 |
Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
Topics: Adult; Aged; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Vessels; Cilazapril; | 1994 |
Comparative effects of atenolol and clonidine on polygraphically recorded sleep in hypertensive men: a randomized, double-blind, crossover study.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Clonidine; Cross-Over Studies; Double-Blind Method; Hum | 1995 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; | 1994 |
Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arteries; Atenolol; Blood Pressure; Double-Bl | 1995 |
Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients.
Topics: Acetylcholine; Adipose Tissue; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inh | 1995 |
Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree?
Topics: Adult; Aged; Atenolol; beta-Thromboglobulin; Blood Platelets; Blood Pressure; Cross-Over Studies; Do | 1995 |
[Effect of 3 hypertensive++ agents on ventricular geometry and function].
Topics: Atenolol; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Midd | 1995 |
Different effects of fosinopril and atenolol on wave reflections in hypertensive patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Female; Fosinopril; Humans; Hypertension | 1995 |
Sequential monotherapy of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Cross-Over Studies; Drug | 1994 |
Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group.
Topics: Adult; Aged; Analysis of Variance; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; | 1995 |
[Prospective study of the effects of an angiotensin converting enzyme inhibitor and a beta blockader on the structure and function of resistant arteries in mild essential hypertension].
Topics: Adult; Arteries; Atenolol; Cilazapril; Clinical Protocols; Female; Humans; Hypertension; Male; Middl | 1994 |
Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Atenolol; Blood Pressure; Chromatography, High Press | 1995 |
Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Arteries; Atenolol; Bl | 1995 |
Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Combined Modality Therapy; Diet, Sodium-Re | 1994 |
Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL).
Topics: Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Clonidine; Drug Therapy, Combination; Female; Hea | 1994 |
Effect of doxazosin or atenolol on exercise performance in physically active, hypertensive men.
Topics: Adult; Aged; Atenolol; Cross-Over Studies; Double-Blind Method; Doxazosin; Exercise Test; Humans; Hy | 1995 |
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.
Topics: Adult; Aged; Amlodipine; Atenolol; Coronary Disease; Diltiazem; Drug Therapy, Combination; Electroph | 1994 |
Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients.
Topics: Administration, Oral; Analysis of Variance; Antihypertensive Agents; Atenolol; Black People; Cross-O | 1995 |
Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cholesterol; Diabetes | 1994 |
Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine.
Topics: Adolescent; Adult; Age Factors; Aged; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulator | 1994 |
Effects of atenolol and diltiazem-SR on exercise and pressure load in hypertensive patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Double-Blind Met | 1994 |
Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Carba | 1994 |
Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Atenolol; Double- | 1994 |
Comparative effects of quinapril, atenolol, and verapamil on blood pressure and forearm hemodynamics during handgrip exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Cross-Over Studies; Double-Blind | 1994 |
Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being.
Topics: Adult; Atenolol; Blood Pressure; Central Nervous System; Delayed-Action Preparations; Double-Blind M | 1994 |
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlorthali | 1994 |
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.
Topics: Acebutolol; Adolescent; Adult; Aged; Atenolol; Blood Pressure; Body Weight; Enalapril; Female; Human | 1994 |
Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Female; | 1994 |
Adding beta-2 agonism does not improve beta-1 blockade exercise responses in hypertensives.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Blood Pressure; Celiprolol; Cross-Over Stud | 1994 |
Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Choles | 1994 |
Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidon | 1994 |
Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity.
Topics: Adult; Aged; Atenolol; Carbohydrate Metabolism; Double-Blind Method; Doxazosin; Female; Hemodynamics | 1994 |
Effects of antihypertensive medications on quality of life in elderly hypertensive women.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Ena | 1994 |
Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
Topics: Apolipoproteins E; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Humans; Hypertension; L | 1994 |
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Albuminuria; Apolipoproteins; Apoprotein(a); Atenolol; Blood Pressure; Circadian Rhythm; Diabetes Me | 1994 |
Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pres | 1993 |
An assessment of lacidipine and atenolol in mild to moderate hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Dihydropyridines; Double-Blind Method; Dru | 1994 |
Improved baroreflex control of the heart rate with chronic beta-adrenergic blockade in mild hypertension.
Topics: Atenolol; Baroreflex; Blood Pressure; Heart Rate; Humans; Hypertension; Middle Aged | 1993 |
The effects of diuretic and beta-blocker treatment on cardiac and vascular structural changes in untreated essential hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Hypertrophy, Left Ven | 1993 |
Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Double-Blind Method; Exercise; H | 1993 |
[Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension].
Topics: Adult; Atenolol; Bisoprolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male | 1993 |
Slowing of mitral valve annular calcium in systemic hypertension by nifedipine and comparisons with enalapril and atenolol.
Topics: Adult; Atenolol; Calcinosis; Echocardiography, Doppler; Enalapril; Female; Heart Valve Diseases; Hum | 1993 |
Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.
Topics: Adult; Aged; Atenolol; Blood Pressure; Celiprolol; Double-Blind Method; Female; Humans; Hyperlipopro | 1993 |
Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Topics: Adult; Antihypertensive Agents; Atenolol; Black People; Chlorthalidone; Double-Blind Method; Drug Co | 1993 |
Conclusions and implications of the systolic hypertension in the elderly program.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
MRC trial of treatment in elderly hypertensives.
Topics: Aged; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Female; Humans; Hydrochlorothiazide; H | 1993 |
Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.
Topics: Adult; Arteries; Atenolol; Blood Pressure; Cilazapril; Double-Blind Method; Humans; Hypertension; Ma | 1994 |
Effect of atenolol and labetalol on serum lipids.
Topics: Atenolol; Female; Humans; Hyperlipidemias; Hypertension; Labetalol; Lipids; Male | 1993 |
Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorothiazide; | 1994 |
Amlodipine versus atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat | 1994 |
Hemodynamic changes induced by cilazapril and atenolol during isometric stress in hypertensive patients.
Topics: Adult; Atenolol; Cilazapril; Exercise Test; Female; Hemodynamics; Humans; Hypertension; Male; Middle | 1993 |
A comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring.
Topics: Adolescent; Aged; Ambulatory Care; Atenolol; Blood Pressure; Blood Pressure Determination; Blood Pre | 1993 |
Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Male; | 1993 |
Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Topics: Administration, Oral; Adult; Aged; Atenolol; Circadian Rhythm; Female; Humans; Hypertension; Intesti | 1993 |
Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Determination; | 1993 |
Enalapril versus atenolol in the treatment of hypertensive smokers.
Topics: Aged; Atenolol; Blood Pressure; Enalapril; Heart Rate; Humans; Hypertension; Male; Middle Aged; Sing | 1993 |
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos | 1993 |
Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Dru | 1993 |
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Captopril; Cloni | 1993 |
Effects of atenolol withdrawal in patients on triple antihypertensive therapy.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Captopril; Double-Blind Method; Drug Therapy, Combinatio | 1993 |
Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention.
Topics: Adult; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Chlorthalidone; Combined Modalit | 1993 |
Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins; Arteri | 1993 |
Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension.
Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Exercise Tolerance; Heart Rate; Heart Ventricle | 1993 |
Left ventricular end-diastolic dimensions measured at the P wave and Q wave during a randomized, double-blind one-year follow-up study comparing the effect of atenolol vs. hydrochlorothiazide + amiloride on blood pressure in men with mild to moderate hype
Topics: Adult; Amiloride; Atenolol; Diastole; Double-Blind Method; Drug Therapy, Combination; Echocardiograp | 1993 |
Effects of antihypertensive drugs atenolol and nifedipine on sexual function in older men: a placebo-controlled, crossover study.
Topics: Aged; Analysis of Variance; Atenolol; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; | 1993 |
Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Comparative effects of cilazapril and atenolol on maximal and prolonged submaximal exercise performance in hypertensive males.
Topics: Adult; Atenolol; Cilazapril; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Physical | 1993 |
Comparison of casual ambulatory and self-measured blood pressure in a long-term study with cilazapril and atenolol.
Topics: Ambulatory Care; Atenolol; Blood Pressure; Blood Pressure Determination; Cilazapril; Double-Blind Me | 1993 |
Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol.
Topics: Atenolol; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension | 1993 |
[Are home blood pressure measurements and 24-hour ambulatory recordings superior to office measurements? Comparison of 3 blood pressure recording methods in a study of cilazapril versus atenolol].
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Blood Pressure Determination; Cilazapril; Double- | 1993 |
Antihypertensive effect of nitrendipine in the hypertensive patient with renal impairment.
Topics: Adult; Atenolol; Diuretics; Female; Follow-Up Studies; Humans; Hypertension; Hypertension, Renal; Ma | 1993 |
Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Atenolol; Bisoprolol; Black People; Blood Pressure; Doubl | 1993 |
A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; | 1995 |
Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Creatin | 1995 |
[The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Artery | 1995 |
Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Celiprolol; Cross-Over Studies; | 1995 |
Losartan potassium as initial therapy in patients with severe hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Biphen | 1995 |
A comparison of the metabolic effects of captopril and atenolol on glucose, insulin and lipoproteins in patients with mild-to-moderate essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Captopril; Double-Blind Method; Hu | 1995 |
A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 1996 |
Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension.
Topics: Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Autonomic Nervous System; Blood Pr | 1995 |
Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aort | 1996 |
The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Cross-Over St | 1995 |
Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Arteries; Atenolol; Bl | 1996 |
A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population.
Topics: Aged; Amiloride; Antihypertensive Agents; Atenolol; Cognition Disorders; Dementia; Drug Combinations | 1996 |
'Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiography; Antihypertensive Agents; Atenolol; Drug Resistance | 1996 |
Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Celiprolol; Double-Blind Method; | 1996 |
Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method | 1996 |
Potential modification of plaque behavior through the European lacidipine study on atherosclerosis.
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Blood Pressure Monitoring, Ambulatory; Calc | 1995 |
Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cross- | 1996 |
Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1996 |
Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 1996 |
Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arteries; Atenolol; Calcium Channel Blockers; Female; Huma | 1996 |
[Comparative antihypertensive action of 20 mg delayed-action nifedipine with either 25 or 50 mg atenolol. A study on the treatment of patients with mild to moderately severe arterial hypertension].
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Delayed-Action Preparations; Dose | 1996 |
Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1996 |
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlor | 1996 |
The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood | 1996 |
Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Apolipoproteins; Atenolol; Double-Blin | 1996 |
ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood | 1995 |
Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blo | 1996 |
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; Double-Blind Metho | 1995 |
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1997 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; | 1997 |
A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function.
Topics: Adult; Antihypertensive Agents; Atenolol; Double-Blind Method; Enalapril; Female; Glomerular Filtrat | 1997 |
Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 1997 |
[Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial].
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Captopril; Double-Blind Me | 1996 |
Inhibitor index: a novel method for measuring pharmacological inhibition of angiotensin-converting enzyme.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiology; Double-Blin | 1997 |
Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men.
Topics: Antihypertensive Agents; Atenolol; Cardiovascular System; Cross-Over Studies; Double-Blind Method; E | 1997 |
Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhib | 1997 |
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients.
Topics: Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Captopril; Double-Blin | 1997 |
Metabolic effects of spirapril and atenolol: results from a randomized, long-term study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibi | 1997 |
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Double-Blind Method; Electrocard | 1997 |
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme | 1997 |
Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Fema | 1997 |
Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Calcium Channel Blockers; Felodipine; Female; Hu | 1997 |
Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Diabetes Mellitus | 1997 |
Comparison of temocapril and atenolol in the long-term treatment of mild to moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1997 |
[Changes in the quality of life influenced by treatment of primary arterial hypertension].
Topics: Adult; Antihypertensive Agents; Atenolol; Enalapril; Humans; Hypertension; Male; Middle Aged; Qualit | 1997 |
Comparison of manual versus automated blood pressure measurements in treated hypertensive patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Atenolol; Black People; Blood Pressure Determination; Bloo | 1997 |
Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pres | 1997 |
A low dose atenolol/bendrofluazide combination in patients with mild to moderate hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Dose-Response Relationship, Drug; Dou | 1997 |
Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; beta-Thromboglobulin; Blood Platelets; Blood Pressure; | 1997 |
Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Benzopyrans; Double-Blind Method; Et | 1998 |
Effect of treatment of isolated systolic hypertension on left ventricular mass.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Female; Follow-Up Studies; Heart | 1998 |
Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study.
Topics: Adrenergic beta-Antagonists; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1997 |
Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; | 1998 |
Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; | 1998 |
A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood | 1998 |
Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Doxazosin; Female; Fibrinolysis; Gonadal | 1998 |
Insulin receptor number in arterial hypertension: response to treatment with fosinopril or atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 1998 |
A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Benzimi | 1998 |
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Cerebr | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Cerebral hemodynamics in young hypertensive subjects and effects of atenolol treatment.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Carbon Dioxide; Cerebral Arteries; Ce | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Valsartan and atenolol in patients with severe essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Female; Humans; Hy | 1998 |
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic beta-Antagonists; Aged; Arteriosclerosis; Atenolol; Blood Pressure; Calcium Channel Block | 1998 |
Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study.
Topics: Adult; Antihypertensive Agents; Atenolol; Cross-Over Studies; Double-Blind Method; Humans; Hypertens | 1998 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiogr | 1998 |
Comparison between moexipril and atenolol in obese postmenopausal women with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Female | 1998 |
Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult | 1998 |
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Body Mass Index; Double- | 1998 |
Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Diabetic Ang | 1998 |
Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Captopril; Diltiazem; Humans; Hyperte | 1999 |
Total arterial compliance in ambulatory hypertension during selective beta1-adrenergic receptor blockade and angiotensin-converting enzyme inhibition.
Topics: Adrenergic Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ao | 1999 |
ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 1999 |
Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Captopri | 1999 |
Supervised atenolol therapy in the management of hemodialysis hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; | 1999 |
Baroreflex sensitivity and the blood pressure response to beta-blockade.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Barorefle | 1999 |
Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Atenolol; Bisopr | 1999 |
Atenolol and fetal growth in pregnancies complicated by hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Embryonic and Fetal Development; Female; Humans; Hypertens | 1999 |
The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1999 |
Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; C | 1999 |
Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Celiprolol; Double-Blind Method; | 1997 |
Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
Topics: Adrenocorticotropic Hormone; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Benzopyra | 1999 |
[Relationship between sympathetic activity and response to treatment with atenolol in hypertensive patients. Investigation group of the study of efficiency and tolerance of atenolol in hypertensive patients with increase in the sympathetic activity].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety; Atenolol; Atrial Fibrillation; Female; Heart Ra | 1999 |
Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ate | 1999 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug | 1999 |
Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; | 1999 |
Does the Dundee Step Test predict outcome in treated hypertension? A sub-study protocol for the ASCOT trial. Anglo-Scandinavian Cardiac Outcome Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Diu | 2000 |
Efficacy and safety of a fixed low-dose perindopril/indapamide combination in essential hypertension. A randomised controlled study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Press | 2000 |
Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressur | 2000 |
A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonis | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
Topics: Acetylcholine; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arteries; Atenolol; | 2000 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
Influence of diabetes and type of hypertension on response to antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2000 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 2000 |
The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure | 2000 |
Difference in blood pressure, but not in heart rate, between measurements performed at a health centre and at a hospital by one and the same physician.
Topics: Adult; Aged; Ambulatory Care Facilities; Antihypertensive Agents; Atenolol; Blood Pressure Determina | 2000 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Birth Weight; Cardiac Output; Double-Blind Method; Fem | 1999 |
Durability of improvement achieved in a clinical trial. Is compliance an issue?
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Enalapril; Follo | 2000 |
Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Coagulatio | 2000 |
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Humans; Hyp | 2000 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2000 |
Effect of celiprolol on cardiac hypertrophy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Celi | 2000 |
Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
Topics: Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Glucose; Heart Ventricles; Humans; H | 2000 |
Combination therapy with beta-adrenergic blockade and amlodipine as second line treatment in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Atenolol; Calcium Channel Blockers; Double-Blind Met | 2000 |
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Electrocardiography; F | 2000 |
Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Bias; Chlorthalidone; Dementia; Disabled Persons; Double-Bl | 2001 |
Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Benzim | 2001 |
[Atenolol use in gestosis: clinical and hemodynamic aspects].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Female; Gestational Age; Hemodynamics; Humans; Hyperte | 2000 |
Effect of prazosin GITS, atenolol, nifedipine SR, and enalapril on ADP-induced platelet aggregation.
Topics: Adenosine Diphosphate; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Angiotensin | 1998 |
Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Delayed-Action Preparations; Female; Heart; Humans; | 1998 |
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Atenolol; Biphenyl Compo | 2001 |
Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arter | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure Monitorin | 2001 |
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Confiden | 2001 |
Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bendroflumethiazide; | 2001 |
Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bendroflumethiazide; | 2001 |
Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bendroflumethiazide; | 2001 |
Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bendroflumethiazide; | 2001 |
Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antioxidants; Atenolol; Biological Availability; Biomarkers; Cal | 2001 |
Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzopyrans; Cross-Over Studies; Dou | 2001 |
Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combi | 2001 |
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Bi | 2001 |
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Bi | 2001 |
Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Dr | 2001 |
Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Ao | 2001 |
Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Clonidine; Diastole; Dilt | 2001 |
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihyper | 2002 |
[The novel method for selection of preparations for treatment of arterial hypertension based on spectral analysis of heart rhythm variability].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agents; Arteries; At | 2002 |
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography; Electrocardiogr | 2002 |
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2002 |
Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressur | 2001 |
Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (
Topics: Aged; Alleles; Angiotensin Receptor Antagonists; Angiotensinogen; Antihypertensive Agents; Atenolol; | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
[Efficacy of native carvedilol in patients with essential hypertension].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Carbazoles; | 1999 |
Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2002 |
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cro | 2002 |
Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Coitus; Double-Blind Method; Humans; | 2002 |
Long-term hypotensive effect of atenolol (ICI 66.082), a new beta-adrenergic blocking agent.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Female; Humans; Hypert | 1976 |
Atenolol, methyldopa, and chlorthalidone in moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy | 1977 |
Relative value of beta blockers and thiazides for initiating antihypertensive therapy. Beta blockers or thiazides in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Bendroflumethiazide; Clinical Trials as Topic; Drug Ev | 1976 |
Relative activity of atenolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Exercise Test; Humans; Hypertension; Metoprolol; Propanolamin | 1977 |
Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Atenolol; Bendroflumethiazide; Clinical Trials as To | 1978 |
Atenolol and three nonselective beta-blockers in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Creati | 1979 |
Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bendroflumethiazide; Chlorthalidone; Diuretics; | 1979 |
Effects of 4 beta-adrenoceptor blocking drugs on blood pressure and exercise heart rate in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Depression, Chemical; Female; Heart Ra | 1979 |
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; E | 1979 |
Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Drug Evaluatio | 1977 |
Metoprolol or atenolol for mild-to-moderate hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Metop | 1979 |
Controlled study of atenolol in treatment of hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood-Brain Barrier; Clinical Trials | 1975 |
Atenolol in hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Propanolamines | 1977 |
Relationship between blood level of atenolol and pharmacologic effect.
Topics: Adult; Atenolol; Biological Availability; Blood Pressure; Clinical Trials as Topic; Dose-Response Re | 1977 |
Atenolol once-daily in hypertension.
Topics: Adult; Atenolol; Clinical Trials as Topic; Drug Administration Schedule; Hemodynamics; Humans; Hyper | 1977 |
Comparison of propranolol and atenolol in hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind M | 1977 |
Atenolol in hypertension: a double-blind comparison of the response to three different doses.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind M | 1977 |
Atenolol and methyldopa in the treatment of hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1977 |
Combination hypotensive therapy with atenolol, bendrofluazide and hydrallazine.
Topics: Angiotensin II; Atenolol; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Double-Blin | 1977 |
Dose response and frequency of administration of atenolol in essential hypertension--once daily treatment with beta-blockade.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; D | 1977 |
Clinical studies with atenolol in hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1977 |
Antihypertensive effect of atenolol--a Swedish multicentre study.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Propa | 1977 |
A double-blind comparison of atenolol ('Tenormin') and methyldopa in the treatment of moderate hypertension in general practice: a multicentre study.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1977 |
A comparison of once and twice daily atenolol in hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Administration | 1977 |
Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.
Topics: Adult; Airway Obstruction; Angina Pectoris; Atenolol; Chronic Disease; Clinical Trials as Topic; Dou | 1978 |
A dose-response study of atenolol in mild to moderate hypertension in general practice.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double- | 1977 |
Atenolol as additive therapy in hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Comb | 1978 |
Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Depression, Chemical; Double-Blind Method | 1977 |
Relative activity of atenolol and metoprolol.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Metoprolol; Propanola | 1978 |
[Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)].
Topics: Adult; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Hyp | 1978 |
Atenolol and metoprolol in mild hypertension.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Metoprolol; Propanola | 1978 |
Atenolol (Tenormin) compared with methyldopa (Aldomet) in the treatment of hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fem | 1978 |
Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system.
Topics: Adult; Aged; Alprenolol; Atenolol; Central Nervous System; Clinical Trials as Topic; Drug Evaluation | 1979 |
Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension.
Topics: Adult; Ambulatory Care; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dose-Res | 1979 |
[Atenelol and bendrofluazide in the treatment of medium and severe hypertension (preliminary report)].
Topics: Atenolol; Bendroflumethiazide; Clinical Trials as Topic; Diastole; Female; Humans; Hypertension; Mal | 1978 |
[Therapeutic differences between atenolol and pindolol in asthmatic patients].
Topics: Asthma; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Hemodynamics; Huma | 1979 |
Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. A South African Multicentre Study.
Topics: Adjuvants, Pharmaceutic; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Met | 1979 |
Atenolol and chlorthalidone in combination for hypertension.
Topics: Adolescent; Adult; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug The | 1979 |
Cardioselective beta-blockade and renal function.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Glomerular Filtration Rate; Humans; Hyperte | 1979 |
Cyclothiazide and atenolol once daily in essential hypertension.
Topics: Adult; Atenolol; Benzothiadiazines; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blin | 1979 |
Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Meth | 1979 |
Home blood pressure monitoring and changes in plasma catecholamines during once or twice daily treatment with atenolol in patients with mild hypertension.
Topics: Adult; Ambulatory Care; Atenolol; Blood Pressure Determination; Clinical Trials as Topic; Drug Admin | 1979 |
Dose response for blood pressure and degree of cardiac beta-blockade with atenolol.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double- | 1979 |
[Evaluation of the hypotensive effect of atenolol].
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; | 1979 |
Mechanism of the haemodynamic interaction between atenolol, a cardioselective beta-adrenoreceptor-blocking agent, and chlorthalidone in hypertensive patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method | 1979 |
[Comparison of the antihypertensive affectiveness of atenolol and methyldopa].
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hypertension; Male | 1979 |
[Comparison of exercise tolerance in hypertensive patients treated with atenolol and methyldopa].
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Exercise Test; Female; Heart Rate; Humans | 1979 |
Beta-blockers, blood sugar control, and renal function.
Topics: Atenolol; Creatinine; Humans; Hypertension; Propanolamines; Propranolol | 1979 |
Blood pressure reduction and vascular adaptation. A study on long-term effects of treatment with mefruside or atenolol.
Topics: Adult; Atenolol; Blood Pressure Determination; Diuretics; Female; Humans; Hypertension; Male; Mefrus | 1979 |
Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy.
Topics: Administration, Oral; Adult; Atenolol; Blood Pressure; Chlorthalidone; Dose-Response Relationship, D | 1979 |
Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity.
Topics: Adult; Aged; Atenolol; Drug Evaluation; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; | 1979 |
Comparison of the effects of atenolol and propranolol in labile hypertension.
Topics: Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Male; Propanolamines; Propranolol | 1979 |
Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.
Topics: Adult; Atenolol; Blood Glucose; Cholesterol; Fatty Acids, Nonesterified; Glucagon; Growth Hormone; H | 1979 |
Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertensi | 1976 |
Once-daily dosing with Atenolol in patients with mild or moderate hypertension.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; | 1976 |
Atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hypertension; Male; | 1976 |
A comparison of the antihypertensive effect of atenolol (ICI 66 082) and propranolol.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic | 1976 |
[Clinical testing of a new beta blocking agent--atenolol--in hypertension].
Topics: Adult; Atenolol; Clinical Trials as Topic; Drug Evaluation; Humans; Hypertension; Middle Aged; Place | 1976 |
Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.
Topics: Adult; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Female | 1976 |
Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol.
Topics: Antihypertensive Agents; Atenolol; Bendroflumethiazide; Clinical Trials as Topic; Humans; Hypertensi | 1976 |
Clinical evaluation of atenolol in hypertension.
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Lung Diseases, Ob | 1976 |
Clinical and haemodynamic study of atenolol (Tenormin) in essential hypertension.
Topics: Adult; Atenolol; Cardiac Output; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middl | 1976 |
Effect of beta-adrenergic blockade on blood pressure variation in patients with moderate hypertension.
Topics: Atenolol; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Hypertension; Placebos; Propanola | 1977 |
Effect of atenolol on exercise haemodynamics in angina pectoris and hypertension (abstract).
Topics: Angina Pectoris; Atenolol; Hemodynamics; Humans; Hypertension; Physical Exertion; Propanolamines; Pr | 1977 |
Atenolol and bendrofluazide in hypertension.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Body Weight; Clinical Trials as Topic; Drug Evaluation; | 1975 |
Comparison of ambulatory and clinic blood pressure and heart rate in older persons with isolated systolic hypertension.
Topics: Aged; Aging; Ambulatory Care; Atenolol; Blood Pressure; Blood Pressure Determination; Circadian Rhyt | 1992 |
Left ventricular mass regression in elderly hypertensives.
Topics: Aging; Atenolol; Blood Pressure; Coronary Circulation; Delayed-Action Preparations; Echocardiography | 1992 |
Effects of antihypertensive agents on carotid pulse contour in humans.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arteries; Female; Humans; Hypertension; M | 1992 |
A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hy | 1992 |
A health-economic comparison of diet and drug treatment in obese men with mild hypertension.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Computer Simulation; Cost-Benefit Analysis; Hu | 1992 |
Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Atenolol; Blood Pressure; Captop | 1992 |
A study of the effects of lisinopril when used in addition to atenolol.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Dipepti | 1992 |
Effects of mild physical activity, atenolol and the combination on ambulatory blood pressure in hypertensive subjects.
Topics: Adult; Atenolol; Blood Pressure; Combined Modality Therapy; Exercise; Exercise Therapy; Female; Huma | 1992 |
A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blo | 1992 |
Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Double-Blind Method; Drug Therapy, Combination; Fe | 1992 |
Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study.
Topics: Aged; Aged, 80 and over; Amiloride; Atenolol; Double-Blind Method; Drug Therapy, Combination; Female | 1992 |
Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men.
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Cardiac Output; Drug Combinations; Heart Rate; Hemodynam | 1992 |
Ambulatory blood pressure monitoring. A tool for more comprehensive assessment.
Topics: Adult; Atenolol; Blood Pressure Monitors; Circadian Rhythm; Enalapril; Female; Humans; Hypertension; | 1992 |
Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Dose-R | 1992 |
Large artery compliance in essential hypertension. Effects of calcium antagonism and beta-blocking.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Blood Pressure; Calcium Channel Blockers; Co | 1992 |
A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bloo | 1992 |
Clinical efficacy of perindopril in hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Double-Blind Method; Dr | 1992 |
Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug | 1992 |
A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; | 1992 |
Classic conditioning and placebo effects in crossover studies.
Topics: Adult; Aged; Atenolol; Blood Pressure; Conditioning, Classical; Female; Heart Rate; Humans; Hyperten | 1992 |
Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitors; Double-Blin | 1992 |
Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Atenolol; Creatinine; Diure | 1992 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
Bioequivalence of a new atenolol formulation.
Topics: Adult; Atenolol; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Hypertension; Male | 1992 |
[Regression of left ventricular mass in arterial hypertension. Efficacy of 3 different treatment protocols].
Topics: Adult; Aged; Atenolol; Blood Pressure; Cardiomegaly; Chlorthalidone; Electrocardiography; Enalapril; | 1992 |
Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Cilazap | 1992 |
Changes in left ventricular dimensions and systolic function in 100 mildly hypertensive men during one year's treatment with atenolol vs. hydrochlorothiazide and amiloride (Moduretic): a double-blind, randomized study.
Topics: Adult; Aged; Atenolol; Cardiomegaly; Double-Blind Method; Echocardiography; Humans; Hydrochlorothiaz | 1992 |
Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Diastole; Humans; Hypertension; Middle Aged; Regression Analy | 1992 |
Are there differences in the blood-pressure-lowering effect of atenolol vs. hydrochlorothiazide + amiloride (Moduretic) when assessed by standard clinic recordings vs. 24-h ambulatory monitoring?
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Blood Pressure Determination; Double-Blind Method; Drug | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients.
Topics: Affect; Aged; Aged, 80 and over; Atenolol; Cognition; Double-Blind Method; Female; Humans; Hypertens | 1992 |
Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group.
Topics: Atenolol; Chlorthalidone; Combined Modality Therapy; Energy Intake; Exercise; Female; Humans; Hypert | 1992 |
Systolic hypertension in older persons.
Topics: Aged; Aging; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; | 1992 |
Cognitive effects of beta blockers.
Topics: Adult; Affect; Arousal; Atenolol; Attention; Cognition; Double-Blind Method; Female; Humans; Hyperte | 1992 |
Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Atenolol; C | 1992 |
Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics.
Topics: Atenolol; Blood Pressure; Double-Blind Method; Female; Fetus; Heart Rate; Hemodynamics; Humans; Hype | 1992 |
Lipid profile in 100 men with moderate hypertension treated for 1 year with atenolol or hydrochlorothiazide plus amiloride: a double-blind, randomized study.
Topics: Adult; Amiloride; Apoproteins; Atenolol; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyp | 1992 |
Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade.
Topics: Aged; Atenolol; Bradycardia; Cervical Plexus; Creatine Kinase; Double-Blind Method; Electrocardiogra | 1992 |
Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Determinat | 1992 |
Lisinopril versus atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 1991 |
Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen.
Topics: Adult; Antihypertensive Agents; Atenolol; Double-Blind Method; Enalapril; Exercise Test; Humans; Hyp | 1991 |
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Glucose; Diabetes Mellitus, Ty | 1991 |
Hemodynamic effects of celiprolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Celiprolol; Dose-Response Relationship, Drug; Ec | 1991 |
The treatment of moderate to severe hypertension with ACE inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Captopril; Double-Blind Method; Drug Therapy, Co | 1990 |
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Doubl | 1991 |
Lisinopril combined with atenolol in the treatment of hypertension. Swedish Lisinopril Study Group.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Double- | 1991 |
A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; | 1991 |
Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Heart Ventricles; Humans; | 1991 |
Comparison of ramipril against atenolol in controlling mild-to-moderate hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Bridged Bicyclo Compoun | 1991 |
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 1991 |
Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Captopril; Double-Bli | 1991 |
A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group.
Topics: Adult; Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Double-Blind Meth | 1991 |
The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension.
Topics: Atenolol; Black People; Body Mass Index; Chlorthalidone; Combined Modality Therapy; Female; Humans; | 1992 |
Effectiveness of atenolol in the treatment of hypertension during pregnancy.
Topics: Adult; Atenolol; Female; Humans; Hypertension; Parity; Pregnancy; Pregnancy Complications, Cardiovas | 1992 |
The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Cardiovascular Diseases | 1992 |
Commentary on the Trial of Antihypertensive Interventions and Management (TAIM) Study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hype | 1992 |
Antihypertensive and metabolic effects of single and combined atenolol regimens.
Topics: Atenolol; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug | 1992 |
Exercise performance during captopril and atenolol treatment in hypertensive patients.
Topics: Atenolol; Captopril; Double-Blind Method; Exercise; Hemodynamics; Humans; Hypertension; Male; Middle | 1991 |
Maintenance of blood pressure control in elderly hypertensives on ketoprofen.
Topics: Acebutolol; Aged; Aged, 80 and over; Aging; Atenolol; Blood Pressure; Double-Blind Method; Drug Ther | 1991 |
The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.
Topics: Adult; Affect; Aged; Atenolol; Blood Pressure; Captopril; Cognition; Double-Blind Method; Female; He | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe | 1991 |
The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Celiprolol; Cholesterol; Humans; Hypertens | 1991 |
Acute effects of alpha- and beta-adrenoceptor blockade on plasma atrial natriuretic peptides during exercise in elderly patients with mild hypertension.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Carteolol; Exercise; Female; Humans; Hypertension; Male; | 1991 |
Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension.
Topics: Adult; Aldosterone; Atenolol; Atrial Natriuretic Factor; Female; Humans; Hypertension; Male; Middle | 1991 |
Effect of isradipine and atenolol on lung function in patients with mild essential hypertension.
Topics: Adult; Aged; Airway Resistance; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Female; | 1991 |
Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Double-Blind Method; Glucose; Humans; | 1991 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
Comparison of lisinopril versus atenolol for mild to moderate essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Lis | 1991 |
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Chronic Disease; Diabetic Nephropathies; Diabetic Retinopa | 1991 |
A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women.
Topics: Aged; Atenolol; Blood Pressure; Diltiazem; Double-Blind Method; Enalapril; Female; Humans; Hypertens | 1991 |
Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.
Topics: Atenolol; Black People; Blood Pressure; Double-Blind Method; Humans; Hypertension; Labetalol; Middle | 1991 |
Effect of atenolol or enalapril on diurnal changes of blood pressure in Japanese mild to moderate hypertensives: a double-blind, randomised, crossover trial.
Topics: Adult; Asian People; Atenolol; Blood Pressure; Circadian Rhythm; Double-Blind Method; Enalapril; Exe | 1991 |
Perindopril and reference antihypertensives.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; | 1991 |
Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Delayed-Action Preparations; Double-Blind Method | 1991 |
Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy.
Topics: Atenolol; Atrial Natriuretic Factor; Blood Pressure; Diltiazem; Double-Blind Method; Drug Administra | 1990 |
A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Double-Blind Method; | 1990 |
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Choleste | 1990 |
Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Blood Pressure; Carbazoles; C | 1990 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Double-Blind Method; Doxazosin; Female; Humans; Hyper | 1990 |
Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Blood Pressure; Doxazosin; Heart Rate; Humans; Hypert | 1990 |
Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Atenolol; Double-Blind Method; Doxazosin; Fem | 1990 |
Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Forced Expiratory Volume | 1990 |
A comparative study of atenolol, nifedipine and their combination in the treatment of hypertension.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyp | 1991 |
The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment.
Topics: Adult; Atenolol; Bendroflumethiazide; Birth Weight; Drug Therapy, Combination; Embryonic and Fetal D | 1991 |
Captopril compared to atenolol in mild to moderate hypertension in a randomized double-blind controlled trial.
Topics: Adult; Atenolol; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperten | 1991 |
Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension.
Topics: Atenolol; Blood Glucose; Humans; Hypertension; Insulin; Kinetics; Lipids; Male; Middle Aged; Nifedip | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
The effects of antihypertensive agents on the quality of life in Indian hypertensives.
Topics: 1-Propanol; Adult; Aged; Atenolol; Captopril; Data Collection; Humans; Hypertension; India; Male; Mi | 1991 |
Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system.
Topics: Adult; Aged; Atenolol; Central Nervous System; Delayed-Action Preparations; Double-Blind Method; Hum | 1991 |
Cardiovascular response to dynamic treadmill exercise in patients with essential hypertension before and after therapy with atenolol or captopril.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Captopril; Exercise Test; Female; Hemodynamics; Humans | 1990 |
[Effects of calcium antagonists or beta-blockade on left ventricular diastolic function in essential hypertension].
Topics: Adult; Atenolol; Diastole; Echocardiography; Echocardiography, Doppler; Female; Humans; Hypertension | 1990 |
[Alpha-1 inhibition. Prevention of coronary risk factors].
Topics: Atenolol; Coronary Disease; Delayed-Action Preparations; Female; Humans; Hypertension; Lipids; Male; | 1990 |
[The prevalence of arrhythmias and repolarization changes in patients with mild or moderate essential hypertension undergoing an exercise test. Their variations with different antihypertensive treatments].
Topics: Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Echocardiogra | 1990 |
The effects of antihypertensive therapy on left ventricular mass in elderly patients.
Topics: Atenolol; Blood Pressure; Cardiomegaly; Double-Blind Method; Echocardiography; Gated Blood-Pool Imag | 1990 |
[Regression of left ventricular hypertrophy in hypertensive patients under long-term therapy with antihypertensive agents].
Topics: Acebutolol; Adult; Antihypertensive Agents; Atenolol; Cardiomegaly; Female; Gallopamil; Humans; Hype | 1990 |
Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Dox | 1990 |
Influence of left ventricular mass regression on cardiac function in hypertensive elderly individuals.
Topics: Aged; Atenolol; Cardiomegaly; Double-Blind Method; Humans; Hypertension; Middle Aged; Physical Exert | 1990 |
A long-term study of atenolol and doxazosin in mild and moderate hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Fema | 1990 |
Special considerations in the elderly patient.
Topics: Age Factors; Aged; Aging; Atenolol; Blood Pressure; Cardiac Output; Cardiomegaly; Chlorthalidone; Do | 1990 |
Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Drug | 1990 |
Influences of propranolol and atenolol on the circadian rhythm of heart rate in elderly patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Atenolol; Blood Pressure; Circadian Rhythm; Electrocardiography; Female; He | 1990 |
Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of captopril and atenolol.
Topics: Affect; Atenolol; Captopril; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Q | 1990 |
Predicting interindividual variations in antihypertensive therapy: the role of sodium transport systems and renin.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Canrenoic Acid; Captopril; Erythrocyte Membrane; Female | 1990 |
Dynamic association between artery shear flow condition and platelet cytosolic free Ca2+ concentration in human hypertension.
Topics: Arteries; Atenolol; Blood Platelets; Calcium; Carteolol; Cytosol; Double-Blind Method; Female; Hemod | 1990 |
A double-blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Exerc | 1990 |
Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; | 1990 |
[Comparative study of the efficacy and tolerance of perindopril, a new converting enzyme inhibitor and of atenolol, a beta blocker].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Double-Bli | 1990 |
Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; F | 1990 |
[A comparative study of atenolol (Tenormin) and the combined preparation atenolol/chlorthalidone (Tenoretic Mite) in essential hypertension. A randomized double-blind study from general practice].
Topics: Adolescent; Adult; Aged; Atenolol; Chlorthalidone; Double-Blind Method; Drug Combinations; Drug Eval | 1990 |
Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Diuretics; Drug Combinations; Drug Tolerance; | 1990 |
Long-term treatment of hypertension in the elderly with a combination of atenolol and nifedipine.
Topics: Aged; Atenolol; Clinical Trials as Topic; Delayed-Action Preparations; Dizziness; Drug Combinations; | 1990 |
The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension.
Topics: Adolescent; Adult; Apolipoproteins; Atenolol; Cholesterol; Clonidine; Double-Blind Method; Humans; H | 1990 |
Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol.
Topics: Adult; Aged; Analysis of Variance; Atenolol; Captopril; Cognition; Double-Blind Method; Enalapril; H | 1990 |
First-dose effects of enalapril and atenolol upon blood pressure and cerebral blood flow in patients with mild hypertension on diuretic therapy.
Topics: Aged; Atenolol; Benzothiadiazines; Blood Pressure; Cerebrovascular Circulation; Diuretics; Enalapril | 1990 |
Comparative effects of dilevalol and atenolol on lung function and airway response to methacholine in hypertensive subjects.
Topics: Adult; Aged; Atenolol; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hypertension; | 1990 |
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.
Topics: Adult; Aged; Atenolol; Black People; Captopril; Delayed-Action Preparations; Dose-Response Relations | 1990 |
Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.
Topics: Age Factors; Antihypertensive Agents; Atenolol; Black or African American; Black People; Captopril; | 1990 |
Hypertension in the elderly: a study of a combination of atenolol and nifedipine.
Topics: Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Female; Heart Rate; Hum | 1990 |
A dose finding study of the combination of atenolol and nifedipine in hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Me | 1990 |
Comparison of the side-effects of pindolol and atenolol in the treatment of hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Bradycardia; Double-Blind Method; Female; Heart Rate; Humans; | 1990 |
Comparison of the efficacy and long-term tolerability of a combination of atenolol and nifedipine with atenolol alone in the treatment of hypertension.
Topics: Adult; Aged; Atenolol; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Male; M | 1990 |
Efficacy of enalapril in essential hypertension and its comparison with atenolol.
Topics: Adult; Aged; Atenolol; Dose-Response Relationship, Drug; Enalapril; Female; Humans; Hypertension; Ma | 1990 |
Hypertension in the elderly: a study of a combination of atenolol, hydrochlorothiazide and amiloride hydrochloride.
Topics: Aged; Amiloride; Atenolol; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 1990 |
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril.
Topics: Analysis of Variance; Atenolol; Blood Pressure; Cognition; Depression; Diuretics; Double-Blind Metho | 1990 |
[Effectiveness of long-term antihypertensive therapy with tenoretic--a combined long-acting drug].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1990 |
Atenolol in essential hypertension during pregnancy.
Topics: Atenolol; Birth Weight; Blood Pressure; Double-Blind Method; Female; Fetal Growth Retardation; Gesta | 1990 |
Atenolol in essential hypertension during pregnancy.
Topics: Atenolol; Female; Fetal Growth Retardation; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy Co | 1990 |
Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients.
Topics: Atenolol; Black People; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Hypertension; Labet | 1990 |
Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Doub | 1990 |
Individualizing antihypertensive therapy with enalapril versus atenolol: the Zurich experience.
Topics: Adult; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 1990 |
Effect of naproxen and sulindac on blood pressure response to atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Drug Interactions; Female; | 1990 |
A double blind comparison of perindopril and atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Dose-Re | 1990 |
Comparative trial of nifedipine retard and atenolol in the treatment of elderly patients with mild to moderate hypertension.
Topics: Aged; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 1990 |
Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.
Topics: Adult; Affect; Atenolol; Blood Pressure; Captopril; Heart Rate; Humans; Hypertension; Male; Oxazepam | 1990 |
Efficacy and safety of combinations of nitrendipine, atenolol, and hydrochlorothiazide in black hypertensive patients.
Topics: Atenolol; Black People; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension | 1990 |
Effects of nitrendipine and atenolol on blood pressure and intracellular sodium in hypertensive blacks.
Topics: Atenolol; Black People; Blood Pressure; Calcium; Double-Blind Method; Erythrocytes; Female; Humans; | 1990 |
Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atenolol; Female; Humans; Hypertension; Kidney | 1990 |
The effect of single-dose phenylpropanolamine on blood pressure in patients with hypertension controlled by beta blockers.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Humans; Hyperten | 1990 |
Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements.
Topics: Acebutolol; Adult; Aged; Atenolol; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Female | 1990 |
Comparison of central and peripheral haemodynamic effects of dilevalol and atenolol in essential hypertension.
Topics: Analysis of Variance; Atenolol; Blood Flow Velocity; Blood Pressure; Cardiac Output; Echocardiograph | 1990 |
Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: a comparison with atenolol.
Topics: Aged; Atenolol; Blood Pressure; C-Peptide; Delayed-Action Preparations; Double-Blind Method; Glucose | 1990 |
Left ventricular filling in hypertensive blacks and whites following adrenergic blockade.
Topics: Adult; Analysis of Variance; Atenolol; Black People; Cardiac Volume; Diastole; Double-Blind Method; | 1990 |
Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients.
Topics: Adrenergic beta-Antagonists; Asthma; Atenolol; Celiprolol; Forced Expiratory Volume; Humans; Hyperte | 1986 |
A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Fe | 1986 |
Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as T | 1986 |
A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Female; Humans; Hype | 1986 |
The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Clinical Trials as Topic; Double-Blind Method; E | 1987 |
Effect of calcium antagonists on ambulatory blood pressure and its variations.
Topics: Adult; Aged; Ambulatory Care; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combinati | 1987 |
Long-term hypotensive treatment with nitrendipine in mild to moderate essential hypertension: preliminary results of a placebo-controlled study versus atenolol.
Topics: Adult; Atenolol; Blood Pressure; Cardiac Output; Double-Blind Method; Female; Heart Rate; Humans; Hy | 1987 |
Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1988 |
Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topi | 1988 |
A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Calcium Channel Blockers; Clinical Tr | 1988 |
Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Double-Blin | 1989 |
Double-blind comparison of tiapamil and atenolol in patients with mild to moderate hypertension: a multicenter trial.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Calcium Channel Blockers; Double-Blind Method; E | 1989 |
[Multicenter study of atenolol, combined with hydralazine and bendroflumethiazide in the treatment of essential, mild, and severe, arterial hypertension].
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Drug Therapy, Combination; Female; Humans; Hydralazine; | 1989 |
Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
Topics: Atenolol; Blood Glucose; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Glucose | 1989 |
[Perindopril: first-line treatment of arterial hypertension].
Topics: Adolescent; Adult; Aged; Amiloride; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials as | 1989 |
[Treatment of essential hypertension with felodipine or atenolol as first line therapy. Comparative double-blind randomized study].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Felodipine; Female | 1989 |
Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Do | 1989 |
A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind | 1989 |
Differential effects of isradipine and atenolol on peripheral hemodynamics and arterial compliance.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Fe | 1989 |
Comparative effects of transdermal clonidine and oral atenolol on acute exercise performance and response to aerobic conditioning in subjects with hypertension.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Atenolol; Clonidine; Dermatitis, Contact; Do | 1989 |
Comparison of enalapril and atenolol in mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; En | 1989 |
[Regression of left heart hypertrophy in hypertensive patients as a result of antihypertensive therapy].
Topics: Acebutolol; Adult; Antihypertensive Agents; Atenolol; Cardiac Output; Cardiac Volume; Cardiomegaly; | 1989 |
Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Asthma; Atenolol; Blood Pressure; Celip | 1989 |
Effects of dilevalol, metoprolol and atenolol on left ventricular mass and function in nonelderly and elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Double-Blind Method; Echocardiography; Female; Heart; H | 1989 |
Treatment of severe hypertension with atenolol and betaxolol with once-daily regimens. Hemodynamic aspects.
Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Double-Blind Method; Drug Administration Schedule; | 1989 |
Antihypertensive effects of tertatolol. A comparative study versus atenolol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atenolol; Female; Humans; Hypertension; Male; M | 1989 |
[The effect of beta blockers on the QT interval: the possible role of mechanisms other than beta block].
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Electrocardiography; Female; Humans; | 1989 |
Carvedilol and atenolol once daily in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Carbazoles; Carvedilol; Doubl | 1989 |
Comparison of a vasodilating beta-blocker and a cardioselective beta-blocker in long-term treatment of hypertension: a European multicentre study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; | 1989 |
The effect of chronic antihypertensive therapy on the index of left ventricular mass in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Cardiac Volume; Clinical Trials as Topic; Echocardiography | 1989 |
A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Captopril; Clinical Trials as Topic; Diabetes | 1989 |
Comparison of nisoldipine and atenolol in the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Captopril; Heart Rate; Humans; Hype | 1989 |
Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.
Topics: Adult; Atenolol; Blood Glucose; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Female; He | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
Comparative long-term vasoactive effects of atenolol and carteolol on the properties of the small and large arteries of the upper extremities in human essential hypertension.
Topics: Adult; Arteries; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery; Carteolol; Double-B | 1989 |
Perindopril: first-line treatment for hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Diuretics; Do | 1989 |
Effects of long-term antihypertensive treatment on glucose metabolism.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus; Dilt | 1989 |
A double-blind comparative study of ketanserin with atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension | 1989 |
[Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Atenolol; Blood Pressure; Drug Therapy, Combination; Fema | 1989 |
Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects.
Topics: Adipose Tissue; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; | 1989 |
Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension.
Topics: Adult; Aged; Aorta; Arteries; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; Extremiti | 1989 |
Effect of pindolol versus atenolol on lipid profile in hypertensive patients.
Topics: Adult; Atenolol; Female; Humans; Hypertension; Lipoproteins; Male; Middle Aged; Pindolol | 1989 |
Antihypertensive efficacy and well-being during monotherapy and combination therapy with ketanserin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atenolol; Diuretics; Drug Therapy, Combination; Female; | 1989 |
Single doses of enalapril and atenolol in hypertensive patients treated with bendrofluazide.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Double-Blind Method; Drug Therapy, Combi | 1987 |
Angiotensin converting enzyme inhibitors in the clinic: first-dose hypotension.
Topics: Atenolol; Bendroflumethiazide; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Hypotensi | 1987 |
Resting and exercise blood pressure with atenolol, enalapril and a low-dose combination.
Topics: Adult; Atenolol; Blood Pressure; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Humans; H | 1987 |
ACE inhibitor versus beta-blocker in the treatment of essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Enalapril; Female; H | 1987 |
[Enalapril, atenolol and hydrochlorothiazide in mild or moderate hypertension. A comparative multicenter trial in general practice in Norway].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; Enala | 1987 |
The neglected time factor and antihypertensive therapy. A pitfall in evaluating side effects in a cross-over study.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Data Collection; Double | 1988 |
Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions.
Topics: Angiotensin II; Atenolol; Atrial Natriuretic Factor; Double-Blind Method; Drug Therapy, Combination; | 1987 |
Effects of atenolol and enalapril on blood pressure, plasma renin activity and urinary prostanoids.
Topics: Adult; Aged; Atenolol; Blood Pressure; Creatinine; Enalapril; Female; Furosemide; Heart Rate; Humans | 1988 |
A plea for more comprehensive blood pressure measurements when evaluating drug treatment of hypertension.
Topics: Atenolol; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Double-Blind Metho | 1988 |
Effects of angiotensin converting enzyme inhibition and beta-blockade on exercise responses in hypertensive patients.
Topics: Atenolol; Enalapril; Exercise Therapy; Hemodynamics; Humans; Hypertension; Lisinopril; Oxygen; Time | 1988 |
Duration of the antihypertensive action of atenolol, enalapril and placebo: a randomized within-patient study using ambulatory blood pressure monitoring.
Topics: Adult; Atenolol; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Double-Blin | 1988 |
Intracellular sodium and calcium during antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Body Fluids; Calcium; Erythrocytes; Humans; Hype | 1985 |
Haemodynamic and metabolic responses to prolonged exercise after chronic beta 1-adrenoceptor blockade in hypertensive man.
Topics: Adrenergic beta-Antagonists; Adult; Arteries; Atenolol; Hemodynamics; Humans; Hypertension; Male; Ph | 1985 |
Cardioselective and nonselective beta-adrenoceptor blocking drugs in hypertension: a comparison of their effect on blood pressure during mental and physical activity.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bicycling; Blood Pressure; Female; H | 1985 |
Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Calcium Channel Blockers; Clinical Tri | 1985 |
A comparison of celiprolol and atenolol in the treatment of hypertension: a placebo controlled double blind study.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Hu | 1985 |
Treating the older hypertensive: beta-blocker or diuretic?
Topics: Adrenergic beta-Antagonists; Aged; Amiloride; Atenolol; Blood Pressure; Diuretics; Double-Blind Meth | 1985 |
Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Clinical Trials as Topic; Electrocardiography | 1985 |
Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1986 |
Enalapril, atenolol, and hydrochlorothiazide in hypertension.
Topics: Atenolol; Clinical Trials as Topic; Double-Blind Method; Enalapril; Humans; Hydrochlorothiazide; Hyp | 1986 |
Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Atenolol; Chlorthalidone; Drug Therapy, Combination; | 1986 |
Swedish trial in old patients with hypertension. A prospective multicentre study in Swedish primary health care.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiloride; Atenolol; Clinical Trials as Topic; | 1986 |
Relaxation therapy for hypertension. Comparison of effects with concomitant placebo, diuretic, and beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Combined Modality Ther | 1986 |
Comparative tolerability of labetalol versus propranolol, atenolol, pindolol, metoprolol, and nadolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Female; Humans; Hypert | 1986 |
Comparison of bevantolol and atenolol for systemic hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Double-Blind Method; Female; Heart Rate; Humans; Hypertension | 1986 |
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Top | 1987 |
Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Top | 1987 |
A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Bl | 1987 |
Post-exercise hypotension: the effects of epanolol or atenolol on some hormonal and cardiovascular variables in hypertensive men.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Benzeneacetamides; Blood Gas Analysis; Blood Pressure | 1987 |
Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Captopril; Female; Forearm; Heart; Heart Rate | 1987 |
Double-blind comparison of once-daily bopindolol and atenolol for mild-to-moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Double-Blind Method; Drug Evaluation; | 1987 |
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication.
Topics: Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Exercise Test; F | 1987 |
[Comparative pharmacoclinical study of 2 beta-blockers: atenolol and betaxolol in slight-to-moderate arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Betaxolol; Female; Humans; Hypertension; Male; Propano | 1987 |
Antihypertensive therapy with celiprolol: a new cardioselective beta blocker.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic | 1988 |
Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.
Topics: Adolescent; Adult; Aged; Atenolol; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, C | 1988 |
Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Enalapril; Female; Humans; Hyp | 1987 |
Comparison of the antihypertensive effects of betaxolol to atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Betaxolol; Blood Pressure; Bradycardia; Clinical Trials as To | 1988 |
Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anesthesia; Atenolol; Clinical Trials as To | 1988 |
Effects of beta-blockade and exercise on cardiovascular and cognitive functioning.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Diastole; Heart Rate; Hemodynamics; Hu | 1988 |
Impact of beta-blockade on complex cognitive functioning.
Topics: Adrenergic beta-Antagonists; Adult; Affect; Atenolol; Blood Pressure; Clinical Trials as Topic; Cogn | 1988 |
Celiprolol and verapamil in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic | 1988 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D | 1988 |
A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Doxazosin; | 1988 |
A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as Topic; | 1988 |
Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Benzothiadiazines; Clinical Protocols; Coronary Diseas | 1988 |
Effects of acute and chronic beta-adrenoceptor blockade on baroreflex sensitivity in humans.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Female; Heart Rate; | 1988 |
Does beta 1-selective agonistic activity interfere with the antihypertensive efficacy of beta 1-selective blocking agents?
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Benzeneace | 1985 |
Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers.
Topics: Adult; Aged; Atenolol; Blood Pressure; Cardiac Output; Exercise Test; Heart Rate; Humans; Hypertensi | 1989 |
Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia.
Topics: Apoproteins; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Eating; Huma | 1989 |
Forearm and finger hemodynamics, blood pressure control, and lipid changes in diabetic hypertensive patients treated with atenolol and prazosin. A brief report.
Topics: Adult; Aged; Atenolol; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Female; Fingers; F | 1989 |
The long-term antihypertensive effects of prazosin and atenolol.
Topics: Atenolol; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertensi | 1989 |
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1986 |
Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1986 |
Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins; Atenolol; Cholesterol; Cholesterol, HDL; Clin | 1986 |
The antihypertensive effects of doxazosin: a clinical overview.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cholesterol | 1986 |
The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1987 |
[Normalization of ventricular compliance and hypertrophy in arterial hypertension. Double-blind study with 2 combinations of a beta blocker and diuretic].
Topics: Adult; Atenolol; Blood Pressure; Cardiomegaly; Chlorthalidone; Clinical Trials as Topic; Double-Blin | 1987 |
Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study.
Topics: Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Dr | 1987 |
[Effects of chronic administration of several calcium antagonists on pituitary release of TSH].
Topics: Adult; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Humans; Hyper | 1987 |
Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Enalapril; Female; Humans; Hydrochlorothiazide; Hyp | 1985 |
Enalapril in moderate to severe hypertension: a comparison with atenolol.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Creatinine; Drug Evaluation; Drug Therapy, Combin | 1986 |
Differential effects of atenolol and enalapril on memory during treatment for essential hypertension.
Topics: Adult; Aged; Atenolol; Enalapril; Female; Humans; Hypertension; Learning; Male; Memory; Memory, Shor | 1986 |
A comparison of lisinopril and atenolol in black and Indian patients with mild-to-moderate essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Black People; Blood Pressure; Clinical Trials as | 1987 |
Enalapril as a first-step agent in essential hypertension: a comparative study with atenolol.
Topics: Adult; Atenolol; Clinical Trials as Topic; Double-Blind Method; Enalapril; Female; Humans; Hypertens | 1986 |
Comparison of urapidil and atenolol in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1988 |
The efficacy and tolerability of atenolol, nifedipine, and their combination in the management of hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Combinati | 1988 |
Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clin | 1988 |
A comparison of captopril and atenolol in addition to hydrochlorothiazide for the treatment of hypertension.
Topics: Adult; Atenolol; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination | 1988 |
[Treatment of essential mild-to-moderate arterial hypertension with once-daily penbutolol. Controlled clinical study vs atenolol].
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte | 1988 |
Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin.
Topics: Adolescent; Adult; Atenolol; Biological Transport; Blood Pressure; Canrenoic Acid; Captopril; Erythr | 1988 |
Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension.
Topics: Acebutolol; Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Drug Adm | 1988 |
[Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension].
Topics: Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Ag | 1988 |
Memory performance by mild hypertensives following beta-adrenergic blockade.
Topics: Adult; Atenolol; Heart Rate; Humans; Hypertension; Male; Memory Disorders; Middle Aged; Propranolol; | 1986 |
Randomised trial of treatment of hypertension in elderly patients in primary care.
Topics: Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Cerebrovascular Disorders; Clinical Trials as T | 1986 |
Acute and long-term effect of antihypertensive treatment on exercise induced microalbuminuria in essential hypertension.
Topics: Adult; Albuminuria; Atenolol; beta 2-Microglobulin; Blood Pressure; Clinical Trials as Topic; Double | 1987 |
Effects of first-line antihypertensive agents on sexual function and sex hormones.
Topics: Adult; Antihypertensive Agents; Atenolol; Captopril; Estradiol; Follicle Stimulating Hormone; Humans | 1988 |
Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.
Topics: Adult; Atenolol; Blood Glucose; Body Weight; Cholesterol, LDL; Cholesterol, VLDL; Drug Administratio | 1988 |
[Verapamil and nitrendipine in beta blocker-resistant hypertensive patients].
Topics: Atenolol; Calcium Channel Blockers; Drug Resistance; Female; Humans; Hypertension; Male; Middle Aged | 1985 |
Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials as Topic; Do | 1985 |
Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients.
Topics: Anesthesia; Atenolol; Coronary Disease; Diuretics; Humans; Hypertension; Intubation, Intratracheal; | 1988 |
No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR.
Topics: Atenolol; Blood Pressure; Health Status; Heart Rate; Humans; Hypertension; Metoprolol; Quality of Li | 1988 |
Intracellular sodium and the response to nitrendipine or atenolol in African blacks.
Topics: Adult; Africa; Aldosterone; Atenolol; Black People; Blood Pressure; Double-Blind Method; Erythrocyte | 1988 |
Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1988 |
Exercise stress test in young hypertensive patients. Response to vasodilators (prazosin) vs. beta-blocker (atenolol) agents.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Hemod | 1988 |
The effect of beta-blockers on mental performance on older hypertensive patients.
Topics: Aged; Aged, 80 and over; Atenolol; Attention; Blood Pressure; Clinical Trials as Topic; Double-Blind | 1988 |
Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Delayed-Action Prepa | 1988 |
Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Creatinine; Double-Blind Method; Dr | 1988 |
Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Dr | 1988 |
Melatonin secretion related to side-effects of beta-blockers from the central nervous system.
Topics: Adult; Atenolol; Circadian Rhythm; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertensi | 1988 |
Behavioral vs beta-blocker therapy in patients with primary hypertension: effects on blood pressure, left ventricular function and mass, and the pressor surge of social stress anger.
Topics: Adult; Aged; Atenolol; Behavior Therapy; Blood Pressure; Humans; Hypertension; Male; Middle Aged; My | 1988 |
Forearm and finger hemodynamics, blood pressure control, and lipid changes in patients with diabetic hypertension treated with atenolol and prazosin.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Female; Fin | 1988 |
A randomised double blind cross over trial of atenolol and propranolol in mild to moderate hypertension.
Topics: Adult; Aged; Atenolol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; | 1987 |
Exercise capacity and hemodynamics in persons aged 20 to 50 years with systemic hypertension treated with diltiazem and atenolol.
Topics: Adult; Atenolol; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Exercise Test; Female; He | 1987 |
Comparison of diltiazem and atenolol in young, physically active men with essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Heart Rat | 1987 |
Comparative efficacy of captopril and atenolol in moderately severe essential hypertension.
Topics: Adult; Atenolol; Bendroflumethiazide; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug | 1986 |
Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension.
Topics: Atenolol; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Diltiazem; Double-B | 1987 |
A comparative study on the effect of atenolol and labetalol on exercise capacity and lipid serum levels in essential hypertension.
Topics: Adult; Atenolol; Clinical Trials as Topic; Combined Modality Therapy; Exercise Test; Female; Humans; | 1987 |
A comparison of a hydrochlorothiazide plus triamterene combination (Dyazide) and atenolol in the treatment of patients with mild hypertension: a multicentre study in general practice.
Topics: Adult; Aged; Atenolol; Drug Combinations; Family Practice; Female; Humans; Hydrochlorothiazide; Hype | 1987 |
Atenolol improves blood pressure control in patients taking captopril and frusemide.
Topics: Adult; Aged; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Dru | 1987 |
Atenolol or propranolol in hypertensive patients poorly controlled on captopril and frusemide.
Topics: Aged; Aldosterone; Atenolol; Blood Pressure; Captopril; Clinical Trials as Topic; Creatinine; Double | 1987 |
Left ventricular function in mild hypertension after adrenergic blockade.
Topics: Atenolol; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Labetalol; Male; Midd | 1988 |
Renal function effects of dilevalol, a nonselective beta-adrenergic blocking drug with beta-2 agonist activity.
Topics: Administration, Oral; Adult; Aged; Atenolol; Double-Blind Method; Female; Glomerular Filtration Rate | 1988 |
Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension.
Topics: Adult; Atenolol; Behavior; Blood Pressure; Emotions; Humans; Hypertension; Male; Memory; Middle Aged | 1988 |
Aims of combination therapy--improved quality of life or better blood pressure control?
Topics: Atenolol; Blood Pressure; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypertensi | 1988 |
Comparison of the effects of pindolol and atenolol on hemodynamic function in systemic hypertension.
Topics: Adult; Atenolol; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Pindolol | 1988 |
The interference of indomethacin and of imidazole salicylate on blood pressure control of essential hypertensive patients treated with atenolol. Preliminary report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Atenolol; Blood Pressure; Drug Interactions; Evaluat | 1987 |
A double-blind study of the blood pressure lowering effect of a thiazide diuretic in hypertensive patients already on nifedipine and a beta-blocker.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Double-Blind Method; Drug Therapy, Combi | 1987 |
Metabolic effects of a change in antihypertensive treatment.
Topics: Animals; Atenolol; Blood Glucose; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Female; G | 1986 |
Effects of two antihypertensive agents on lipids, lipoproteins, and apoproteins A and B. Comparison of prazosin and atenolol.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Atenolol; Blood Pressure; Cholesterol, HDL; Chole | 1986 |
Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension.
Topics: Atenolol; Benzothiadiazines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Top | 1986 |
Comparative study of the antihypertensive effect of verapamil and atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Echocardiograp | 1986 |
Low-dose atenolol-chlorthalidone combination for treatment of mild hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combi | 1986 |
Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combin | 1986 |
Chronic treatment with tibalosine in essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; | 1986 |
Placebo controlled double-blind randomised cross-over trial of atenolol, hydrochlorothiazide and amiloride, and the combination (Kalten) in patients over 60 years of age.
Topics: Aged; Amiloride; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Blind Method; D | 1986 |
[Beta-blockers or thiazides for middle-aged and elderly patients with hypertension? A multicenter study in general practice].
Topics: Aged; Atenolol; Bendroflumethiazide; Clinical Trials as Topic; Humans; Hypertension; Middle Aged; Po | 1986 |
Changes in blood pressure, heart rate and thyroid hormones after sudden withdrawal of pindolol and atenolol in hypertensive patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart | 1986 |
Effects of beta 1-adrenoceptor blockade in the treatment of hypertension during pregnancy in diabetic women.
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hypertensi | 1986 |
[Systolic-diastolic function of the left ventricle and flowmetry of the lower limbs in the treatment of moderate essential arterial hypertension with atenolol-chlorthalidone].
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug | 1986 |
Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial.
Topics: Adult; Atenolol; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Humans; | 1987 |
Atenolol vs. amiloride-hydrochlorothiazide in the treatment of mild to moderate hypertension: a double-blind, crossover, placebo-controlled study.
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Dru | 1987 |
[Alphamethyldopa vs. atenolol in the treatment of arterial hypertension].
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Femal | 1986 |
[Results of a multicenter trial of antihypertensive treatment with atenolol, alone or in combination with chlorthalidone, of patients with mild, moderate and severe hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Thera | 1987 |
A comparative study of atenolol/nifedipine and atenolol/diuretic in hypertension.
Topics: Atenolol; Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fe | 1986 |
Verapamil in essential hypertension: a comparison with atenolol plus hydralazine.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Echocardiogra | 1987 |
Altered calcium metabolism in red blood cells of hypertensives: persistent marker or sequel of essential hypertension?
Topics: Atenolol; Calcium; Erythrocytes; Humans; Hypertension; Potassium; Sodium | 1987 |
Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pr | 1987 |
Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.
Topics: Adult; Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Drug Administration Schedule; Drug Thera | 1987 |
The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication.
Topics: Adult; Aged; Atenolol; Blood Flow Velocity; Blood Pressure; Gait; Humans; Hypertension; Intermittent | 1986 |
Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.
Topics: Adult; Apoproteins; Atenolol; Blood Pressure; Body Weight; Cholesterol, HDL; Heart Rate; Humans; Hyp | 1986 |
Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Body Weight; Chlo | 1986 |
The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function.
Topics: Aged; Atenolol; Cardiac Output; Cardiovascular System; Heart Rate; Humans; Hypertension; Labetalol; | 1986 |
Effect of beta-blockers on plasma lipids.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Female; Heart Rate; Humans; Hypertension; Lipids; Male | 1986 |
Beta-blocker versus diuretic for control of the blood pressure response to stress in hypertensive patients.
Topics: Adult; Amiloride; Atenolol; Chronic Disease; Drug Combinations; Female; Heart Rate; Humans; Hydrochl | 1986 |
Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial.
Topics: Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina | 1985 |
Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Th | 1985 |
Long-term effects of captopril and atenolol in essential hypertension.
Topics: Adult; Aged; Atenolol; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combi | 1985 |
[Comparative study of the effects of prazosin and atenolol on plasma lipids of hypertensive patients].
Topics: Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosi | 1985 |
A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic | 1985 |
Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication.
Topics: Adult; Atenolol; Blood Pressure; Clinical Trials as Topic; Disability Evaluation; Double-Blind Metho | 1985 |
A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.
Topics: Adult; Atenolol; Chlorothiazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans | 1985 |
[Comparison of hypotensive effectiveness of propranolol and atenolol in combined treatment of primary hypertension].
Topics: Adult; Atenolol; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1985 |
[Therapeutic prospectives in the field of hypertension].
Topics: Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Drug Tolerance; | 1985 |
Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives.
Topics: Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combina | 1985 |
Third-line therapy. A cautionary note.
Topics: Atenolol; Bendroflumethiazide; Captopril; Chlorthalidone; Female; Humans; Hypertension; Male; Methyl | 1985 |
[Atenolol-chlorthalidone combination vs placebo: controlled clinical trial in patients with medium-mild arterial hypertension].
Topics: Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Drug Tol | 1985 |
Haemodynamic effects of prazosin combinations during dynamic and isometric exercise.
Topics: Adult; Atenolol; Clinical Trials as Topic; Clonidine; Drug Therapy, Combination; Electrocardiography | 1985 |
Atenolol as an anti-hypertensive drug.
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combinati | 1985 |
Double-blind trial comparing labetalol with atenolol in the treatment of systemic hypertension with angina pectoris.
Topics: Adult; Angina Pectoris; Atenolol; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Fema | 1985 |
Prazosin once or twice daily?
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1985 |
Effects of atenolol, labetalol and propranolol on the peripheral circulation in hypertensive patients without obstructive vascular disease.
Topics: Adolescent; Adult; Atenolol; Blood Circulation; Ethanolamines; Female; Fingers; Humans; Hypertension | 1985 |
Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison.
Topics: Acebutolol; Adult; Aged; Atenolol; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Ma | 1985 |
Effect of beta 1-selective and nonselective beta blockade on blood pressure relative to physical performance in men with systemic hypertension.
Topics: Adult; Atenolol; Blood Pressure; Cardiac Output; Double-Blind Method; Exercise Test; Heart Rate; Hum | 1985 |
Comparison of atenolol 50 mg and 100 mg as initial treatment in uncomplicated mild to moderate hypertension.
Topics: Adult; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Mal | 1985 |
The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
Topics: Adult; Aged; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Delayed-Action Preparation | 1985 |
Blood pressure, heart rate and A-V conduction responses to nicardipine in hypertensive patients receiving atenolol.
Topics: Adult; Atenolol; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heart | 1985 |
Comparison of the duration of antihypertensive action of atenolol and metoprolol over a 24-hour period.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension | 1985 |
Atenolol versus pindolol: side-effects in hypertension.
Topics: Adolescent; Adult; Atenolol; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Muscle Cra | 1985 |
Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.
Topics: Adult; Aged; Atenolol; Delayed-Action Preparations; Exercise Test; Female; Humans; Hypertension; Mal | 1985 |
Effect of atenolol in angina pectoris of effort.
Topics: Adult; Angina Pectoris; Atenolol; Double-Blind Method; Exercise Test; Female; Humans; Hypertension; | 1972 |
673 other studies available for atenolol and Blood Pressure, High
| Article | Year |
|---|---|
Effect of Blood Pressure Reduction on Intraocular Pressure and Ophthalmic Artery Blood Flow Velocity in Hypertension.
Topics: Amlodipine; Atenolol; Blood Flow Velocity; Blood Pressure; Humans; Hypertension; Intraocular Pressur | 2022 |
Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database.
Topics: Adrenergic beta-Antagonists; Atenolol; Drug-Related Side Effects and Adverse Reactions; Female; Huma | 2022 |
Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Hypertension; Hypote | 2023 |
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atenolol; Chlorthali | 2019 |
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Gout; H | 2020 |
Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Asian People; Atenolol; Blood Pressure; Body M | 2020 |
Passive Cigarette Smoking Impact on Blood Pressure Response to Epinephrine and Felypressin in 1K1C Hypertensive Rats Treated or not with Atenolol.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Drug I | 2020 |
Short Editorial - Effect of Passive Smoking on Blood Pressure Response to Epinephrine and Felypressin in 1K1C Hypertensive Rats Treated or not with Atenolol.
Topics: Animals; Atenolol; Blood Pressure; Cigarette Smoking; Epinephrine; Felypressin; Hypertension; Rats; | 2020 |
Atenolol increases dental mineralization in male offspring of treated hypertensive rats and normotensive rats.
Topics: Animals; Atenolol; Dental Enamel; Dentin; Female; Hardness; Hypertension; Male; Pregnancy; Rats; Rat | 2020 |
Different Responses of Arterial Stiffness between the Aorta and the Iliofemoral Artery during the Administration of Phentolamine and Atenolol in Rabbits.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Blood Flow Velocity; Blood Pressure Determination | 2021 |
Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Hypertension; Male; Nebivolol; Rats; Rat | 2021 |
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Carvedilol; D | 2021 |
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholest | 2021 |
Combination of anti-hypertensive drugs: a molecular dynamics simulation study.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Dimyristoylphosphatidylcholine; Humans; Hydrogen Bond | 2017 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Arginine; Atenolol; Blood Pressure; Enzyme Inhibitors; Hype | 2017 |
Beating, Fast and Slow.
Topics: Angina Pectoris; Atenolol; Biopsy; Bradycardia; Chest Pain; Diabetes Mellitus, Type 2; Diagnosis, Di | 2017 |
Drug utilization among hypertensive patients in the outpatient department of medicine in a tertiary care hospital: A cross-sectional study.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Drug Prescriptions; Drug Uti | 2018 |
Alteration of serum immunoglobins, C-reactive protein, vitamin D, and electrolyte by atenolol and amlodipine in stress-induced hypertensive rats.
Topics: Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Atenolol; C-Reactive Protein; Calcium; | 2018 |
β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2018 |
Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Dietary Supplements; Disease Models, Ani | 2019 |
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
Topics: Antihypertensive Agents; Atenolol; Brazil; Captopril; Cell Survival; Cells, Cultured; DNA Damage; Do | 2018 |
Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black or Af | 2018 |
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Bestrophins; Blood Pressure; Female; Genet | 2018 |
Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure | 2013 |
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenas | 2013 |
Association of an oral formulation of angiotensin-(1-7) with atenolol improves lipid metabolism in hypertensive rats.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin I; Animals; Atenolol; Hypertension; L | 2013 |
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
Topics: Adult; Antihypertensive Agents; Atenolol; Black or African American; Cluster Analysis; Female; Genom | 2013 |
Atenolol use is associated with long-term mortality in community-dwelling older adults with hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Arterial Pressure; Atenolol; Confidence Intervals; Cro | 2014 |
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chromosomes, Human, Pair 17; Diuretics; Fe | 2013 |
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antihypertensive Agents; Atenolol; ATP Binding | 2013 |
Modulation of microRNAs in hypertension-induced arterial remodeling through the β1 and β3-adrenoreceptor pathways.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Atrial Remodeling; Benzopyrans; Cardiomegaly; | 2013 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations | 2014 |
Cardiovascular protection by β-blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Humans; Hyperten | 2014 |
Comparison of epinephrine and felypressin pressure effects in 1K1C hypertensive rats treated or not with atenolol.
Topics: Animals; Atenolol; Blood Pressure; Epinephrine; Felypressin; Heart Rate; Hypertension; Hypotension; | 2015 |
Effects of antihypertensive treatment on cardiovascular autonomic control: a prospective study.
Topics: Antihypertensive Agents; Atenolol; Atrial Fibrillation; Autonomic Nervous System; Cohort Studies; En | 2014 |
[My hypertensive patient wants beta blockers. Are they not obsolete?].
Topics: Adrenergic beta-Antagonists; Atenolol; Drug Substitution; Germany; Guideline Adherence; Humans; Hype | 2014 |
Effects of hippadine on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats.
Topics: Amaryllidaceae Alkaloids; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Crinum; Dose-R | 2014 |
Long-term treatment of clonidine, atenolol, amlodipine and dihydrochlorothiazide, but not enalapril, impairs the sexual function in male spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Clonidine; Drug Administration Schedule; Enalapril; Hydr | 2015 |
Comment on Kuyper et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Humans; Hypertension; Stroke | 2015 |
Reply to letter from Li et al.--Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Humans; Hypertension; Stroke | 2015 |
Comparison of atenolol versus bisoprolol with noninvasive hemodynamic and pulse wave assessment.
Topics: Anthropometry; Antihypertensive Agents; Atenolol; Biomarkers; Bisoprolol; Cardiography, Impedance; C | 2015 |
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Black People; Blood Pre | 2015 |
Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressu | 2016 |
Heart rate dependent and independent effects of beta-blockers on central hemodynamic parameters: a propensity score analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Blood Pressure; Cross-Sectional | 2016 |
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Fe | 2016 |
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
Topics: Adult; Age Factors; Antihypertensive Agents; Atenolol; Black or African American; Blood Pressure; Fe | 2016 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
[Lowering blood pressure and more? AT1 antagonist reduced plaque volume].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Caro | 2008 |
Anterior spinal cord syndrome after initiation of treatment with atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension; Hypotension; Infarction; Intervertebral | 2010 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; Franc | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumeth | 2008 |
Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Cat Diseases; Cats; Female; Heart Rate; | 2008 |
Addressing the relationship between sympathetic activity and inflammation.
Topics: Antihypertensive Agents; Atenolol; C-Reactive Protein; Female; Humans; Hypertension; Imidazoles; Inf | 2008 |
The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats.
Topics: Amlodipine; Animals; Atenolol; Blood Pressure; Drug Therapy, Combination; Hemodynamics; Hypertension | 2009 |
Diabetes and hypertension: which is the best approach?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Dise | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Ch | 2009 |
Atenolol versus other beta-adrenergic blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Humans; Hypertension | 2009 |
Atenolol is dead: long live beta-blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp | 2009 |
Comparison of hypotensive and hypolipidemic effects of Catharanthus roseus leaves extract with atenolol on adrenaline induced hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Body Weight; Catharanthus | 2009 |
Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation.
Topics: Adolescent; Antihypertensive Agents; Aortic Coarctation; Atenolol; Benzimidazoles; Biphenyl Compound | 2009 |
Effect of antihypertensive drug therapy on short-term heart rate variability in newly diagnosed essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Arrhythmia, Sinus; Atenolol; Enalapril; Female; Heart Ra | 2010 |
Atenolol hepatotoxicity: report of a complicated case.
Topics: Acute Disease; Adrenergic beta-Antagonists; Atenolol; Chemical and Drug Induced Liver Injury; Female | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Cardiovascular autonomic dysfunction in a novel rodent model of polycystic kidney disease.
Topics: Animals; Antihypertensive Agents; Atenolol; Atropine Derivatives; Autonomic Nervous System; Barorefl | 2010 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
Assessment of the genotoxicity of atenolol in human peripheral blood lymphocytes: correlation between chromosomal fragility and content of micronuclei.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Case-Control Studies; Chromosome Fragile Sites; Chro | 2010 |
Radiating abdominal pain and hypertension.
Topics: 3-Iodobenzylguanidine; Abdominal Pain; Adrenal Gland Neoplasms; Aged, 80 and over; Antihypertensive | 2009 |
Malignancy-associated multicentric reticulohistiocytosis.
Topics: Antihypertensive Agents; Antineoplastic Agents; Arthralgia; Atenolol; Combined Modality Therapy; Dru | 2011 |
Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2009 |
[Beta blockers in hypertension treatment Will stepping back come soon?].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Antihypertensive Agents; Atenolol; Clinical Trials a | 2007 |
Elevated heart rate in hypertension: a target for treatment?
Topics: Anti-Arrhythmia Agents; Atenolol; Heart Rate; Humans; Hypertension; Tachycardia; Treatment Outcome | 2010 |
An unusual phenomenon with entropy during induction of general anaesthesia.
Topics: Adrenergic beta-Antagonists; Amlodipine; Anesthesia, General; Anesthetics, Intravenous; Antihyperten | 2010 |
Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Base Sequence; Blood Pressure; Case-Control Stud | 2010 |
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2010 |
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Impact of arterial stiffness reduction on urinary albumin excretion during antihypertensive treatment: the Japan morning Surge-1 study.
Topics: Aged; Albuminuria; Ankle Brachial Index; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Bra | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2010 |
Atenolol in uncomplicated hypertension: time for changes.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension | 2010 |
Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Atenolol; Hypertension; Losartan; Male; Mal | 2010 |
Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2010 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease | 2010 |
Atenolol blunts blood pressure increase during dynamic resistance exercise in hypertensives.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Exercise; Female; Humans; Hypertension; Ma | 2010 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
Hemodynamic responses to aortic depressor nerve stimulation in conscious L-NAME-induced hypertensive rats.
Topics: Angiotensin II; Animals; Aorta; Atenolol; Atropine Derivatives; Baroreflex; Blood Pressure; Electric | 2011 |
More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension.
Topics: Antihypertensive Agents; Aorta; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery; Card | 2011 |
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Capto | 2011 |
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Topics: Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Case-Control Stu | 2011 |
Expanding our therapeutic options: Beta blockers for breast cancer?
Topics: Adrenergic beta-Antagonists; Atenolol; Breast Neoplasms; Diabetes Complications; Disease-Free Surviv | 2011 |
Beta blockers and breast cancer mortality: a population- based study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Breast Neoplasms; Disease Progression; Female; Humans; | 2011 |
The enhanced effect of atenolol on hypertension in metabolic syndrome.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Body Mass Index; Case-Control | 2011 |
Does atenolol reduce adverse cardiovascular outcomes in adult patients with hypertension?
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension | 2011 |
Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disea | 2011 |
Ask the doctor. My blood pressure has wide swings each day. It can go as high as 210/110 with even minor stress like grocery shopping, then fall to 100/50, which makes me tired and needing rest. I take 15 mg of isosorbide dinitrate and a slow-release nitr
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Isosorbide Dinitrate; Vasodilator Agents | 2011 |
Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Anim | 2011 |
An economic evaluation of antihypertensive therapies based on clinical trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination | 2012 |
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
Topics: Adult; Antihypertensive Agents; Atenolol; Black or African American; Blood Pressure; Chromosomes, Hu | 2013 |
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Carbazoles; Carvedilol; Databases, Fact | 2012 |
Retinitis preceding systemic lupus erythematosus in absence of anti-phospholipid antibodies.
Topics: Adolescent; Antibodies, Antiphospholipid; Atenolol; Cyclophosphamide; Diagnosis, Differential; Drug | 2012 |
Effects of potassium-sparing versus thiazide diuretics on glucose tolerance: new data on an old topic.
Topics: Amiloride; Atenolol; Blood Glucose; Female; Humans; Hydrochlorothiazide; Hypertension; Male | 2012 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
Cardioselective beta-blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks?
Topics: Adrenergic beta-1 Receptor Antagonists; Asthma; Atenolol; Dose-Response Relationship, Drug; Humans; | 2012 |
I take three different blood pressure medications-six pills total-every day. They are isosorbide mononitrate, amlodipine, and atenolol. They seem to do a good job bringing down my blood pressure, but before my 6 p.m. atenolol and then later before my 10 p
Topics: Amlodipine; Atenolol; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Drug Administr | 2011 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-R | 2002 |
Anti-hypertensive drugs in pregnancy and fetal growth: evidence for "pharmacological programming" in the first trimester?
Topics: Antihypertensive Agents; Atenolol; Embryonic and Fetal Development; Female; Humans; Hypertension; In | 2002 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
[Preventing stroke. Which antihypertensive drugs can do it better?].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as T | 2002 |
Circadian blood pressure overswinging in a physically fit, normotensive African American woman.
Topics: Adrenergic beta-Antagonists; Atenolol; Black People; Blood Pressure; Blood Pressure Monitoring, Ambu | 2002 |
[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Female; Humans; Hypertension; Los | 2002 |
Interaction between ECT and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Atenolol; Combined Modality | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losart | 2002 |
Was the LIFE trial independent?
Topics: Antihypertensive Agents; Atenolol; Conflict of Interest; Drug Industry; Humans; Hypertension; Losart | 2002 |
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cl | 2002 |
[German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
[What are the consequences of the LIFE Study for general practice].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenol | 2002 |
[A case of familial restrictive cardiomyopathy].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Atenolol; Atrial Fibrillation | 2002 |
[Noonan syndrome coexisting with essential arterial hypertension in 8 year old boy].
Topics: Antihypertensive Agents; Atenolol; Child; Humans; Hypertension; Male; Noonan Syndrome; Time Factors; | 2002 |
Differential effects of antihypertensive drug therapy on arterial compliance.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Blood Pressure; Drug Combinations; He | 2002 |
[The role of depressive disorders in hypertensive disease and possibilities of their correction: assessment of the effect of tianeptine].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antidepressive A | 2002 |
[The use of combination therapy with lacidipine and beta-adrenoblockers in patients with hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Dihydropyridines; Dr | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol | 2003 |
[Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2002 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
[Beta blocker enhances NO liberation in the endothelium. Vascular tone long-term improvement].
Topics: Acetylcholine; Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Endothelium, Vascular; E | 2002 |
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hype | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Indus | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
[Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihyper | 2003 |
[Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
Topics: Aged; Antihypertensive Agents; Atenolol; Cause of Death; Double-Blind Method; Humans; Hypertension; | 2003 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
Effect of beta-adrenoceptor antagonist and angiotensin-converting enzyme inhibitor on hypertension-associated changes in adenylyl cyclase type V messenger RNA expression in spontaneously hypertensive rats.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Aging; Angiotensin-Converting Enzyme Inhibitors; Ani | 2003 |
For the patient. New treatments for heart failure in Black people. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal re
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Losartan and atenolol on hypertension induced by adenosine receptor blockade.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 2 Receptor Blocker | 2003 |
Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Baroreflex; Bisoprolol; Blood Pressure; Body Weight; | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
Anterior hypothalamic beta-adrenergic activity in the maintenance of hypertension in aortic coarctated rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anterior Hypothalamic Nucleus; Aorti | 2004 |
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives.
Topics: Adenine; Adult; Aged; Alleles; Antihypertensive Agents; Atenolol; Collagen Type I; Cytosine; Elastic | 2003 |
Proportion of treatment effect (PTE) explained by a surrogate marker.
Topics: Antihypertensive Agents; Atenolol; Biomarkers; Confidence Intervals; Data Interpretation, Statistica | 2003 |
Impact of atenolol consumption on the development of chronic renal allograft dysfunction.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Blood Urea Nitrogen; Humans; Hypertension; In | 2003 |
[Effects of monotherapy with an alpha1-adrenoblocker doxazosin and its combination with beta1-adrenoblocker atenolol on hemodynamics, reversible myocardial ischemia in postmyocardial infarction patients with arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 2003 |
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Los | 2003 |
Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2004 |
Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Evaluation, Preclinical | 2004 |
Hypertension and insulin resistance are not directly related in obese dogs.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Atenolol; Blood Glucose; Clonidine; Diet, Sodium-Rest | 2004 |
Effects of losartan in hypertension without vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp | 2004 |
The LIFE Trial in 2004.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Human | 2004 |
Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice.
Topics: Angiotensins; Animals; Atenolol; Blood Pressure; Heart Rate; Housing, Animal; Hypertension; Male; Mi | 2004 |
Ask the doctor. How does a beta blocker affect my heart rate and exercise?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension | 2004 |
Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive.
Topics: Action Potentials; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Female; Humans; H | 2004 |
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; | 2004 |
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; | 2004 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
Abdominal coarctation in a hypertensive female collegiate basketball player.
Topics: Adolescent; Antihypertensive Agents; Aorta, Abdominal; Aortic Coarctation; Aortography; Atenolol; Ba | 2004 |
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.
Topics: Analysis of Variance; Antihypertensive Agents; Apolipoproteins B; Atenolol; Biphenyl Compounds; Fema | 2004 |
Newly diagnosed hypertension and depressive symptoms: how would you treat?
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Antihypertensive Agents; Atenolol; Coronary Arte | 2005 |
[The double messages about atenolol must be an issue for the SBU board].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Consensus; Evidence-Based Medicine; | 2004 |
Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraga
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Atenolol; Blood Pr | 2004 |
Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Blood Pressure; Disease Models, Anima | 2005 |
Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective.
Topics: Aged; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; H | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Hypertension therapy with beta blocker plus diuretic. "We are at the point of leaving behind an era"].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blo | 2005 |
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2005 |
Keeping tabs on your heart while treating BP.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan | 2005 |
[Regulatory-adaptive abilities of hypertensive patients treated with lisinopril and atenolol].
Topics: Adaptation, Physiological; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; H | 2005 |
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Humans; Hypertension; Hypertrophy, Left | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Bli | 2005 |
C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2005 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Rec | 2005 |
Pulse pressure and antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2005 |
beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-3 Receptor Antagonists; Adrenergic beta-Anta | 2005 |
[Cardiac protection of atenolol: want of proof].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; | 2005 |
Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
Topics: Adult; Aging; Antihypertensive Agents; Atenolol; Case-Control Studies; Cohort Studies; Drug Prescrip | 2005 |
[Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Humans; Hypertension; Metoprolol; Tr | 2005 |
Effects of atenolol and propanolol on platelet aggregation in moderate essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Platelet Aggregation; Propranolol | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chi-Square Distribution; Coronary Disea | 2005 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D | 2005 |
[The ASCOT study: the end of the treatment of hypertension with beta-blockers?].
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension | 2005 |
Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Atenolol; Biomarkers; Blood Pressure; Blottin | 2006 |
[Diabetic with hallucination].
Topics: Atenolol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
Neurotensin-induced myocardial noradrenergic effects in spontaneously hypertensive rats.
Topics: Animals; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Hypertension; In Vitro Techniqu | 2006 |
Atenolol and cardiovascular risk: an issue close to the heart.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension | 2006 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr | 2006 |
Atenolol-induced breast pain in a woman with hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Breast Diseases; Female; Humans; Hyp | 2006 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Case-Control Studies; Cohort Studies; Coron | 2006 |
Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.
Topics: Amlodipine; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
Successful vaginal delivery for a parturient with complete aortic coarctation.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Intravenous; Anesthetics, Local; Ao | 2006 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Calcimycin; Do | 2006 |
Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
A pilot study of open label sesame oil in hypertensive diabetics.
Topics: Aged; Antihypertensive Agents; Antioxidants; Atenolol; Blood Glucose; Body Mass Index; Diabetes Comp | 2006 |
[Antihypertensive agents used as first line agents: beta-blockers under pressure].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Dihydropyridines; Diuretics; Drug Th | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Aut | 2006 |
Letter by Dart et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; E | 2006 |
Letter by Nieminen et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
Letter by Cameron et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
Letter by Safar and Fournier regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
Different effects of atenolol and nebivolol on coronary flow reserve.
Topics: Adult; Antihypertensive Agents; Atenolol; Benzopyrans; Coronary Circulation; Ethanolamines; Female; | 2006 |
[Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
Update on beta-blockers in hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Clinical Trials as Topic; Humans; Hypertension | 2006 |
Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
Topics: Antihypertensive Agents; Atenolol; Enalapril; Female; Genotype; Heterozygote; Humans; Hypertension; | 2006 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically | 2007 |
Pulse pressure: a help in medical semiology for metabolic syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Blo | 2007 |
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Age | 2007 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?
Topics: Adrenergic beta-Antagonists; Aging; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diab | 2006 |
Does atenolol differ from other beta-adrenergic blockers?
Topics: Adrenergic beta-Antagonists; Atenolol; Bayes Theorem; Humans; Hypertension; Meta-Analysis as Topic; | 2007 |
Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2007 |
Hypertension treatment: how important is consistency of effect?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure Determination; Cardiovascular Diseases; Cohort Stu | 2007 |
Ask the doctor. Can I stop taking my blood pressure medicine?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Deter | 2007 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis.
Topics: Antihypertensive Agents; Atenolol; Child; Cyclophosphamide; Enalapril; Female; Glomerulosclerosis, F | 2007 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Me | 2007 |
The effect of Ramadan fasting on ambulatory blood pressure in hypertensive patients using combination drug therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2008 |
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Antineoplasti | 2007 |
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atenolol; Blood Pressure; Blood Pr | 2007 |
Cardiovascular effects of L-glutamate injected in the medial prefrontal cortex of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Analysis of Variance; Animals; Atenolol; Blood Pressure; Bra | 2008 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |
Superficial migratory thrombophlebitis in a hypertensive patient: response to antihypertensive therapy.
Topics: Adult; Antihypertensive Agents; Atenolol; Diagnosis, Differential; Female; Humans; Hypertension; Rec | 2008 |
Atenolol reduces salivary activity in pups of spontaneously hypertensive and normotensive rats treated during pregnancy and lactation.
Topics: Adrenergic beta-Antagonists; Amylases; Animals; Atenolol; Female; Hypertension; Lactation; Male; Org | 2008 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Undiagnosed Graves' Disease contributing to sleep disordered breathing in a child undergoing adenotonsillectomy.
Topics: Acetaminophen; Adenoidectomy; Adenoids; Analgesics, Non-Narcotic; Analgesics, Opioid; Antihypertensi | 2008 |
Bilateral posterior ischemic optic neuropathy associated with use of sildenafil.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cytochrome P-450 Enzyme Inhibi | 2008 |
Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2008 |
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Brachial Arter | 2008 |
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Ventricles; Humans; Hypert | 2008 |
Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Female; Heart Rate; Hemod | 1984 |
Atenolol-induced regulation of leukocyte beta 2-adrenoceptors in hypertension.
Topics: Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Leukocytes; Male; Middle Aged; Mo | 1984 |
Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Atenolol; Blood Chemical Analysis; Blood G | 1980 |
Detection of some antihypertensive drugs and their metabolites in urine by thin-layer chromatography: II. A further five beta blockers and dihydralazine.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Chromatography, Thin Layer; Dihydralazine; Humans | 1980 |
[Cardioselective beta-blocking agents and respiratory function].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Female; Humans; Hypertension; Lung Diseases, Obstructi | 1980 |
The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Cold Temperature; Female; Hand; Humans; Hypertension; | 1981 |
Atenolol: a long-acting beta 1- adrenoceptor antagonist.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension; Kinetics; Propanolamines; Propranolol | 1982 |
[Carbohydrate metabolism and beta-blocking agents: effects of atenolol therapy].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Carbohydrate Metabolism; Diabetes Compl | 1981 |
Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Cardiac Output; Female; Glomerular Fil | 1982 |
Beta adrenergic blocking agents to control hypertension in aviation personnel.
Topics: Adrenergic beta-Antagonists; Adult; Aerospace Medicine; Atenolol; Humans; Hypertension; Male; Middle | 1982 |
Treatment of hypertension in pregnancy with beta-adrenoceptor antagonists.
Topics: Abnormalities, Drug-Induced; Acebutolol; Adrenergic beta-Antagonists; Adult; Apgar Score; Atenolol; | 1982 |
[Role of renin profile and age in the choice of the therapeutic approach of arterial hypertension (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Chlorthalidone; Diuretics; Drug The | 1981 |
Abrupt and gradual change from clonidine to beta blockers in hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Clonidine; Drug Interactions; Female; Humans; Hypertension; M | 1982 |
Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Dru | 1982 |
[Clinical evaluation of a beta-blocking agent in a single daily dose].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; | 1982 |
Treatment of hypertension with beta-adrenoceptor blocking drugs.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Male; Propranolol | 1982 |
Effect of sympathetic stimulation on inactive renin.
Topics: Acoustic Stimulation; Adrenergic alpha-Antagonists; Adult; Atenolol; Blood Pressure; Enzyme Precurso | 1982 |
Effects of different beta-receptor antagonists on handgrip in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1982 |
Possible significance of the pharmacological differentiation of beta-blocking agents in hemodynamic effects in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Atenolol; Carteolol; Hemodynamics; Humans; Hypertension; Me | 1983 |
Beta-blockers for pregnancy hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Labetalol; Pregnancy; Pregnancy | 1983 |
Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol.
Topics: Adrenergic beta-Antagonists; Alprenolol; Atenolol; Hemodynamics; Humans; Hypertension; Metoprolol; P | 1983 |
Modification of blood pressure and systolic time intervals by diuretics and beta-blockers in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Diuretics; Female; Furosemide; Heart R | 1983 |
Which beta-blocker in pregnancy-induced hypertension?
Topics: Atenolol; Birth Weight; Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Labetalol; Pre | 1983 |
[Beta-blockers in geriatrics. Results of a symposium on Tenormin].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Heart Diseases; Humans; Hypertension | 1983 |
Effects of acute and chronic treatments with atenolol and propranolol on cardiovascular responses to handling stress in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Ha | 1983 |
The effects of beta adrenoceptor blockade with atenolol on myocardial cellular and subcellular hypertrophy in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Body Water; Body Weight; Cardiomegal | 1983 |
The effect of two beta-adrenoceptor blockers (mepindolol and atenolol) on blood lipids and platelet aggregation in normal volunteers and essential hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Humans; Hypertension; Lipids; | 1984 |
Development of autonomic control of heart rate in genetically hypertensive and normotensive rats.
Topics: Adrenergic beta-Antagonists; Age Factors; Animals; Atenolol; Atropine Derivatives; Autonomic Nervous | 1984 |
Genetic and environmental influences on developing autonomic control of heart rate.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Atropine Derivatives; Autonomic Nervous System; Brai | 1984 |
Fetal heart rate during treatment of maternal hypertension with beta-adrenergic antagonists. A preliminary report.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Fetal Heart; Heart Rate; Humans; Hypertension; Pindol | 1984 |
Do beta blockers prevent pressor responses to mental stress and physical exercise?
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Female; Heart Rate; Humans; Hypertension; Isometric Co | 1984 |
Beta blockers in pregnancy.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Humans; Hypertension; Kinetics; Methyldopa; Oxprenolo | 1984 |
Pressor response to beta-blocking drugs.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Female; Humans; Hypertension; Isoproterenol; | 1984 |
Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives.
Topics: Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Glomerular Filtration Rate; Heart Rate; Human | 1984 |
Effect of beta-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats.
Topics: Animals; Aorta; Atenolol; Heart Ventricles; Hydralazine; Hypertension; Male; Norepinephrine; Organ S | 1980 |
[Antihypertensive efficacy of atenolol].
Topics: Adult; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Propanolamines | 1982 |
Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine.
Topics: Adult; Atenolol; Cardiomegaly; Echocardiography; Electrocardiography; Female; Heart Conduction Syste | 1983 |
Psoriasiform reaction to atenolol.
Topics: Atenolol; Drug Eruptions; Female; Humans; Hypertension; Middle Aged; Psoriasis | 1984 |
[Combined effect of hydrochlorothiazide and atenolol in antihypertensive therapy of 42 patients].
Topics: Adult; Atenolol; Blood Pressure; Drug Therapy, Combination; Electrolytes; Heart Rate; Humans; Hydroc | 1983 |
[Efficacy of the association of atenolol with an amiloride-hydrochlorothiazide combination in the treatment of persistent arterial hypertension].
Topics: Adult; Aged; Amiloride; Atenolol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydr | 1984 |
Effects of oral atenolol and propranolol on blood pressure, heart rate and plasma cyclic adenosine 3':5'-monophosphate in borderline hypertensive patients.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Cyclic AMP; Female; Heart Rate; Humans; Hypertension; M | 1982 |
Aldosterone response to antihypertensive treatment.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Dipepti | 1982 |
The ratio of cardiac to vascular beta-receptor blockade of atenolol and propranolol in spontaneously hypertensive rats in vivo.
Topics: Animals; Atenolol; Blood Vessels; Female; Heart; Hemodynamics; Hypertension; Isoproterenol; Propanol | 1982 |
[Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
Topics: Adult; Atenolol; Blood Pressure; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertensi | 1983 |
The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Atenolol; Blood Pressure; Body Weight; Drug Interactions; Femal | 1984 |
Acute effect of atenolol on hemodynamic, plasma renin activity and plasma aldosterone concentration in the once daily oral administration.
Topics: Administration, Oral; Adult; Aldosterone; Atenolol; Blood Pressure; Cardiac Output; Female; Heart Ra | 1984 |
Low dose thiazide combined with a beta blocker.
Topics: Atenolol; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Propanolamines | 1983 |
Clinical evaluation of 'Tenormin' (Atenolol) in hypertension.
Topics: Adult; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance | 1984 |
[Antihypertensives and the prevention of development of genetic hypertension in the hypertensive SHR rat].
Topics: Animals; Antihypertensive Agents; Atenolol; Captopril; Cardiomegaly; Dihydralazine; Dose-Response Re | 1980 |
Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Combinations; Drug Tolera | 1984 |
The prolonged antihypertensive effect of once daily atenolol: a study of continuous non-invasive arterial blood pressure monitoring.
Topics: Adult; Atenolol; Blood Pressure; Depression, Chemical; Drug Administration Schedule; Drug Tolerance; | 1984 |
Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; Dia | 1984 |
Treatment of hypertension in mild asthmatic patients with atenolol.
Topics: Adult; Albuterol; Asthma; Atenolol; Blood Pressure; Electrocardiography; Exercise Test; Female; Hear | 1984 |
[Beta-adrenergic blockers and renin-angiotensin-aldosterone system in healthy individuals and patients with arterial hypertension].
Topics: Adult; Atenolol; Female; Humans; Hypertension; Hypertension, Renal; Male; Middle Aged; Propranolol; | 1984 |
The effects of beta blockers on exercise capacity and on training response in elderly subjects.
Topics: Aged; Atenolol; Coronary Disease; Ethanolamines; Exercise Test; Female; Humans; Hypertension; Labeta | 1984 |
Flurbiprofen interaction with single doses of atenolol and propranolol.
Topics: Adult; Aldosterone; Atenolol; Blood Pressure; Body Weight; Female; Flurbiprofen; Heart Rate; Humans; | 1984 |
[A short-term clinical observation during the treatment of essential hypertension by atenolol composite tablets].
Topics: Adult; Atenolol; Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; | 1984 |
Propranolol-induced depression: mechanism and management.
Topics: Adult; Angina Pectoris; Atenolol; Depressive Disorder; Female; Humans; Hypertension; Male; Middle Ag | 1983 |
Effect of atenolol treatment on urinary prostaglandins E2 and F2 alpha in essential hypertension.
Topics: Adult; Atenolol; Dinoprostone; Female; Humans; Hypertension; Male; Middle Aged; Prostaglandins E; Pr | 1983 |
Atenolol and metoprolol. A comparison of their excretion into human breast milk.
Topics: Atenolol; Female; Fetal Blood; Humans; Hypertension; Metoprolol; Milk, Human; Pregnancy; Pregnancy C | 1984 |
Influence of the beta 1-adrenoceptor blocker atenolol on antenatal cardiotocography.
Topics: Apgar Score; Atenolol; Birth Weight; Female; Fetal Heart; Fetal Monitoring; Heart Rate; Humans; Hype | 1984 |
[Use of atenolol in tooth extraction for hypertensive and coronary patients].
Topics: Adult; Aged; Atenolol; Blood Pressure; Coronary Disease; Electrocardiography; Female; Heart Rate; Hu | 1984 |
Acute psychotic behavior associated with atenolol.
Topics: Atenolol; Humans; Hypertension; Male; Middle Aged; Psychoses, Substance-Induced | 1983 |
Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Forearm; Humans; Hypertension; Male; Middle Aged; Nitroprussi | 1983 |
Effect of chronic atenolol therapy on the cardiovascular response to handgrip in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Female; Hand; Heart Rate; Hemodynamics; Humans; Hypertension; Isome | 1983 |
[Treatment of hypertension with the cardioselective beta-adrenergic blockader tenormin].
Topics: Adult; Atenolol; Echocardiography; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Myocardial | 1983 |
Predictability of antihypertensive efficacy of selective beta 1 blockers.
Topics: Adult; Aldosterone; Atenolol; Blood Pressure; Cardiac Output; Catecholamines; Echocardiography; Fema | 1983 |
[Behavior of the arterial pressure in patients taking atenolol and propranolol under the influence of alcohol].
Topics: Alcohol Drinking; Atenolol; Blood Pressure; Female; Humans; Hypertension; Male; Propranolol | 1983 |
Multicentric clinical study on the antihypertensive efficacy of atenolol administered alone or with a diuretic combination.
Topics: Atenolol; Diuretics; Drug Evaluation; Drug Therapy, Combination; Humans; Hypertension | 1983 |
[Effect of atenolol in the treatment of hypertension and angina pectoris].
Topics: Angina Pectoris; Atenolol; Female; Humans; Hypertension; Male; Middle Aged | 1983 |
Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Topics: Adolescent; Adult; Atenolol; Ethanolamines; Female; Fetus; Humans; Hypertension; Infant, Newborn; La | 1983 |
[Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol].
Topics: Adolescent; Adult; Atenolol; Delivery, Obstetric; Ethanolamines; Female; Fetal Heart; Fetal Monitori | 1983 |
Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients.
Topics: Adult; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Drug Resistance; Female; Humans; Hydr | 1983 |
[Nifedipine in hypertensive emergencies and severe hypertension].
Topics: Acute Disease; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Therapy, Combination; F | 1984 |
Painless postpartum thyroiditis seen initially as severe hypertension.
Topics: Adult; Atenolol; Diagnosis, Differential; Female; Humans; Hypertension; Pregnancy; Puerperal Disorde | 1984 |
Atenolol in human plasma and breast milk.
Topics: Adult; Atenolol; Female; Humans; Hypertension; Infant, Newborn; Milk, Human; Pregnancy; Puerperal Di | 1984 |
Comparative effects of prazosin and atenolol on plasma lipids in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Cholesterol; Female; Heart Rate; Humans; Hypertension; Lipid Metabo | 1984 |
Essential hypertension and pregnancy: successful outcome with atenolol.
Topics: Adult; Atenolol; Female; Fetal Blood; Humans; Hypertension; Maternal-Fetal Exchange; Pregnancy; Preg | 1984 |
[Effect of pretreatment with atenolol and propranolol on sympatho-adrenal and cardiovascular responses to acute insulin-induced hypoglycaemia in the hypertensive patient].
Topics: Adult; Atenolol; Blood Glucose; Blood Pressure; Catecholamines; Female; Heart Rate; Hemodynamics; Hu | 1982 |
Effects of propranolol and atenolol on plasma renin activity and systolic time intervals in borderline hypertension.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Depression, Chemical; Electrocardiography; Female; Hear | 1982 |
[Treatment of hypertension with tenormin 100 (atenolol). A general practice study (author's transl)].
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Drug Evaluation; Female; Humans; Hypertension; Ma | 1980 |
Emergency treatment of high blood pressure with oral atenolol.
Topics: Atenolol; Cerebral Infarction; Humans; Hypertension; Hypotension; Male; Middle Aged; Propanolamines | 1981 |
[Withdrawal syndrome following beta blocker therapy (author's transl)].
Topics: Adult; Angina Pectoris; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Middle Aged; Myocard | 1981 |
Atenolol: side effects in a newborn infant.
Topics: Atenolol; Bradycardia; Female; Humans; Hypertension; Hypotension; Infant, Newborn; Male; Maternal-Fe | 1982 |
[Effect of atenolol on the excretion of catecholamines and their metabolites and dihydroxyphenylalanine (DOPA) in patients with essential hypertension].
Topics: Adult; Atenolol; Catecholamines; Dihydroxyphenylalanine; Humans; Hypertension; Male; Middle Aged; Pr | 1982 |
Atenolol: side effects in a newborn infant.
Topics: Atenolol; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal E | 1982 |
Atenolol in hypertension: efficacy - compliance study.
Topics: Adult; Aged; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Propanol | 1982 |
Hemodynamic effects of atenolol in labile hypertension.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Blood Volume; Cardiac Output; Female; Heart Rate; Hemod | 1983 |
[Efficacy of atenolol in moderate-to-mild essential hypertension and in ischemic cardiopathy. Evaluation with the bicycle ergometer].
Topics: Adult; Aged; Angina Pectoris; Atenolol; Coronary Disease; Drug Evaluation; Drug Tolerance; Exercise | 1983 |
[Short term treatment of essential arterial hypertension with atenolol: effect on the renin-angiotensin-aldosterone system and on hemodynamic parameters].
Topics: Adult; Atenolol; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanol | 1983 |
[Therapeutic effect of the cardioselective beta-blocking agent tenormin and its action on the indices of systemic, intracardiac and regional hemodynamics in patients with hypertension].
Topics: Adult; Atenolol; Hemodynamics; Humans; Hypertension; Middle Aged; Myocardial Contraction; Plethysmog | 1983 |
[Treatment of arterial hypertension with orally administered atenolol].
Topics: Administration, Oral; Atenolol; Humans; Hypertension; Propanolamines | 1983 |
[Atenolol in the treatment of arterial hypertension: clinical study].
Topics: Aged; Atenolol; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanolamines | 1983 |
[The effect of antihypertensive treatment with atenololo on the dimensions and function of the left ventricle].
Topics: Adult; Atenolol; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension; Male; Middle Aged | 1982 |
[Protection of the hypertensive patient: comparative atenolol-metoprolol study].
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Exercise Test; Female; Heart Rate; Humans; Hyp | 1982 |
[Effect of the anti-hypertensive therapy with atenolol on the dimensions and function of the left ventricle].
Topics: Adult; Atenolol; Body Weight; Echocardiography; Female; Hemodynamics; Humans; Hypertension; Male; Mi | 1982 |
Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.
Topics: Adult; Aged; Atenolol; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 1980 |
Withdrawal of antihypertensive drugs in mild hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Female; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1981 |
beta-Adrenoreceptor blockage and genetic hypertension development in rats.
Topics: Acebutolol; Animals; Atenolol; Blood Pressure; Body Weight; Depression, Chemical; Hemodynamics; Hype | 1980 |
Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration.
Topics: Administration, Oral; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Kin | 1980 |
Captopril and hypertension development in the SHR.
Topics: Angiotensin II; Animals; Atenolol; Blood Pressure; Captopril; Dihydralazine; Hypertension; Male; Pro | 1980 |
Role of the renin-angiotensin and of the adrenergic system in the blood pressure regulation at exercise in normotensive subjects and in hypertensive patients.
Topics: Adaptation, Physiological; Atenolol; Blood Pressure; Brachial Artery; Hemodynamics; Humans; Hyperten | 1981 |
[Treatment of severe resistant arterial hypertension with captopril. 58 patients, including 38 treated for more than 6 months (author's transl)].
Topics: Adult; Aged; Atenolol; Captopril; Diet, Sodium-Restricted; Drug Therapy, Combination; Female; Humans | 1981 |
[Atenolol, a new beta-adrenergic blocking agent, in treatment of hypertension: therapeutic effect and hemodynamic changes (author's transl)].
Topics: Adolescent; Adult; Atenolol; Female; Heart; Hemodynamics; Humans; Hypertension; Male; Middle Aged; P | 1981 |
Atenolol (Tenormin) - another "cardioselective" beta-blocker for hypertension.
Topics: Atenolol; Heart; Humans; Hypertension; Organ Specificity; Propanolamines | 1982 |
[Hypertensive therapy. Improvement of compliance with a daily regimen of a two-drug combination].
Topics: Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combinations; Heart Rate; Humans | 1982 |
A comparison of antihypertensive effects of atenolol and propranolol in the spontaneously hypertensive, DOCA/saline hypertensive and renal hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Desoxycorticosterone; Hypertension; Hypertension, Renal; | 1982 |
Atenolol in the treatment of essential hypertension during pregnancy.
Topics: Atenolol; Blood Pressure; Female; Fetus; Heart Rate; Humans; Hypertension; Infant, Newborn; Pregnanc | 1982 |
[Dry eyes].
Topics: Aged; Atenolol; Diagnosis, Differential; Female; Humans; Hypertension; Keratoconjunctivitis; Propano | 1982 |
Substitution of atenolol for propranolol in a case of propranolol-related depression.
Topics: Angina Pectoris; Atenolol; Depressive Disorder; Female; Humans; Hypertension; Imipramine; Middle Age | 1982 |
[Effects of therapy with a association of nifedipine and atenolol in patients with systemic arterial hypertension and angina pectoris].
Topics: Adult; Angina Pectoris; Atenolol; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged | 1982 |
[Clinical results of the combined use of a diuretic and a beta-blocking agent in the therapy of arterial hypertension].
Topics: Aged; Atenolol; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Inda | 1982 |
[Effect of atenolol on selected hemodynamic parameters studied by echocardiography and polycardiography].
Topics: Atenolol; Echocardiography; Heart Function Tests; Hemodynamics; Humans; Hypertension; Male; Middle A | 1982 |
Clinical evaluation of atenolol in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Electrocardiography; | 1981 |
[Evaluation of the combination of atenolol and indapamide in the therapy of arterial hypertension (with data concerning toxicity and tolerance in the experimental animal)].
Topics: Adult; Aged; Animals; Atenolol; Blood Pressure; Body Weight; Diuretics; Dogs; Drug Therapy, Combinat | 1981 |
[Prolonged hypotension after the first dose of atenolol (author's transl)].
Topics: Acute Kidney Injury; Adult; Atenolol; Diazoxide; Drug Synergism; Humans; Hypertension; Hypotension; | 1981 |
Total body and serum potassium during treatment with atenolol in combination with chlorthalidone.
Topics: Adult; Antihypertensive Agents; Atenolol; Body Composition; Chlorthalidone; Drug Combinations; Femal | 1981 |
[Effect of propranolol and atenolol on peripheral tissue blood flow and effective plasma flow through the kidneys].
Topics: Adult; Atenolol; Blood Circulation; Humans; Hypertension; Leg; Male; Neurocirculatory Asthenia; Plas | 1981 |
[Use of metoprolol and atenolol, singly or in combination with a diuretic, in the treatment of arterial hypertension].
Topics: Adult; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Meto | 1980 |
Interaction of atenolol with furosemide and calcium and aluminum salts.
Topics: Adult; Aluminum; Atenolol; Blood Pressure; Calcium; Drug Interactions; Female; Furosemide; Heart Rat | 1981 |
Serum lipoprotein changes during atenolol treatment of essential hypertension.
Topics: Atenolol; Female; Humans; Hypertension; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoprot | 1981 |
[Atenolol in hypertension].
Topics: Atenolol; Bradycardia; Erectile Dysfunction; Humans; Hypertension; Male; Propanolamines | 1981 |
[Effect of atenolol on airway resistance in hypertensive patients with chronic obstructive lung disease].
Topics: Airway Resistance; Atenolol; Double-Blind Method; Humans; Hypertension; Lung Diseases, Obstructive; | 1981 |
[Antihypertensive effect of tienilic acid prescribed individually or in combination with atenolol].
Topics: Adult; Aged; Atenolol; Drug Therapy, Combination; Female; Glycolates; Humans; Hypertension; Male; Mi | 1981 |
Treatment of Jamaican hypertensives with atenolol and chlorthalidone.
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Female; Humans; Hypertension; | 1981 |
The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma.
Topics: Adolescent; Adult; Aged; Atenolol; Erythrocytes; Female; Humans; Hypertension; Male; Middle Aged; Pi | 1981 |
Effects of treatment on circadian rhythms of blood pressure.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Circadian Rhythm; Heart Rate; Humans; Hypertensio | 1981 |
Withdrawal of long-term therapy with atenolol in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; Middle Ag | 1981 |
[Hypotensive effects of practolol and atenolol after blood-brain barrier lesion in normotensive and hypertensive rats].
Topics: Animals; Atenolol; Blood Pressure; Blood-Brain Barrier; Cerebrospinal Fluid; Cetrimonium Compounds; | 1980 |
Atenolol in the treatment of pregnancy-induced hypertension.
Topics: Adult; Atenolol; Female; Fetus; Humans; Hypertension; Kinetics; Pregnancy; Pregnancy Complications, | 1981 |
[Treatment of arterial hypertension: comparative study of atenolol + chlorthalidone vs. timolol maleate-hydrochlorthiazide-amiloride association].
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1981 |
[Clinical value of selective beta 1 block in antihypertensive therapy].
Topics: Adult; Atenolol; Female; Humans; Hypertension; Male; Oxprenolol; Pindolol; Propanolamines | 1981 |
Atenolol in hypertension: a cardioselective drug.
Topics: Adult; Airway Resistance; Atenolol; Blood Pressure; Female; Humans; Hypertension; Lung Volume Measur | 1980 |
Retroperitoneal fibrosis associated with stenolol.
Topics: Atenolol; Humans; Hypertension; Male; Middle Aged; Propanolamines; Retroperitoneal Fibrosis | 1980 |
[Analysis of the variability of arterial pressure in patients with labile and stable hypertension and changes induced with atenolol].
Topics: Adult; Atenolol; Blood Pressure; Humans; Hypertension; Middle Aged; Propanolamines | 1980 |
Retroperitoneal fibrosis associated with atenolol.
Topics: Atenolol; Blood Sedimentation; Humans; Hypertension; Male; Propanolamines; Retroperitoneal Fibrosis | 1980 |
Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
Topics: Adult; Atenolol; Chlorthalidone; Drug Therapy, Combination; Half-Life; Humans; Hypertension; Male; P | 1980 |
Vascular adaptation to long-term blood pressure reduction.
Topics: Atenolol; Blood Pressure; Diuretics; Humans; Hypertension; Mefruside; Propanolamines; Vascular Resis | 1980 |
Adverse interaction between nifedipine and beta-blockade.
Topics: Angina Pectoris; Atenolol; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Hypot | 1980 |
Atenolol and chlorthalidone for hypertension in black South Africans.
Topics: Atenolol; Black or African American; Black People; Chlorthalidone; Diet; Humans; Hypertension; Propa | 1980 |
Haemodynamic changes during treatment of arterial hypertension with atenolol (Tenormin).
Topics: Adult; Atenolol; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Propanolamines | 1980 |
Contrasting effect of antihypertensive treatment on the renal response to L-arginine.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 1995 |
Influence of arotinolol hydrochloride on heart rate spectrum in hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1994 |
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; | 1994 |
Miscompliance by proxy.
Topics: Antihypertensive Agents; Atenolol; Controlled Clinical Trials as Topic; Humans; Hypertension; Male; | 1995 |
Effects of propranolol and atenolol on immobilization stress-induced hypertension and down-regulation of central beta-adrenoceptors in rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cerebral Cortex; Dihydroalprenolol; | 1995 |
Peritoneal fibrosis--an expression of atenolol toxicity.
Topics: Atenolol; Fibrosis; Humans; Hypertension; Male; Middle Aged; Peritoneal Diseases; Peritoneum; Tissue | 1994 |
Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats.
Topics: Animals; Arginine; Atenolol; Atropine; Autonomic Nervous System; Blood Pressure; Ganglionic Blockers | 1993 |
Regulation of the beta-adrenoceptor-cAMP-system during dynamic exercise in patients with primary hypertension after acute beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Cyclic AMP; Exercise Test; Humans; Hyp | 1994 |
Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats.
Topics: Aging; Animals; Atenolol; Blood Pressure; Body Weight; Calcium; Endothelium, Vascular; Heart Rate; H | 1994 |
Renoprotective effect of nisoldipine in rats with severe hypertension.
Topics: Animals; Aorta; Arterioles; Atenolol; Blood Pressure; Creatinine; Desoxycorticosterone; Enalapril; H | 1994 |
Organic anxiety syndrome after withdrawal of atenolol.
Topics: Aged; Anxiety Disorders; Atenolol; Diltiazem; Humans; Hypertension; Lorazepam; Male; Substance Withd | 1994 |
Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects.
Topics: Adult; Aging; Atenolol; Baroreflex; Blood Pressure; Heart Rate; Humans; Hypertension; Middle Aged; S | 1994 |
Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Child; Chromatography, High Pressure Liquid; Exercise T | 1994 |
[The effects of treatment with atenolol and benazapril on 24-hour pressure variability].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Benzazepines; Bl | 1993 |
Postexercise syncope: evidence for increased activity of the sympathetic nervous system.
Topics: Adult; Arousal; Atenolol; Bradycardia; Epinephrine; Exercise Test; Heart Arrest; Humans; Hypertensio | 1993 |
[Paroxysmal atrial fibrillation and flutter and "occult" arterial hypertension. The importance of the ambulatory monitoring of the blood pressure. Apropos 2 cases].
Topics: Atenolol; Atrial Fibrillation; Atrial Flutter; Blood Pressure Monitors; Diltiazem; Drug Therapy, Com | 1993 |
Hyperdynamic beta-adrenergic syndrome among Croatian soldiers engaged in battle.
Topics: Adult; Arousal; Atenolol; Blood Pressure; Croatia; Heart Rate; Humans; Hypertension; Male; Middle Ag | 1993 |
[Thrombocytopenia from a pharmacological cause].
Topics: Atenolol; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged; Thromb | 1993 |
Impaired elimination of atenolol in a nephropathic patient with self-medication overdose.
Topics: Atenolol; Diabetes Mellitus, Type 2; Drug Overdose; Female; Humans; Hypertension; Metabolic Clearanc | 1993 |
Response of the rat mesenteric vasculature to chronic treatment with nitrendipine alone and in combination with atenolol: evidence of a significant drug interaction.
Topics: Animals; Atenolol; Blood Pressure; Drug Interactions; Electric Stimulation; Hypertension; Male; Mese | 1993 |
Incidence of and mortality from cancer in hypertensive patients.
Topics: Age Factors; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Incidence; Male; Middl | 1993 |
Cancer mortality and atenolol treatment.
Topics: Atenolol; England; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Risk Factors | 1993 |
The role of renal dopamine in the reduction of high blood pressure by beta 1-selective beta-blocker with intrinsic sympathomimetic activity in spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 1995 |
Comparison of early and late start of antihypertensive agents and baroreceptor reflexes.
Topics: Aging; Animals; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Enalapril; Heart Rate | 1996 |
Baroreflex control of heart rate in Dahl hypertensive (SS/Jr) and normotensive (SR/Jr) rats.
Topics: Animals; Atenolol; Atropine; Autonomic Nervous System; Baroreflex; Blood Pressure; Heart Rate; Hyper | 1995 |
Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system.
Topics: Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Female; Health Education; Hospitals, Veter | 1996 |
[Corotenol, its effectiveness and tolerance in light of new studies].
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Disease; Humans; Hypertension | 1996 |
Should diuretics be combined with calcium antagonists?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diuretics; | 1996 |
Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Amylases; Antihypertensive | 1996 |
Effects of chronic administration of bopindolol on the binding characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes in cardiac muscles of spontaneously hypertensive rats (SHR).
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Hypertension; In Vitro Techniques; Membranes; Myocar | 1996 |
Antihypertensive effect of drugs: statistical distribution of the trough-to-peak ratio.
Topics: Analysis of Variance; Antihypertensive Agents; Atenolol; Biometry; Blood Pressure; Data Interpretati | 1996 |
Atenolol induced memory impairment: a case report.
Topics: Adrenergic beta-Antagonists; Amnesia; Atenolol; Diagnosis, Differential; Humans; Hypertension; Male; | 1996 |
[The therapeutic correction of disorders in thrombocyte-vascular hemostasis and of changes in the rheological properties of the blood in patients with arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Platelet Disorder | 1996 |
Sympathetic modulation of the effect of nifedipine on myocardial contraction and Ca current in the rat.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Calcium Channel Blockers; | 1997 |
Effect of atenolol on birth weight.
Topics: Analysis of Variance; Anthropometry; Antihypertensive Agents; Atenolol; Birth Weight; Female; Fetal | 1997 |
Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Contrast Media; Female; Glomerular Filtration Ra | 1997 |
Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Epinephrine; Female; Hemodynamics; Humans; Hypertensio | 1997 |
[Syncope with postoperative beta blocker medication after spinal anesthesia--case report].
Topics: Adrenergic beta-Antagonists; Anesthesia, Spinal; Atenolol; Blood Pressure; Drug Interactions; Heart | 1997 |
Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study.
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Captopril; Female; Humans; Hypertension; Kidne | 1997 |
Atenolol, bendrofluazide and their use in combination.
Topics: Antihypertensive Agents; Atenolol; Bendroflumethiazide; Drug Therapy, Combination; Humans; Hypertens | 1998 |
Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Bisoprolol; C | 1998 |
Antihypertensive therapy in type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Development of tablets for controlled joint release of nifedipine and atenolol.
Topics: Atenolol; Calcium Channel Blockers; Chemical Phenomena; Chemistry, Physical; Delayed-Action Preparat | 1998 |
Stroke in the elderly treated for systolic hypertension (SHEP).
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlor | 1991 |
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiovascular Diseases; Celiprolol; Female; Hum | 1997 |
Preliminary communication on intralymphocyte ionized magnesium in hypertensive patients under treatment with beta-blockers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Calcium; Female; Humans; Hy | 1999 |
Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cells, C | 1999 |
[New central agents in the treatment of arterial hypertension].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Adult; Antihyp | 1999 |
Hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2000 |
Behavioural parameters in hypertensives on atenolol therapy.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Attention; Behavior; Blood Pr | 1999 |
In vitro and in vivo evaluation of the antihypertensive drug atenolol in cultured human lymphocytes: effects of long-term therapy.
Topics: Antihypertensive Agents; Atenolol; Cells, Cultured; Centromere; Humans; Hypertension; In Situ Hybrid | 2000 |
Ask the doctor. I take atenolol and lisinopril for my blood pressure. I have a blood pressure monitor that I use at home and I find that, on average, my pressure is 150/85 in the morning and 130/80 in the afternoon. Should I be worried about the high morn
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Humans; Hypertension; Lisinopril | 2000 |
A study of pulmonary profile of hypertensive patients--comparison of atenolol vs amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Humans; Hypertension; Total Lung Capacity; Vital Capa | 1998 |
Permanent pacing-aid to carry out long-term lithium therapy in manic patient with symptomatic bradycardia.
Topics: Adrenergic beta-Antagonists; Aged; Antimanic Agents; Atenolol; Bipolar Disorder; Bradycardia; Glauco | 2000 |
Recent outcome trials of newer antihypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Captopril; Diabetic Ang | 1999 |
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement | 2000 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mell | 2000 |
Cardiac vagal responsiveness during development in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Drug Therapy, Combination; Enalap | 2000 |
Antihypertensive monotherapy and cardiovascular responses to an acoustic startle stimulus.
Topics: Acoustic Stimulation; Adrenergic alpha-Agonists; Analysis of Variance; Antihypertensive Agents; Aten | 2001 |
Atenolol induced high grade AV block.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Heart Block; Humans; Hypertension; Male; | 1998 |
[Increase of arterial pressure caused by generic atenolol].
Topics: Adult; Antihypertensive Agents; Atenolol; Drugs, Generic; Female; Humans; Hypertension; Therapeutic | 2001 |
[When hypertension damages microcirculation. A-II-antagonist corrects damage, beta blocker does not].
Topics: Atenolol; Clinical Trials as Topic; Follow-Up Studies; Humans; Hypertension; Losartan; Microcirculat | 2001 |
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].
Topics: Adult; Antihypertensive Agents; Atenolol; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy | 2001 |
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; D | 2001 |
[ELSA Studies studies progression of atherosclerosis. Calcium antagonist arrests the process more than a beta-blocker].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Dihydropyridines; | 2001 |
The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2001 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human | 2001 |
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Bendroflumethiazide; Cardi | 2001 |
Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hypertension; Hypertroph | 2001 |
Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Atenolol; Black or African American; Blood Pressure | 2001 |
Recent onset severe hypertension requiring multiple antihypertensive medications.
Topics: Aged; Antihypertensive Agents; Atenolol; Diuretics; Drug Therapy, Combination; Female; Humans; Hyper | 2001 |
[Calcium antagonists lower not only blood pressure. Arteriosclerosis is braked too].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Carotid Stenosi | 2001 |
[Pulling the wool over our eyes].
Topics: Atenolol; Drugs, Generic; Humans; Hypertension; Male; Middle Aged; Treatment Failure | 2001 |
Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 2002 |
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; El | 2002 |
Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Benzopyrans; Blood Pressure; Body Weight; Dru | 2002 |
Monitoring one-year compliance to antihypertension medication in the Seychelles.
Topics: Adult; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cross-Sectional Studies; Drug Monitor | 2002 |
Guidelines on high blood pressure in pregnancy give new classifications of disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Contra | 2000 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pr | 2002 |
Long-term control of hypertension in dialysis patients by low dose atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2002 |
ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Humans; Hyp | 2002 |
[LIFE-study: losartan reduces cardiovascular risk factors more than atenolol].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Risk Factors | 2002 |
[Effect of atenolol combined with chlortalidone on characteristics of 24-hour blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Circadian Rhythm | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients.
Topics: Antihypertensive Agents; Arteriosclerosis; Atenolol; Blood Pressure; Cilazapril; Endothelium, Vascul | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diure | 2002 |
Letter: Once-daily atenolol for hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension; Propanolamines | 1976 |
Letter: Daily antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension; Propanolamines | 1976 |
Raynaud's phenomenon as side effect of beta-blockers in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Female; Humans; Hypertension; Male; Methyldopa; Middle | 1976 |
Acute renal effects of new beta-adrenergic receptor site blocking agents on renal function.
Topics: Acebutolol; Adrenergic beta-Antagonists; Aminohippuric Acids; Atenolol; Chlorides; Glomerular Filtra | 1976 |
Once-daily treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Hypertension; Metoprolol; Pindolol; | 1976 |
Plasma renin activity vs. concentration.
Topics: Adrenergic beta-Antagonists; Atenolol; Humans; Hypertension; Metoprolol; Renin | 1976 |
Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1978 |
[Place of beta-blockers in the treatment of essential arterial hypertension].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Depression, Chemical; D | 1978 |
[Left ventricular function in hypertension treated with beta blockers].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Echocardiography; Female; Heart Rate; Heart Ventricles | 1978 |
[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)].
Topics: Adult; Atenolol; Humans; Hydrogen-Ion Concentration; Hypertension; Middle Aged; Propanolamines; Spec | 1978 |
Prevention and reversal of isolation-induced systolic arterial hypertension in rats by treatment with beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Heart Rate; Hypertension; Male; Metoprolol; Proprano | 1979 |
Dependence of deoxycorticosterone/salt hypertension in the rat on the activity of adrenergic cardiac nerves.
Topics: Adrenergic beta-Antagonists; Adrenergic Fibers; Amines; Animals; Atenolol; Blood Pressure; Cardiac S | 1979 |
[Left ventricular function in hypertension. Echographic evaluation before and after beta blockade (atenolol)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Flow Velocity; Cardiac Volume; Diast | 1979 |
[Evaluation of cardiac performance in the hypertensive patient. Effect of a beta-blocking agent: atenolol].
Topics: Atenolol; Cardiac Output; Depression, Chemical; Humans; Hypertension; Male; Myocardial Contraction; | 1978 |
Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1).
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Catecholamine | 1975 |
Effect of atenolol, a new cardioselective beta-blocker, on plasma renin activity in treatment of hypertension.
Topics: Adult; Aged; Atenolol; Drug Evaluation; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; | 1977 |
Angiotensin II blockade during combined thiazide-beta-adrenoreceptor-blocker treatment.
Topics: Adult; Angiotensin II; Atenolol; Blood Pressure; Female; Humans; Hydrochlorothiazide; Hypertension; | 1979 |
Effect of once-daily atenolol on ambulatory blood pressure.
Topics: Aged; Atenolol; Blood Pressure Determination; Circadian Rhythm; Drug Administration Schedule; Female | 1979 |
Effect of once-daily atenolol on ambulatory blood pressure.
Topics: Atenolol; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Humans; Hypertension; Post | 1979 |
Effect of once-daily atenolol on ambulatory blood pressure.
Topics: Atenolol; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Humans; Hypertension; Prop | 1979 |
Effect of once-daily atenolol on ambulatory blood pressure.
Topics: Adult; Atenolol; Blood Pressure; Blood Pressure Determination; Humans; Hypertension; Physical Exerti | 1979 |
Hemodynamic adjustments in hypertensive patients developing circulatory congestion during beta-adrenergic blockade.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Cardiac Output; Drug Evaluation; Female; Heart F | 1979 |
Nylidrin: a potent anti-hypertensive agent in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Desoxycorticosterone; Heart Rate; Hypert | 1979 |
Reduction of beta-blocking drugs in hypertensive patients treated with minoxidil.
Topics: Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart | 1979 |
The effects of a beta 1-blocking agent, atenolol, on blood pressure, plasma renin activity and prostaglandin F2 alpha excretion in patients with essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Drug Evaluation; Electrolytes; Heart Rate; Humans; Hypertension; Ki | 1979 |
Multicentre general practitioner assessment of 'Tenormin' and methyldopa.
Topics: Adult; Aged; Atenolol; Female; Humans; Hypertension; Male; Methyldopa; Middle Aged; Propanolamines | 1979 |
The renin-angiotensin system and the antihypertensive effect of atenolol in man.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Male; Middle | 1979 |
Assessment of the antihypertensive effect of atenolol with 24 h ambulatory monitoring of blood pressure.
Topics: Adult; Atenolol; Blood Pressure; Circadian Rhythm; Electrocardiography; Female; Humans; Hypertension | 1979 |
[Efficacy of a new beta-blocking drug (atenolol, ICI 66082) in treating arterial hypertension].
Topics: Adult; Atenolol; Blood Pressure; Drug Evaluation; Female; Heart Rate; Humans; Hypertension; Male; Mi | 1979 |
Pharmacokinetics of atenolol in patients with renal impairment.
Topics: Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Kidney Diseases; Kinetics; Propanolamine | 1977 |
[Atenolol (Tenormin) in the treatment of hypertension].
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; | 1977 |
[Changes in peripheral arterial blood flow and venous capacity in arterial hypertension and their relationship to the antihypertensive action of beta blockers].
Topics: Atenolol; Forearm; Humans; Hypertension; Plethysmography, Impedance; Propanolamines; Regional Blood | 1977 |
Circadian variations of blood pressure in patients with different degrees of hypertension. Changes induced by hypotensive treatment.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Circadian Rhythm; Humans | 1977 |
[Validity of "unrestricted" continuous monitoring of arterial pressure for the diagnosis of hypertension and for beginning hypotensive therapy. Preliminary trials of atenolol].
Topics: Adult; Atenolol; Blood Pressure Determination; Evaluation Studies as Topic; Humans; Hypertension; Ma | 1977 |
[Response to some pressor tests in patients with labile and stable hypertension, before and after administration of atenolol].
Topics: Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Hypertension; Male; Propanolamines | 1977 |
Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats.
Topics: Animals; Atenolol; Blood Pressure; Body Weight; Heart; Heart Rate; Hypertension; Male; Organ Size; P | 1978 |
Blood-pressure control round the clock.
Topics: Atenolol; Humans; Hypertension; Metoprolol; Time Factors | 1978 |
[Haemodynamic response to antihypertensive treatment with atenolol in patients with hypertension (author's transl].
Topics: Adolescent; Adult; Atenolol; Cardiac Output; Female; Heart Rate; Hemodynamics; Humans; Hypertension; | 1978 |
Relative activity of atenolol and metoprolol.
Topics: Atenolol; Heart Rate; Humans; Hypertension; Metoprolol; Physical Exertion; Propanolamines; Research | 1978 |
[The hypertensive heart. VII. Effect of atenolol on the function, coronary haemodynamics and oxygen uptake of the left ventricle (author's transl)].
Topics: Adult; Atenolol; Coronary Circulation; Heart; Heart Rate; Humans; Hypertension; Myocardium; Oxygen C | 1978 |
Use of minoxidil in resistant hypertension. Beneficial effects, adverse reactions and indications.
Topics: Adolescent; Adult; Aged; Atenolol; Child; Child, Preschool; Drug Resistance; Female; Furosemide; Hum | 1978 |
Hemodynamic response to graded exercise after chronic beta-adrenergic blockade.
Topics: Adult; Atenolol; Blood Pressure; Body Surface Area; Cardiac Output; Female; Heart Rate; Hemodynamics | 1977 |
Atenolol and plasma renin concentration in hypertensive patients.
Topics: Atenolol; Hemodynamics; Humans; Hypertension; Physical Exertion; Propanolamines; Propranolol; Renin | 1977 |
Atenolol in hypertension a study of long-term therapy.
Topics: Adult; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans | 1977 |
Response to atenolol in arterial hypertension in relation to renal function, pharmacokinetics and renin activity.
Topics: Adolescent; Adult; Atenolol; Blood Pressure; Female; Glomerular Filtration Rate; Half-Life; Heart Ra | 1977 |
Dopamine-beta-hydroxylase activity and catecholamine concentrations in plasma: experimental and essential hypertension.
Topics: Adult; Animals; Atenolol; Dopamine beta-Hydroxylase; Epinephrine; Humans; Hypertension; Norepinephri | 1977 |
Haemodynamic long-term effects of atenolol at rest and during exercise in essential hypertension.
Topics: Adult; Atenolol; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Physical Exertion; Propanola | 1977 |
Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension.
Topics: Adult; Atenolol; Blood Pressure; Cardiac Output; Heart Rate; Hemodynamics; Humans; Hypertension; Mal | 1976 |
A study of once daily tenormin (atenolol) in hypertension: some implications in patient compliance.
Topics: Adult; Atenolol; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance | 1976 |
[Studies on the relationships between plasma-adrenaline, plasma-renin and the blood-pressure-lowering effect of the beta-receptor blockader ICI 66082 (atenolol) in patients with essential hypertension].
Topics: Atenolol; Blood Pressure; Epinephrine; Humans; Hypertension; Propanolamines; Renin | 1976 |
Dopamine-beta-hydroxylase after treatment with beta-blockers in hypertension.
Topics: Atenolol; Blood Pressure; Dopamine beta-Hydroxylase; Humans; Hypertension; Male; Propanolamines; Pro | 1975 |
Letter: Atenolol and renin release.
Topics: Atenolol; Depression, Chemical; Humans; Hypertension; Propanolamines; Renin | 1976 |
[A noninvasive assessment of the gain in baroceptor control of the heart rate in man].
Topics: Adult; Atenolol; Blood Pressure; Electrocardiography, Ambulatory; Heart Rate; Humans; Hypertension; | 1992 |
[Antihypertensive effects of atenolol and nitrendipine alone or in combination on three hypertensive models of rats].
Topics: Animals; Atenolol; Blood Pressure; Desoxycorticosterone; Drug Therapy, Combination; Female; Hyperten | 1992 |
[Doubt about atenolol in the treatment of hypertension. Beta blockers, diuretics and the aged].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Diuretics; Humans; Hypertension | 1992 |
[Doubt about atenolol in the treatment of hypertension. Beta blockers, diuretics and the aged].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Diuretics; Humans; Hypertension | 1992 |
A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cold Temperature; G | 1992 |
Effects of mental and physical stress on plasma catecholamine levels before and after beta-adrenoceptor blocker treatment.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Double-Blind Method; Epinephrine; Humans; Hypertension | 1992 |
Preserved ventricular pump function after a marked reduction of left ventricular mass.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressu | 1992 |
Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Output; Dipeptides; Female; | 1992 |
[Treatment of hypertension in the elderly--diuretics/atenolol?].
Topics: Aged; Atenolol; Diuretics; Humans; Hypertension; Myocardial Infarction | 1992 |
Regional hemodynamic effects of betaxolol, a new selective beta 1-blocker, and atenolol in conscious spontaneously hypertensive rats.
Topics: Animals; Atenolol; Betaxolol; Blood Pressure; Cardiac Output; Heart Rate; Hypertension; Male; Micros | 1992 |
Changes in the haemodynamics of large arteries induced by single doses of nicardipine, enalapril, atenolol and urapidil.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; Enalapr | 1992 |
[Treatment of hypertension in the elderly--diuretics/atenolol?].
Topics: Age Factors; Aged; Atenolol; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Humans; Hyperte | 1992 |
Atenolol and visual loss.
Topics: Aged; Atenolol; Humans; Hypertension; Male; Vision, Ocular | 1992 |
Effects of chronic administration of atenolol on the in situ perfused mesentery of normotensive and hypertensive rats.
Topics: Animals; Atenolol; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Hypertens | 1992 |
Accelerated hypertension caused by severe phimosis.
Topics: Adolescent; Atenolol; Blood Pressure; Humans; Hypertension; Male; Nifedipine; Phimosis; Urination Di | 1992 |
[Effect of halving the dosage of atenolol in essential hypertension].
Topics: Atenolol; Blood Pressure; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Dru | 1992 |
Effects of a new dihydropyridine derivative, FRC-8653, on blood pressure in conscious spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Dihydropyridines; Heart Rate; | 1992 |
[Doubts about atenolol in the treatment of hypertension].
Topics: Atenolol; Humans; Hypertension | 1992 |
[Doubt about atenolol in the treatment of hypertension].
Topics: Aged; Atenolol; Humans; Hypertension | 1992 |
Stimulating effects of atenolol on vasodepressor prostaglandin generation in spontaneously hypertensive rats.
Topics: Animals; Atenolol; Blood Vessels; Dinoprostone; Dose-Response Relationship, Drug; Hypertension; Indo | 1991 |
Stress and sodium hypertension in baboons: neuroendocrine and pharmacotherapeutic assessments.
Topics: Animals; Atenolol; Atrial Natriuretic Factor; Creatinine; Dopamine; Epinephrine; Hydrochlorothiazide | 1991 |
[Effects of antihypertensive therapy with selective and non-selective beta blocking agents on dimensions and function of the left ventricle].
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Echocard | 1991 |
Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure; Cromakalim; Heart Rate; Human | 1990 |
[The relationship between the effect of atenolol on the baroreceptor reflex and its hypotensive action in hypertension patients].
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Sinus; Drug Evaluation | 1991 |
[Prolonged cardioselective blockade of beta-1 adrenoreceptors in combination with increased diuresis as a method of choice in the treatment of hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Combinations; Humans; Hypertens | 1991 |
An investigation of the relationship between compliance with antihypertensive therapy and the Type A behaviour pattern.
Topics: Adult; Aged; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Type A P | 1991 |
Development of cardiac hypertrophy and its relationship to the cardiac baroreflex deficit in hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Atropine; Blood Pressure; Cardiomegaly; Heart Rate; Hype | 1991 |
[The effect of lowered pressure on the diastolic ventricular function after antihypertensive treatment].
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Cardiomegaly; Diastole; Female; | 1991 |
Atenolol induced hypotension.
Topics: Adult; Atenolol; Female; Humans; Hypertension; Hypotension | 1991 |
[Therapy of hypertensive coronary patients. Open long-term study with a combination of atenolol and nifedipine].
Topics: Aged; Atenolol; Coronary Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hyperten | 1991 |
The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cost-B | 1990 |
Spectral analysis to assess increased sympathetic tone in arterial hypertension.
Topics: Atenolol; Blood Pressure; Computer Graphics; Electrocardiography; Heart Rate; Humans; Hypertension; | 1991 |
The circadian heart rate but not blood pressure profile is influenced by the timing of beta-blocker administration in hypertensives.
Topics: Atenolol; Blood Pressure; Drug Administration Schedule; Heart Rate; Humans; Hypertension; Middle Age | 1991 |
Pheochromocytoma associated ventricular tachycardia blocked with atenolol.
Topics: Adrenal Gland Neoplasms; Adult; Atenolol; Dopamine; Electrocardiography; Epinephrine; Humans; Hypert | 1990 |
Analysis of left ventricular function by radionuclide ventriculogram in hypertensive patients treated with atenolol.
Topics: Adult; Atenolol; Exercise Test; Female; Humans; Hypertension; Male; Middle Aged; Radionuclide Ventri | 1990 |
Angiotensin converting enzyme inhibitors, thiazide diuretics and magnesium balance. A preliminary study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Benzothiadiazines; Diuretics; Drug Therap | 1990 |
Left ventricular hypertrophy in hypertension.
Topics: Aged; Atenolol; Cardiomegaly; Humans; Hypertension; Middle Aged; Placebos; Verapamil | 1990 |
[Reduction of the left ventricular mass in essential hypertension patients chronically treated with monotherapy].
Topics: Adult; Atenolol; Blood Pressure; Cardiomegaly; Drug Administration Schedule; Enalapril; Female; Huma | 1990 |
Atenolol therapy for exercise-induced hypertension after aortic coarctation repair.
Topics: Adolescent; Aortic Coarctation; Arm; Atenolol; Blood Pressure Determination; Child; Exercise; Exerci | 1990 |
Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.
Topics: Adult; Atenolol; Body Weight; Captopril; Creatinine; Female; Furosemide; Humans; Hypertension; Lupus | 1990 |
[The clinical profile of hypertensive patients can predict the need for combining a second or third drug with atenolol in the initial treatment of light and moderate essential arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Diet, Sodium-Restricted | 1990 |
Grinspan's syndrome: a drug-induced phenomenon?
Topics: Aged; Aged, 80 and over; Atenolol; Bendroflumethiazide; Chlorpropamide; Diabetes Mellitus, Type 2; D | 1990 |
A pressor effect of noncardioselective beta-blockers in mildly hypertensive patients during acute hospitalization.
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Blood Pressure; Echocardiography; Female; Heart Rate; Hosp | 1990 |
Atenolol-induced pseudolymphoma.
Topics: Aged; Atenolol; Humans; Hypertension; Lymphoma; Male; Skin; Syndrome | 1990 |
Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
Topics: Atenolol; Blood Pressure; Cerebrovascular Disorders; Electrocardiography; Female; Humans; Hypertensi | 1990 |
Mechanism of smooth muscle contraction: relevance to safety of beta-adrenergic blockade in hypertensive patients with reversible chronic obstructive airways disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Bronchi; Calcium Channel Blockers; Calmodulin; Celiprolol; Cy | 1986 |
Nifedipine and/or atenolol for mild to moderate hypertension: a general practice study.
Topics: Atenolol; Delayed-Action Preparations; Drug Combinations; Humans; Hypertension; Nifedipine | 1989 |
Effects of atenolol on left ventricular hypertrophy and early left ventricular function in essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Capillary Resistance; Cardiac Output; Cardiomegaly; Echocardi | 1989 |
Comparison of antihypertensive therapies by noninvasive techniques.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure Determination; Echoc | 1989 |
[Comparative study of antihypertensive effects of enalapril and atenolol in patients with mild to moderate hypertension].
Topics: Adult; Atenolol; Blood Pressure; Enalapril; Female; Humans; Hypertension; Male; Middle Aged | 1989 |
The effect of triple drug therapy on renal function in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Antihypertensive Agents; Atenolol; Betaxolol; Blood | 1989 |
The antihypertensive effect of atenolol and bopindolol in the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Drug Evaluation; Female; Humans; Hypertens | 1989 |
[Changes in the platelet-vascular system of hemostasis in patients with ischemic heart disease and hypertension after the treatment].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Coagulation; Calcium Channel Blockers; Cor | 1989 |
Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.
Topics: Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Exercise; Exercise Test; Felodipine; Femal | 1989 |
[Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle
Topics: Adult; Aged; Atenolol; Cardiomyopathy, Hypertrophic; Chlorthalidone; Diastole; Drug Evaluation; Drug | 1989 |
[Significance of brain renin for pathogenesis of hypertension: effect of antihypertensive drugs on active and inactive renins in the brain of spontaneously hypertensive rat].
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Brain; Captopril; Enzyme Activation; Enz | 1989 |
Mechanism of antihypertensive action of dilevalol compared with that of "cardioselective" beta-blocking agents.
Topics: Adult; Aged; Atenolol; Female; Heart; Heart Rate; Humans; Hypertension; Labetalol; Male; Metoprolol; | 1989 |
[Value of heart rate recordings in selecting the initial treatment of hypertension].
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; | 1989 |
Comparison of blood pressure response to heat stress in sauna in young hypertensive patients treated with atenolol and diltiazem.
Topics: Adult; Atenolol; Diltiazem; Female; Hemodynamics; Hot Temperature; Humans; Hypertension; Male; Middl | 1989 |
The acute withdrawal of diltiazem and atenolol: a possible challenge to affective stability.
Topics: Adult; Angina Pectoris; Atenolol; Atrial Flutter; Bipolar Disorder; Diltiazem; Female; Humans; Hyper | 1989 |
Altered vascular beta adrenoceptor-mediated relaxation in deoxycorticosterone-salt hypertensive rats.
Topics: Animals; Atenolol; Bucladesine; Butoxamine; Desoxycorticosterone; Fenoterol; Hypertension; Isoproter | 1988 |
Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination.
Topics: Aldosterone; Angiotensin II; Atenolol; Atrial Natriuretic Factor; Drug Interactions; Drug Therapy, C | 1988 |
[Enalapril, atenolol and hydrochlorothiazide in mild and moderate hypertension].
Topics: Atenolol; Enalapril; Humans; Hydrochlorothiazide; Hypertension | 1988 |
[Effects of dynamic exercise on the blood pressure of patients with hypertension treated with atenolol and enalapril].
Topics: Adult; Atenolol; Blood Pressure; Enalapril; Exercise Test; Female; Heart Rate; Humans; Hypertension; | 1988 |
Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Drug Therapy, Combinati | 1985 |
Beta-adrenergic blocking agents. Effect of chronic dosage on a fit, middle-aged man: a case study and review.
Topics: Adrenergic beta-Antagonists; Atenolol; Energy Metabolism; Ethanolamines; Exercise Test; Hemodynamics | 1985 |
A comparison of celiprolol and atenolol in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Drug Evaluation; Humans; Hypertension; Propanolam | 1985 |
Side-effects of beta-blockers assessed using visual analogue scales.
Topics: Acebutolol; Adrenergic beta-Antagonists; Analysis of Variance; Atenolol; Dreams; Fatigue; Humans; Hy | 1985 |
A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Blood Proteins; Female; Half-Life; | 1985 |
Increased plasma vasopressin in low renin essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Arginine Vasopressin; Atenolol; Blood Pressure; Body Weight; Die | 1986 |
[Regression of left-ventricular myocardial hypertrophy in patients with hypertension during long-term treatment with beta-adrenergic blockaders].
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; Cardiomegaly; Drug Therapy, C | 1986 |
Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Diuretics; Drug Therap | 1985 |
Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Debrisoquin; Genetic Variation; Humans; Hypertension; | 1986 |
Benefits and potential harm of lowering high blood pressure.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1987 |
Beta-blocking agents and plasma lipids: an update.
Topics: 1-Propanol; Adrenergic beta-Antagonists; Atenolol; Cholesterol, LDL; Coronary Disease; Humans; Hyper | 1987 |
A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hype | 1987 |
Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Antihypertensive Agents; Atenolol; Celiprolol; Diabe | 1988 |
Balance among autonomic controls of heart rate in neonatal spontaneously hypertensive and borderline hypertensive rats.
Topics: Age Factors; Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Atropine Derivatives; Aut | 1988 |
Exercise haemodynamics and maximal exercise capacity during beta-adrenoceptor blockade in normotensive and hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Female; Hemodynamics; Humans; Hypertension; Male; Midd | 1988 |
[Cardiovascular response to isometric exercise test during beta blocker and diuretic treatment in essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Diuretics; Drug Evalua | 1988 |
Antihypertensive therapy in pregnancy directed by noninvasive hemodynamic monitoring.
Topics: Atenolol; Cardiac Output; Female; Hemodynamics; Humans; Hydralazine; Hypertension; Pregnancy; Pregna | 1989 |
Toxic effects of atenolol consumed during breast feeding.
Topics: Atenolol; Breast Feeding; Female; Humans; Hypertension; Infant, Newborn; Milk, Human; Pregnancy; Pue | 1989 |
Increase in plasma atrial natriuretic peptides during acute volume expansion in hypertensive man.
Topics: Atenolol; Atrial Natriuretic Factor; Blood Volume; Diuresis; Hemodynamics; Humans; Hypertension; Mal | 1986 |
Significance of physical exercise in hypertension. Influence of water temperature and beta-blockade on blood pressure, degree of cardiac hypertrophy and cardiac function in swimming training of spontaneously hypertensive rats.
Topics: Animals; Atenolol; Blood Pressure; Cardiomegaly; Heart; Hypertension; Male; Physical Exertion; Rats; | 1986 |
Factors regulating myocardial hypertrophy in hypertension.
Topics: Animals; Atenolol; Blood Pressure; Captopril; Cardiomegaly; Hypertension; Isoenzymes; Male; Myocardi | 1987 |
Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol.
Topics: Adult; Atenolol; Cardiomegaly; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Hum | 1987 |
Chronic beta 1-blockade and control of left ventricular hypertrophy in hypertension.
Topics: Adult; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Cardiomegaly; Electrocardiography; Female; Hu | 1987 |
Long-term effect of antihypertensive therapy on left ventricular hypertrophy.
Topics: Adult; Antihypertensive Agents; Atenolol; Cardiomegaly; Drug Therapy, Combination; Echocardiography; | 1987 |
[Photoallergy to Neotri and cross reaction to tenoretic--detection by systemic photoprovocation].
Topics: Aged; Atenolol; Chlorthalidone; Diuretics; Drug Combinations; Drug Eruptions; Humans; Hypertension; | 1988 |
Reappearance of end-diastolic velocity in a pregnancy complicated by severe pregnancy-induced hypertension.
Topics: Adult; Atenolol; Blood Flow Velocity; Diastole; Female; Humans; Hypertension; Pre-Eclampsia; Pregnan | 1988 |
[Comparative study of penbutolol and atenolol in the therapy of essential hypertension].
Topics: Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Penbut | 1988 |
[Combination of enalapril with diuretics in the treatment of arterial hypertension].
Topics: Atenolol; Drug Therapy, Combination; Enalapril; Humans; Hydrochlorothiazide; Hypertension | 1986 |
Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension.
Topics: Acebutolol; Adult; Aged; Aldosterone; Atenolol; Atrial Natriuretic Factor; Cyclic GMP; Female; Human | 1987 |
Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
Topics: Acebutolol; Atenolol; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Pindolo | 1988 |
Atenolol vs captopril as monotherapy in mild to moderate hypertension: alternative to empirical step care approach.
Topics: Adult; Atenolol; Blood Pressure; Captopril; Female; Humans; Hypertension; Male; Middle Aged | 1988 |
Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents.
Topics: Adolescent; Adult; Aldosterone; Atenolol; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; C | 1985 |
White coat hypertension--do we need ambulatory blood pressure monitoring to manage hypertensive patients?
Topics: Adult; Ambulatory Care; Atenolol; Blood Pressure Determination; Humans; Hypertension; Iatrogenic Dis | 1988 |
Beware beta-adrenergic blockers in patients with severe urticaria!
Topics: Aged; Angioedema; Atenolol; Drug Hypersensitivity; Female; Humans; Hypertension | 1988 |
Acute lipoprotein changes associated with atenolol therapy for hypertension in non-insulin dependent diabetes.
Topics: Adult; Aged; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Lipoproteins; Male; | 1988 |
[Thrombocytopenia caused by drugs: new molecules as the cause].
Topics: Aged; Aged, 80 and over; Atenolol; Captopril; Chlorthalidone; Drug Therapy, Combination; Female; Hum | 1987 |
[Hemolytic anemia precipitated by asymptomatic arterial hypertension].
Topics: Adult; Anemia, Hemolytic; Atenolol; Female; Humans; Hypertension | 1988 |
Fixed combination of atenolol and nifedipine in cardiovascular medicine. Partial proceedings of a workshop. London, 21 January, 1987.
Topics: Atenolol; Coronary Disease; Drug Therapy, Combination; Humans; Hypertension; Nifedipine | 1988 |
Treatment of hypertension with a combination of nifedipine and atenolol compared with atenolol alone. Preliminary report.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypert | 1988 |
Tolerability, safety and dosage of a fixed combination of sustained release nifedipine plus atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Delayed-Action Preparations; Drug Therapy, Combination; Drug | 1988 |
Impaired vasodilation during long-term beta 1-selective beta-blockade in hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Epinephrine; Exercise Test; Female; Heart Rate; Hemodynamics; Human | 1988 |
The statistical analysis of treatment effects in 24-hour ambulatory blood pressure recordings.
Topics: Activity Cycles; Ambulatory Care; Atenolol; Blood Pressure; Blood Pressure Determination; Chlorthali | 1988 |
[Validity of a fixed atenolol/hydrochlorothiazide/amiloride combination (100/25/2.5 mg) in the therapy of essential arterial hypertension].
Topics: Adolescent; Adult; Amiloride; Atenolol; Drug Evaluation; Drug Therapy, Combination; Female; Follow-U | 1988 |
Nifedipine as a second line antihypertensive drug in pregnancy.
Topics: Adult; Atenolol; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypertensio | 1987 |
The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cardiomyopathy, Hypertrophic; Cerebrovascular Dis | 1987 |
Use of nifedipine as the drug of third choice in management of hypertension.
Topics: Adult; Aged; Atenolol; Benzothiadiazines; Blood Pressure; Diuretics; Humans; Hypertension; Middle Ag | 1986 |
Fetal and uteroplacental haemodynamics during short-term atenolol treatment of hypertension in pregnancy.
Topics: Adult; Atenolol; Blood Flow Velocity; Blood Pressure; Female; Fetal Blood; Heart Rate; Heart Rate, F | 1987 |
Production and reversal of DOCA-salt hypertension in baboons.
Topics: Animals; Atenolol; Biofeedback, Psychology; Clonidine; Desoxycorticosterone; Disease Models, Animal; | 1987 |
A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.
Topics: Adult; Aged; Aging; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Heart Rate; Humans; Hydr | 1987 |
Postmarketing survey of the effects of an atenolol/chlorthalidone combination in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Chlor | 1987 |
Hypersomnolence with beta-adrenergic blockers.
Topics: Aged; Atenolol; Disorders of Excessive Somnolence; Humans; Hypertension; Male; Propranolol; Sleep Wa | 1987 |
[Clinico-therapeutic evaluation of the hypertensive patient by the isometric exertion test].
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clonidine; Female; Humans; | 1986 |
Episodic hypertension secondary to panic disorder.
Topics: Adult; Anxiety Disorders; Atenolol; Blood Pressure Determination; Fear; Heart Rate; Humans; Hyperten | 1986 |
A comparison of the hypotensive and metabolic effects of 50 and 100 mg atenolol per day.
Topics: Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Drug Administration Schedule; Heart Rate; H | 1986 |
Atenolol induced systemic lupus erythematosus syndrome.
Topics: Atenolol; Female; Humans; Hypertension; Lupus Erythematosus, Systemic; Middle Aged | 1986 |
Mechanism of antihypertensive effect of atenolol in patients with borderline hypertension during short-term treatment. A comprehensive study.
Topics: Adult; Atenolol; Blood Pressure; Electrolytes; Female; Glomerular Filtration Rate; Hemodynamics; Hum | 1986 |
Once-a-day triple therapy with low-dose minoxidil for moderate hypertension.
Topics: Adult; Atenolol; Blood Pressure; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; | 1986 |
Severe confusion in a patient receiving electroconvulsive therapy and atenolol.
Topics: Aged; Atenolol; Blood-Brain Barrier; Delirium; Delusions; Depressive Disorder; Electroconvulsive The | 1986 |
Reserpine versus beta-blocker as an additive to a diuretic in the treatment of Kenyan hypertensives.
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Drug Combinations; Drug Therapy, Combi | 1986 |
Alteration of left ventricular diastolic filling in hypertensive patients: effects of nitrendipine and atenolol.
Topics: Adult; Atenolol; Blood Pressure; Diastole; Female; Heart; Heart Rate; Heart Ventricles; Humans; Hype | 1986 |
[Long-term therapy with atenolol and chlorthalidone in medium- and high-grade arterial hypertension].
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Follow- | 1986 |
Pseudoakathisia associated with atenolol.
Topics: Akathisia, Drug-Induced; Atenolol; Humans; Hypertension; Male; Middle Aged | 1986 |
[Comparative evaluation in the treatment of arterial hypertension between prolonged-action clonidine and atenolol].
Topics: Adult; Aged; Atenolol; Clonidine; Delayed-Action Preparations; Female; Humans; Hypertension; Male; M | 1985 |
Changes in blood pressure and thermographic values resulting from use of a beta-blocker plus diuretic and of an alpha-beta-blocker plus diuretic.
Topics: Adult; Atenolol; Body Temperature; Chlorthalidone; Drug Therapy, Combination; Heart Rate; Humans; Hy | 1985 |
Effect of atenolol on serum beta 2-microglobulin level in hypertensive diabetic patients.
Topics: Atenolol; beta 2-Microglobulin; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabete | 1985 |
Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Atenolol; Blood Pressure; Dinoprostone; Drug Interactions; Glom | 1985 |
Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Vessels; Electrocardiography; | 1985 |
The cardiovascular effects of centrally administered 5-hydroxytryptamine in the conscious normotensive and hypertensive rat.
Topics: Animals; Atenolol; Atropine Derivatives; Blood Pressure; Bradycardia; Drug Interactions; Heart; Hear | 1986 |
Time-related effects of chronic atenolol treatment on cardiovascular responses to handgrip.
Topics: Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Isometric Contraction; Ma | 1985 |
Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.
Topics: Administration, Oral; Angina Pectoris; Atenolol; Drug Interactions; Drug Therapy, Combination; Femal | 1985 |
[Effects of atenolol and an atenolol-chlorthalidone combination on blood pressure values in hypertensive patients].
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Drug Combinations; Female; Humans; Hypertensi | 1985 |
Afterload reduction by nifedipine--the acute haemodynamic response to exercise in hypertensive subjects.
Topics: Adult; Atenolol; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Exercise Test; Hemodynam | 1985 |
Regimen for the control of blood pressure and symptoms during clonidine withdrawal.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlordiazepoxide; Clonidine; Female; Heart Rate; Humans; Hype | 1985 |
Platelet adhesion in hyperlipidemic and hypertensive patients.
Topics: Adult; Arteriosclerosis; Atenolol; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinem | 1985 |